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ABSTRACT.
Carotid chemosensory activity was recorded from the peripheral
end of the cut sinus nerve in anaesthetised cats and rabbits. The
effects on chemoreceptor discharge of various putative transmitters
were studied, and selective agonists and antagonists were used to
characterise the pharmacological receptors involved in the responses
observed.
Intracarotid injection of noradrenaline (NA) caused dose-related
chemodepression via dopamine D2-receptors; the effect was potentiated
after administration of the 8j-adrenoceptor antagonists metoprolol or
betaxolol. Chemodepression was followed in 67% of recordings by
transient ('Ex') excitation, which was not blocked by potent adreno¬
ceptor antagonists. When injected, NA also caused secondary ('E2')
excitation which correlated with an increase in blood pressure and
heart rate. Excitation was also caused by the 8-adrenoceptor
agonists isoprenaline and salbutamol; it was concluded that this
effect, and E2-excitation evoked by NA, depended on changes in cardiac
output, since both were reduced after selective antagonists which also
blocked cardiovascular changes contributing to alterations in cardiac
output evoked by adrenoceptor agonists. The a2~agonist oxymetazoline
caused excitation, but the ax-agonist phenylephrine did not; both were
equipotent with NA in causing hypertension. Vasoconstrictive hyper¬
tension alone does not, then, account for the 'vascularly'-mediated
chemoexcitatory effect of NA. Infusion of NA depressed chemoreceptor
firing, and was capable of suppressing the chemoreceptor response to
hypoxia or hypercapnia; excitation was less commonly observed during
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infusions of NA. The persistence of responses to hypoxia after
adrenoceptor blockade implies that adrenergic mechanisms are not
fundamental to chemoreception.
The use of novel 5-hydroxytryptamine (5-HT) antagonists showed
that the occasional initial transient chemoexcitation, and the consis¬
tent depression of discharge evoked by 5-HT are mediated through
receptors sensitive to the 'neuronal' antagonist MDL 72222, and the
less intense, more delayed excitatory effect is mediated by receptors
sensitive to the 5-HT2-antagonist ketanserin. The response to hypoxia
was largely unaltered after 5-HT antagonists, suggesting that 5-HT
mediated mechanisms are not essential for chemoreception.
Opioid peptides evoked chemodepression, and the pharmacological
profile was consistent with mediation of the effect through the '6'
subtype of opioid receptor. Infusions of [Met]enkephalin depressed
responses to hypoxia and hypercapnia. Potentiation of responses to
hypoxia after the 6-selective antagonist ICI 174864 suggests that
endogenous opioids may tonically inhibit chemoreceptor activity.
Effects of [Metjenkephalin infusions on responses to injections of
monoamines were equivocal, and better means of quantifying the effects
observed are required before the possibility of interactions between
monoamines and opioids can be determined.
The effects of substance P (SP) were indeterminate, but the
potentiation of responses to 5-HT during SP infusion suggests further
investigations of SP's possible role as a modulator of the actions of
other transmitters should be attempted. An excitatory effect of
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vasoactive intestinal polypeptide (VIP) was confirmed, but variable
changes in the effects of monoamines injected during VIP infusions
were observed.
Overall the results suggest that NA and 5-HT can affect the
chemoreceptors both directly and indirectly, and, in common with
polypeptides, are able to modulate chemosensory activity. Circum¬
stances of their release in response to stimuli are awaited before
final conclusions on their roles, if any, in arterial chemoreception
can be reached.
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The mammalian carotid body is a relatively small sensory organ
(about 1mm3 in the cat) located bilaterally at the bifurcation of the
common carotid artery (see Fig. 1.1). Its location, gross structure,
and innervation is remarkably similar between species (cf. Adams,
1958), although considerable variations can occur from one individual
to another.
Situated within the carotid body are arterial chemoreceptors
which can be activated by low Pa02, high PaC02 or decreased arterial
blood pH; their activity is also altered by changes in temperature and
tonicity (the physiological significance of which is uncertain) and by
the exogenous administration of substances such as cyanide (CN~),
acetylcholine (ACh), or dopamine (DA); these latter two substances
have established roles as neurotransmitters in various parts of the
nervous system, and are also present in the carotid body. The carotid
body chemoreceptors are important in homeostasis, mediating reflex
effects upon the CNS through sensory discharges of the carotid sinus
nerve.
The functional elements of the carotid body are the 'type I'
cells, 'type II' cells, and sensory nerve endings, but there is little
agreement as to the identity of the primary receptor element, or the
mechanisms responsible for the induction of sensory discharge in the
sinus nerve. Stimuli acting upon the type I cells may release the
'transmitter' substances that they contain, but it is unknown whether
released chemicals are required for the initiation of sensory
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Figure 1.1: Schematic representation of the left carotid bifur¬
cation of the cat, and the nerves associated with the carotid
body (adapted and re-drawn from Adams, 1958).
AFA: ascending pharyngeal artery;
CCA: common carotid artery;
CS: carotid sinus;
ECA: external carotid artery;
ICA: internal carptid artery;
LA: lingual artery;
SCG: superior cervical ganglion;
sym: cervical sympathetic trunks;
PG: petrosal (Andersh's) ganglion,
is also known as Ehrenritter's
C3: carotid body;
CNS: central nervous system
(i.e the brain stem);




STA: superior thyroid artery;
X: vagus nerve;
of which the rostral part (EG)
(or the superior) ganglion;
The glossopharyngeal nerve is usually exposed when the cannul-
ated lingual artery is deflected towards the superior cervical
ganglion; the carotid sinus nerve is then dissected out from beneath
the common carotid artery, and the recording electrodes positioned
between the artery and the mid-line.
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impulses, or merely serve to modulate an already ongoing discharge,
which could be a property of spontaneously active nerves. This study
is concerned specifically with the effects of neuroactive polypeptides
and monoamines upon carotid body chemoreceptor activity in the cat,
with the inclusion of the results of a small number of experiments
carried out in rabbits. The purpose of this work was to elucidate the
actions of these substances (which have been shown to be present in
the carotid body), their interactions with one another and their
effects upon the response of chemoreceptors to 'natural' stimuli such
as hypoxia. Experiments were designed to provide information as to
whether these substances could act as chemical transmitters in the
basic processes of chemosensory transduction. The remainder of this
introduction describes some of the previous studies on the structure
and function of the carotid body, together with the main theories of
chemotransduction that have been proposed.
1 .1 Early studies on structure and function.
Luschka (1862) accorded the first anatomical description of a
carotid body to von Haller (1762), although there are earlier
descriptions of a structure at the carotid bifurcation (e.g Taube,
17*13). Pfbrtner (1865) appears to be the first to have described the
carotid body in the cat. Luschka's own opinion was that the carotid
body is a gland, whereas Arnold (1865) considered it to be merely a
vascular organ. The demonstration of chromaffin cells by Kohn (1900)
led him to define the carotid body as a paraganglion, an idea which
might be suggested both by the close proximity of the carotid body to
the superior cervical and the nodose ganglia, and by the clear sym¬
pathetic innervation of the carotid body and the adjacent sinus region
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by fibres from the superior cervical ganglion, the ganglioglomerular
nerves.
The nature and function of the carotid body were at times greatly
disputed or relegated to obscurity until De Castro, in the late
1920's, laid the foundations for the current interest in and studies
of the carotid body structure and function. He demonstrated histolog¬
ically the innervation of the carotid body by a branch of the
glossopharyngeal nerve, and the presence of nerve endings on the cells
of the carotid body parenchyma (1925, 1926). His studies revealed a
spatial arrangement of 'type I' cells within the carotid body, one
pole being adjacent to a blood vessel ('pole sanguine'), the other
being associated with nerve terminals ('pole nerveux'). By 1928 he
had clearly differentiated baroreceptors in the 'sinus caroticum' wall
from the chemosensory receptors in the carotid body itself, and had
shown experimentally that the innervation of the carotid body is
afferent, or sensory (rather than efferent, or motor), leading to his
prediction that "the 'glomus caroticum' represents a sense organ that
detects qualitative variations in the blood, a function which, by
reflex action, will have an influence on the functional activity of
other organs".
His interpretation of the carotid body as a chemosensory organ
was confirmed physiologically by Heymans et al (1930) and by Heymans &
Bouckaert (1930) who showed the carotid body to be the site of an
arterial chemoreceptor system sensitive to the chemical composition of
the blood, which, when stimulated, initiates respiratory and cardio¬
vascular reflexes (see Table 1.1). This function had been noted, but
not understood, by Pagano (1900) who observed reflex hyperventilation
and bradycardia when either prussic acid or nicotine was injected into
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Table1.1:Reflexf ectsresultingfromstimulationfcaro idbody chemoreceptors. A.Respiratoryeffects 1.Increasedtid lvolume,frequency, andmi utevolume 2.Increasedbronchiolart n B.Cardiovasculareffe ts 1 .Bradycardia 2.Increasedpulmonaryvascularsistance 3.Systemicvasoconstriction C.Othereffects 1.Increasedmotorcor xac ivity 2.Increasedsecretionfromadr nal medullaandcortexHeymanstal,1930nd Heymans&Bouckaert,1930 Daly&Schweitzer,1951 Daly&Scott,1958 Daly8cl ,1959 Daly8cUngar,1966 Schmidt8cCo roe,1940 Anichkovetal,1960
the common carotid artery in dogs. No such reflex was obtained if the
injection was made into the internal carotid artery, bypassing the
carotid body.
1 .2 Peripheral arterial chemoreceptors.
It is generally accepted that the systemic effects of both
hypercapnia and acidaemia are exerted mainly through actions upon
respiratory 'centres' in the medulla and brain stem, whereas the
systemic response to hypoxia is dependent, almost exclusively, upon
the integrity of the peripheral arterial chemoreceptors. Carotid
chemoreceptor activity accounts for some 40$ of the respiratory
response to hypercapnia during hyperoxia (Berkenbosch et al, 1979).
Even so, hypercapnia or acidaemia, in the presence of hypoxia, exert a
more than additive effect upon chemoreceptor discharge (Otey & Bern-
thai, 1960; Eyzaguirre & Lewin, 1961; Joels & Neil, 1961), and the
elimination of central chemosensitivity (by coagulation of ventral
medullary areas driving respiration in response to H+ ions - Schlaefke
& Loeschke, 1967) results in total dependence of respiratory activity
upon peripheral chemoreceptor function (Schlaefke et al 1969). It has
been proposed (Schlaefke et al, 1979) that central chemosensory function
amplifies the responses to hypoxia and hypercapnia mediated by the
peripheral chemoreceptors.
Arterial chemoreceptor function is not confined to the carotid
body, but is also found in the aortic arch region ('aortic bodies' -
Diamond & Howe, 1956; Paintal & Riley, 1966; Abbott & Howe, 1972;
Sampson & Hainsworth, 1972), and in 'miniglomera' found in the region
of the carotid bifurcation, though separate from the carotid body
itself (de Castro, 1962), and, in the cat at least, around the common
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carotid artery (Matsuura, 1973). It appears that both physiological
and ultrastructural features of such miniglomera are identical to
those of carotid and aortic bodies, and they are innervated, like the
aortic bodies, by fibres projecting from the nodose ganglion. Abdom¬
inal chemoreceptors have also been identified (e.g Hollinshead, 1941),
but only in the mouse and rat, which have poorly developed, or no
aortic bodies. These structures are histologically identical with the
carotid body (Andrews etal, 1972) and have been shown to mediate a
consistent but slight chemoreflex in mice (Hollinshead, 1946); this
chemoreflex is variable in the rat and absent in the cat, guinea-pig
and rabbit (Hollinshead, 1946). Chemosensory activity has been
recorded from filaments of the vagus nerve innervating these "vagal
paraganglia' in the rat (Andrews et al, 1972.; Howe etal, 1981).
1.3 Elements constituting the chemosensory complex.
The term 'glomoid' (Seidl, 1975) appears to be gaining favour for
describing the functional arrangements of capillaries, cells, and
nerve endings. The non-neural components of the glomoid are clusters
of cells associated with the capillaries (see Fig. 1.2). Groups of
cells in intimate apposition to the capillaries are invested with
collagenous connective tissue, through which many myelinated and non¬
myelinated nerve fibres are seen to pass; nerve endings impinge upon
both cells and blood vessels.
1.3.1 Vascular elements.
1.3.1.1. Blood supply.
The blood supply to the carotid body is from a small arterial
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Figure 1 .2: Schematic representation of a 'glomoid' (Seidl, 1975),
taken from Eyzaguirre and Zapata (1984).
Type I cells (TI) surrounding a fenestrated capillary (C) are
innervated by sensory nerve endings (NE), which are the terminals of
fine branches of the carotid sinus nerve. Nerve terminals contain
clear-cored vesicles (0), whilst type I cells are characterised by
dense-cored vesicles (©), surrounded by a clear 'halo'; type I cells
also contain clear-cored vesicles, particularly in the vicinity of
nerve terminals. This arrangement of type I cells and nerve endings
is almost completely enveloped by processes of type II (Til) cells.
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branch originating from some aspect of the bifurcation (see Adams,
1958; Seidl 1976), which attaches the carotid body to the artery, and
may project through the carotid body to supply adjacent structures,
particularly the superior cervical ganglion (Chungcharoen et al,
1952). The venous drainage originates in a capsular plexus, from
which three or four veins emerge, to run into larger veins in the
vicinity. Both arteries and veins may receive a barosensory
innervation (de Castro, 19-40; Abraham, 1968).
1.3.1.2. Innervation of blood vessels.
Carotid body blood vessels are extensively innervated both by
sympathetic nerves, with their cell bodies in the superior cervical
ganglion, and by parasympathetic fibres, the cell bodies of which are
found in the carotid body (McDonald & Mitchell, 1975a,b). Besides
conventional transmitters, there is evidence that vasoactive intes¬
tinal polypeptide (VIP) and substance P (SP) are found in the
terminals of nerves making contact with blood vessels (Lundberg et
al, 1979a; Wharton et al, 1980; Cuello & McQueen, 1980).
1.3.1.3- Arteriovenous anastamoses.
Tissue oxygen levels can vary in different parts of the carotid
body (Acker & LUbbers, 1975; Whalen & Nair, 1975) and local flow in
the organ can be altered independently of total flow (e.g. Acker &
LUbbers, 1975). De Castro and Rubio (1968) observed that hypoxia,
anoxia, and hypercapnia decreased blood flow through the carotid body
and reduced its size; conversely, breathing a hyperoxic gas mixture
increased blood flow through the capillary network, and enlarged the
organ. These changes appear to result from the opening and closing of
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the arteriovenous anastamoses which are a prominent feature of the
carotid body structure (Goormaghtigh & Pannier, 1939; de Castro, 19*10)
and which arise where some of the small terminal arterioles feed direc¬
tly into small venules (Serafini-Fracassini & Volpin, 1966; Schafer
et al 1973).
Using more refined methods, Acker (1980) demonstrated a decrease
in local blood flow during hypoxia, but not in response to hypercapnia.
Autonomic stimulation had no effect upon local blood flow or P02
within the carotid body, although total blood flow through the organ
was decreased by the vasoconstriction elicited by stimulation of
the sympathetics, and increased vasodilatation resulted from stimulation
of the peripheral end of the cut sinus nerve (Acker & O'Regan, 1981).
The autonomic nerves appear to control the arteriovenous anastamoses
which thus act as 'shunts', whilst other mechanisms must regulate the
local flow within the carotid body capillary network, independently of
total blood flow, by an as yet ill-defined P02-dependent mechanism
(Acker, 1980).
1 .3.1 . *1 Capillaries.
The 'functional' vasculature of the carotid body is to be found
in the capillary network (e.g. Seidl, 1976). These capillaries, which
have a continuous fenestrated epithelium (and are thus not simply
intercellular sinusoids)^ are in intimate contact with the 'type I'
cells (Fig. 1.2). Variability in the diameter of the lumen has been
noted (Seidl, 1975) so that considerable changes in blood flow
velocity might occur at different points of the network.
-11-
1.3.2 Cellular elements.
1.3.2.1. Type I cells.
Most numerous of the cells, which fall broadly into two types (cf.
Fig. 1.2), are those of 'type I' (also termed 'glomus', 'chief',
'epithelioid', or 'granular'). These cells are small (-10 pm), with a
large nucleus containing diffuse, lightly-staining chromatin. They
are generally enveloped by the 'type II' cells ('interstitial',
'sustentacular*, 'enclosing', or 'satellite' cells), and extend cyto¬
plasmic processes towards other cell clusters or towards capillaries
(Nishi, 1976). They exhibit many of the features of secretory cells:
abundant mitochondria, much endoplasmic reticulum, Golgi bodies, and
single or polysomic ribosomes, and are characterised, in particular,
by the presence of many large (30-120 nm) dense-cored vesicles (DCVs)
that are similar to, but smaller than, those present in the adrenal
medulla (HellstrOm, 1975a: Hess, 1968; Lever & Boyd, 1957; Lever et al
1959; Verna, 1977, 1979). It is generally accepted that these vesicles
are the site of storage of catechol- and indole- amines (see later),
since labelled catecholamine precursors are taken up by the vesicles
(Chen & Yates, 1969) as are 'false' precursors such as 5-hydroxydopa
and 6-hydroxydopamine (Hellstrbm, 1975b; Hess, 1976). They appear
also to shrink after catecholamine depletion by reserpine (Hess, 1977b).
These vesicles also contain Ca2+, ATP, and proteins (Chen et al,
1969), and it has been suggested that the carotid body might exercise
a secretory function (Karnauchow, 1965; Pearse, 1969; Capella &
Solcia, 1971; Kobayashi, 1975), either related to, or independent of
the chemoreceptor function. However, autoradiographic studies using
tritiated leucine, monoamines, and ATP have shown that the turnover of
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these substances in type I cells is slow in comparison with the
turnover of secretory products in endocrine cells of the adrenal
medulla or gut (Kobayashi, 1976, 1977).
Type I cells in a glomoid are separated one from another, and
from the type II cells by an intercellular space of about 20 nm, which
is accessible to vascularly injected horseradish peroxidase (HRP;
Woods, 1975). Junctions have been observed between adjacent type I
cells in several species (e.g. Biscoe & Stehbens, 1966; Hess, 1968,
1975a), but especially in the rat (Hess, 1975a; McDonald & Mitchell,
1975a; Morgan et al, 1975). Also, in the rat, more specialised
junctions have been described, and it has been suggested from their
morphology, and the presence of apparent synaptic vesicles that these
are 'synapses' (McDonald & Mitchell, 1975a). The term 'synapse' is
only properly applied to a junction between two nerves, but its use is
perhaps justified in this instance if the type I cells are considered
to be 'paraneurones' - see below. A similar junction has been
described between a type I and a type II cell (Hess, 1975a), but the
accumulation of vesicles reported at the membrane of type II cells
abutting the interstitial connective spaces (Verna, 1979) is hardly
suggestive of a synapse. More well defined are the junctions between
type I cells and the sensory nerve endings (see later) .
The histochemical demonstration of neurone-specific enolase in
type I cells (Kondo et al 1982), indicates that these cells are
derived from neural tissues and may thus be classified as 'para¬
neurones' (Fujita & Kobayashi, 1979). The paraneurone concept
envisages a 'continuity' of neurones and endocrine or secretory cells,
which are considered to form a continuous spectrum with regard to
structure (presence of neurosecretion-like vesicles), products
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(peptides, amines, neurohormones, and neurosecretions), and function
(recepto-secretory).
The type I cells can also be classified as APUD cells (Amine Pre¬
cursor Uptake and Decarboxylation cells - Pearse, 1969), which are
derived from neuroendocrine-programmed cells originating from the
ectoblast. Such cells characteristically produce peptides with
hormonal or neurotransmitter activity, as well as bio-active amines.
They could constitute a third division of the nervous system, support¬
ing, modulating, or amplifying the actions of neurones in the somatic
and autonomic divisions. According to Pearse (1978) the type I cells
of the carotid body could be considered as 'neurocrine' in function -
cells secreting into or onto neurones.
Both concepts have been formulated to smooth out some of the
anomalies that surround non-neuronal cells which appear to have some
important role in nerve function.
1.3-2.2 Type II cells.
Type II cells are some 3-5 times less numerous than type I
cells (Biscoe & Pallot, 1972; McDonald & Mitchell, 1975b), which they
surround with a thin cytoplasmic layer, sometimes only 0.2 pm thick
(Verna, 1979). Cytoplasmic extensions have been seen to intrude
between adjacent type I cells, and to project towards the centre of
the cluster; this appears to occur more commonly in the cat than in
the rat carotid body.
The flattened, often lobulated,nucleus is more electron-dense
than that of type I cells, the chromatin being more compact. The
cytoplasm contains much the same organelles as the type I cell, but
DCVs are characteristically absent, as is the capacity to take up and
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store tritiated monoamines.
The envelopment of nerve endings and type I cells by type II
cells is analagous to the investment of nerve cells and neurones by
glial or Schwann cells. A certain proportion of the membrane of both
nerve endings and type I cells is not covered by type II cell proces¬
ses, but remains exposed to surrounding connective spaces through a
basement membrane. In man there is evidence that the number of type
II cells can be increased by prolonged hypoxaemia or systemic
hypertension (Heath et al, 1982).
1.3.3 Neural elements.
1.3.3.1 Afferent (sensory) innervation.
De Castro (1926), Biscoe & Stehbens (1967), Hess (1968), and Hess
& Zapata (1972) showed that transection of the glossopharyngeal nerve
leads to degenerative changes in nerve fibres with terminals assoc¬
iated with type I cells. Some junctions between nerve terminals and
type I cells persist after this procedure (Hess & Zapata, 1972), and
the nerve terminals are most likely sympathetic preganglionic fibres
from the ganglioglomerular nerves (McDonald & Mitchell, 1975a,b).
Electron microscopy studies (de Castro & Rubio, 1968) showed that
fibres innervating type I cells have their cell bodies in the sensory
(petrosal) ganglia (see Fig 1.1). Axoplasmic flow studies may be used
to trace neuronal projections (Lasek et al, 1968), and tritiated amino
acids administered to the petrosal ganglion (Fidone et al 1975;
Fidone et al 1976; Smith & Mills, 1976) were detected in the nerve
endings making contact with type I cells, confirming that they origin¬
ate from cells in the petrosal ganglion. Antidromic application of
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HRP to the carotid sinus nerve (Berger, 1980) showed 96$ of the cell
bodies to be located in the caudal part of the petrosal ganglion, and
the remaining 4$ in the rostral part. The use of antidromic mapping
techniques (Jordan & Spyer, 1977) has shown that the chemoreceptor
afferent activity projects mainly to the ventrolateral part of the
nucleus tractus solitarius; this area of the medulla also contains the
'dorsal' group of inspiratory neurones (Merrill, 197-4). The 'lateral'
group of inspiratory neurones appear not to receive a direct input
from the carotid chemoreceptors (see Mitchell & Herbert, 1974). It
remains to be established whether it is the frequency or the pattern
of impulses that is important for the coding of chemosensory informat¬
ion at the level of the respiratory and cardiovascular centres in the
brain stem.
The carotid sinus nerve is composed of myelinated (mainly A type)
and non-myelinated C type fibres. Both chemoreceptor and baroreceptor
afferents are found in this nerve, each modality being transmitted by
both A and C fibres. Fidone and Sato (1969) estimated that about 61$
of the A fibres in the cat sinus nerve are chemoreceptor afferents
and 39$ are baroreceptor afferents, whilst of the C fibres, some 17$
of the total population appear to be chemoreceptor afferents, 29$
baroreceptor afferents, and the remaining 54$ are efferent in origin,
both sympathetic and non-sympathetic. The ratio of myelinated to non¬
myelinated fibres appears to vary along the length of the sinus nerve-
(Eyzaguirre & Uchizono, 1961), and it has been suggested (Laurent &
jager-Barrfes, 1964) that unmyelinated fibres are the terminal parts of
myelinated fibres. Generally, the threshold of A fibres is lower than
that of C fibres, the response latency shorter, the acceleration of
discharge more rapid, and the discharge frequency higher, regardless
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of whether their modality is chemoreceptor or baroreceptor.
Chemoreceptor fibres (whether A or C type) show a characteris¬
tically irregular discharge under normoxic conditions in anaesthetised
animals. This 'aperiodic' discharge (Eyzaguirre & Lewin, 1961) is
characterised by the random distribution of the interval between
impulses. Intervals between action potentials have been measured in
normally circulated and in perfused carotid bodies (Biscoe & Taylor,
1963; Biscoe, 1965), and were found to be distributed exponentially,
with the standard deviation of the intervals equal to the mean, thus
satisfying two mathematical criteria for randomness. The pattern of
discharge of A fibres tends to become more regular as frequency
increases above 10 impulses s-1 (Biscoe & Taylor, 1963). Some A
fibres may exhibit a regular pattern of discharge even at low rates of
firing (Fidone & Sato, 1969); the conduction velocity of these
particular fibres was observed to be at the lower limit of their
calculated range for A fibres, 4-53 m s-1.
1.3.3.2 Synaptic contacts.
Nerve endings on type I cells are morphologically complex (Nishi
& Stensaas, 1974), and no consensus exists as to the type of terminals
present (e.g. calyciform endings, boutons, 'en-passant' arrangements,
cf. Verna, 1979). It is likely ( Biscoe & Fallot, 1972; Nishi &
Stensaas, 1974; Eyzaguirre & Gallego, 1975; Kondo, 1976) that any one'
afferent fibre will innervate several type I cells, after branching,
possibly by means of terminals of differing size and form.
Many synaptic-like microvesicles are present in the nerve
a.b
terminals (Nishi & Stensaas, 1974; McDonald & Mitchell, 1975, 1976;
McDonald, 1977), the abundance of which is reduced by stimulation of
- 17 -
chemoafferent activity by hypoxia. It is unknown whether these
vesicles contain a synaptic transmitter.
Various kinds of junction between nerve endings and type I cells
have been described: i) 'efferent-like' junctions, with an accumulat¬
ion of vesicles on the neural side (e.g. Biscoe & Stehbens, 1966;
Kobayashi, 1971; Smith & Mills, 1976); ii) 'afferent-like' junctions,
in which the accumulation of vesicles is on the type I cell side
(Verna, 1979), and iii) the so-called 'reciprocal synapses' (McDonald
& Mitchell, 1975a,b; Smith & Mills, 1976), which are not particularly
numerous, and are better described as 'paired' junctions of opposite
polarity, since they appear to represent the occurence of an
'efferent' junction close to an 'afferent' junction. Structurally,
junctions between type I cells and nerve endings are similar to
chemical synapses in the nervous system (Verna, 1979).
1.3.3.3 Denervation studies.
Sectioning of the sinus nerve appears to produce little
alteration in the ultrastructure of type I cells (Biscoe & Stehbens,
1967; Abbott et al 1972; Hess, 1977a), but catecholamine stores become
less sensitive to depletion by reserpine (Hess 1975b), from which it
might be deduced that the intact sinus nerve exerts a retrograde or
trophic effect upon type I cells. Centrifugal activity in the sinus
nerve also appears to influence DCV content of type I cells (Yates et '
al, 1970), and the synthesis and release of catecholamines (Mills &
Slotkin, 1975; Sampson et al, 1975). Type II cells appear to undergo
hypertrophic and proliferative cytoplasmic changes after denervation
of the carotid body (Hess, 1977a), but the significance of the effect
is uncertain.
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1.3.3.4. Efferent (non-sensory) innervation.
In addition to the afferent innervation of type I cells, they may
be innervated from several other sources. Ganglion cells intrinsic to
the carotid body, although few in number (about 1 per 3^8 type I cells
in the rat - McDonald & Mitchell, 1975b) may establish contact between
their dendrites and type I cell processes (Kondo, 1976).
In the rat perhaps H% of the nerve endings on type I cells appear
to originate from preganglionic, possibly cholinergic fibres (McDonald
& Mitchell, 1975b). In the cat, however, extirpation of both the
nodose and the superior cervical ganglia has no significant effect
upon the number of nerve endings on type I cells (McDonald 8c Mitchell,
1981).
Postganglionic sympathetic fibres from the superior cervical
ganglion innervate not only blood vessels (Biscoe *8c Stehbens, 1966,
1967; Rees, 1967; McDonald 8c Mitchell, 1975b), but also type I and
type II cells (Kondo, 1971; Verna, 1975). These fibres may project to
the carotid body via the ganglioglomerular nerves, or as postganglio¬
nic fibres leaving the superior cervical ganglion and travelling to
the carotid body in the sinus nerve; they may also arise from
sympathetic ganglion cells located in the carotid body itself (Verna,
1979).
Stimulation of the sympathetic supply may cause inhibitory, or
excitatory effects upon afferent discharge (O'Regan, 1977). Excit¬
ation is either slow in onset, susceptible to a-adrenoceptor blockade,
and thus attributable to a vasoconstrictor effect, or it is transient,
resistant to blockade with a-adrenoceptor antagonists, and so non-
vasomotor in nature. The possibility exists that noradrenaline (NA)
released from these nerves may reach the chemosensory mechanism
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resulting in stimulation.
De Castro (1926) provided histological evidence of efferent
fibres in the carotid sinus nerve, and action potentials have been
recorded from the central end of the cut sinus nerve
by Biscoe and Sampson (1967, 1968), who showed two types of
efferent activity: one group of neurones, with cell bodies in the
superior cervical ganglion, displayed a cardiac or respiratory
rythmicity in their pattern of discharge, whilst a second group of
fibres showed a non-rythmical pattern of activity, but increased
their firing in response to systemic hypoxia, hypercapnia, or
intravenously injected adrenaline (ADR). Others have confirmed these
findings in cats (Neil & O'Regan, 1969, 1971b; Majcherczyk et al,
197^; Willshaw, 1975) and in the rabbit (Laurent & Jdger-Barrbs,
1969), and by recording from the central end of the cut aortic nerve
(Neil & O'Regan, 1971b) which innervates the aortic chemoreceptors.
The cell bodies of these neurones have not been succesfully
located using the methods already described for tracing neuronal
projections, but would appear to be sited in the brain stem (cf. de
Groat et al, 1979; Berger, 1980). Electrical stimulation or hypoxic
activation of this efferent pathway causes depression of afferent
activity (Sampson & Biscoe, 1970; Neil & O'Regan, 1971a,b). Goodman
(1973) attributed this effect to antidromic depression or to vasomotor
effects. Although vascular effects may be partially responsible for
'efferent inhibition', such inhibition has been demonstrated in the
ischaemic carotid body (O'Regan, 1975), where there is no blood flow,
and hence, no vasomotor activity, and, according to Willshaw (1975),
efferent inhibition is not accompanied by significant changes in blood
flow. McDonald and Mitchell (1981) showed the antagonism of efferent
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inhibition by haloperidol and dihydroergotamine, and suggested the
effect was due to antidromic stimulation of the sensory nerves, resul¬
ting in release of dopamine (DA). Belmonte and Eyzaguirre (197*0 and
McCloskey (1975) did not observe efferent inhibition in the absence of
carotid body perfusion, but the possibility exists that there are
efferent inhibitory mechanisms which are not mediated by alterations
in blood flow.
1.A Theories of the mechanism of chemotransduction.
Pharmacological studies using selective neurotranmitter agonists
and antagonists have proved valuable in establishing the nature of
chemical transmission occuring in the motor nervous system, and these
techniques have been widely adopted in investigating the mechanisms
involved in the sensory process of chemoreception in the carotid body,
where the release of transmitter (generator) substances has been
postulated (e.g. de Castro, 1928; Eyzaguirre et al, 1972). The case
for chemical transmission in the carotid body has yet to be proved,
and hypotheses exist (see later) which, whilst attempting to explain
chemoreception without invoking chemical transmission, may also be
considered as mechanisms underlying the release of transmitter
substances.
1.4.1. Information provided by the nature of the hypoxic stimulus.
The prime stimulus of an increase in the frequency of chemorec-
eptor discharge is hypoxia. Four differing types of hypoxia have been
defined: i) hypoxic - low Pa02; ii) anaemic - normal Pa02, but with
low haemoglobin content; iii) stagnant - normal Pa02, but with low
blood flow, low 02 flow, and tissue 'asphyxia'; iv) histotoxic -
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normal Pa02, but with poisoning of the cytochrome enzyme system of
cellular oxidation.
Hypoxic or histotoxic hypoxia of the perfused carotid body
provokes chemoreceptor reflexes (Heymans & Rijlant, 1933). In cont¬
rast, anaemic hypoxia, as a result of formation of carboxyhaemoglobin
(Comroe & Schmidt, 1938) does not cause reflex hyperpnoea or
hypertension, even when 70? of the haemoglobin content of the blood
has been converted to carboxyhaemoglobin (Duke et al, 1952). Comroe
and Schmidt (1938) suggested that at normal Pa02 (-100 mm Hg) the
small amount of 02 carried in physical solution in the plasma (3 ml 02
per litre of blood) is sufficient to satisfy the oxygen usage of the
carotid body. Direct measurements of carotid and aortic chemoreceptor
activity in the cat (Lahiri et al, 1981b) have shown that most carotid
chemoreceptors are not stimulated by 60? carboxyhaemcglobinaemia at
'normal' Pa02 (82-98 mm Hg) and isocapnia (PaC02 -30 mm Hg). The
aortic chemoreceptors are, however, stimulated by even 10? carboxy-
haemoglobinaemia, and the response is augmented by lowering Pa02.
Chemosensory discharge in the carotid sinus and aortic nerves
increases in response to stagnant hypoxia resulting from haemorrhagic
hypotension (Landgren & Neil, 1951). Neil (1951) proposed that the
type I cells are ordinarily maintained on the verge of anaerobic
metabolism, but that blood flow is normally sufficient for the
dissipation of released anaerobic metabolites. Under conditions of
reduced blood flow the accumulation of these metabolites would cause
excitation of the chemosensory mechanism. From this idea stems the
general concept that chemosensory discharge originates from the supply
or removal of neuroactive substances.
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1.4.2 Oxidative phosphorylation as a determinant of chemoreception.
If the carotid body is perfused with hypoxic-hypercapnic, or
cyanide-containing solutions, the elevation of discharge gradually
declines to a less active steady-state in which the application of
ACh (which stimulates sensory nerve endings directly) provokes a brisk
chemoreceptor stimulation, proving that the nerve endings remain
capable of initiating action potentials (Joels & Neil, 1962). It may
be inferred that in this state the type I cells have been exhausted of
something that mediates the elevated discharge in response to hypoxia;
perfusion with ATP-containing solutions will offset this exhaustive
process (Joels & Neil, 1963), and both Anichkov (1951) and Belen'kii
(1951) have argued that chemosensory activity is evoked by reduced
concentrations of cellular ATP and other high-energy phosphate cont-
ning compounds. The uncoupling of oxidative mechanisms from ATP
synthesis (e.g. using 2,4-dinitrophenol) causes marked chemoreceptor
stimulation (Joels & Neil, 1963).
1.4.3. Possible function of type I cells as the chemotransducer.
De Castro (1928) and Eyzaguirre et al (1972) suggested the type I
cell to be the stimulus transducer, causing subsequent depolarisation
of the afferent nerve terminal, possibly by release of a transmitter.
Stimulation of the superfused carotid body in vitro induces release
of substances capable of exciting a second carotid body, downstream,
even if the stimulated carotid body has been previously denervated
(Eyzaguirre et al, 1965; Eyzaguirre & Zapata, 1968). It is not clear,
however, whether release of such substances from type I cells occurs
at synaptic sites, or is associated with the extracellular space.
'Non-synaptic' release of transmitter does not preclude its affecting
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the nerve terminals, since they could respond to a general concentrat¬
ion of a transmitter, rather than to a localised high concentration
within a finite synaptic cleft (Torrance, 1968). Paintal (1969)
raised serious doubts that release of transmitters could be respon¬
sible for the effect seen in these 'Loewi-type' experiments; he
estimated that the amount of ACh required to be released to cause the
effects seen would be some 50? of the carotid body's total mass (-2 mg
in the cat). The alternative explanation offered by Paintal was that
changes in P02 of the superfusate would account for the excitation of
the second carotid body.
The cellular component appears to be necessary for the generation
of afferent activity, since chemosensitivity is lost if the cells are
destroyed. Verna and co-workers (1975) destroyed type I cells and
the carotid body in the rabbit by cryocoagulation, and showed the
recovery of chemosensory activity in the regenerating sinus nerve
terminals only after they re-established connections with surviving
type I cells. This prerequisite of nerve contact with type I cells
has also been shown following sinus nerve crush (Zapata et al 1976);
in these experiments chemoreception did occur when nerve to cell
contacts were relatively few, and immature, indicating that the
normally high number of such contacts represents a large safety
factor, being greater than would appear strictly necessary. Smith and
Mills (1979) observed that the regenerated sinus nerve, following
extirpation of both carotid bodies, in cats, did not respond to the
usual adequate chemoreceptor stimuli, but only to direct electrical
stimulation.
Chemosensitivity can be induced in 'foreign* (vagal or superior
laryngeal) nerve fibres implanted into the carotid body (de Castro,
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1951; Zapata etal, 1969). It is not possible, though, to determine
whether the type I cells are the primary transducer, or whether they
'condition' nerve endings to become chemosensitive (Eyzaguirre et al,
1977), only that their functioning is obligatory to chemoreception.
Ischaemia studies (Nishi et al, 1981) also suggest the require¬
ment of type I cells for chemoreception. One hour after ischaemia,
induced by arterial occlusion, signs of destruction were seen in type
I cells, whilst nerve endings appeared intact. There was a specific
lack of response to asphyxia and to cyanide, yet the responses to ACh
and HC1 were retained. After prolonged ischaemia (2-3 hours) there
was also destruction of nerve terminals, and a decrease in responsive¬
ness to all forms of stimulation.
1.4.4 Are the nerve terminals the chemoreceptors?
Evidence that the nerve terminals themselves are the chemotrans-
ducers is slender; Mitchell and co-workers (1972) found that some
nerve fibres in a neuroma formed from the cut end of the sinus nerve
of the cat show normal chemoreceptive properties in the supposed, but
by no means certain, absence of type I cells. The reinnervation of
the carotid body itself, or of ectopic chemoreceptor tissue (Matsuura,
1973) cannot be ruled out, especially since 12-18 months elapsed
between the original surgery and the testing of chemoreceptor activity.
Similar claims have been made for comparable experiments in the rabbit'
by Kienecker's group (1978), and by Tan et al (1981), where allowance
was made for the criticisms levelled against the earlier experiments
in the cat, but species differences cannot be ruled out.
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1.4.5 Are the sensory nerve endings spontaneously active?
The idea that the regenerative region of the nerve terminals is
spontaneously active has been propounded by Biscoe (1971). The
pattern of chemoreceptor discharge is compatible with a Poisson (i.e.
random) distribution, which might be explained by a fluctuation.in
excitability of small nerve endings consequential to thermal noise
(hence spontaneous activity) or a fluctuation in excitability caused
by random release of quanta of transmitter (?from type I cells).
Theoretical considerations of fibre dimension and geometry, K+ depolar-
isation predicted from the Nernst equation (Em = RT/F .ln[K+]0/[K+]j_,
assuming permeability to K+ ions only), and the activity of Na+/K+
ATPase and oxidative phosphorylation processes (Biscoe, 1971) have
been used to argue that nerve endings are sensitive to local oxygen
levels. Experimental support might be sought in the reinervation
experiments (Kienecker et al, 1978; Tan et al, 1981), but other
confirmation (e.g. the geometry and size of the nerve endings) is
largely negative.
McDonald and Mitchell (1975a,b), assuming the nerve endings to be
chemosensitive, ascribed to the type I cells the function of 'inter-
neurones' in an inhibitory feed back loop, releasing dopamine (to
inhibit the sensory terminals) after they themselves have been excited
by a transmitter released from the sensory nerve terminals during natural
stimulation. Such a theory is speculative, in as much as the contents'
and synaptic nature of the vesicles occuring in the afferent fibres
are unknown, and the vesicles are presumed to be 'synaptic' only from
morphological comparison with other structures.
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1.4.6. 'Mechanical' theory.
Paintal (1977) reviewed the common features of sensory receptors:
a non-neural element, sensitive to the magnitude and rate of change of
the stimulus, which provides a measure of the stimulus, undergoes
physical or dimensional changes, transmitting information mechanically
to the 'generator' region of the sensory nerve ending. This induces a
local change in the membrane potential ('generator potential' e.g.
stretching of the crustacean stretch receptor causes deformation of
the dendrites, and a reduction in membrane potential - Eyzaguirre &
Kuffler, 1955), which reflects the intensity and duration of the stim¬
ulus; the signal is, however, rapidly attenuated, unless the stimulus
is maintained or increased, resulting in the flow of more current,
spreading to the adjacent region of the nerve fibre (e.g. the first
node of the ending of a medullated fibre), leading to the initiation
of an action potential at this 'regenerative' region, and which is
propagated along the nerve fibre. The generator potential is graded
in amplitude, depending upon the stimulus, but the action potential
is 'all-or-none' in character, as is typical of any nerve fibre.
Because of the diverse chemical structures of the many substances
that stimulate chemoreceptors, Paintal suggested that these all act
non-specifically at the regenerative region of the sensory nerve
terminals. His argument that CN~ is not a specific chemoreceptor
stimulant, but also stimulates mechanoreceptors (Paintal, 1971), has
not been upheld. McQueen (1980a) showed that low doses of ACh and
other drugs with nicotinic properties would be unlikely to stimulate
baroreceptors when injected i.e.; in addition he demonstrated that CN~
is a specific chemoreceptor stimulant in cats since it did not
activate carotid baroreceptors at doses causing maximal chemoreceptor
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stimulation.
In rejecting a requirement for chemical transmission, Paintal
proposed that type II cells are chemosensitive, responding with a
'physical change' which results in excitation of the afferent nerve
endings. A modification by Jones (1975) suggests the contraction of
type II cells is effected by the release of ACh from type I cells.
1.4.7 'Cytochrome-metabolic' theory.
Mills and JObsis (1972) demonstrated the existence of an 'oxygen
sensor* containing a cytochrome-a3 with an unusually low affinity for
oxygen, partial unsaturation occuring even at P02 of 140-150 mm Hg.
The location of this 02-sensor has been suggested to be the type II
cells. Activation of the system would lead to the release of an
excitatory 'transmitter' to act upon the afferent terminals. These
authors have suggested that K+ ions could leak out from the type II
cells when their energy metabolism becomes compromised by hypoxia, and
would be expected to depolarise nearby nerve endings, and perhaps type
I cells also.
1.4.8 Theories based upon hydrogen ion activity.
Torrance's hypotheses (1976, 1977) on modulation of chemoreceptor
activity as a function of intercellular acidity were formulated to
explain the convergence of hypoxia and hypercapnia in afferent impulse
generation in the same fibre. It was proposed that nerve endings
respond to changes in local extracellular [H+], that pH in the finite
space surrounding the nerve endings is controlled by H+ inflow and
HC03" outflow to or from the glomeral blood, and that activity of the
HC03~ pump controlling this exchange is dependent upon P02. This
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theory relies upon the presence of extracellular carbonic anhydrase
rapidly converting C02 to carbonic acid. Since benzolamide, a non-
permeant inhibitor of carbonic anhydrase, was less effective than
acetazolamide, which is freely permeant into cells, in slowing the
chemoreceptor response to C02 (Hanson et al, 1981), the theory has
been modified so that chemoreceptor discharge would be a function of
intracellular pH.
Carbonic anhydrase has been located in type I cells (Lee, 1968)
and in type II cells, (Becker et al, 1967). However, variations in cell
pH during hypoxia in the carotid body in vitro have not been detected
(Garcia-Sancho et al, 1978). It is also known that C02 and H+ ions
stabilise the membrane of peripheral nerve fibres (Shanes, 1958), and
hyperpolarise spinal motorneurones whilst increasing their input resis¬
tance (Marshall & Engberg, 1980); furthermore, barosensory nerve
endings are depressed by low pH (Eyzaguirre & Zapata, 1968). It is
possible that chemosensory afferents may have properties different to
those of other sensory nerves. Indeed, intracellular recordings from
the petrosal ganglion suggested that different Na+ and Ca2+ currents
underly the action potentials in chemosensory and barosensory fibres
(Belmonte & Gallego, 1983). Of course, pH changes at the surface of
the type I cells could also promote the release of transmitters.
1.5 Neurotransmitters in the carotid body.
Since type I cells contain many putative transmitter substances
(see, for example, Eyzaguirre & Fidone, 1980), it is possible that one
or more of these substances is an endogenous transmitter, released
during natural or hypoxic stimulation and directly responsible for the
initiation of neural discharge. Alternatively, the nerve endings
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themselves may be spontaneously active, being depolarised by an oxygen-
sensitive mechanism, and these transmitter substances could then act
to modulate this spontaneous activity. Many substances have been
proposed as possible chemotransmitters, none of which fully accounts
for the whole body of experimental results obtained.
The fact that a large increase in blood pressure will abolish
increased chemoreceptor discharge or reflex effects (Gernandt et al,
1945), and the failure of anaemic hypoxia to stimulate the carotid
chemoreceptors suggests that chemosensory discharge is dependent less
upon the amount of 02 the blood supplies than upon the flow of blood
through the carotid body, which supplies the chemoreceptors with some¬
thing, the lack of which causes them to discharge, or alternatively,
that the blood usually carries away some substance released in the
carotid body, which is necessary for the excitation of sensory nerve
endings.
Since chemoreceptor activity can persist after death, (perhaps
for 30 minutes or more - Joels & Neil, 1963), the nerve fibres have
minimal 02 requirements for their functioning, and the apparent high
02 consumption of the carotid body (e.g. 90 yl g-1 min-1; Daly et al,
195*0 is assumed to be a property of the (type I) cells (Joels & Neil,
1963). In the absence of oxygen these cells could release anaerobic
metabolites or they could depolarise, releasing chemical transmitters
that excite the sensory nerve endings. When there is no blood flow,
as after death, or during intense vasoconstriction, the continued
presence of metabolites or transmitters would maintain the discharge
of chemoreceptors.
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1.5.1 Acetylcholine as the 'essential' excitatory transmitter.
A long-favoured candidate as 'the' excitatory transmitter acting
upon nerve terminals is ACh (e.g. Schweitzer & Wright, 1938; Landgren
et al, 1952, 1954). However, hexamethonium may suppress reflex
responses to injected ACh, without changing reflex responses to
cyanide or hypoxia (Douglas, 1952), or it may reduce the chemoreceptor
response to all forms of stimulation (Joels & Neil, 1962). McQueen
(1977) showed that a number of agents affecting the chemoreceptor
response to injected ACh had little or no effect upon sensitivity to
hypoxia or CN~; from the quantitative nature of his study, it appears
doubtful that ACh is the primary agent involved in chemotransduction.
Furthermore, Docherty and McQueen (1979) showed that in the rabbit
exogenous ACh depresses chemoreceptor discharge. As the carotid body
contains large amounts of cholinesterases (Hollinshead & Sawyer, 1945;
Koelle, 1950), it seems unlikely that sufficient ACh would remain
active, after death, to maintain the prolonged high level of discharge
described above.
1.5.2 Catecholamines.
Evidence has been provided from both fluorescence microscopy
studies and from autoradiographic studies of catecholamines in the
carotid body to support the notion that these substances are stored
in the type I cell DCVs (cf. Biscce, 1971). Quantitative studies show'
little agreement as to how much of each CA is stored in the carotid
body (see Table 1.2), although it is thought that dopamine (DA), and
noradrenaline (NA) are present in greater abundance than adrenaline
(ADR) . These differences can result from differing sensitivities and
selectivities of the methods used, or, perhaps more importantly, from
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the physiological status of the animal prior to the removal of tissue.
1.5.2.1 Synthesis & Precursors.
Catecholamines are synthesised from tyrosine and the rate
limiting enzyme, tyrosine hydroxylase (TH), has been demonstrated in
the carotid body of the rat, cat, and the rabbit (Gonzalez et al,
1978, 1979a,b, 1981; Hanbauer, 1977; Hanbauer et al, 1977; Bolme et al,
1977). The activity of this enzyme persists after sympathectomy or
sensory denervation (Fidone et al, 1980; Hanbauer & HellstrOm,
1978). TH-induction by prolonged or repeated exposure to hypoxia has
been reported in rat carotid bodies (Hanbauer et al, 1977; Gonzalez
et al, 1979b), implying that chemosensory activity could regulate
catecholamine synthesis.
Aromatic L-amino acid decarboxylase (DOPA decarboxylase) has been
demonstrated indirectly in the carotid body of the cat (Chiocchio et al,
1971) and in the type I cells of the rat carotid body (Bolme et al,
1977), and it is concluded that type I cells have the capacity to
synthesise DA.
Dopamine-g-hydroxylase (DgH) activity has been shown in the
carotid body of the cat (Belmonte et al, 1977; Morgaao et al, 1976),
and also of the rat (Hanbauer, 1977), where activity is apparently
unaltered by repeated exposure to hypoxia (Hanbauer et al, 1977). High
levels of this enzyme are contained in the ganglioglomerular nerves,
but the enzyme persists in the sympathectomised carotid body of the
cat (Belmonte et al, 1977; Morgado et al 1976). Amine levels are
little affected by chronic sympathectomy (3~7 days; Zapata et al,
1969), indicating that in the cat the major contribution to the NA
content of the carotid body is from the type I cells. In the rat,
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chronic sympathectomy (5-7 days) causes a reduction of some 50% in the
NA content of the carotid body (Hanbauer & HellstrOm, 1978), and the
distribution of DgH in rat type I cells is sparse (Bolme et al, 1977),
from which it might be concluded that there is variation between
species in the proportion of NA contributed by type I cells and by
sympathetic nerve terminals. Since, in the rat carotid body, the NA
content is also reduced by diethyldithiocarbamate-induced inhibition
of DfSH (HellstrOm, 1977), NA is at least partly synthesised in situ
in addition to possible accumulation by uptake from the plasma.
Phenylethanolamine N-methyltransferase (PNMT) was not detected in
type I cells of the rat carotid body (Bolme et al, 1977), which may
explain the generally negative reports on the ADR content of the
carotid body (see table 1.2).
[3H]-tyrosine incorporation in the rabbit carotid body has been
reported (Fidone et al, 1980, 1981), and prior exposure of animals to
hypoxia resulted in increased formation of [3H]-DA, but no significant
increase in levels of [3H]-NA.
It is unclear whether NA and DA are stored in the same DCV,
in separate DCVs in the same cell, or in separate DCVs in different
cells. Two varieties of type I cell have been described, on the basis
of the electron density of their cytoplasm (Lever et al, 1959;
Hoglund, 1967; Grimley & Glenner, 1968; Chen et al, 1969; Morita et al,
1969; Abbott et al, 1972), or according to size and density of the
DCVs contained in the cells (Kobayashi, 1968, 1975; Morita et al,
1969; McDonald & Mitchell, 1975b; HellstrOm, 1975), but there is no




Many reports have appeared describing the effects of catechol¬
amines upon ventilation and upon chemosensory discharge. The more
salient features of the responses evoked by DA and by ADR or NA (and
isoprenaline - ISO) are listed in tables 1.3, and 1.4 respectively.
It appears that there are some marked species differences in the
effects upon the chemoreceptors of exogenous catecholamines. DA
causes chemodepression in the cat, and ADR and NA transient chemodep-
ression followed by an excitation. Both DA and NA appear to cause a
stimulation of chemoreceptors in the dog, although low doses of DA
also have chemodepressant effects in this species too (e.g. Bisgard
et al, 1979). DA causes chemodepression in the rabbit in vivo
(Docherty & McQueen, 1979), but in vitro studies are consistent with a
predominant chemoexcitatory action (e.g. Eyzaguirre & Monti-Blocn,
1980).
'Biphasic' responses to NA have been variously reported, and
varying explanations have been offered, most of which preclude an
action at adrenergic receptors directly linked to the chemoreceptor
complex. Respiratory excitation in response to NA or ADR is common,
is blocked by a-adrenoreceptor antagonists such as phenoxybenzamine
(Matsumoto etal, 1981; Yasuharaetal1980) and is abolished by sectioning
of the sinus nerves (Joels & White, 1968; Matsumoto etal, 1980a).
Excitatory effects of NA upon chemoreceptor discharge may be
blocked by a-antagonists (e.g. Llados & Zapata, 1978b), and in the in
vitro preparation, where vascular complications are said to be
avoided, NA and ADR do not cause chemoexcitation (Eyzaguirre &
Koyano, 1965; Zapata, 1975, 1977; Zapata et al, 1969) - or only very
occasionally, and then in only a few preparations (Zapata, 1975, 1977).
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Table 1.3: The effects of dopamine (DA) upon respiration or chemoreceptor
activity.




Jacobs & Comroe Dog
(1968)
Black et al (1972) Cat
Sampson (1972) Cat
Mitchell 8c McDonald Cat
(1975)
Zapata (1975) *Cat














Welsh et al (1978)
Bisgard et al (1979)
Docherty 8c McQueen Rabbit
(1979)
Mishra et al (1979) Rat
Bainbridge 8c Heistad Man
(1980)
Cardenas 8c Zapata Cat
(1980)







Chemodepression, antagonised by DBZ.
DA effects antagonised by DHE.
Chemodepression, antagonised by SPIR, or
DIB; repeated doses of DA lead to chemo-
excitatory response instead of depression.
ACh or CN~-evoked excitation reduced by
simultaneous administration of DA.
Cat Chemodepression, antagonised by PHENT 3c DHE.
Cat Chemodepression, blocked with HAL or
trifluperidol, but not by low doses of
a-antagonists.
*Cat 8c Hyperpolarisation of nerve terminals.
*Ra'obit
*Cat Chemodepression, antagonised by DHE.
Cat DA effects antagonised by fluphenazine, with
depression 'converted' to chemoexcitation.
Cat DA effects antagonised by droperidol.
Cat Chemodepression, antagonised by ct-FLU.
Cat DA chemodepression mimiced by apomorphine
8c amantidine; amphetamine or tyramine
did not cause chemodepression.
DA effects antagonised by HAL, SPIR, CHLORP,
or PERPH, resulting in chemoexcitatory
response to DA.
Cat PHENB & DBZ not direct antagonists of DA
effects, which are also resistant to
PROP 8c DCI.
Man Indirect evidence of chemodepression.
Dog Low doses - chemodepression; high doses-
chemodepression preceded by chemoexcitation.
Antagonism by HAL, DHE.
Chemoexcitation.
Indirect evidence of chemodepression.
Reduced sensitivity to low [CN~] , but








Monti-Bloch & Eyza- *Rabbit
guirre (1980a)
Lahiri & Nishino Cat
(1980)
Lahiri et al (1980) Cat
Matsumoto et al Rabbit
(1980)
Zapata & Zuazo (1980) Cat
Donelly et al (1981) Cat
Lahiri et al (1981a) Cat
Nishino & Lahiri Cat
(1981)





Receptor hyperpolarisation & reduced
discharge, antagonised by HAL.
Receptor depolarisation & increased
discharge, antagonised by HAL.
DA blockade results in chemoexcitatory
response to DA.
Decreased sensitivity to hypoxia & hyper-
capnia during DA infusion,
but response potentiated after HAL.
Chemoreflex depression of ventilation.
Decreased ventilation.
Enhanced basal discharge and sensitivity




DA depresses aortic chemoreceptors, but
less so than the carotid chemoreceptors;
effect reduced or reversed in severe
hypoxia.
Chemodepression, blocked by HAL & SPIR.
CHLORP: Chlorpromazine; DBZ: Dibenzyline; DCI: Dichloroisoprenaline;
DHE: Dihydroergotamine; DIB: Dibenamine; a-FLU: a-Flupenthixol;
HAL: Haloperidol; PERPH: Perphenazine; PHENB: Phenoxybenzamine; PHENT:
Phentolamine; PROP: Propranolol; SPIR: Spiroperidol.
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Table 1.4: Effects of adrenaline (ADR) noradrenaline (NA) and isopren-
aline (ISO) upon respiration or chemoreceptor activity.
(* and t denote in vitro and decerebrate preparations respectively;
for other abbreviations see below).
Author species, drug and effect








Kuznetzov & Belen'kii tCat
(1963)
Biscoe (1965) *Cat
Eyzaguirre & Koyano *Cat
(1965)




Joels & Neil (1968) Cat
Joels & White (1968) tCat
Zapata et al (1969) *Cat
Black et al (1972) Cat
Heistad et al (1972) Man
Sampson (1972) Cat
Zapata (1975) *Cat
Flandrois et al Dog
(1977)
Llados & Zapata Cat
(1978b)
Wasserman et al Cat
(1979)
Eclache et al (1979) Man




ADR,NA: No detectable change in chemo¬
receptor activity.
ADR ,NA: Reflex hyperpnoea.
ADR: Increased ventilation, resistant to
sinus nerve section.
NA: Enhanced respiratory response to
hypoxia.
ADR: Mild stimulation of respiration.
ADR,NA,ISO: Chemoexcitation, blocked by
pronethalol or DCI; hypoxia and ACh
effects also blocked by DCI.
ADR ,NA: Chemodepression.
Hypoxia and CN~ responses unaffected by a-
or B-adrenoceptor blockade.
NA: less effective than DA, but caused
hyperpnoea; effect blocked by PHENT,
but not by PROP.
ADR ,NA (but not DA): Chemoexcitation.
ADR: Increased ventilation, except when
breathing 10055 02 or after sectioning
buffer nerves; increased chemoreceptor
discharge.
NA: Reflex hyperventilation, increased
chemoreceptor discharge during NA infusion.
ADR ,NA: No clear effects.
NA: chemodepression, but inconsistently.
ISO: abrupt hyperpnoea.
ADR,NA: chemodepression with secondary
chemoexcitation; effects blocked by DBZ.
NA: No clear effect.
Adrenal medullectomy decreased plasma
[ADR], but not plasma [NA], with resultant
hyperpnoea, even under resting conditions.,
NA: Chemoexcitation and increased discharge
during infusion (blocked by a-antagonists);
occasional chemodepression (enhanced by DIB,
blocked by DA antagonists).
ISO: Chemoexcitation only.
ISO: Chemoexcitation and reflex hyperpnoea,
not abolished by 100$ 02.
Increased plasma [NA] produced hyperpnoea,






















ISO: Intense hyperpnoea, blocked by section
or cooling of carotid sinus nerve.
NA: Increased discharge during infusion,
with hypopnoea, not abolished by sinus
nerve section.
ISO: Intense hyperpnoea & increased
discharge; chemoexcitation augmented by
hypoxia and hypercapnia and partially
blocked by PROP. Hypoxia and hypercapnia
responses not blocked by PROP
ADR ,NA: Chemodepression (blocked by HAL)
and chemoexcitation (blocked by PROP).
ISO: Chemoexcitation only, partially
blocked by PROP.
Hypoxia response abolished by propranolol.
ISO: chemoexcitation, blocked by PROP; hyp¬
oxia effect not blocked by PROP.
DCI: Dichloroisoprenaline; DIB: Dibenamine; HAL: Haloperidol; PHENT:
Phentolamine; PROP: Propranolol.
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It is widely accepted that the effect, in the carotid body in situ,
stems from stagnant hypoxia or asphyxia caused by intense vasoconstric¬
tion (cf. Neil & Joels, 1963), and it is possible that a-adrenoceptors
associated with the chemoreceptor complex are located on vascular
smooth muscle cells controlling blood flow within the carotid body.
The situation may, in fact, be rather less simple since ISO is
also a potent chemoreceptor stimulant (e.g. Gonsalves et al, 1983)
which also causes reflex hyperpnoea (see table 1.4) through activ¬
ation of g-adrenoceptors which would, presumably, be susceptible to
activation by ADR and perhaps also by NA. Again, there is an apparent
correlation of chemoreceptor excitation with vascular effects of the
drug, in this case, the pronounced systemic hypotension evoked by ISO,
and dichloroisoprenaline (DCI) and propranolol (PROP) block both ISO-
evoked hypotension, and chemoexcitation in vivo (Llados & Zapata,
1978b); it is significant that ADR, which stimulates both and g2-
receptors (for the origins of the classification of adrenoceptors,
which are the bases of contemporary nomenclature, see Ahlquist, 1948,
and Lands et al, 1967a,b) as does ISO, does not cause chemoexcitation
in vitro (Zapata, 1975; Zapata et al, 1969).
Biscoe (1965) reported that g-adrenoceptor blockade, which
reduced chemoreceptor responses of the superfused cat carotid body in
vitro to catecholamines, resulted also in depression of responses to
hypoxia and ACh. In a comparable experiment Zapata et al (1969)
could show no clear excitatory effect of catecholamines, and the
depressant effects of DCI were considered to result from its local
anaesthetic properties, rather than to its g-receptor blocking
actions. Many g-blockers, because of their high lipid-solubility, may
exert membrane stabilising effects, and allowance must be made for
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the possible depression of chemoreceptor discharge as a result of
local anaesthetic actions of some of these drugs.
More recently, Folgering et al (1982) reported that the g-
adrenoceptor antagonists PROP and metoprolol (MET, a g-antagonist with
'less' membrane stabilising capacity than PROP) reduced or completely
abolished the response of chemoreceptors to hypoxia. PROP, however,
does not abolish reflex hyperpnoea in man (Heistad et al, 1972;
Patrick & Pearson, 1978) or dog (Kontos & Lower, 1969), and Lahiri et
al (1981a) could not demonstrate blockade of the hypoxic or hypercap-
nic response by PROP in the cat. Silva-Carvalho et al (1981) have
more specifically demonstrated local anaesthetic blockade of chemorecep-
tor activity by PROP, by comparing the effects of administration of PROP
or pindolol (a g-antagonist with considerably less membrane stabilising
capacity than PROP), close to the carotid body, upon the respiratory
changes elicited by injection of lobeline in the dog.
Mir et al (1984a)reported the presence of membranous g-adreno-
ceptors in homogenates of rat and rabbit carotid bodies, using
[12sI]-cyanopindolol binding techniques. These receptors appear to be
of the g2-subtype, and are linked to the formation of cyclic adenosine
monophosphate (cAMP). It was found that ISO, salbutamol (SAL), ADR,
and histamine all significantly increased the cAMP content of the rat
carotid body in vivo. NA, DA, and 5-hydroxytryptamine (5-HT) were
ineffective, and the response to ISO was selectively blocked by g2-,
but not by gt- antagonists. The precise location (and function) of
these g-receptors remains to be determined.
DA-induced chemodepression is found consistently in cats, and
the effect is blocked by a number of different classes of DA
antagonist: butyrophenones, phenothiazines , thioxanthines, and
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ergoloids. The effect is not mediated by vascular changes since it
is also seen in the in vitro preparation (Zapata, 1975), where
comparison of the weak effects of DA upon barosensory discharge also
support the association of DA receptors with the carotid body
chemoreceptors.
More recent evidence from receptor labelling studies (Dinger et
al, 1981; Mir et al, 1984b), or pharmacological studies (McQueen,
1984) supports the designation of these receptors as D2-receptors
(Kebabian & Calne's classification, 1979). These DA-receptors could
be associated with the sensory nerve endings (Okajima & Nishi, 1981),
but perhaps also with the type I cells (Matsumoto et al, 1982)
since DA, in low concentrations, can change the resting membrane
potential of these cells.
Fitzgerald et al (1977) and Mir et al (1984b) failed to
detect DA-sensitive adenylate cyclase in rabbit or cat carotid body
homogenates, and so the predominant effects of DA appear to be
mediated through DA receptor mechanisms that are independent of, or
negatively linked to cAMP formation; the lack of positive linkage to
adenylate cyclase is a distinguishing feature of Kebabian and Calne's
D2-receptor subtype.
In in vitro preparations sensory nerve endings are hyperpol-
arised in response to DA in the cat (e.g. Eyzaguirre & Monti-Bloch,
1980), but in the rabbit it is unclear whether DA induces
depolarisation (Eyzaguirre & Monti-Bloch, 1980; Monti-Bloch & Eyza¬
guirre, 1980a) or hyperpolarisation (Sampson & Vidruk, 1977) of the
sensory nerve endings.
The chemodepression elicited by NA in many of the experiments
reported to date has been shown to be enhanced after a-adrenoceptor
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blockade with dibenamine (Llados & Zapata, 1978b), or blocked by DA
antagonists such as haloperidol (Folgering et al, 1982), and is
perhaps a consequence of non-specific activation of DA inhibitory
receptors. There are indications that NA exhibits some affinity for
mammalian brain dopamine receptors (Seeman et al, 1978).
In dogs and in cats pre-treated with drugs blocking the
depressant effects of DA, chemoexcitation or reflex hyperpnoea is
sometimes observed in response to DA. The effect is not blocked by
dibenamine (Zapata & Zuazo, 1982) and does not then represent a non¬
specific action of DA at a-adrenoceptors (which may be activated by
high doses of DA - Goldberg, 1972).
'Primary* DA-induced chemoexcitation (that is, the excitation
that does not require prior application of blockers of DA depressant
effects before it becomes detectable) in dogs was reported to be
blocked by D-tubocurarine (but not by succinylcholine or gallamine -
Bisgard et al, 1979). DA-evoked hyperpnoea in cats pre-treated with
spiroperidol persisted after D-tubocurarine administration (Zapata &
Zuazo, 1982), and hyperventilation evoked by DA in dogs was resistant
to blockade with hexamethonium. The DA excitatory effect is,
therefore, unlikely to be mediated by nicotinic ACh receptors known to
be present in the carotid body (Eyzaguirre & Zapata, 1968).
Excitatory DA receptors appear to have no affinity for
apomorphine (which stimulates receptors mediating the depressant
effects of DA) since apomorphine does not elicit chemoexcitatory
effects after blockade of inhibitory effects (Llados & Zapata, 1978a;
Zapata & Zuazo, 1982) in cats.
Zapata (1975) demonstrated an apparently labile character of the
DA-receptors mediating depressant effects; following repeated injec-
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tions of DA at short intervals a delayed excitatory response emerged
following the chemodepression, and successive injections of DA
ultimately resulted in a purely excitatory response to this catechol¬
amine. The inhibitory effects of DA were blocked by spiroperidol and
by dibenamine; neither antagonist, however, caused blockade of the
excitatory component of the response to DA. DA-induced chemoexcitat-
ion following administration of spiroperidol is unchanged after the
additional administration of haloperidol (Zapata & Zuazo, 1982).
DL-DOPA was also found capable of inducing chemoexcitation, but not
chemodepression (Zapata, 1975) and it has a rather poor affinity for
brain DA receptors (Seeman et al, 1978).
In the cat carotid body in vitro the inhibitory effects of DA
may partially, or even wholly, counteract the chemoreceptor
stimulating properties of simultaneously applied CN~ or ACh, and in
those preparations where an excitatory response to DA is observed, the
excitatory effects of the catecholamine and of simultaneously
administered chemoreceptor stimulants are additive (Zapata, 1975).
Nishi (1977) has shown the reduction of chemoreceptor excitation in
response to hypoxia or NaCN by the simultaneous application of DA.
1.5.2.3 Depletion Studies.
Depletion of catecholamine stores in cats by prolonged exposure
to reserpine reduced chemoreceptor responses to ACh (Koppanyi & Cowan,
1962) or to hypoxia (Cowan & Greene, 1965), completely abolished chemo¬
receptor activity (Comroe, 1964), or had no effect upon chemoreceptor
activity or responsiveness (Zapata et al, 1969; Nishi, 1977). It has
been reported that chronic treatment with 6-hydroxydopamine (6-OHDA)
causes a reduction in catecholamine fluorescence in the rat carotid
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body (Lassman & Bock, 1972; Hess, 1975a). Others have failed to ob¬
serve this effect upon catecholamine fluorescence (Hansen & Ord,
1978), or content (HellstrOm, 1977). Zuazo and Zapata (1978) observed
no changes in chemoreceptor responses to CM- and hypoxia in the cat up
to seven hours after intracarotid injection of 6-OHDA, but, unfortun¬
ately, they made no determination of the degree of catecholamine
depletion (if any) caused by this manouevre. Heymans et al (1968)
showed that the response of chemoreceptors to hypoxia persisted after
reserpine treatment in dogs.
1.5.2.4 Release of catecholamines.
It has been reported that the number of DCVs in type I cells
following hypoxia is either unchanged (Zapata et al, 1969) or
increased (Al-Lami & Murray, 1968) in the cat, unchanged in the
hamster (Chen et al, 1969), increased in the rabbit (Miller, et al,
1974), and reduced in the rat (Hoffman & Birrel, 1958; BlUmcke et al,
1967). It is uncertain whether a reduced number of DCVs reflects a
specific effect of hypoxia, or results from pathological changes,
nor is it certain that the number of DCVs reflects the amine content
of the cell.
The amounts of DA, ADR, and NA measured in the cat carotid body
before (see table 1.2) and after hypoxic stimulation in vivo and in
vitro appear not to differ according to Zapata et al (1969). Mills '
and Slotkin (1975), however, found the total amount of NA and ADR in
the cat carotid body was significantly reduced following hypoxia (8-
40?, for 60-90 minutes), and that the extent of the reduction was
dependent upon both the magnitude and the duration of the hypoxic
stimulus; sectioning the sinus nerve attenuated hypoxia-induced
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depletion of carotid body NA and ADR. Electrical stimulation of the
sinus nerve also causes depletion of DCVs in the hamster type I cell;
the effect may be blocked with atropine (200 mg kg-1; Yates et al,
1970), although the effects associated with such a large dose of
antagonist may not be specific or meaningful.
DA, but not NA,levels have been reported to be significantly
decreased in rat carotid bodies after the animals had been exposed to
hypoxia, and the effect was seen whether or not the carotid sinus
nerve had been previously sectioned (HellstrOm et al, 1976). DA-
depletion was partially relieved by administration of atropine, but
preferentially stimulated by the muscarinic agonist methacholine. It
was proposed that release of DA from type I cells is triggered by the
activation of muscarinic receptors on the cell membrane by ACh. The
source of this ACh was suggested to be either intrinsic cholinergic
neurones or the type I cells themselves. Further studies (Hanbauer
and HellstrOm, 1978) confirmed the preferential depletion of DA over
NA by hypoxia and,further, showed that it represents an increased
release of DA, rather than an increased turnover of DA; in their study
chronic sinus nerve section caused an increase in the NA content of
the carotid body. Gonzalez and Fidone (1977) have suggested that in
the rabbit too chemoreceptor stimulation leads to the release of DA.
Sampson et al (1975) demonstrated an increase in the intensity
of formaldehyde-induced fluorescence in type I cells of the carotid
body of normal cats, following stimulation of the cut end of the
sinus nerve, and a reduction in fluorescence intensity in cats pre-
treated with MK-486, a DgH inhibitor. This has been taken to indicate
that efferent discharge in the sinus nerve may stimulate the synthesis
and release of catecholamines.
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1.5.2.5 Hypotheses on the role of catecholamines.
The most marked and most consistent effects of catecholamines
are those obtained with DA. Osborne and Butler (1975) proposed a
model suggesting that DA is released from type I cells and depresses
activity in otherwise spontaneously-active sensory nerve endings.
When the chemoreceptors are stimulated DA secretion is reduced and
the nerve endings are 'disinhibited' so that afferent nerve activity
increases. The hypothesis also suggests that a chemical transmitter,
perhaps ACh, is released from the sensory nerve endings, to act upon
type I cells, further reducing DA secretion as a consequence of a
positive feedback loop.
The prominent feature of this hypothesis is that chemosensory
activity is not the result of activation of otherwise quiescent nerve
endings by an excitatory transmitter, but is due to disinhibition of
spontaneously active nerve endings. Krammer (1978) has lent support
to the model, and suggests that the release of NA, as a result of
stimulation of a specific population of type I cells, decreases the
otherwise continuous release of DA, which normally tonically inhibits
the nerve endings. These hypotheses tend to rely upon the diminution
of DA secretion during hypoxic stimulation; evidence already cited
suggests that DA release is, in fact, either unchanged, or increased
during hypoxia. It would be difficult to reconcile the potent
excitatory effects of DA in the dog without invoking the principle of'
'species variation', although it has also been shown that the effects
of low doses of DA in the dog are depressant.
McDonald and Mitchell (1975a) have suggested that the sensory
nerve endings are themselves chemosensitive whilst the type I cells
are dopaminergic 'interneurones' exerting local control. They proposed
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that afferent nerve endings are coupled to type I cells by 'reciprocal
synapses', and that when stimulated the nerves release a transmitter
which promotes DA release from the type I cells, which in turn acts
upon the sensory nerves (negative feedback), to suppress afferent
activity. This hypothesis has the advantage that DA secretion would
be expected to increase during stimulation; Zapata (1975) supports the
concept that endogenous DA may modulate afferent chemoreceptor
activity, acting as a 'brake'. No role for carotid body NA has been
postulated in this theory, which Krammer (1978) views as an oversight
on the part of McDonald and Mitchell, who took no account of the
possible separation of type I cells into two distinct populations
(McDonald & Mitchell, 1975b). Krammer herself has suggested that
the cytochrome mechanism of Mills and Jbbsis (see above) could reside
in one class of type I cell which appears to be presynaptic to the
other class of type I cell; the cytochrome-containing cells would
release NA during hypoxia, by an 02-dependent rise in cytosol Ca2+ (cf.
Douglas, 1968, 1974). The role of the second series of type I cells
would be that of dopaminergic interneurones, forming the final common
pathway for modulation of the activity of the sensory nerve endings.
1.5.3 Indoleamines - 5-hydroxytryptamine.
1.5.3.1 Location within the carotid body.
The 5-hydroxy- derivative of tryptamine (5-HT) functions as a
neurotransmitter, eliciting responses in both central nervous tissue
and at locations in peripheral organs, by actions at 'tryptamine'
(Gaddum, 1953) receptors.
Hamberger et al (1966) identified 5-HT-containing cells in the
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human carotid body using fluorescence microspectrophotometry. Quan¬
titative estimations of the 5-HT content of the cat and rat carotid
bodies have since been made, and some of the results are listed in
table 1.5, with the levels of DA determined in the same experiments
shown for comparison.
Like catecholamines, 5-HT may be stored in DCVs in the carotid
body type I cells of cats (Chiocchio et al, 1967) and hamsters (Chen
et al, 1969), although GrOnblad and Korkala (1977) have suggested that
5-HT is located in the interlobular mast cells of the (rat) carotid
body.
1.5.3.2 Pharmacological studies.
Intravenous injection of 5-HT was reported to stimulate ventil¬
ation in the dog (Page, 1952), a phenomenon attributed to carotid
chemoreceptor stimulation (Douglas & Toh, 1953; Comroe and Mortimer,
1964), an action of 5-HT upon the C.N.S. (Heymans & van den Heuval-
Heymans, 1953), or to the initiation of cardiac and pulmonary reflexes
(Schneider & Yonkman, 1954). Ventilatory responses to 5-HT are
species-dependent: it is normally a respiratory stimulant in dogs and
rabbits, but in the cat excitation is commonly preceded by apnoea
(Schneider & Yonkman, 1954). Ginzell and Kottegoda (1954) showed that
the secondary excitation of respiration in the cat was abolished by
section of the carotid sinus nerve.
McCubbin et al (1956) recorded afferent chemoreceptor activity in
the sinus nerve of the dog and found that i.e. injection of 5-HT
caused a marked stimulation of chemosensory discharge, suggesting that
the ventilatory response to 5-HT in the dog, at least, is due to
direct chemoreceptor stimulation. This was repeated and confirmed by
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Black et al (1972), but in cats they found a consistent immediate apnoeic
to 5-HT, which was not abolished by sinus nerve section.
Eyzaguirre and Koyano (1965) found that 5-HT normally caused
slight depression of the cat carotid chemoreceptors in vitro, although
in a single experiment it caused chemoexcitation. Black et al (1972)
reported that, in the in situ cat carotid body, injection of 5-HT
could cause depression, excitation, or no change in spontaneous
activity.
The most comprehensive pharmacological study, to date, of the
effects of 5-HT upon chemoreceptors is that of Nishi (1975). He
reported a brief, intense stimulation of chemoreceptors, in vivo,
followed by a depression or block of activity lasting several
seconds. Repeated injections of 5-HT at short intervals led to a
rapid diminution of the response: this desensitisation or tachy-
phylactic effect may be the cause of the inconsistency of responses
reported in this species. According to Nishi the effects of 5-HT
upon carotid sinus baroreceptor afferents were qualitatively similar
to the effects upon chemoreceptor activity, and he suggested that the
indoleamine exerts non-specific effects upon sensory nerve endings and
is thus unlikely to function as a chemical transmitter in the process
of carotid body chemotransduction.
(+)-Lysergic acid diethylamide (LSD), methysergide, and gramine,
which are (non specific) 5-HT antagonists, were found to block the
vascular responses to 5-HT, but not the chemoreceptor responses
(Nishi, 1975), suggesting that chemoreceptor and vascular responses
are mediated by different 5-HT receptor types. It should be noted
that LSD has agonist properties at some 5-HT receptor sites, and
Nishi did note an excitatory effect of LSD itself upon chemoreceptors.
There appear to be no reports, as yet, of the release of 5-HT
from carotid body cells during chemoreceptor stimulation, nor is there
much information concerning the presence and distribution of the
enzymes of 5-HT metabolism in the carotid body, although monoamine-
oxidases (catabolising catecholamines and 5-HT) are present (Lee &
Mattenheimer, 1964). Since 5-HT is present in the
carotid body, and can promote changes in afferent activity, further
studies seem warranted to determine whether it might have some role in
the processes of chemotransduction.
1.5.4 Polypeptides.
A number of polypeptides have been demonstrated in the nervous
system which fulfil the criteria demanded of neurotransmitters (for
reviews, see Lord et al, 1977; Iversen, 1979; HOkfelt et al, 1980;
Snyder, 1980), and much has been made of the ability of these peptides
to act both 'discretely' as neurotransmitters as well as more general¬
ly as hormones (as is also the case with NA).
The application of immunohistochemical and radioimmunoassay
techniques has led to the demonstration of enkephalin (ENK)-like,
substance P (SP)-like, and vasoactive intestinal polypeptide (VIP)-
like immunoreactivity in the carotid body (Lundberg et al, 1979a;
Wharton et al, 1980; Cuello & McQueen, 1980; Fitzgerald et al, 1981).
A major limitation of these techniques is the frequent lack of
specificity of the immune reaction, so that a more or less broad
spectrum of related peptides is demonstrated, rather than an
individual substance.
HOkfelt (1979) has defined several distinguishing features of the
'classical' small molecular weight neurotransmitters and the peptides
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(Table 1.6). Peptides are produced only on the ribosomes of the cell
soma, probably in the form of larger precursor molecules (Gainer etal,
1977), from which the active peptides are liberated by enzymatic
cleavage. High concentrations of the small classical transmitters are
maintained by local synthesis in the nerve endings, active reuptake of
*
released transmitters from the synaptic space, and by axonal transport
of transmitters or precursors from the soma (Iversen, 1967).
No reuptake mechanisms appear to operate for neurotransmitter
peptides, and their replenishment in the nerve terminals is dependent
upon axonal transport. The apparently inefficient (or conservative)
mechanism of peptide turnover may be reflected in the dynamics of the
synaptic events they mediate (Bloom, 1977). The effects of peptides
are often subtle, but of prolonged duration, and it could be that
peptides are largely responsible for 'resetting' the resting membrane
potential, rendering a cell more or less susceptible to excitation
or inhibition by other (classical) transmitters.
1.5.*1.1 Opioid peptides - methionine and leucine enkephalins.
Extracts of porcine brain yielded a morphine-like substance that
mimicked the effects of morphine upon electrically induced smooth
muscle contraction (Hughes, 1975), with equal susceptibility to
blockade with the opioid antagonist naloxone (NAL). This substance
contained two pentapeptides, methionine enkephalin ([Met]enk)and leu¬
cine enkephalin f[Leu]enk), differing only in the amino acid residue at
the carboxyl terminal (see Appendix 2). These peptides were later
isolated also from calf brain (Simantov & Snyder, 1976), and
radioreceptor assay demonstrated that they were localised in nerve
endings (Simantov etal, 1976), and thus might be neurotransmitters.
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Table1.6.Differencesbetwe nclassicalsmalneurotran mittersa d putativepep dn urotransmitters(cf.HOkf lt,1979). Classical transmitters
Peptide transmitters
Molecularweight: Synthesis: Siteofsynthesis: Storage: Supplyforrelease: Inactivation:
-200 Enzymatic. Nervendings (soma,axon). Smallvesicles. Localsynthesis, reuptake,axonal transport Reuptake, enzymatic, diffusion.
-600(enkephalins) >1000(others) Ribosomal. Cellsoma. Largevesicles. Axonaltransport, cleavagefrompre¬ cursors. Enzymatic, diffusion.
Ca2+-dependent release of ENK in response to depolarisation in brain
tissue has been described (e.g. Smith et al, 1976; Iversen etal, 1978).
The five residues constituting [Met]enk are contained within the
91 amino acid residues of g-lipotropin, isolated from the pituitary by
Li (1964). A variety of g-lipotropin fragments, including g-endorphin
(g-END), and all containing [Met]enk possess opiate activity (e.g.
Ling et al, 1976). Hughes (1978) considered g-END to be a 'proto¬
type' opioid peptide, interacting equally with a variety of opioid
receptors, whilst [Met]- and [Leu]- enk, which are more susceptible
to rapid proteolytic inactivation, act more selectively at specific
receptor subtypes. It is possible that g-END would function primarily
as a neuroendocrine agent, whilst enkephalins may be more effective as
discrete neurotransmitters.
Mechanisms of the cellular effects of opioids have been studied
in a number of preparations. [Leu]enk increases the threshold for
spike-generation in cultured mouse spinal neurones (Barker etal,
1978, 1980),and the effects of the peptide upon voltage-dependent ion
conductances were antagonised by NAL. Similarly, evoked calcium
spikes in the cell bodies of cultured avian sensory neurones are
diminished in the presence of opioids (Mudge et al, 1979), and also by
catecholamines; both opioids and catecholamines were inhibitors of the
release of SP from these cells. In the frog spinal cord in vitro
[Met]enk hyperpolarises primary afferent terminals, depressing the
amplitude of both spontaneous and evoked depolarisations (Nicoll etal,
1980).
The slow inhibitory post-synaptic potentials (IPSPs) set up in
sympathetic ganglion cells, following pre-synaptic activation, are not
antagonised by NAL, even though [Met]enk can hyperpolarise ganglion
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cells by a NAL-sensitive mechanism (Wouters & van den Bercken, 1979;
1980). In this case the pharmacological effect of the peptide is,
presumably, different to the physiological processes of IPSP generat¬
ion, which are more likely to result from the activity of DA or ACh,
both of which can also hyperpolarise ganglion cells, the effects of
each, and the generation of IPSPs being antagonised by DA or ACh
antagonists (cf. Kuba & Koketsu, 1978). [Met]enk can depress slow
IPSPs, coincidently with its hyperpolarising action at the pre-gang-
1ionic component of the synapse, and it has been suggested (Wouters &
van den Bercken, 1979; 1980) that the peptide suppresses release of a
transmitter mediating inhibition.
Studies of the guinea-pig myenteric plexus in vitro (North et
al, 1979) have revealed a NAL-sensitive hyperpolarising response to
bath application of opioid peptides. Focal application of the
peptides to the region of the cell body produced a depolarisation,
associated with an increase in membrane resistance, which was not
antagonised by NAL. When the site for iontophoresis was a neural
process, NAL-sensitive hyperpolarising responses were recorded which
could lead to a diminished release of other transmitters from the cell.
Despite the lack of knowledge concerning the mechanisms that
underlie opioid actions upon nerve cells, ligand binding studies have
suggested the involvement of more than one type of receptor site
(u,5,K,a), with differing affinities for the opioid peptides that may'
be found in the intact organism (e.g. Paterson et al, 1983; see also
Section 8).
ENK-like immunoreactive material has been detected in cells, but
not in the nerves of the cat carotid body (Lundberg et al, 1979aJ
Wharton et al, 1980), with [Metjenk being some three to four times
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more abundant than [Leu]enk (Wharton et al, 1980).
The two forms of ENK appear to be equipotent depressants of
chemosensory discharge in cats when injected into the carotid artery
in vivo (McQueen & Ribeiro, 1980), but it has been reported (Monti-
Bloc'n and Eyzaguirre (1980b) that [Metjenk increases chemosensory
activity in the in vitro preparation. Excitatory responses to
injected ACh or C02-equilibrated Locke solution were slightly poten¬
tiated during i.e. infusions of [Metjenk (McQueen & Ribeiro, 1980),
but cyanide evoked chemoexcitation was reduced. This study was not
sufficiently wide in its scope for more to be said than that opioid
peptides appear to be able to modify evoked responses, as well as
spontaneous discharge.
Low doses of NAL greatly reduce or abolish chemodepression evok-
ked by END, but part of the depressor response to ENK is resistant
to NAL blockade (McQueen & Ribeiro, 1980; 1981b), and ENK may exert
actions at 5-receptors (which are less susceptible to naloxone) whilst
B-END may have greater activity at q-receptors (which are more readily
blocked by NAL - see Lord et al, 1977; Pert et al, 1980). Chemoex¬
citation in response to ENK or END has been seen after treatment with
NAL, which could be due to activity at NAL-insensitive (<?) receptors,
or to non-specific effects. Pokorski and Lahiri (1981) showed an
enhanced chemoreceptor response to hypoxia in NAL-treated cats,
implying that endogenous opioids normally exert some tonic depressant •
action upon the chemoreceptors. NAL had no obvious effect upon
responses to hypercapnia, although the ventilatory increase in
response to C02 was enhanced after the antagonist, suggesting a more
important mediation of ventilatory responses to C02 at central sites.
In parts of the nervous system ENK (and B-END) can affect Ca2+
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uptake leading to a reduction of transmitter release (Guerrero-Munoz
et al, 1979). DA, a 'prime' inhibitor of chemosensory discharge,
continues to depress spontaneous discharge in the presence of NAL
(McQueen & Ribeiro, 1980), and the depressant effects of ENK are not
appreciably affected by the DA antagonist o-flupenthixol (McQueen,
1981 ).
ENK-like immunoreactivity has been demonstrated in the carotid
body type I cells (Hansen et al, 1982) where it appears that opioid
peptides are co-stored with NA, as in the adrenal medulla (Schultzberg
et al, 1978). It is not known whether opioid receptors in the carotid
body would respond to circulating opioids released from the adrenal
glands (Costa, 1980; Viveros et al, 1980) or by sympathetic nerves
(Wilson et al, 1980; Konishi et al, 1981), and the conditions under
which carotid body opioids are released remain to be determined.
1.5.4.2 Substance P.
To date no certain physiologically important role of SP has been
proven. This vasodepressor substance occurs in gut tissue and in
neural tissue, particularly the dorsal root ganglion cells, where
Ca2+/Mg2+-dependent, K+-evoked release of SP has been demonstrated
(Otsuka & Konishi, 1976). Of particular interest when studying
carotid body chemoreception is the finding that release of SP from
sensory terminals in the spinal cord depends upon activation of more '
slowly conducting non-myelinated or thinly myelinated A6 and C fibres
(Jessell et al, 1979; Yaksh et al, 1980). A role as a sensory
transmitter in the mediation of pain reflexes is popularly accepted
(cf. Gobel & Binck, 1977); opiates block the release of SP in spinalcord
(Jessell & Iversen, 1977; Mudge et al, 1979) and this could perhaps
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contribute to opiate analgesia. The possibility of interactions
between SP and ENK is further suggested by the finding of SP- and ENK-
containing neurons in juxtaposition in the raphe nuclei, ventral
tegmental area, the septum, and the amygdala (see HOkfelt et al,
1980).
The mechanisms of action of SP remain uncertain. Iontophoresis
or perfusion with SP has been shown to alter the membrane potential of
myenteric neurones (Katayama et al, 1979; Katayama & North, 1980),
commonly resulting in depolarisation of the cell and an increase in
membrane resistance. The effect is voltage dependent, reversing at
about -95 mV, suggesting that decreased K+ conductance contributes to
the depolariasation. This pharmacological effect of SP has yet to be
correlated with the characteristic synaptic events, slow depolarisat-
ions, seen, for example, in myenteric neurones (Wood & Mayer, 1978,
1979; Johnson et al, 1980a).
Application of SP to frog spinal cord motoneurones appears to
cause an increase in membrane conductance and a direct depolarisation
of about 5mV, which is insufficient to attain threshold for the
generation of action potentials (Nicoll, 1978). In the presence of
SP subthreshold motoneurone excitatory post-synaptic potentials
(EPSPs), generated by stimulating synaptic inputs from sensory fibres,
were able to trigger action potentials, which may be a consequence of
the partially depolarised state of the motoneurone in the presence of •
this polypeptide.
At the frog neuromuscular junction (Steinecker, 1977) brief
exposure to SP causes a transient decrease in presynaptic quantal
content, resulting in a decrease in end-plate potential; there then
follows a period of several hours during which both quantal content
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and end-plate potential are increased. Together these results
suggest that SP can facilitate transmission between sensory and motor
neurones and at the neuromuscular junction.
Quantitative studies have shown that pancreatic acinar cells
release K+ ions in response to a rise in intracellular [Ca2+] evoked
by SP and by muscarinic or a-adrenoceptor agonists (Putney etal,
1980). Supramaximal doses of any two agonists did not produce addit¬
ive effects and Putney (1977) proposed that K+ efflux is dependent
upon activation of an homologous population of Ca2+ channels,
regardless of the receptor specificity of the activating agonist
applied. Comparing the kinetics of the binding of radiolabelled
ligands Putney and co-workers (1978) found that the same biological
response resulted from the occupation of about 15000 o-adrenoceptors,
1800 muscarinic receptors, or just 200 SP receptors, implying that the
amplification of the effects of SP binding is far in excess of that
for the other agonists. This equates well with the proposition,
already cited, that peptidergic neurotransmission is 'conservative' in
nature.
Cuelio and McQueen (1980) demonstrated the presence of SP-like
immunoreactive material in both cells and nerve endings of the carotid
body. When injected i.e. SP has been shown to cause an initial
slight chemodepression followed by a dose-related increase in
discharge; these effects were more delayed, longer lasting, and less '
intense than those evoked by ACh or DA injections, and the excitation
appeared to correlate with a rise in PaC02, which may, in turn, have
been consequential to SP-induced changes in bronchiolar tone or
cardiac output (McQueen, 1980b). Responses to ACh and DA were reduced
during SP infusion, whereas responses to NaCN were potentiated
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(McQueen, 1980b). Some of these effects could have been due to blocking
or modulatory actions of SP at nicotinic ACh receptors (cf. similar
actions of SP on Renshaw cells - Ryall & Belcher, 1977). SP did not
overcome or prevent chemodepression caused by i.e. infusion of
[Met]enk (McQueen & Ribeiro, 1981b). Monti-Bloch and Eyzaguirre (1980b)
reported that SP reduced spontaneous discharge in the cat carotid body
in vitro, and similarly in rabbits and mice (unpublished observations,
see Eyzaguirre & Fidone, 1980).
No studies appear yet to have established whether there are SP-
receptors (see Section 9) in the carotid body itself, or whether SP is
at any time released from sites in the carotid body.
1.5.4.3 Vasoactive intestinal polypeptide.
VIP is a highly basic 28 amino acid peptide which shares many
sequential similarities and metabolic or gastrointestinal properties
with other ' intestinally' -derived peptides such as glucagon and secret¬
in (Said & Mutt, 1969, 1970; Mutt & Said, 1974). Although originally
isolated from extracts of porcine duodenum, this peptide has been
found in neurones throughout the gastrointestinal tract, and in fibres
of the peripheral nervous system innervating the lungs, pancreas, and
urogenital tract (Fahrenkrug, 1979). In all such areas these fibres
are associated with smooth muscle close to mucosal surfaces, glandular
epithelia, and around blood vessels, the pattern of distribution
equating well with the peptide's established pharmacological effects
such as smooth muscle relaxation, vasodilatation, and enhanced
secretion from exocrine glands (Said, 1980).
VIP or related peptides have been found in the CNS of many
mammalian species (Fahrenkrug, 1979, 1980) where the distribution
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of VIP-like immunoreactivity appears to be concentrated in forebrainareas
(cf. Fahrenkrug et al§, 1978; Loren et al, 1979; Emson et al, 1979).
In the CNS there also seems to be an association between VIP and the
pial and cerebral blood vessels suggesting that VIP-neurones may
control local or regional blood flow (Larsson et al, 1976, Lindvall
et al, 1978).
Ca2+-dependent release of the peptide from rat hypothalamic
slices in vitro and from synaptosomal preparations made from rat
cerebral cortex, hypothalamus, and striatum has been reported
(Giachetti et al, 1977; Emson et al, 1978). The presence of VIP,
that can be released in response to stimulation, has been shown in
the small-diameter primary afferent fibres of the cat spinal cord (Go
& Yaksh, 1980). In association with the peripheral nervous system,
VIP has been measured in venous blood, the amount increasing when the
parasympathetic nerves to the gastrointestinal tract are stimulated
(Fahrenkrug et al, 1978; Bloom & Edwards, 1980a).
Coexistance of VIP and ACh in the postganglionic fibres that
innervate salivary, sudiferous, and nasal mucosal glands has been
reported in the cat (Lundberg et al, 1979b,1980, 1981), and both
substances can be released by stimulation of the postganglionic nerves
(Bloom & Edwards, 1980b; Lundberg, et al 1980, 1931); ACh causes an
atropine-sensitive increase in secretion and VIP induces vasodilat¬
ation close to the site of release of secretory products. The
simultaneous infusion of ACh and VIP markedly potentiates both
vasodilatation and secretory responses in the salivary gland (Lundberg
et al, 1980), the effects of the two substances applied together being
more than additive, suggesting a synergistic function.
Membrane binding sites for VIP have been demonstrated in guinea-
§Fahrenkrug & Schaffalitzky de Muckadell
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pig and rat brain (Robberecht et al, 1978, 1979; Gammeltoft et al,
1980; Taylor & Pert, 1979); in brain slice and synaptosomal
preparations VIP has been shown to stimulate cAMP formation (Quik et
al, 1978, 1979; Borghi et al, 1979; Kerwin et al, 1980), although
the distribution of VIP binding sites is poorly correlated with the
distribution of VIP-stimulated cAMP formation. This stimulation of
cAMP formation is unaffected by phenoxybenzamine, propranolol, a-flu-
penthixol, or naloxone, implying that VIP-sensitive adenylate cyclase
is independent from the receptors activated by other neurotransmitters
that stimulate formation of cAMP.
Application of VIP to neurones in the cerebral cortex, hippocam¬
pus, and spinal cord causes depolarisation and neuronal excitation;
many cortical cells responding to VIP react also to ACh, but the
effects mediated by the peptide are resistant to blockade by atropine
(Phillis et al, 1978).
Since femtomolar amounts of VIP excite rat hippocampal preparat¬
ions (Dodd et al, 1979; Dingledine et al, 1980), this peptide might
possess extraordinary potency as a neurotransmitter.
Few studies of the effects of VIP upon chemoreceptor activity
have been reported. Fitzgerald et al (1981) showed a slight elevation
of spontaneous discharge during the close arterial infusion (5-25 yg
in 0.5 ml over 10s) of VIP in the cat in vivo, and McQueen and
Ribeiro (1981a) confirmed that a rise in discharge occurs which is
sustained throughout a 5 minute infusion of VIP (0.5 yg min-1) into
the carotid artery. The response to injected VIP was variable - low
doses (<0.25 yg) causing chemodepression, higher doses (>0.25 yg)
chemoexcitation (McQueen & Ribeiro, 1981a); infusion of the peptide
reduced chemoexcitation evoked by ACh, NaCN, or C02-equilibrated Locke
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solution, and also chemodepression evoked by [Met]enk.
1 .6 Scope of the present study.
The coexistence of peptides with classical transmitters (and ATP)
is now largely accepted (cf. Burnstock et al, 1979), as is the
occurence of receptors to different agents in the same tissue. In
particular, coexistance has been found in the adrenal medullary cells
(e.g. Schultzberg et al, 1978), and, more importantly, in the carotid
body (Lundberg et al, 1979a; Hansen et al, 1982).
The presence of neuropeptides and classical neurotransmitters in
the carotid body, together with their apparent importance in neuro¬
transmission in other parts of the nervous system, prompted the present
investigation of their effects upon carotid body chemoreceptors, and
this thesis includes experiments where the effects of the two types of
transmitter have been studied together. Attempts have been made to
clarify the actions of catecholamines, in particular NA, since there
is much dispute as to the effects of these transmitters and their
significance. Use has been made of newer and more selective agonists
and antagonists for determining the receptor types responsible for
the observed affects upon chemosensory activity, and as far as
possible the effects of these drugs upon the chemoreceptor responses
to physiological stimulation by hypoxia or hypercapnia (the natural







Experiments were performed on 11 adult male cats (weight range:
2.0-3.9 kg; mean weight [± s.e.m.]: 2.95 ± 0.17 kg; median weight: 2.9
kg) and 74 adult female cats (weight range: 2.2-4.0 kg; mean weight [±
s.e.m.]: 2.89 ± 0.05 kg; median weight: 2.9 kg), and 13 rabbits (male,
New Zealand white strain; weight range: 2.5-3.5 kg; mean weight [±
s.e.m.]: 3.05 ± 0.13 kg; median weight: 3.2 kg).
2.1 Anaesthesia.
56 cats were anaesthetised by intraperitoneal (i.p.) injection of
pentobarbitone sodium (Sagatal, 60 mg ml-1), 42 mg kg-1, supplemented
every one to two hours with 6-12 mg injected i.v. The other 29 cats
were anaesthetised with a-chloralose, 1$ in 0.9$ saline, injected
intravenously (i.v.) at a dose of 60-70 mg kg-1, following induction
of anaesthesia by inhalation of 5$ halothane in oxygen. Supplementat¬
ion of the anaesthetic was rarely necessary, but if required, a
further 40 mg was injected i.v. In five cats which were difficult to
manage, or distressed by handling, anaesthesia was induced with
halothane prior to injection of pentobarbitone.
Rabbits were anaesthetised with pentobarbitone sodium (Sagatal, '
60 mg ml-1, diluted 1:2 with 0.9$ saline), 30-40 mg kg-1, administered
through an ear vein, and supplemented as necessary.
2.2 General.
Experimental procedures employed were common to both cats and
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rabbits. Following a midline incision in the ventral aspect of the
neck, a tracheal cannula was inserted below the level of the larynx.
Both femoral arteries were cannulated with nylon catheters (external
diameter 1.34 or 1.65 mm). One catheter was connected to a blood
pressure transducer (Bell and Howell, 4-442), the signal from which
was displayed on an oscilloscope (Tektronix, 5103N), and simultan¬
eously recorded on a pen-recorder (Electromed, MX6) and on one channel
of an FM tape recorder (Tandberg 100; frequency response d.c. to 1250
Hz). The second catheter was used for the withdrawal of blood
samples for blood gas analysis, generally at hourly intervals, when
arterial blood pH, P02, and PC02 were measured using a Radiometer gas
monitor (BMS 3, with PHM 71 meter). Arterial samples were also
analysed after steady state had been achieved following a change in
the composition of inspired gases, or during some drug infusions, when
a minimum interval of 3 mins between samples was found to be most
practical.
A femoral vein was cannulated (as above) for the administration
of anaesthetic supplements, neuromuscular blocking drugs, drugs
soluble only in large volumes of solvent or in an acid medium, and
drugs with known membrane-stabilising properties.
Heart rate was monitored with an E.C.G. amplifier, the signal
being relayed to a loudspeaker and to one channel of the oscilloscope,
and in some experiments the output from the E.C.G. amplifier was also •
recorded on one channel of the tape recorder.
Rectal temperature was monitored continuously, and maintained at
38 ± 0.5°C by an electric heating blanket.
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2.3 Respiration and neuromuscular blockade.
Animals were artificially ventilated with room air by a respirat¬
ory pump (S.R.I.) , operating at 18-19 strokes per minute for cats, and
25 strokes per minute for rabbits. Stroke volume was adjusted so as
to maintain PaC02 in the region of 30-35 mm Hg, and end tidal C02,
continuously monitored by an infra-red C02 analyser (Med 1A, Grubb
Parsons), at 4-5$. Under such conditions, Pa02 was generally 90-100
mm Hg. The inspired gas was room air, but animals could be made
hyperoxic or hypoxic by ventilating with specific mixtures of oxygen
and nitrogen. The proportion of each gas was regulated using
calibrated flow-meters, with the gases being mixed in a reservoir
prior to administration to the animal. A 'standard hypoxia test' was
carried out by ventilating the animal with 10$ 02:90$ N2 for 4
minutes, followed by 100$ N2 for 1 minute, and recovery on 100$ 02 for
2 minutes. Hypercapnia could be induced by adding carbon dioxide to
the inspired gases, and by adding carbon dioxide to a mixture of 25-
30$ oxygen in nitrogen, PaC02 was raised with no significant change in
Pa02 from that measured during air-breathing.
Once a suitable recording of chemoreceptor activity was obtained,
spontaneous respiration was arrested by paralysing the animal with
gallamine triethiodide (Flaxedil, 40 mg ml-1), 3 mg kg-1 i.v., the
dose being repeated as required, usually when supplementing the
anaesthetic. Neuromuscular blockade was employed to prevent movement'
of the nerve on the recording electrodes as a result of spontaneous
muscle contraction, or muscle movements induced by close-arterial
injection of ACh, and to prevent spontaneous or drug-induced respir¬
atory movements which would alter arterial blood gas tensions.
Chemoreceptor discharge shows no marked variation when comparing
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results obtained in the spontaneously breathing, and the artificially
ventilated animal, nor does gallamine triethiodide appreciably affect
chemoreceptor activity evoked by NaCN or ACh (see McQueen, 1977).
2.H Dissection.
The carotid bifurcation was approached through the ventral
incision in the neck, and dissected free of surrounding tissues. A
nylon catheter (external diameter 0.63 or 0.75 mm) was inserted into
the lingual artery, and advanced until its tip lay in the common
carotid artery, 1.5-2.0 cm caudal to the carotid bifurcation. In some
experiments a second such catheter was inserted into the same common
carotid artery via the superior thyroid artery, the tip being advanced
caudally to terminate some 2.0-3.0 cm from that of the lingual
catheter. The dead-spaces of the lingual and thyroid catheters were
-0.1 and -0.2 ml respectively. The patency of either catheter, and
the effectiveness of its location could be confirmed by the injection
of a low dose of a chemoreceptor stimulant such as NaCN.
The lingual catheter was used for intracarotid (i.e.) administ¬
ration of drugs to the carotid body by injection or infusion; the
thyroid catheter was used for infusion of drug solutions whilst
allowing the injection of a second drug via the lingual catheter
simultaneously, thus permitting the combined effects of the two drugs
to be studied.
2.5 Recording of carotid sinus nerve activity.
The carotid sinus nerve ipsilateral to the catheterised common
carotid artery was identified distally to the carotid body at the site
of its junction with the glossopharyngeal nerve and cut centrally.
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Exposed tissues were covered with warmed (37°C) mineral oil. The
connective tissue outer sheath of the cut sinus nerve was stripped
back towards the carotid body and the exposed nerve was placed on a
small mirror to facilitate further dissection of fine filaments from
the nerve using fine (26G) needles and watchmaker's forceps.
Extracellular afferent electrical activity in filaments of the
nerve was recorded using bipolar platinum-iridium wire electrodes.
The original signal was amplified by a factor of 10,000 by passage
through an a.c. amplifier (Neurolog, Digitimer), displayed on the
oscilloscope, and recorded on one channel of the tape recorder. The
neural information being recorded on magnetic tape was constantly
monitored by relaying the signal to the tape recorder back to another
channel of the oscilloscope. The output from the amplifier was also
passed through a voltage discriminator, the number of action potent¬
ials of a selected amplitude counted, and converted to an analogue
signal proportional to the frequency of discharge, which was displayed
on the pen recorder.
Chemoreceptor units were identified by their irregular pattern of
discharge, their increase in frequency in response to: a) injection of
NaCN (2.5-5.0 pg) into the ipsilateral common carotid artery; b)
hypoxic ventilation with 105? 02 in nitrogen; c) asphyxia evoked by
tracheal occlusion, and by the substantial reduction in discharge
frequency during hyperoxia (ventilation with 1 005? 02). Single chemo-'
receptor units were identified from the constant shape and amplitude
of the superimposed action potential; such units are characterised
also by a delay of at least 7 ms between successive spikes (Biscoe and
Taylor, 1963). Twenty four recordings of single chemoreceptor units
were obtained in cats, and the majority of the other recordings were
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of two to four units, of which it was often possible to count one unit
separately. Recordings of chemoreceptor activity were obtained in
nine rabbits, but none of these was of a single unit.
In all experiments on cats the sympathetic innervation of the
carotid sinus region was eliminated by sectioning the ganglioglomer-
ular nerves (a group of distinct nerve fibres projecting from the
superior cervical ganglion to the carotid sinus region), in order to
prevent reflex effects of sympathetic activity upon carotid sinus
nerve discharge (e.g. Floyd and Neil, 1952; Eyzaguirre and Lewin,
1961). This procedure could not always be performed successfully in
the rabbit, since the ganglioglomerular nerves tend to be much less
discrete than in the cat, and these nerve fibres are also united with
the sinus nerve close to its point of exit from the carotid body, so
that sectioning of the sympathetic nerves also often results in
denervation of the carotid body (Docherty, 1980).
2.6 Drug administration.
Intracarotid (i.e.) injections were generally made in a volume of
0.1 ml into the common carotid artery, and washed in with 0.2 ml of
modified Locke solution which had been bubbled with 5$ C02 in air at
37°C. Injections were made at the peak of the inspiratory phase of
the respiratory cycle, and were accomplished within one respiratory
cycle. A period of at least three minutes was allowed between injec-'
tions, or longer if the drug under investigation was known to cause
tachyphylaxis. Other drugs were injected i.v. in an appropriate
volume, and the catheter flushed with 0.5-1.0 ml modified Locke
solution, or 0.9$ w/v saline. Infusions of drugs were made using a
Braun 'Unita' pump, at a standard rate of 0.1 ml min-1, and the amount
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of drug infused per unit time was determined by altering the concent¬
ration of the solution infused.
Control injections of 0.1 ml modified Locke solution equilibrated
with room air were made, and the catheter flushed with 0.2 ml Locke
solution bubbled with 5% C02 in air at 37°C. These injections were
made throughout each experiment, and served as a control to determine
the effect upon chemoreceptor discharge of the drug vehicle, and of
the injection procedure.
2.7 Drugs used.
Drugs were dissolved in modified Locke solution (millimolar
composition: NaCl, 102.7; KC1, 5.6; CaCl2, 1.6; Tris base, 49.5; pH
7.41 at 37°C) or, in the case of peptides and related substances, 0.9%
w/v saline. Rauwolscine was dissolved in saline containing an equal
weight of ascorbic acid, and domperidone, prazosin, and ICI 118,551
were dissolved in saline with the addition of a few drops of 0.1N HC1
and the application of gentle heating. ICI 174,864 was suspended in
half the final volume of saline and dissolved by addition of an equal
volume of saline containing an equivalent amount of L-arginine.
Prenalterol was obtained as a commercial solution ('Hyprenan') cont¬
aining 1.0 mg ml-1.
The drugs used, their sources, and details of their structures
and molecular weights are to be found in appendices 1 and 2. Doses
referred to in the text are those of the salt.
2.8 Data analysis.
The output of the tape channel containing the action potentials
was passed through a Neurolog filter module (d.c.-10 KHz with 50 Hz
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notch) and fed to a pulse height discriminator (W.P.I, model 120)
permitting the counting of selected action potentials. The number of
pulses occuring in 0.1 s intervals ('bins') was collected, and stored
in the memory of a PET 32 K microcomputer (Commodore, 303 series),
programmed to collect data over a specified period of up to 500 s.
Having initiated the collection of data, a marker was set to indicate
the point at which injection of a drug, or a change in inspiratory gas
was made. Data were stored on floppy disc and subsequently analysed
quantitatively using the microcomputer.
A computer-drawn plot of the frequency of action potentials as a
function of time was displayed upon the computer screen, from which
discharge was analysed in the 'control' (e.g. pre-injection) period,
and either subjectively (i.e. during periods when discharge appeared
to be increased or decreased with respect to control), or during
defined intervals, such as the first five seconds after injection of a
drug. When analysing the effects of injection of a drug, the control
period was taken as approximately 15 s immediately preceding the
injection. For injections of opioid peptides, which caused prolonged
depression of discharge, the 'test' period chosen was the first 30 s
after injection. In studying the effects of drug infusions, or of
changes in inspired-gas composition, collection of data was started 30
or 60 s prior to onset of infusion or ventilation with a selected gas
mixture, and discharge was then analysed in succesive 10, 15, or 30 s '
intervals.
The period 't' seconds, during which the computer was required to
process discharge frequency was delineated using a moving cursor,
which directed the computer to the memory-stored data represented upon
the screen. For each test the following calculations were performed
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by the computer:
i) Ex: the total counts (number of action potentials) occuring in the
period t seconds, for control and for test periods. Units: 'counts'.
ii) x c.p.s.: the mean counts per second occuring in each period t
seconds. Hence, x (control) = Ex(control)/t(control),
and x (test) = Zx(test)/t(test).
Units: 'counts per second' (c.p.s.).
iii) Ax: the difference in the mean discharge occuring in test and
control periods. Thus, Ax = x(test) - x(control). Units: c.p.s.
iv) Ax%: derived by expressing Ax as a percentage change from the
control mean discharge. Units: 'percent' (%).
v)AZx: the 'absolute difference' of discharge from control levels,
given by: AZx = Zx(test) - [x(control) x t(test)]. Units: 'counts'.
vi) max: the maximum number of action potentials counted in any one
second of a period t seconds. Units: 'counts'.
vii) Amax: the difference between the maxima determined in the test
and control periods. Units: 'counts'.
Of the above, iii, iv, and v may have negative values, where
there is a depression of discharge, and i, ii, and vi may be equal to
zero. Data integrated with respect to control (i.e. AEx) take account
of the two-dimensional character of responses, and both the magnitude',
and the duration of the induced change in discharge are included in the
analysis of the response (see McQueen, 1977). This parameter measures
the increment or decrement in discharge in the test period, relative
to the pre-injection discharge which, it is assumed, would have remain¬
ed constant in the absence of any modifying effect of the drug.
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Whenever possible, dose-response studies were performed and an
appropriate parameter expressing the change from control was plotted
against log10 dose. The range of doses over which the relationship
was approximately linear was determined by inspection and a straight
line fitted to the points in this part of the dose-response curve
either by eye, or, for greater precision, and more usually, by the
method of least squares. Where feasible, data from more than one
experiment were pooled, and the overall mean of parameters such as
IDS0 or ED30 (drug doses causing respectively a 505? reduction, or a
30% increase in discharge when compared to pre-injection control
discharge) were expressed as the arithmetic mean (x = Ix-j/n), ±
standard error of the mean (s.e.m.). Pooled data for measurements of
blood gas tensions were expressed similarly.
2.9 Analysis of hypoxia tests.
Discharge (x c.p.s.) was quantified in succesive 15 s periods
both before (control) and after the onset of hypoxia. Discharge reached
a 'plateau' or 'maximal level of discharge some 1.5 to 2 minutes after
the onset of hypoxia. The rising phase of the response was generally
a linear function of time, and a straight line was fitted to this part
of the response using the least squares method. In any experiment
the plateau discharge during steady-state hypoxia (105? 02) before the
administration of antagonists was arbitrarily defined as 100?, and the
other levels of discharge measured at different phases of the test
were expressed as a percentage of this value. The gradient of the line
reflecting the rate of rise of chemoreceptor discharge was calculated
in terms of % max s-1, and was used as an index of chemoreceptor
responsiveness. The time taken to achieve maximal (plateau) discharge
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was also measured.
2.10 Statistical treatment of results.
In order to determine whether changes in discharge observed were
statistically significant, responses were compared with appropriate
controls, using the non-parametric Mann Whitney test or Student's t-
test (when data could not be paired), and the Wilcoxon signed ranks
test (when the number of pairs exceeded seven) or Student's paired t-
test (when there were less than six pairs of results; cf. Colquhoun,
1971; Sard, 1978). The null hypothesis was rejected at the level of P
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SECTION 3
STUDIES ON THE EFFECTS OF INJECTION OF NORADRENALINE AND
SELECTIVE ADRENOCEPTOR AGONISTS AND ANTAGONISTS UPON CHEMORECEPTOR
ACTIVITY IN THE CAT.
3.1 Introduction.
Catecholamines are present in the cat carotid body (see Section
1) where, it has been suggested, NA is predominant (Mills et al,
1978). A more recent study (Mir et al, 1982) confirmed that NA is
present in substantially greater amounts than DA in the carotid body
of the cat and the guinea-pig (and perhaps in the rat), with the
reverse distribution in the rabbit and the ferret. Evidence already
cited suggests that in the cat a large amount of the total catechol¬
amine content of the carotid body is derived from the cellular
component rather than from the sympathetic nerve terminals. In the
rat, at least, it appears that much of the NA is contributed by the
sympathetic nerves (Mir et al, 1982). In vitro experiments have
indicated that, in the absence of a functioning vasculature, the
carotid chemoreceptors are not affected by the catecholamines ADR and
NA (see Section 1), but both substances tend to cause chemoexcitation
in vivo, which has generally been attributed to actions mediated by
vascular a-adrenoceptors (e.g. Sampson, 1972; Llados & Zapata, 1978b),'
causing localised stagnant hypoxia (Joels & Neil, 1963). g-selective
adrenoceptor agonists also cause chemoexcitation and according to
some workers (Biscoe, 1965; Folgering et al, 1982) B~selective
antagonists reduce the chemoexcitatory effects of ADR, NA, or ISO.
Furthermore, Folgering and co-workers (1982) reported that the
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response of chemoreceptors to hypoxia was greatly reduced or even
abolished by g-antagonists, leading to the proposition that g-mediat-
ed catecholarainergic mechanisms are important, if not fundamental, to
the processes of ohemotransduction. It has been argued (Zapata et al,
1969) that the results of Biscoe (1965) could equally well be a
result of non-specific nerve block consequent to membrane-stabilisat¬
ion by the g-antagonist DCI.
Early reports often describe a transient depression of discharge
preceding NA-evoked chemoexcitation, which has, more recently, been
shown to be a 'non-specific' action of NA at DA receptors mediating
chemodepression (e.g. Folgering, et al; 1982). It should be noted
that, according to some earlier reports (cf. Section 1), chemodep¬
ression caused by DA was blocked (albeit non-specifically - Llados
& Zapata, 1978b) by a-antagonists.
The present experiments were designed to determine which adreno¬
ceptor subtypes could mediate the response of chemoreceptors to
exogenously applied NA, and whether they might play some role in the
chemoreceptor response to natural stimulation such as hypoxia. The
following agonists and antagonists were employed, their commonly
accepted selectivities for receptors (cf. Fig. 3.1) being indicated
in parentheses: agonists - NA (cXi/c^/Si), phenylephrine (PHEN; ax ),
oxymetazoline (OXM; a2) - Starke et al, 1975a,b; isoprenaline (ISO;
gi/$2 ~ Konzett, 19^0 a,b; Lands et al, 1967a.b), dobutamine (DOB; g, - '
Tuttle & Mills, 1975), prenalterol (PREN; gx - Carlsson, et al, 1977b),
and salbutamol (SAL; g2 - Brittain et al, 1968); antagonists - coryn-
anthine (COR) and rauwolscine (RAU; a, and ct2 respectively - Weitzell
et al, 1979), metoprolol (MET; gj - ^blad et al, 1975), betaxolol
































Figure 3.1. Schematic representation of the range of actions of
agonists and antagonists.at adrenoceptors. Width of bar gives an
indication of the occurance or otherwise of an effect at that sub¬
class of receptor. (0l : ADR>NA ,PHEN»ISO; ct2 : 0XM>NA>>IS0;
31.: ISO>NA£ ADR>>SAL; S2: SAL£ISO>ADR>>NA - cf. Lees, 1981).
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and domperidone (D2-antagonist - Baudry etal, 1979).
3.2 Results.
3.2.1 Chemoreceptor responses to noradrenaline.
NA was injected into the common carotid artery in 53 cats, where
the effects a wide range of doses (0.001-100 pg i.e.) were studied. No
clear changes in chemoreceptor discharge were noted with doses of NA
less than 0.5 pg; at higher doses the chemoreceptor response was
characteristically biphasic. An initial depression of discharge was
followed by a period of increased activity which, in some experiments,
could be separated into two characteristically different phases (cf.
Fig. 3.2). All components of the response were highly variable bet¬
ween experiments making quantitative analysis of chemoreceptor
activity difficult and of questionable relevance (see Section 10).
3.2.1.1 Initial chemodepression.
An initial phase of chemodepression was observed in all experi¬
ments where the effects of injected NA were studied, and it was
markedly greater than the artefactual depression of discharge
occasionally associated with the injection of the drug vehicle (Locke
solution - see Section 2). The threshold for chemodepression was
about 1-5 pg, and the latency of onset very short, depression of dis-'
charge usually being seen to commence during or upon completion of
the injection. The magnitude of this chemodepression was always less
than that seen after i.e. injection of equivalent doses cf DA (see
Figs 3-3, 3-h, 3.5, 3-7). Depression of chemosensory activity was
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Figure 3*3. Effects upon chemoreceptor discharge and femoral
arterial blood pressure of i.e. injections (at arrows) of NA: A, 1
pg; B, 5 ug; C, 10 Mg, and D, DA, 1 yg. A ramped counter output below
each neurogram shows the number of action potentials counted in
successive 0.1 s intervals. In this experiment chemoexcitation was
more apparent after injecting 5 and 10 pg NA and was temporally
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Figure 3-4. Analysis of data obtained in a single experiment.
Magnitude (AZx - top panels) and duration (s - lower panels) of the
ohemoreceptor response to i.e. injection of NA (• •) and DA (■ - ■ ) ,
plotted against log10 dose, before (control) and after (DP 10)
injection of domperidone, 10 pg kg-1 i.e.
^ = effect of injecting Locke solution, 0.3 ml. Lines were fitted
by eye to give a better assimilation of the data points.
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Figure 3.5. (1) Responses of 2-3 chemoreceptor units to i.e.
injection of NA (•) and DA (A). Immediate chemodepression (-AEx)
plotted against dose, before (A) and after BET 0.1 (B), 1 (C), and
2.12 (D) mg kg-1. Open circles denote effects of injection of Locke
solution, 0.3 ml.
Chemodepression was potentiated after increasing doses of antagonist,
as a consequence of the marked increase in duration of the response
shown in part (2) of the figure, where duration (in seconds) of the
chemodepressant effect is plotted against dose, before (A) and after
BET 0.1 (B), 1 (C), and 2.12 (D) mg kg-1. Lines were fitted to the
data points by eye.
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cps
Figure 3*6. Computer-drawn plots of frequency of chemoreceptor
discharge and the effects of i.e. injection (at arrows) of Locke
solution, 0.3 ml, and NA 1, 5, 10, 25, and 50 pg. With higher doses
of NA there were two distinct excitatory components to the response,
the first of which (marked with an asterisk) became less distinct as
the dose injected was increased. The tendency for a progressive
increase in the basal rate of discharge should also be noted. Data
are from a single experiment.
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during which discharge frequency gradually increased towards pre-
injection control levels. The magnitude of the overall response (AEx)
was commonly log-linearly related to the dose of NA, as was the
duration of the effect (Fig. 3.4).
3.2.2 Chemodepressor effects of selective adrenoceptor agonists.
Much evidence from previous reports (cf. Section 1) suggested
that NA-evoked chemodepression was mediated by DA-receptors, but it
had also been suggested that a-antagonists could block DA-evoked
chemodepression (e.g. Sampson 1972) or potentiate chemodepression
caused by NA (e.g. Llados & Zapata, 1978b). The capacity of selective
adrenoceptor agonists to elicit depression of discharge was examined
to determine whether part of the chemodepression evoked by NA could
be explained by effects at receptors other than DA-receptors, bearing
in mind the possibility that chemodepression in response to NA could
result from release of endogenous DA by NA (cf. Krammer, 1978).
Two a-selective agonists were studied. OXM (a2; 0.1-200 pg i.e.)
was virtually devoid of any chemodepressant activity (Fig. 3.11),
causing no chemodepression in three experiments (60$) and transient,
non-dose-dependent chemodepression in two (40$).
In nine experiments PHEN (cxx; 1 pg - 2 mg i.e.) only occasionally
caused chemodepression; the effect was small but did show some
evidence of being dose-dependent (Fig. 3.12).
Of the g-selective agonists examined (cf. Figs 3-12, 3.13) ISO
(Bi/S2I 0.01-100 pg i.e.) injected in seven experiments, SAL (82; 0.1
pg - 1 mg i.e.) in thirteen experiments, and PREN (Si; 0.1 pg - 1 mg
i.e. or (n=1 )f 5 mg i.v.) in three experiments did not cause depression
of discharge other than a small inconsistent effect comparable to the
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artefactual chemodepression occasionally associated with vehicle
(Locke solution) control injections.
Dose response data for DOB, an hydroxylated aryl-alkyl derivative
of DA with putative gj-receptor selectivity, were obtained in one
experiment, where injection of 1-50 yg i.e. caused mild chemodepres¬
sion of almost constant magnitude and duration, but greater than that
caused by injection of Locke solution (cf. Table 3.1). In a separate
experiment i.e. injection of 100 yg DOB caused marked depression of
discharge (-86% reduction from pre-injection control) lasting some two
minutes.
3.2.3 Effects of antagonists upon NA-evoked chemodepression.
In eight out of nine experiments (89%) domperidone (DP; 10-100
yg kg-1) blocked NA-induced chemodepression together with that evoked
by DA (Fig. 3.4).
NA-evoked chemodepression was also partially reduced by the a2-
selective antagonist RAU (1 mg kg-1; n=2 - see Figs 3.24 and 3.25),
under which conditions the chemodepression caused by DA was also
slightly reduced.
The g-antagonists BET and MET at high doses (e.g. 1 mg kg-1 or
more) tended to potentiate both NA- and DA- evoked chemodepression.
This potentiation was due to a marked prolongation of the period of
chemosensory depression (cf. Figs 3.5, 3.14, 3.15, 3.18). Even when •
so potentiated, chemodepression was abolished by subsequent administ¬
ration of DP or RAU.
3.2.4 Chemoexcitatory responses to MA.
Some degree of chemoexcitation followed chemodepression in all
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experiments, although this part of the response was feeble in some
recordings and intense in others. Close inspection of the response
shows it to consist of two components which may be designated Ex and
E2 , Ex-type excitation preceding E2-type. The excitatory component of
the response to NA was analysed in terms of AEx, Ax?, Amax (see
Section 2), and the duration of the response; Ex-excitation could not
generally be analysed separately because of the narrow range of doses
of NA that clearly elicited the response, and because it appeared to
be obscured by chemodepression or E2-excitation at higher doses.
E^excitation could be clearly identified in 35 (67.3?) of the
recordings, but only at lower and mid-range doses of NA (Figs 3.2,
3.6). This phase of intense excitation was of short duration, lasting
only a few seconds, and appeared to occur at the time when blood
pressure and heart rate were actually increasing in response to NA.
According to dose, Et-excitation could appear as a transient burst of
action potentials briefly interrupting the period of chemodepression
and separate from E2-excitation (e.g. Fig. 3-2); in other instances,
this type of excitation preceded E2-excitation as a distinct event,
but with higher doses (Fig. 3.6) it became merged into, and indistin¬
guishable from the more delayed E2-excitation. When analysed in terms
of AEx, Ax?, or AmaXj Ex-excitation was inversely related to dose (Fig.
3.7).
E2-excitation was observed in all recordings, although the
magnitude of the response quantified by the parameter AIx was highly
variable between experiments. The onset of this chemoexcitatory
effect of NA appeared to be delayed until the establishment of
equilibrium after the rapid rise in blood pressure, and the stabilis¬
ation of diastolic and systolic pressures (cf. Figs 3.2 and 3.3) at
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Figure 3.7. Responses of two chemoreceptor units to i.e. injec¬
tions of NA.
A: AZx for NA-evoked chemodepression and E2-excitation (•), NA-evoked
Ej-excitation (a), and DA-evoked chemodepression (■) plotted against
dose (note scale of the ordinate applied to E^excitation).
B: The same results expressed in terms of Ax$,related to dose.
C: Maximum discharge in the pre-injection control period (0), the
period of NA-evoked E2-excitation (•), and of Ej-excitation (a),
plotted against dose.
D: Mean discharge in the pre-injection control period (0), the period
of NA-evoked E2-excitation (•), and of Ej-excitation (a), plotted against
dose.
E: Duration of chemodepression (a), E^chemoexcitation (a), and E2-
chemoexcitation (•) evoked by NA, plotted against dose of NA.
0 or ♦ = effect of injecting Locke solution, 0.3 ml. Lines were fitted
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the maxima attained in response to NA.
In general Ax% appeared to be a poor index of the dose-dependency
of chemoreceptor responses (e.g. Fig. 3.8A) since the change in mean
discharge frequency, compared to pre-injection control frequency, was a
near-constant function of dose. An obvious dose-dependency of the
magnitude of the response emerged when discharge was integrated with
respect to pre-injection control discharge (AZx; Fig. 3.8A); this was
related to dose in virtually all experiments. The integrated response
takes account not only of changes in discharge frequency but also of
the duration of the response,which was found to be a linear, or more
often, an exponential function of dose (Fig. 3.8D). The 'excitability'
of the c'nemoreceptors was not obviously related to dose in these
experiments since the parameters Amax (cf. Fig. 3.8B) and the drug-
evoked increase in mean discharge (Ax) were not dependent upon dose.
These measures of chemoreceptor excitation usually showed a small but
constant increase, with no apparent dependency upon dose of NA.
Where the two excitatory components could be studied separately
the magnitude of the integrated response for E2-excitation was greater
than that of the E,-type (Fig. 3.7). due to the considerably longer
duration of the more delayed type of excitation (Fig. 3.7E).
With lower doses of NA E,-type excitation appeared to be the
major component of the overall excitatory response to NA, whilst E2-
effects predominated at higher doses (cf. Fig. 3.9).
After administration of DA-antagonists such as DP it has often
been noticed that there is an increase in basal discharge frequency
(e.g. McQueen, 1984). After DP NA-induced chemoexcitation was charac¬
terised by an increase in the excitability of the chemoreceptors, as
shown by the emergence of a larger and clearly dose-dependent increase
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Figure 3.8. Analysis of the response of 2-3 chemoreceptor units to
intracarotid injection of NA.
A: AEx (•) and Ax$ (0) for the chemodepression and chemoexcitation
evoked by NA, plotted against dose. For both depression and excitation
AIx increases (positively and negatively respectively) as dose is in¬
creased, whilst Ax$ remains largely a constant function of dose.
B: Maximum number of action potentials counted in any one second of
the control period (0) and of the NA-evoked excitation (•), plotted
against dose.
C: Mean discharge in the pre-injection control period (0), and in the
period of increased discharge following injection of NA (•).
D: Duration of the chemodepression evoked by NA (□), and chemoexcitat¬
ion (•) which follows NA-evoked chemodepression, plotted against dose.
0 or ♦ = effects of injecting Locke solution, 0.3 ml. Lines were
fitted by eye, to give a better assimilation of the data points.
i
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Figure 3-9. Responses of a single chemoreceptor unit to the i.e.
injection of NA.
A: Integrated chemodepression and E2-excitation evoked by NA (•—•)
plotted axgainst dose. Also included is the Ex-type chemoexcitation
evoked by 1, 5, and 10 pg of NA (A - A).
B: Ax$ for NA-evoked chemodepression, E2-chemoexcitation (•), and
E!-excitation (A), expressed as a percentage change from pre-injec-
tion control discharge, and plotted against dose.
C: Maximum discharge (in any one second), and D, mean discharge
frequency (per second) for pre-injection control (0), E2-excitation
(•), and Ex-excitation (A) plotted against dose.
E: Duration of the chemodepression (□) and the overall (gross)
excitation (•) evoked by NA, plotted against dose.
0 or ♦ = effect of injecting Locke solution, 0.3 ml. Lines were fitted
by eye to give a better assimilation of the data points.
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in Amax and Ax (Figs 3.10, 3.16).
3.2.5 Chemoexcitatory responses to selective adrenoceptor agonists
and the effects of selective antagonists.
Since NA is a non-selective agonist with potential to activate
ai~> <*z~ > or Si- receptors, the capacity of putatively more selective
adrenoceptor agonists to cause excitation of the chemoreceptors was
examined to determine the possible contribution to the NA-evoked
response of effects mediated by particular receptor subtypes.
3.2.6 Effects of q-selective agonists and antagonists.
3.2.6.1 Phenylephrine (ct,-agonist) and corynanthine (c^-antagonist).
In nine cats PHEN(1 pg - 2 mg i.e.) caused only slight changes in
chemoreceptor discharge, including variable but insignificant chemoex-
citation (following depression, if present - see Fig. 3.12), which did
not appear to increase with dose. Although this feeble excitatory
effect was commonly, though not always, inversely related to dose (cf.
Fig. 3-12) it was not comparable to Ej-excitation evoked by NA (see
above), being neither intense nor transient. The maximal discharge
(Amax) evoked by PHEN was much smaller than that following injection
of NA. Delayed dose-related chemoexcitation concomitant with the
marked hypertensive increase in systolic and diastolic blood pressure'
was not observed in any experiment, although the pressor responses to
PHEN (see later) were as great as those elicited by similar doses of
NA.
The (*!-selective antagonist COR (0.1-1 mg kg-1 i.e.) was injected
in four cats; small chemoexcitatory responses to NA injection (in part-
- 95 -
Figure 3.10. Effects of DP (0.1 mg kg-1) and MET (2.9 mg kg-1) upon
responses of a single chemoreceptor unit to i.e. injection of NA.
Top panels: Chemodepression and chemoexcitation quantified in terms of
AEx, and plotted against dose. Chemodepression was reduced by DP;
chemoexcitation was enhanced by DP, and reduced by MET.
Second row: Maxima (per second) for control (0) and NA-evoked chemoex¬
citation (•). Before antagonists, excitation in response to NA was
largely unrelated to, or a near-constant function of dose. After DP
background discharge increased, as evidenced by the increase in
maximum discharge, and the maximum for NA-evoked excitation became
more dose-dependent. Both maxima were reduced by MET.
Third row: Amax plotted as a function of dose.
Bottom panels: Duration of the NA-evoked chemodepression (a), and
chemoexcitation (•). The duration of both phases of the response to
NA were generally reduced, and less dose-dependent following DP, with
no appreciable further changes observed after injecting MET.
Lines were fitted by eye to give a better assimilation of the data
points.
 
icular E1-type) still occurred after this antagonist (cf. Figs 3.16,
3.25), and biological activity of the drug was gauged from its
antagonism of PHEN-induced hypertension and its partial blockade of
the pressor effects of NA (see later).
3.2.6.2 Oxymetazoline (q7-agonist) and rauwolscine (q2-antagonist).
OXM (0.1-200 yg i.e.) was injected in five cats. Chemoexcit-
ation was evoked by injections of OXM in three experiments, the
threshold dose being in the order of 10 yg (Fig. 3.11), but, in common
with NA, quantification of the response was highly varied when differ¬
ent experiments were compared. As with NA there was some evidence
in the one experiment where tested (Fig. 3-11) of potentiation of
chemoexcitation evoked by this agonist, after injecting BET (see
below).
The antagonist RAU (0.01-4 mg kg-1) was injected in ten experi¬
ments; chemoexcitation in response to NA injection was still apparent in
five out of six (83?) of the recordings where it was possible to
examine the effects of NA after the antagonist (e.g. Fig. 3.25), but
the excitatory effects of OXM were reduced or abolished (Fig. 3.11).
3.2.7 Chemoexcitatory responses to g-adrenoceptor agonist3 and the
effects of selective g-adrenoceptor antagonists.
3.2.7.1 Effects of isoprenaline (gt/6? agonist).
Injection of ISO in seven cats caused a general increase in chemo-
receptor discharge, without any initial depression. The effect was
neither rapid nor intense, unlike the early (Ej) excitation frequently
evoked by NA, but was comparable to the prolonged E2-type excitation
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Figure 3.11. Effects upon chemoreceptor discharge of injecting OXM,
1-200 pg i.e.; the major component of the response was chemoexcitation,
which followed a small, non-dose-dependent depression of discharge.
A. Responses (from a single experiment) integrated with respect to
pre-injection control discharge.
B. Amax for the excitatory component of the response.
Qualitatively similar excitatory responses were obtained in a separate
experiment, although there was no initial depression of discharge:
C. Responses integrated with respect to pre-injection control
discharge, before (0) and after BET 100 pg kg-1 (♦) , RAU 100 pg kg-1
(•) and RAU 1 mg kg-1 (■).
D. Amax for the excitatory response, showing a potentiation after
BET, and attenuation after administration of RAU.
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seen in response to NA. The onset and duration of ISO-evoked excitat¬
ion was concomitant with dose-dependent systemic hypotension (see
later), and could persist for several minutes, according to dose. In
two experiments dose-response data were obtained over a range of 0.001-
100 yg, and chemoexcitation occured with doses as low as 0.1 yg. In
both experiments AEx was dose-related although the correlation was
poor in one. The parameter Amax was an approximately linear function
of dose, in contrast to changes in Amax seen after NA (Fig. 3.12).
After ISO injections basal discharge appeared to be 'reset' at a
slightly higher frequency than in the pre-injection control, even though
blood pressure returned to near control levels.
3.2.7.2 Effects of Bi-selective agonists.
The DA-derivative DOB was studied in three experiments, and the
chemodepressant effects of this drug have been described above. No
chemoexcitation occured in response to injecting 1-100 yg (i.e.), nor,
in one experiment, to 5 mg of the drug injected intravenously.
The effects of PREN (gt) were studied in three cats over the
range 0.1 yg - 1 mg i.e., or, (n=1) 5 mg i.v. Dose response data
were obtained in one experiment where integration of the responses
showed a small excitatory effect, largely unrelated to dose (Fig.
3.13), following chemodepression. The parameter Amax was log-linearly
related to dose, even though the effect was small. Injection of 5 mg '
of the drug intravenously caused no obvious significant change in
chemoreceptor discharge (Fig. 3.13).
3.2.7.3 Effects of the gt-antagonist metoprolol.
The effects of MET upon chemoreceptor responses to NA were
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Figure 3-12. A. Integrated responses of chemoreceptors, in the same
experiment, to i.e. injection of PHEN (0—0), ISO (■--■) and SAL
(• •) plotted on the same log-molar scale. Dose-related chemodep-
ression for the response to PHEN was greater than that seen in
response to g-agonists, which may be considered to be artefactual. ISO
was more potent in stimulating excitatory responses than was SAL, and
excitation evoked by PHEN was weak, and inversely related to dose.
♦ denotes effects of injecting Locke solution, 0.3 nil; lines were
fitted to the data by the method of least squares.
B. Amax for excitatory responses to PHEN (0—0), ISO (■--■) and
SAL (• —■ •) plotted on the same log-molar scale. Data points in
parentheses were omitted when calculating coordinates of the straight
lines by the method of least squares.
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Figure 3-13. Response of chemoreceptors to injection of PREN (0.1-
100 pg i.e.).
A. Integrated response (AEx) for initial chemodepression and sub¬
sequent chemoexcitation plotted against dose.
B. Amax during excitation plotted against dose. The line was fitted
to the data by the method of least squares.
C. Effects upon end tidal C02 (ET C02, calibration 0-3.2?) femoral
arterial blood pressure (BP, mm Hg) and chemoreceptor discharge
(c.p.s. - analogue signal proportional to rate of discharge) of
injection of PREN, 5 mg i.v. Although blood pressure was increased
transiently, during and immediately after the injection, chemorecep¬
tor discharge was not obviously affected.
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studied in nine experiments. The range of doses used was 0.1 pg - 1
mg, and this was extended to a maximum dose of 3 rag kg-1 in one
experiment.
Although the rate of chemoreceptor discharge usually decreased
after injection of the antagonist, quantitative analysis of the
altered chemoexcitatory response to NA was not comparable between
experiments. When expressed in terms of AZx, NA-induced chemoexcitat-
ion was decreased after MET. The threshold dose of antagonist after
which the excitatory response appeared to be reduced varied between
experiments. MET was effective at doses of 1 pg kg-1 (n=1), 100 pg
kg-1 (n=1), or 1 mg kg-1 (n=2) (see Fig. S.I1*)- This reduction of AZx
was generally associated with a decrease in Amax and Ax (Fig. 3.14),
but with variable changes in the duration of the excitatory phase.
Low doses of MET (1-10 pg kg-1) were frequently followed by an
enhanced chemoexcitatory response to NA both in the absence of DP
(Fig. 3-14) or following prior administration of DP. This was coin¬
cident with an elevation of resting heart rate (accompanied by a
decreased chronotropic response to injected NA - see later) following
low doses of MET.
In experiments where Er- and E2- type excitatory responses to NA
could be studied separately E^excitation appeared to be largely unaf¬
fected by MET, whilst the later E2-excitation was more susceptible to
blockade by this antagonist. Ej-excitation appeared to persist after'
MET, even when chemodepression was more marked (Fig. 3.1*0; under such
circumstances quantitative analysis of this 'excitation' with respect
to the pre-injection control may result in negative values of AZx,
Amax, or Ax, even when it is clear that the chemoreceptors are
being excited, albeit transiently (Fig. 3.15).
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Figure 3.m. Responses of a single chemoreceptor unit to NA (1-100
pg i.e.), before (A) and after (B-E) injection of MET (0.1-3 nig kg-1
i.e.).
Top panels: Chemoreceptor discharge during chemodepression and
chemoexcitation integrated with respect to pre-injection control
discharge (AEx), and plotted against dose. Chemodepression was
enhanced following higher doses of the antagonist whilst excitation
was reduced.
Second row: Amax for the chemoexcitation evoked by NA. This parameter
was increased after a low dose of antagonist, but reduced (at mid-
range doses of NA) following higher doses of MET.
Third row: Duration, in seconds, of the chemoexcitatory response.
Fourth row: Duration, in seconds, of the chemodepressor response,
showing a general tendency to increase with successive doses of
antagonist.
Bottom panels: Ax for NA-evoked chemoexcitation, which was increased
after a low dose of the antagonist, and reduced by higher doses.
Arrows indicate the effect of injecting Locke solution, 0.3 ml.
Lines were fitted to the data by eye.
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CONTROL MET 3mg
Figure 3«15. Computer-drawn plots of chemoreceptor discharge
(single unit recording) as a function of time. Responses to i.e.
injections of NA 10, 50, and 100 pg are shown before and after MET 3
mg kg-1. NA-evoked chemodepression was greatly prolonged after the
antagonist, although depression of discharge was less absolute than in
the control. Asterisks denote a presumptive 'E j, '-excitation occuring
during the period of reduced chemoreceptor discharge. Data were
collected over 90 or 120 s, as indicated, and the pre-injection
control period is delineated by the vertical lines below each plot.
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'Reversal' of the MET-blockade of NA-induced chemoexcitation
(i.e. prominent chemoexcitation occured once again in response to
injection of NA) was noted following injection of ICI 118551 (n=3; cf.
Fig. 3.16) or RAU (1 mg kg-1 - n=1).
3.2.7.4 Effects of the gx-antagonist betaxolol.
The chemoreceptor response to NA was studied after BET in seven
experiments. The effects upon basal chemoreceptor discharge were
variable, with either a slight increase or decrease, or no significant
change in frequency being noted.
In the absence of other antagonists (n=4) the administration of
BET 1-10 or even 100 yg kg"1 was followed by an enhanced excitatory
response to injected NA. Where they could be separately identified
both E!- and E2- excitatory components of the response to injected NA
were potentiated after these lower doses of antagonist (Fig. 3*17),
Amax being most obviously increased. Raising the dose of BET to 1 mg
kg-1 or more resulted in the attenuation or abolition of E2-excitation,
whereas Ex-excitation persisted as a near constant function of dose
(Fig. 3.1T), and continued to be a characteristically 'intense' effect
(cf. Fig. 3.18).
Two features of this persistent chemoexcitation are worthy of
note. First, it occured during the period of enhanced MA-evoked
chemodepression which followed high doses of BET. Second, the effect'
was either an intense and transient excitation, when discharge frequen¬
cy clearly exceeded that of the pre-injection control period, or it
was a small, but none-the-less identifiable entity (cf. the similar
response after MET, Fig. 3.15), and although discharge frequency was
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Figure 3.16. A and B: Responses of two different recordings , in
the same animal, to i.e. injection of NA; in the second recording,
results were obtained also after DP (10 yg kg-1), MET (1 mg kg-1),
ICI 113551 (•; 1 mg kg-1) and, finally, COR ( ♦; 1 rag kg-1 - plotted
on the same axes as the results after ICI 118551). Data are presented
as integrated responses (AEx), Amax, and the duration of the excitat¬
ory effect.
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Figure 3.17. Excitatory responses to NA in an experiment where both
types of excitation could be analysed separately. Early Ex-(open
circles) and delayed E2-(closed circles) components are plotted
__
against dose; data are presented for the changes in (A) Amax, (B) Ax,
(C) AEx, and (D) duration of the response.
Duration of Ei-excitation was a near-constant function of dose, unlike
that of E2-excitation. The excitability of the system (e.g. Amax),
contributing to the magnitude of AIx was decreased by increasing
doses of the antagonist BET (0.1-5 mg kg-1), with respect to E2-
excitation, whilst Ej-excitation remained largely unnaffected.
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Figure 3.18. Computer-drawn plots of chemoreceptor discharge as
a function of time. Responses to injection of Locke solution, 0.3 ml,
and NA 1, 5, 10, 25, 50, and 100 pg i.e. are shown, before and after
BET 0.1 and 5 mg kg -1, in the same experiment. A solid asterisk
denotes Ei-excitation, and an unfilled asterisk denotes an Ex-
excitation occurring during the period of chemodepression, and for
which small or negative values of parameters such as Amax may be
obtained (cf. NA 50 pg , after BET 0.1 mg kg-1) when comparing with
the pre-injection control. The paired vertical lines beneath each
illustration delineate the pre-injection control period.
Calibration of the ordinate in each case is in counts per second
(c.p.s.). Data collection was for 90 s, or 120-180 s, as indicated.
(continued)




























Figure 3.18. Computer-drawn plots of chemoreceptor discharge as
a function of time, from the same experiment as shown previously.
Responses to injection of (A) DA 10 yg and (3) SAL 50 yg, before
(CONT) and after 3ET 0.1 and 5 mg kg -1. The paired vertical lines
beneath each illustration delineate the pre-injection control period
Calibration of the ordinate in each case is in counts per second
(c.p.s.). Data collection was for 90 s.
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were linearly related to dose (though negative in sign, with respect
to control),
3.2.7.5 Effects of salbutamol (82-agonist) and ICI 1 18551 (3..-ant¬
agonist) .
Single injections or the injection of a range of doses of SAL
(0.1 pg - 1 mg i.e.) in thirteen cats caused chemoexcitation. Eight
dose-response curves for the SAL-evoked chemoexcitation were obtained
(Fig. 3.19), and there was a linear relationship between AEx and dose
in seven (88)5). There was, however, considerable variation in the
magnitude of the response between experiments. Mean discharge during
chemoexcitation,expressed as a percentage change from pre-injection
control, did not show such a clear dependence upon dose (cf. Fig. 3.20
[2]). The disparity between pre-injection control and post-injection
max discharge frequencies (Amax - Fig. 3.20 [3]) did not obviously
increase with dose (but see Fig. 3.22). When the mean discharge
frequency of the pre-injection and SAL-evoked chemoexcitation were
plotted on the same axes (Fig. 3*20 [5]), it can be seen that though
there was a tendency for background discharge to increase the change
in mean frequency evoked by SAL was nearly constant; thus AEx was
predominantly a function of the duration of the response (Fig. 3-20
[4]) rather than of mean frequency, as was also observed with NA.
Chemoexcitation evoked by SAL was not consistently altered
following injection of the 82-antagonist ICI 118551 (0.1 or 1 mg kg-1
i.e. or i.v.). ICI 118551 substantially reduced SAL-evoked chemo¬
excitation in one experiment only (Fig. 3.21 A,B), and in two other
experiments caused no obvious change (e.g. Fig. 3.22), or a slight
potentiation of the effect. The 8,-selective antagonists BET or MET
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Figure 3-19. Eight sets of dose response data for the integrated
response of chemoreceptors, in separate experiments, to i.e. injection
of SAL, plotted on the same axes. Lines were fitted to the data by
the method of least squares.
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Figure 3-20. Cheraoreceptor responses to SAL recorded in two
separate experiments (A and B): both recordings were of multiple
units, and data are plotted against dose.
1. Chemoexcitation integrated with respect to pre-injection control.
2. Mean discharge during chemoexcitation expressed as a percentage
change from pre-injection control.
3. Amax, showing no clear dependency upon dose.
4. Duration of the response (in seconds).
5. Mean discharge during pre-injection control (open symbols) and
during drug-evoked excitation (closed symbols) showing the general
progressive increase in background rate of discharge, and the relative¬
ly small, constant increase in discharge evoked by SAL.
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Figure 3.21. A. Integrated responses of chemoreceptors to SAL (1-
100 yg i.e.) before (0) and after (•) ICI 118551 (100 yg kg"1, i.e.).
The antagonist clearly reduced the excitatory response to the drug.
B. Amax in the same experiment, showing no clear dose-relationship
either before, or after the antagonist, but an obvious reduction in
magnitude following ICI 118551.
C. Integrated response of chemoreceptors to injection of SAL (5-500 yg
i.e.) in a separate experiment, before (0) and after ICI 118551 100 yg
kg-1 (•) and 1000 yg kg-1 (♦), showing no attenuation , but perhaps a
slight potentiation of the response. After injection of MET (100 yg
kg-1; □) chemoexcitation evoked by SAL was markedly attenuated.
D. Amax for the same responses as those presented in (C), showing
only slight dose-dependency, and slight reduction of the effect by ICI
118551, and a much larger reduction after MET.
'L* denotes the effect of injecting Locke solution, 0.3 ml i.e. The
straight lines fitted to the data were determined by the method of
least squares.
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Figure 3.22. Dose response data from a single experiment for i.e. in¬
jections of NA (0.5-25 pg) and SAL (1-50 yg), before (0) and after
(•) ICI 118551 (100 yg kg-1). Chemodepression was evoked only by NA,
and both parts of the integrated response to NA were potentiated by
the antagonist, whilst the integrated response to SAL was not markedly
altered.
$ or ♦ denotes the effects of injecting Locke solution, 0.3 ml.
Duration of the response [t(s)] was approximately log-linearly
related to dose in the case of SAL, and remained unchanged by the
antagonist, despite a reduction in the hypotensive effects of SAL
after ICI 118551; the duration of NA-evoked excitation was not related
to dose before the antagonist, but appeared slightly more so after
administration of ICI 118551.
Amax in the case of NA-evoked excitation was exponentially related to
dose before ICI 118551, and increased after the antagonist, with a
reduction in the maximum discharge attained. With SAL this parameter
was more constant, and less clearly changed by the antagonist.
Amax
also reduced SAL-evoked chemoexcitation, either alone (MET; 4.11 mg
kg-1 in cumulative doses), or following ICI 118551 (Fig. 3.21 C,D).
Where the chemoexcitatory response to SAL was initially reduced by BET
the effect was not further attenuated by administration of ICI 118551.
Chemoexcitatory responses to SAL that persisted in the presence of g-
receptor blockade were generally comparable to the Et-type responses
associated with NA (e.g. Fig. 3.26).
In the four experiments where the effects of NA upon chemorecep-
tor discharge were studied before and after injecting ICI 118551 this
antagonist only slightly affected the responses evoked by NA. There
was a slight reduction in the chemoexcitatory response to NA in two
experiments (Fig. 3.23), and a small potentiation of the response in
the other two (e.g. Fig. 3.22). Subsequent administration of gx-
antagonists caused no further attenuation of the response in two
experiments. Injection of either MET or BET in two other experiments
was followed by a loss of chemoexcitatory responses to NA (e.g. Fig
3.23), together with a potentiation of the initial depressant effect.
3.2.8 Persistance of chemoexcitation after adrenoceptor blockade.
A degree of chemoexcitation (notably the Ej-type) appeared to
persist in the presence of combinations of adrenoceptor antagonists
(e.g. Figs 3.24, 3.25) in ten experiments, as shown in table 3.2.
E!-excitation in response to injecting 10 yg doses of NA was stud¬
ied more closely in one experiment where it was found to be largely
unaltered by raising or lowering arterial pH* it was initially
reduced after injection of BET (100 yg kg-1 i.e.), but subsequently
was not markedly changed after injecting, in turn, ICI 118551 0.1 and
1 mg kg-1, RAU 0.1 mg kg-1, COR 0.1 yg kg-1, mecamylamine 1 mg
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Table3.2:Detailsofn agoni tsus d,ft rwh chthereas ll excitatoryresponsetheinj ionofnoradrenaline. ExptSequenceofantagonists,ndd ses(mgkg-1) 1ICI18551,0.1;BET, 2DP,0.1;MET,.001..1ICI18551, 3DP,0.1;BET,.001..1ICI18551,;COR, 4BET,0.01.1;RAU,1;ICI18551,0. ; 5MET,0.1;DP1,3JlRAU,PROP,.7;COR 6BET,0.01,.11;RAU;COR.3+ 7ICI118551,0.1;RAU;BET,PROP5 8 8ICI118551,0.1,;MET 9DP0.01;MET1;RAU,ICI18551,.3 ;COR 10BET0.1;ICI118551,,RAU. ;CORMecamylamine
&Atropine
Figure 3.23. Responses of 2-3 chemoreceptor units to i.e. injection
of NA 1-50 tag before (0) and after ICI 1 18551 (1 mg kg-1; •) and BET
(100 yg kg-1; A).
A. The integrated response (AEx) plotted against dose; chemodepres-
sion was markedly potentiated after BET, whilst the chemoexcitatory
response was abolished.
B. Ax for the excitatory effect of NA plotted against dose; there was
a slight reduction after ICI 118551, and this form of analysis yielded
negative values after BET, when comparing delayed chemoexcitation with
pre-injection control.
C. Amax, which was enhanced after ICI 118551, becoming a dose-depend¬
ent function; after BET the ability of NA to cause an increase in
discharge was no longer apparent.
D. Duration (s) of the excitatory response to NA.





















Figure 3.24. A. Responses to injections of NA 10 yg i.e., under
control conditions and after increasing and reducing once again PaC02.
Initial chemodepression is denoted by the open bars, Ex-excitation by
the solid bars, and E2-excitation by the hatched bars.
3. Responses to NA 10 yg after BET 100 yg kg-1, ICI 118551 0.1 and 1
rag kg-1, showing the persistence of Er-type excitation.
C. Responses to NA 10 yg after RAU (0.1 mg kg-1), COR (0.1 mg kg-1),
mecamylamine (MEC; 1 mg kg-1), and atropine (ATR). Et-excitation was
present in response to each injection, and was not markedly variable
in magnitude. Inset below are the effects of four injections of Locke
solution (0.3 ml i.e.), where the progressive reduction of an
excitatory response to injection of vehicle (between two doses of NA
causing Ex-excitation) suggests that the effect is not artefactual.
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Figure 3.25. Records of end-tidal C02 (C02; calibration 0-5.5%),
femoral arterial blood pressure (BP 0-200 mm Hg) and rate of
chemoreceptor discharge (proportional analogue signal - 0-10 c.p.s.)
in a single experiment.
A. Responses to NA, 1-10 yg i.e., before antagonists.
B. Responses to SAL, 1-50 yg i.e., before antagonists.
C. Effects of injecting BET 0.01 mg kg-1, which attenuated inotropic
and chronotropic responses to injected NA (0.5-10 yg i.e.). Effects
of injecting Locke solution (L 0.3 ml) were negligible, and the
response to DA (1 yg) was not radically different from pre-antagonist
control (not shown).
D. Response to SAL, 10 and 50 yg, after the low dose of -antagonist.
E. Effects of injecting BET, 1 mg kg-1 i.e., after which NA (0.5-50)
caused prolonged depression of chemoreceptor discharge, an effect not
associated with injection of Locke solution (L 0.3 ml) i.e.
F. NA 25 yg i.e., before, and after (G) RAU 1 mg kg-1, where chemodep-
ression was abolished, and replaced by a more prominent excitation of
chemoreceptor discharge.
H. Response to NA after injecting COR 0.3 rag kg-1 (after the other
antagonists); vascular responses to NA injection were virtually
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kg-1, and a large unknown dose of atropine (Fig. 3.24). Following
COR four injections of Locke solution (0.3 ml) were made; with the
first there was an obvious Ex-chemoexcitatory response, which was not
observed with the third and fourth such injections (see Fig. 3-24).
Subsequently, 10 pg NA caused Ex-excitation as previously, suggesting
the effect is not an injection artefact. Before injection of BET
there was prominent E2-excitation, but this was no longer such a
marked effect after this, or subsequent antagonists.
3.2.9 Comparison of the route of injection.
In two experiments a comparison was made of the effects of NA
injected close to the carotid body (i.e.), or distally, by injecting
into the femoral artery or femoral vein. Similar injections of NaCN
and DA were made in one experiment for comparison. Results are shown
in table 3-3. Chemodepression was not observed when NA was injected
i.v. or i.a., but chemoexcitation occured whichever route of injection
was used, although the duration, latency, and intensity varied.
3.2.10 Cardiovascular effects of injected adrenoceptor agonists and
antagonists.
The monitoring of arterial blood pressure and gas tensions,
E.C.G, and end-tidal C02 was performed routinely to assess the state
of the animal during the experiment. These measurements also provided
evidence of the biological activity or relative potency of a particular
drug where effects upon chemoreceptor activity were equivocal.
Injections of more than 1 to 5 pg of NA caused a dose-related
increase in systemic arterial blood pressure, with a latency of some
20 s (Fig. 3-26). Heart rate (cf. Figs 3-27 and 3.28) and pulse
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Table 3.3: Comparison of the effects of NA, DA, and NaCN injected
intracarotidally (i.e.), intravenously (i.v.), & intra-arterially (i.a ).
i.e.
-Ax? +Ax? d t Am
i^v.
-Ax? +Ax? d t Am
i.a.
-Ax? +Ax? d t Am
NA
10 yg -89 96 48 22 0 86 27 125
NA
1yg -65 0 — — 0
5yg -81 29 14 40 3
10yg -86 56 21 79 3
NaCN
5 tig 0 1050 2 13 43
50 yg - - -
0 27 3 17 1
0 49 12 43 3
0 66 15 50 4
0 25 6 47 1
0 25 9 21 0
0 23 4 23 1
0 20 1 49
0 21 1 102 3
0 0 0 0 0
0 24 1 71 1
DA -Ax? d t -Ax? d t -Ax? d t
1 yg -85 0 16
10 yg -
50 yg -
-8 8 25 0 0 0
0 0 0
-16 9 19
-Ax?: Ax? for chemodepression; +Ax?: Ax? for chemoexcitation; d: delay
(s) before chemoexcitation, or, in the case of DA, chemodepression;
t: duration (s) of chemoexcitation (or, for DA, chemodepression);
Am: A max.
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Figure 3.26. A: The effects upon end-tidal C02 (ET C02, 0-5.H%),
femoral arterial blood pressure (BP, 0-200 mmHg), and chemoreceptor
discharge (cps - analogue signal proportional to discharge rate - 0-8
and 0-16 counts per second) of injecting NA (0.5, 1, 5, 10, 25 yg i.e.
at arrows).
B: Effects of injecting the same doses of NA after administration of the
S2-adrenoceptor antagonist ICI 118551, 100 yg kg-1.
C: The effects upon end-tidal C02, femoral arterial blood pressure,
and chemoreceptor discharge (cps - analogue signal proportional to
discharge rate -0-10 and 0-20 counts per second), in the same
experiment, of injecting SAL (1, 5, 10, 50 yg i.e. at arrows).
D: Effects of injecting the same doses of SAL, and Locke solution (0.3
ml), after administration of the g2-adrenoceptor antagonist, ICI
118551, 100 yg kg"1.




















pressure were also increased (Fig. 3-26); end tidal C02 increased
concomitant with the peak increase in blood pressure following each
injection of NA (Fig. 3-26). The higher doses of NA were often
associated with heart arrythmias, effectively limiting the upper range
of doses that could be applied.
3.2.10.1 Effects of a,-selective agonists and antagonists.
In nine cats PHEN (1 pg - 2 mg i.e.) caused a marked, dose-related
increase in systemic arterial blood pressure which was substantially
reduced, or more usually abolished, by the antagonist COR.
COR itself (0.1-1 mg kg-1 i.e.; n=4) caused no discernable
changes in the tracing of femoral arterial blood pressure. The
pressor response to NA was similarly attenuated in three (75%), and
unaltered in one (25%) out of four experiments. The antagonism of NA-
evoked pressor responses by COR was generally less than its antagonism of
the hypertensive effects of the more selective agonist PHEN.
3.2.10.2 Effects of a2-selective agonists and antagonists.
OXM (0.1-200 pg i.e.) injected in five cats caused a pronounced,
dose-dependent increase in blood pressure which was consistently
reduced or abolished by the antagonist RAU (0.1 or 1 mg kg-1).
The antagonist RAU (0.01-4 mg kg-1, i.e.) was injected in ten
experiments. Doses of 100 pg kg-1 or greater often caused severe
hypotension (mean blood pressure fell to -50-60 mm Hg or less), which
was not readily reversed by injection of 2.5% dextran-5^ glucose
solution. In four of the experiments the chemoreceptor recording was
lost very soon after administering the antagonist, and in at least one
experiment hypotension was the immediate cause of death. The antag-
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onist blocked pressor responses to injected OXM, and in all nine
experiments where examined, NA-evoked increases in blood pressure were
substantially reduced after the antagonist.
In the presence of COR and RAU together changes in systemic
arterial blood pressure were no longer seen to occur after injection
of NA (Fig. 3-25). Although NA caused hypertension and changes in
heart rate, neither of the a-selective agonists was associated with
changes in heart rate.
3.2.10.3 Effects of g-selective agonists.
In twelve cats ISO (g j./) caused dose-dependent hypotension,
increased pulse pressure, and tachycardia; the duration of these
effects was similarly dose-dependent.
The f^-selective agonist DOB was studied in four experiments, in
three of which no discernable changes in the cardiovascular or respir¬
atory parameters monitored occured after injecting DOB over the range
1-100 yg i.e. or (n=1) 5 mg i.v. In the fourth experiment, where pHa
was near the upper limit of normal (>7.40), DOB (100 yg i.e.) caused a
slight but transient rise in blood pressure.
As with DOB, no changes in cardiovascular or respiratory activity
were detected after injecting prenalterol (PREN) in three cats over
the range 0.1 yg - 1 mg i.e., or, (n=1) 5 mg i.v. (Fig. 3-13).
Single injections, or the injection of a range of doses of SAL
(0.1 yg -1 mg i.e.) in thirteen cats caused systemic hypotension, an
increase in arterial pulse pressure, an increase in end-tidal C02, and
chemoexcitation. Blood pressure changes were dose-dependent with
respect to magnitude and duration (Fig. 3-26), and were reduced or
abolished by the antagonist ICI 118551 (0.1 or 1 yg kg-1; cf. Fig.
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3.26) in the six experiments where this combination of drugs was
studied. There appeared to be a direct temporal relationship between
blood pressure effects, changes in end-tidal C02, and chemoexcitation.
In one experiment, as blood pressure returned to normal following
SAL injection, chemoreceptor discharge stabilised to a new level,
approximately double the rate of discharge in the pre-injection
control period. In the new steady-state, after SAL, Pa02 was 75 mm
Hg; PaC02, 23 mm Hg, and pHa, 7.35. These data could be compared with
results of blood gas analysis performed some 40 min before injecting
SAL when Pa02 was 85 mm Hg, PaC02, 19 mm Hg, and pHa, 7.43.
3.2.10.4 Effects of g-selective antagonists.
MET ((^-selective) was injected over a range of 0.1 pg - 1 mg
kg-1 i.e. in thirteen cats, and caused a reduction in arterial blood
pressure, pulse pressure, and resting heart rate. End-tidal C02
tended to decrease slightly with the decrease in blood pressure, from
which there was some degree of recovery after about five minutes.
Table 3.4A shows the results of blood gas analyses performed
before and after the administration of MET. Only Pa02 was signif¬
icantly altered (increased) as a result of injecting MET, but the
effect is possibly time-dependent, as shown in table 3.^B.
This antagonist reduced the NA-evoked increase in heart rate in
a dose-dependent manner (Fig. 3-27C11) although, following initial
low doses of the antagonist (Fig. 3.27[2] ), basal heart rate (recorded
before injections of NA) was significantly higher than the same
measurements made before injecting MET.
3ET was studied in ten experiments; doses of 100 pg kg-1 or more
caused a fall in blood pressure, a short lasting reduction of end-
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Figure 3-27. 1. Cardiac acceleration (A b.p.m. -_x beats per minute
at time of peak increase in blood pressure minus x beats per minute in
pre-injection control period) plotted as a function of dose.of NA,
before (A - 0) and after MET 10 (D - •) and 100 (E - A) yg kg-1.
2. Mean heart rate before (A; n=4) and after met 0.1 (B; n=3), 1 (C;
n=3)» 10 (D; n=4), and 100 (E; n=4) yg kg-1. Mean heart rate was
calculated in the control period before individual injections of NA,
at each stage of the experiment. * = statistically different from
control (P<0.05 - Student's t-test).



















Table 3.4: A: Pa02 , PaC02 , and pHa before and after metoprolol; B:
results of blood gas analyses in a single experiment taken before,
five, and eleven minutes after injecting metoprolol 0.1 mg kg-1.
Ax represents the mean difference between results obtained before and
after the drug.
A.
Pa02 (mm Hg) PaC02 (mm Hg) pHa
Control MET Control MET Control MET Dose (kg
74 70 44 44 7.22 7.21 0.1 Ug
64 67 46 49 7.17 7.17 1 yg
82 93 - - 7.36 7.36 10 yg
81 89 38 38 7.22 7.26 10 yg
87 91 36 35 7.25 7.28 0.1 mg
110 112 35 36 7.23 7.25 0.1 mg
90 95 30 21 7.38 7.37 0.5 mg
67 82 47 27 7.25 7.31 3.1 mg
77 75 39 38 7.24 7.26 3.1 mg
X 5.0 -3.4 0. 02
.m. 2.2 2.7 8 x 10~3
PC0.05 P>0.1 P>0 .05 (paired t-
B.
CONTROL MET After 5' After 11'
(0.1 mg kg~x)
93 128 115 101
29 29 27 27







tidal C02, reduced pulse pressure, and bradycardia. Cardiovascular
effects of lower doses of BET (1-10 yg kg-1) were only very slight,
but the tachycardia and increased pulse pressure elicited by injected
NA were reduced following doses of BET as low as 10 yg kg -1 (figure
3.28). Blood gas analyses carried out before and after injection of
BET show no significant changes (paired t-test-) in Pa02 , PaC02, or pHa
(table 3.5).
The g2-selective antagonist ICI 118551 was injected in ten
experiments. At a dose of 0.1 or 1 mg kg-1 it caused slight hyper¬
tension, a reduction in pulse pressure, and no change, or a slight
increase or small decrease in end-tidal C02. The most marked and
consistent effect of the antagonist, even at the lower dose of 100 yg
kg-1, was the almost complete blockade of hypotension caused by
injecting SAL (Fig. 3.26) or infusing ISO. It did not appear to alter
the cardiovascular response to NA (Fig. 3.26). Blood gas analyses
carried out before and after injection of the antagonist are shown in
table 3.6.
3.2.10.5 Effects of catecholamine-induced changes in blood pressure
upon arterial blood gas tensions.
In a few cases blood samples were taken before and after changes
in blood pressure to determine whether there was any change in blood
gas tensions that might correlate with the increased chemoreceptor
discharge that occured concomitant with both hypei— and hypo- tensive
effects of adrenoceptor agonists. Samples were taken when the change
in blood pressure evoked by a drug was maximal, and in two cases a
second sample was taken immediately after the first. Differences in
values obtained before and after changes in blood pressure were
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Figure 3-28. 1. Cardiac acceleration (A b.p.m. -_x beats per minute
at time of peak increase in blood pressure minus x beats per minute in
pre-injection control period) plotted as a function of dose of NA
before (A) and after BET 1 (B), 10 (C), and 100 (D) yg kg-1. Lines
were fitted to the data using the method of least squares.
2. Before BET, SAL (50 yg i.e.) caused tachycardia (A); the effect was
reduced by BET 1 yg kg-1 (B) and 10 yg kg"1 (C), with little further
attenuation of the response after BET 100 yg kg-1.
3. 0XM (100 yg kg-1) elicited very little increase in heart rate (A),
which was not obviously detectable after BET.
4. Mean heart rate before (A; n=4) and after BET 1 (B; n=5), 10 (C;
n=5), 100 (D; n=4) kg"1. Mean heart rate was calculated in the
control period before individual injections of NA, at each stage of
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Table 3-5: Pa02, PaC02, and pHa before and after betaxolol.
Ax represents the mean difference between results obtained before and
after the drug.
Pa07 (mm Hg) PaC07 (mm Hg) pHa
Control bet Control bet Control bet Dose (kg-1
106 115 — — 7.12 7.20 0.1 mg
103 111 33 31 7.21 7.15 0.2 mg
77 79 26 27 7.29 7.31 10 pg
61 58 27 28 7.30 7.31 1 pg
129 134 29 31 7.26 7.26 10 pg
1 24 120 31 31 7.26 7.23 0.1 mg
120 116 31 32 7.23 7.25 1 mg
80 78 30 32 7.23 7.20 0.1 mg
83 82 24 23 7.20 7.27 5 mg
72 77 33 32 7.21 7.23 0.1 mg
68 76 33 30 7.20 7.23 1 mg
64 77 30 32 7.22 7.24 2.12 mg
ix 3.0 0.2 0 .01
:.m. 1 .7 0.5 0 .01
p=■<0. 05 P== <0.2 P= <0,.4 (paired t-
Table 3.6: Pa02, PaC02, and pHa before and after ICI 118551.
Ax represents the mean difference between results obtained before and
after the drug.
Pa07 (mm Hg) PaC07 (mm Hg) pHa
Control ICI Control ICI Control ICI Dose (kg-1)
89 106 30 32 7.16 7.15 100 yg
76 78 29 28 7.32 7.36 100 yg
104 120 34 33 7.24 7.24 1 mg
110 115 37 38 7.21 7.21 100 yg
lX 10. 0 0. 3 8X10-3
:.m. 3. 8 0. 8 0.01
p<=<0 ino p:= >0 .05 p= >0.05 (paired t-
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compared using a paired t-test; results are shown in table 3.7.
Supplementation of anaesthetic was not accompanied by a change in
discharge frequency, although there was a rapid but short-lasting fall
in blood pressure. Changes in Pa02, PaC02 and pHa were not signific¬
ant (P>0.05).
At peak increase in blood pressure after injecting NA, Pa02 fell
(0.1>P>0.05); pHa was not significantly changed but the increase in
PaC02 was significant at the 0.05 level. After injection of SAL both
Pa02 and PaC02 were increased, but the differences were not significant.
The effects of DOB and OXM were studied in one experiment each;
DOB caused no changes in either Pa02 or PaC02. Pa02 at the peak of
the blood pressure increase in response to OXM was increased and PaC02
was reduced, compared with pre-injection control.
3.3 Summary of results presented in section 3-
1. The cardiovascular effects of the adrenoceptor agonists and antag¬
onists studied were consistent with those reported in the general
literature, and were used as an index of biological activity of the
drugs injected.
2. Dose-dependent depression of chemoreceptor discharge was caused by
DA and NA; chemodepression evoked by DOB and PHEN was not clearly relat¬
ed to dose. Injections of OXM, PREN, ISO and SAL were not associated
with chemodepression. The chemodepressant effect of both NA and DA
was antagonised by the DA D2-receptor antagonist domperidone, and to
a lesser extent by the a2-antagonist RAU. It was potentiated by the
6j-antagonists BET and MET.
3. Chemoexcitation was evoked by NA and OXM, and the effect was
coincident with their hypertensive and cardiovascular effects.
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Table 3.7: Pa02f PaC02, and pHa before and at peak of drug-induced
blood pressure changes.






































63 58 34 37 7.19 7.23 NA 50 yg
63 (57 31 (35 7.25 (7.25 NA 50 yg
(60 (38 (7.25
91 86 32 39 7.35 7.25 NA 50 yg
100 (91 38 (39 7.23 (7.24 NA 50 yg
(84 (42 (7.26
106 85 33 42 7.22 7.16 NA 25 yg
147 104 28 32 7.29 7.23 NA 10 yg
Ax -14.8 4.7 0.03
E.M. 6.1 1 .1 0.02
0.1>P>0.05 P= <0.05 P=>0.05 (paired t-test)
Pa02 (mm Hg) PaC0? (mm Hg) pHa
Before After Before After Before After Drug
116 126 32 35 7.25 7.22 SAL 50 yg
110 117 32 30 7.30 7.29 SAL 0.5 mg*
Ax 8.5 0.5 -0.02
E.M. 2.3 6.3 0.0001
P>0.05 P>0.05 P>0.05 (paired t-test)
Pa02 (mm Hg) PaCO, (mm Hg) pHa
Before After Before After Before After Drug (mg)
98 105 30 28 7.30 7.31 0XM 0.1
90 92 20 21 7.34 7.33 DOB 0.1
t=Pentobarbitone; *=after ICI 118551 1 mg kg -1
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Excitation caused by ISO and SAL was concomitant with the hypotensive
and other cardiovascular effects resulting from injection of these
drugs. PHEN, DOB, and PREN did not cause significant chemoexcitation
at the doses studied.
4. An initial transient but intense excitatory response often occured
in response to injection of NA or SAL, preceding the more 'diffuse'
delayed excitatory response that appeared to be induced at the peak of
the blood pressure change.
5. Delayed excitatory responses temporally associated with cardio¬
vascular changes were generally reduced by appropriate a- or g-
antagonists, either alone, or in combination. Some excitatory effects
of NA, particularly early Ej-excitation, were potentiated after low
doses of the 8i-antagonists BET and MET. However, the potentiation of
chemodepression by these antagonists may complicate the quantitative
analysis of this effect. Ej-excitation could persist after administrat¬
ion of a1~, a2-1 Bi-, B2 — > and D2-antagonists (and in one experiment
mecamylamine and atropine also). There was evidence that the effect
was not simply an injection artefact.
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SECTION l»
EFFECTS OF INFUSIONS OF CATECHOLAMINES AND SELECTIVE ADRENOCEPTOR
AGONISTS AND ANTAGONISTS, AND INTERACTIONS WITH HYPOXIA
OR HYPERCAPNIA IN THE CAT
SECTION 4.
EFFECTS OF INFUSIONS OF CATECHOLAMINES AND SELECTIVE ADRENOCEPTOR
AGONISTS, AND INTERACTIONS WITH HYPOXIA OR HYPERCAPNIA IN THE CAT.
4.1 Effects of infusing adrenoceptor agonists.
The infusion of a drug over a period of minutes should allow the
study of the drug's effects in steady-state or equilibrium conditions,
which do not exist following the injection of a bolus of the
substance. Intracarotid infusions of catecholamine-related drugs were
made at a rate of 0.1 ml min-1, for up to 38 minutes. The mean
discharge frequency was calculated in consecutive 15 s intervals; the
mean steady-state discharge, when there are no longer any marked
changes in the frequency of discharge, may be expressed in terms of a
percentage change from the mean discharge in the pre-injection control
period.
Chemoreceptor responses to infusion of NA (e.g. Fig. 4.1) were
studied in eight experiments. Table 4.1 summarises the results obtain¬
ed; in seven (88%) , depression of discharge was elicited by NA at all
doses studied. In one experiment (12?) infusion of NA 1-25 pg min-1
caused chemoexcitation, whilst infusion of greater amounts (50-100 pg
min-1) depressed discharge. Comparison between the columns of table '
4.1 shows that the chemodepressant effect is not markedly dose-relat¬
ed, and comparison between rows shows that the effect was variable in
magnitude from one experiment to another. Comparison of the
depressant effects of infusion of NA 10 pg min-1 using a paired t-test
shows a significant reduction in discharge, as compared with the
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Table 4.1: Effects upon chemoreceptor discharge frequency of the in¬
fusion of NA. Mean frequency in steady-state conditions expressed as
percentage change from pre-infusion control discharge.
Expt. Locke (0.1ml NORADRENALINE (pg min-1)
min-1) 1 5 10 25 50 100
1 + 7 -52© _ _ _
2 + 12.5 -14 -154t - - - -
3 -13 - - -50© - - -
4 + 9 - - -50© - - -
5 0 - -42+ -80© -50 + -29 -
6 + 9 - -4 + -82© -28+ - -
7 + 7 -92 -97+ - - - -
8 + 20 + 33 + 40 + 45© + 50 -92 -20
X + 6.4 -24.3 -51.4 -44.8* -9.3 -60.5* -20
s.e.m. 3.4 36.5 34.1 19.0 30.3 31 .5 -
n 8 3 5 6 3 2 1
* = P<0.05, with respect to control (non-paired t-test).
t = 0.1>P>0.05, ® = PC0.05 (paired t-test).
Table 4.2: Effects upon chemoreceptor discharge frequency of the in¬
fusion of ISO. Mean frequency in steady-state conditions expressed as































(* = 0.1>P>0.05, Student's paired t-test).
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Figure 4.1. Data obtained in a single experiment showing the changes
in chemoreceptor discharge, blood pressure and end-tidal C02 evoked
during six minute infusions of adrenoceptor agonists.
1 . Effects upon chemoreceptor discharge of infusing Locke solution
(0.1 ml min-1), and NA 5, 10, 25, and 50 pg min-1 for six minutes
(solid bar).
Mean discharge (calibration: 0-10 c.p.s) has been calculated in
successive 15 s intervals, and plotted against time. Pre-infusion
control is denoted by filled blocks.
The effects of the infusions (indicated by the horizontal bars)
upon end-tidal C02 (C02, calibration: 0-5%), and femoral arterial
blood pressure (BP, calibration: 0-200 mm Hg) are shown on the right.
(Note reduced time scale).
Results of blood gas analyses performed before (C) and at three and
six minutes after onset of infusion are appended below.
Infusion PaO? (mm Hg) PaCOi, (mm Hg)
c
pHa
3m 6m(rate, min-1) C 3m 6m r 3m 6m
Locke 0.3 ml 93 105 105 28.5 25.5 28.5 7.40 7.41 7.39
NA 5 pg 105 102 102 28.5 29.0 29.0 7.39 7.38 7.38
NA 10 pg 104 104 98 26.0 29.0 29.0 7.41 7.38 7.38
NA 25 pg 102 95 91 27.0 27.0 32.0 7.39 7.39 7.37
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Figure 4.1. 2. Data obtained in a single experiment showing effects
upon chemoreceptor discharge, end-tidal C02, and blood pressure, of
infusing SAL 10 and 50 pg min-1, OXM 10 and 100 pg min-1, and DA 1 pg
min-1. Treatment of data is as described for figure 4.1 (1).
Results of blood gas analyses performed before (C) and at three and six
minutes after onset of infusion are appended below.
Infusion PaO, (mm Hg) PaCCi2 (mm Hg) pHa
(rate, min-1) C 3m 6m C 3m 6m C 3m 6m
SAL 10 pg 92 95 91 27.0 32.0 33.0 7.36 7.36 7.34
SAL 50 pg 78 81 82 29.0 29.0 30.0 7.34 7.36 7.34
OXM 10 pg 86 91 91 28.0 26.0 26.0 7.3^ 7.36 7.34
OXM 100 pg 99 94 102 22.0 28.0 23.5 7.35 7.37 7.38
DA 1 pg 94 94 93 27.0 26.0 28.0 7.36 7.33 7.34
1 ' ' 1 ■ ■ ' I I <11111
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Figure 4.1. 3. Data obtained in a single experiment showing effects
upon ohemoreceptor discharge, end-tidal C02, and blood pressure, of
infusing PHEN 10 and 100 ug min-1; treatment of data is as described
for figure 4.1 (1).
Results of blood gas analyses performed before (C) and at three and six
minutes after onset of infusion are appended below.


























Figure 4. 1 . Data obtained in a single experiment showing effects
upon chemoreceptor discharge, end-tidal C02, and blood pressure, of
infusing NA 10 and 50 pg min-1, SAL 50 pg min-1, OXM 100 pg min-1, and
DA 1 pg min-1, after injecting MET, 1 mg kg-1 i.e. Treatment of data
is as described for figure 4.1 (1).
Results of blood gas analyses performed before (C) and at three and
six minutes after onset of infusion are appended below.
Infusion Pa02 (mm Hg) PaCC12 (mm Hg)
C
pHa
3m 6m(rate, min-1) C 3m 6m C 3m 6m
NA 10 pg 93 91 99 24.0 25.0 25.0 7.39 7.38 7.37
NA 50 pg 89 94 93 24.5 23.0 25.0 7.38 7.42 7.40
SAL 50 pg 86 83 86 26.0 24.5 22.0 7.40 7.42 7.40
OXM 100 pg 91 88 92 22.5 26.0 24.0 7.39 7.40 7.39
DA 1 pg 91 85 89 26.0 26.5 26.0 7.39 7.38 7.39
after
MET I mg kg'1 4
i 1 1 1 1 1 1 1 r ii i m i





















Figure 4.1. 5. Top: data obtained in a single experiment showing
effects upon chemoreceptor discharge, end-tidal C02, and blood
pressure, of infusing NA 50 yg min-1, following injection of
domperidone, 10 yg kg-1 i.e. (in the presence of MET, 1 mg kg-1).
Bottom: data obtained in the same experiment showing effects upon
chemoreceptor discharge, end tidal-C02, and blood pressure of infusing
NA 50 yg kg-1, after administering an additional 0.5 mg kg-1 MET i.e.
Treatment of data is as described for figure 4.1 (1).
Results of blood gas analyses performed before (C) and at three and six
minutes after onset of infusion are appended below.
Infusion PaO;, (mm Hg)





NA 50 yg 79 82 91 23.5 27.0 30.0
(after domperidone 10 yg kg-1)
7.38 7.36 7.38
NA 50 yg 95
(+MET 0.5 mg kg-1)
91 91 21.0 24.0 25.0 7.37 7.38 7.36
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respective Locke infusion controls (PC0.05, n=4). Only two sets of
data were significantly different from control when compared using a
non-paired t-test, and including all data obtained.
The effects of MET (1 mg kg-1, i.e.) upon chemoreceptor responses
to NA infusion were examined in two experiments; MET reduced the
chemodepression evoked by the lower level of NA infusion (10 yg
min-1) in both experiments, but potentiated chemodepression elicited
by higher rates of NA infusion (Fig. 4.2).
Domperidone was studied in one experiment, after MET. A dose of
10 yg kg-1 greatly attenuated the MET-enhanced depressant effect of NA
infusion (50 yg min-1; Fig. 4.1(5)); after a further dose of MET (0.5
mg kg-1) had been administered, infusion of NA (50 yg min_i) caused a
30? increase in discharge (Fig. 4.1(5)).
ISO was infused i.e. in seven experiments and caused slight
chemodepression in two (29?) but clear chemoexcitation in the other
five (71?) experiments. Results are summarised in table 4.2 and,
again, there was considerable variation in magnitude of the response
between experiments, with no striking correlation between dose and
response.
DA, infused in two experiments, caused chemodepression. In one
of these experiments infusion of DA 1 yg min-1 for six minutes caused
a progressive reduction in discharge with three distinct plateaux:
there was a 13? reduction in discharge in the second minute of
infusion, a 50? reduction in the fourth minute, and an 89? reduction
by the sixth minute, with discharge returning rapidly to near control
level upon cessation of the infusion (Fig. 4.3). Infusion of DA 10 yg
min-1 in this experiment caused an initial 75? decrease in discharge,












Figure 4.2. Results obtained in two separate experiments showing
the effects of six minute infusions of (1) NA 10 and 25 and (2) NA 10
and 50 yg min-1 (A) before, and (B) After injecting MET, 1 mg kg-1.
Mean discharge in the steady state attained in the first (i) and
second (ii) three minutes of the infusions have been expressed as
percentage changes from the mean discharge in the appropriate pre-
infusion control (note that the initial depression of discharge by the
higher doses was not sustained, before MET, and so, in the second
three minutes of the infusion there was no net change in discharge as
compared to control). These changes in steady-state discharge were
apparent after taking arterial blood samples at the third minute of
the infusion.
After injecting MET (B) the chemodepressant effect of infusing NA at
a rate of 10 yg min-1 was reduced, whilst greater chemodepression was
evoked at the higher rates of infusion, after the antagonist.
In both experiments, before the antagonist, discharge increased during
infusion of NA at the higher rates after taking a blood sample at the
third minute of infusion. During the remaining three minutes of
infusion there was no net overall difference from discharge before
starting infusion.
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Figure 4.3. Comparison of the effects upon chemoreceptor discharge
of infusing DA 1 and 10 ug min~l, SAL 10 and 50 pg min"1, PHEN 10 and
100 pg min-1, and OXM 10 and 100 pg min-1 in two separate experiments,
(A) and (B).
Discharge was calculated in succesive 15 5 intervals and plotted
against time; the mean discharge in steady-state conditions, expressed
as a percentage change from the mean discharge in the respective pre-
infusion control period is shown in this figure.
In the first experiment the chemodepression evoked by DA was progres¬
sive, and so two or three different degrees of reduced discharge are
presented (see text). The steady-state discharge during infusion of
OXM (100 pg min-1) was slightly reduced after taking an arterial blood
sample at the third minute of infusion. During all other drug-
infusions a new steady-state level of discharge was rapidly attained
after starting the infusion, and well sustained, and only a single
percentage change is indicated.
In the second experiment (B) the effects of infusing DA 1 pg min-1,
SAL 50 pg min-1, and OXM 100 pg min-1 were examined after injecting
MET 1mg kg-1. The depressant effect of DA infusion was slightly
reduced, whilst the excitatory effects of infusing SAL or OXM were
potentiated.
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remaining four minutes of infusion remained constant at some 60? of
control (Fig. 4.3). In the other experiment there was a 64?
depression of discharge, within 30 seconds of onset of infusion, and
the degree of depression remained constant throughout the period of
infusion. After MET (1 mg kg-1, i.e.), DA infusion (1 pg min-1)
caused only a 55? reduction in discharge.
SAL infusion caused slight but dose-related chemoexcitation in
one experiment, with infusions of 10 and 50 pg min-1 causing 5? and
24? increases in discharge (at steady-state) respectively. When the
infusion of SAL (50 pg min-1) was repeated after MET (1 mg kg-1,
i.e.), it caused a 35? increase in discharge (Fig. 4.1). In the other
experiment SAL (50 pg min-1) caused an 18? reduction of discharge,
this experiment being one of those in which infusion of ISO also
caused depression.
The infusion of PHEN (n=2) had only minimal effects upon
chemoreceptor discharge (e.g. Fig. 4.1). Thus, in one experiment,
infusing 10 pg min-1 reduced discharge by some 11?, and increasing the
rate to 100 pg min-1 resulted in a mere 4? increase in discharge; in
a separate experiment infusion of PHEN 100 pg min-1 reduced discharge
by 2.5? (Fig. 4.3).
In contrast, OXM was markedly more effective, causing a 25?
increase in discharge frequency when infusing 10 pg min-1
(n=2; see Fig. 4.3). When the level of infusion was increased to 100'
pg min-1 discharge was increased to 58? of control in one experiment
but reduced by 22? in the other (a freshly prepared dilution of OXM
similarly reduced discharge by 20? in the same experiment). In the
experiment where the high dose of OXM caused only chemoexcitation the
effect was potentiated after MET (1 mg kg-1; Fig. 4.1, and Fig. 4.3).
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Although in most instances infusion of a drug led to the rapid
establishment of a new and stable steady-state of discharge, it was
occasionally noticed that dishcarge could be separated into two
distinct plateaux (e.g. NA 50 pg min-1 infusion, Fig. 4.1(1); Fig.
4.2). This change in steady-state, which sometimes resulted in the
replacement of an excitatory effect by chemodepression, or vice
versa, was seen to occur at the time of taking samples for arterial
blood gas analysis at the third minute of infusion; during this
procedure there was generally a transient rise fall and rise in
arterial blood pressure.
Cardiovascular effects of the infusion of catecholamines and
selective agonists were comparable to those elicited by injecting the
same substances. Thus NA, PHEN, and OXM caused hypertension when
infused, ISO and SAL, hypotension, and NA, ISO, and SAL infusions
caused tachycardia. DA infusion was not associated with any clear
changes in blood pressure or heart rate.
4.2 Interaction of ISO and changes in blood gas tensions likely to
affect the chemoreceptors.
Because the purely excitatory effects of ISO infusions are probab¬
ly less complex with respect to the underlying mechanism than is
likely to be the case with NA (which produces more than one type of
change in chemoreceptor activity) the effects of ISO were studied in
more detail in three cats, and NA in one.
Infusion of ISO 10 pg min-1 i.e. caused hypotension, a marked
reduction in Pa02 , and an increase in the rate of chemoreceptor
discharge. In one experiment this excitation represented an increase
of 150% and 178% over control discharge (Figs 4.4 and 4.6). In a
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Figure 4.4. Data obtained in a single experiment showing effects
upon Pa02 (ran Hg), PaC02 (mm Hg.), pHa, and frequency of chemoreceptor
discharge (x c.p.s.) of infusing ISO (10 ug min-1) for 15 minutes
(solid bar). Chemoreceptor discharge was averaged in consecutive 15
intervals. The animal was ventilated with room air, but the arterial
oxygen tension throughout the experiment was consistent with mild
hypoxia.
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Figure 4.5. Data obtained in a single experiment showing (A) the
effects upon Pa02 (mm Hg)^ PaC02 (mm Hg), pHa, and frequency of
chemoreceptor discharge (x c.p.s.) of infusing ISO (10 pg min-1)
for 18 minutes (solid bar). Chemoreceptor discharge was averaged in .
consecutive 15 s intervals. Heart rate during the pre-injection
control period was 214 beats per minute (b.p.m.), rising to 242 b.p.m.
(+13*) when the fall in blood pressure caused by ISO-infusion had
stabilised, and to 247 b.p.m. (+15*) at the end of the infusion.
(B): Mean discharge (c.p.s.) has been plotted as a function of
arterial oxygen tension (Pa02; mm Hg); the straight line was fitted to
the data points using the 'least-squares' method, and the correlation
coefficient was -0.94.
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separate experiment discharge was increased to 328? of control,
rising further to 571? of control (Fig. 4.5); discharge in this case
correlated very well with Pa02 (Fig. 4.5).
The effects of hypercapnia in one experiment are shown in Figs
4.5 and 4.7. In the first example, at a relatively high level of
Pa02, ISO increased discharge concomitant with the fall in Pa02;
the addition of 1? and 3? C02 to the inspired gas caused further
increases in discharge, to 183? and 250? of control, respectively.
Although Pa02 also decreased during the period of C02-breathing it
did not fall below 100 mm Hg. Upon cessation of the infusion of ISO
(10 yg min-1), during C02-breathing, discharge decreased from 250? to
167? of control.
Under rather more hypoxic conditions (Fig. 4.7) ventilation with
1? CO2 caused a 117? increase in discharge; infusion of ISO (10 yg
min-1) caused a further 61? increase in discharge which was then
raised to 211? of control by increasing the inspired C02 to 3?.
Effects of hypercapnia in another experiment are shown in Fig.
4.8, for data obtained before and during infusion of ISO (10 yg
min-1). It was apparent (Fig. 4.9D) that the proportional response to
C02 during infusion of ISO is not necessarily greater than in the
absence of infusion when the percentage increase in discharge is
related to the rate of discharge measured immediately prior to onset
of hypercapnia.
In the third cat normoxia (Pa02 110-120 mm Hg) largely
suppressed the response of chemoreceptors to hypercapnia (Fig. 4.10).
When Pa02 was reduced and, more especially, during the infusion of
ISO (10 yg min-1; Fig. 4.10), the response to hypercapnia appeared to
be restored. In this experiment the effects of NA infusion were also
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Figure 4.6. Measurements of Pa02 (mm Hg), PaC02 (mm Hg), pHa, and
discharge frequency (x c.p.s. - averaged in consecutive 15 s
intervals) recorded in a single experiment. ISO (10 pg min-1) was
infused for 24 minutes (solid bar), during which period C02 (156) was
added to the inspired gas (hatched bar) and then increased to 3%
(stippled bar); ventilation with 3% added C02 was continued after
stopping the infusion, and a slight fall in discharge rate was then
apparent, allowing the estimation of ISO's contribution to the
increased discharge.
Figure 4.7. Measurements of Pa02 (mm Hg), PaC02 (mm Hg), pHa, and
discharge frequency (x c.p.s. - averaged in consecutive 15 s
intervals) recorded in a single experiment. \f C02 was added to the
inspired gas (hatched bar) and then raised to 356 (stippled bar); six
minutes after the initial increase in inspired C02, ISO (10 yg min-1)
was infused for 22.5 minutes (solid bar), enhancing the increase in
discharge evoked by C02.
-OSI-
Figure 4.8. (A): Measurements of Pa02 (mm Hg), PaC02 (mm Hg), pHa,
and discharge frequency (x c.p.s. - averaged in consecutive 15 s
intervals) recorded in a single experiment, and showing the effects of
adding C02 (hatched bar), 3% C02 (stippled bar) and 5% C02 (cross-
hatched bar) to the inspired gas.
(B): In this experiment the same parameters were measured during
similar changes in inspired gas composition but during the infusion of





Figure 4.9. Changes in chemoreceptor discharge and Pa02 in the
absence of, and during ISO infusion (10 pg min~1), related to arterial
C02 tension; this figure illustrates data presented in the previous
figure which have been further processed.
A: Average discharge in each 'steady-state' has been plotted as a
function of PaC02 before (0) and during (•) infusion of ISO (10 pg
min-1).
B: Pa02 plotted as a function of PaC02 before (0) and during (•)
infusion of ISO (10 pg min-1).
C: Average discharge during each phase of the experiment expressed as
a percentage change from the appropriate air-breathing control (100?)
plotted as a function of PaC02 before (0) and during (•) infusion of
ISO (10 pg min-1).
D: The data plotted in (C) above have been reworked so as to express
the changes elicited by raised C02 during ISO infusion as a percentage
change from the discharge during ISO infusion whilst breathing
air; in this case, there is no obvious difference in the effects of
increasing the proportion of C02 in the inspired gas.
Lines have been fitted to the data by eye.
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Figure *1.10. Data obtained in a single experiment showing (A)
effects of the infusion of Locke solution (0.3 ml min-1; solid bar)
whilst ventilating with \% (hatched bar) and 3% (stippled bar) C02
added to the inspired gas. Pa02 values (measurements of Pa02 and
PaC02 were made in mm Hg) were normoxic throughout the test. Discharge
was averaged in consecutive 15 s intervals.
(B): Effects of infusing ISO (10 pg min-1; solid bar) in the same











studied. A striking observation was the suppression by NA (10 pg
min-1) of the response to hypercapnia (Fig. 4.11), an effect that
became even more noticeable after administration of the -antagonist
BET (0.1 mg kg-1; Fig. 4.11). Stopping the infusion of NA during
hypercapnia was followed by an instantaneous increase in chemoreceptor
activity.
4.3 Interactions of ISO and NA with the 'standard' hypoxia test.
The 'standard' hypoxia test (see Section 2) was carried out
during the infusion of NA, ISO, and Locke solution, in three cats.
Discharge rate during 10? 02 in the control experiment (infusion of
Locke solution, 0.1 ml min-1) was taken as 100? in each experiment
(cf. Section 2), and discharge at the other levels of ventilation, and
during infusions was compared with this. Figure 4.12 shows the
effects of hypoxia during infusion of Locke solution, and during
infusion of ISO at two different rates. Before onset of hypoxia ISO
increased discharge in a dose-related manner; 'plateau' discharge
during 10? 02-hypoxia was slightly enhanced by infusion of ISO, but
'peak' discharge during ventilation with nitrogen was not obviously
altered. The depression of discharge during ventilation with 100? 02
was much less effective during infusion of ISO. On returning to air-
breathing, during continued ISO infusion,discharge rate was greater
than during Locke infusion, but dose-dependency was less marked than
in the period before the onset of hypoxia.
In Fig. 4.13 the effects of infusing Locke solution, NA (10 pg
min-1), and a very high dose of ISO (100 pg min-1) are compared in the
same experiment; at this dose, ISO enhanced chemoreceptor discharge
at all stages of the experiment, whilst NA depressed discharge before
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Figure 4.11. Data obtained in a single experiment showing (A)
effects of the infusion of NA (10 yg min-1; solid bar) whilst
ventilating with (hatched bar) and 3% (stippled bar> C02 added to
the inspired gas. Pa02 values (measurements of Pa02 and PaC02 were
made in mm Hg) were generally normoxic. Chemoreceptor
discharge was averaged in consecutive 15 s intervals.
(B): Effects of infusing NA (10 yg min-1; solid bar) in the same
experiment, and under the same conditions, but following the injection
of BET, 0.1 mg kg-1.
 
and at the onset of hypoxia, without significantly altering 'plateau'
or 'peak' discharge.
Infusion of ISO usually caused a rapid initial increase in chemo-
receptor discharge showing an 'overshoot' before rate of discharge
stabilised at a new steady-state (cf. Figs 4.12, 4.13, 4.14).
Results of an experiment in which hypoxia tests were performed
during catecholamine infusions before and after injecting the
antagonist BET (0.4 mg kg-1) are shown in Fig. 4.14. After the
antagonist the depressant effects of NA were enhanced and only a
weak response to 10? 02-hypoxia was obtained. During the infusion of
NA or ISO the response to ventilation with 100? N2 was potentiated,
when compared to control curves obtained before the antagonist. The
excitatory effect of ISO was clearly not blocked by the Bj-selective
antagonist, and the severe hypoxic stimulus of ventilating with 100?
N2 still elicited an increase in chemoreceptor discharge frequency.
In Fig. 4.15 the effects of simultaneous infusion of catechol¬
amines upon the response to hypoxia are demonstrated. ISO infusion (1
and 10 pg min-1; Fig,4.15(l)) slightly reduced chemoreceptor discharge
before onset of hypoxia. During 10? 02-hypoxia the chemoreceptor
response was increased in comparison to the Locke-infusion (0.1 ml
min-1) control. Infusion of ISO 100 pg min-1 caused a pronounced
enhancement of discharge at all stages of the test. In a second,
separate experiment (Fig.4.15(2)) low levels of ISO infusion (1 and 5 '
pg min-1) were accompanied by an increase in discharge prior to the
onset of hypoxia, whilst the responses to 10? 02 and 100? M2 were
reduced with respect to control. Infusion of ISO 50 pg min-1 was
accompanied by an increase in discharge at all stages of the test,
















Figure 4.12. Hypoxia tests in a single experiment showing the
effects of concomitant infusion of ISO. Discharge, averaged in
consecutive 15 5 intervals, has been plotted as a function of time.
Hypoxia tests (4 min ventilation with 10? 02 - open bar; 1 min
ventilation with 100? N2 - solid bar; 2 min recovery on 100? 02 -
stippled bar) were performed whilst infusing Locke solution, 0.1 ml
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Figure 4.13. Hypoxia tests (4 min ventilation with 10? 02 - open
bar; 1 min ventilation with 100? N2 - solid bar; 2 min recovery on
100? 02 - stippled bar) carried out during infusion of (A) Locke
solution 0.1 ml min-1 (a), (3) ISO 100 pg min~l (T), and (C) NA 10 pg.
min-1 (•) in a single experiment. Chemoreceptor discharge was
averaged in consecutive 15 5 intervals. The three sets of data have
been superimposed to allow comparison of the differing effects of ISO
infusion (which tended to increase the rate of chemoreceptor discharge,
except during ventilation with 100? Na) and NA (which depressed























20 0 20 min
Figure 4.14. Data obtained in a single experiment showing results
of hypoxia tests (4 min ventilation with 10? 02 - open bar; 1 min
ventilation with 100? N2 - solid bar; 2 min recovery on 100? 02 -
stippled bar) carried out during infusion (horizontal bar) of Locke
solution 0.1 ml min-1, ISO 10 yg min-1, and NA 10 yg min-1, before (A)
and after (B) injecting BET 0.4 mg kg-1. Discharge was averaged in
consecutive 15 5 intervals.
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Figure 4.15. Average steady-state discharge during pre-infusion
control (C), steady-state during infusion, prior to hypoxia (I),
plateau discharge during 10? 02-hypoxia (10? 02), and peak discharge
whilst ventilating with nitrogen (100? N2) during infusion of Locke
solution (0.1 ml min-1) or ISO (1-100 yg min-1) in a single
experiment. To standardise results between individual tests the
plateau discharge evoked by 10? 02-ventilation during Locke infusion
was arbitrarily taken as 100? and discharge frequency during the other
tests has been related to this level of discharge.
In the first experiment (1), infusion of ISO at the rate of 1 and 10
yg min-1 initially decreased chemoreceptor discharge, but there was an
increased plateau discharge relative to the Locke infusion control,
and a reduced peak discharge during ventilation with 100? N2. Infusion
of ISO 100 yg min-1 produced a more marked increase in chemoreceptor
discharge.
In the second experiment (2), using the same protocol, ISO (1, 5, and
50 yg min-1) caused a dose related increase in discharge, but no
marked changes in the responses elicited by hypoxia.
In the same experiments and under the same conditions, infusion of NA
(10 yg min-1) in the first experiment (3) did not markedly alter
discharge during the hypoxia test, when compared to Locke control,
although infusion of NA caused a reduction in discharge prior to the
onset of hypoxia.
In the second experiment (4) infusion of NA 1 and 5 yg min-1, was
accompanied by an initial reduction in rate of discharge, and a small
reduction in the response of chemoreceptors to hypoxia.
Locke 0.1 ISO I ISO 10 ISO I00 jjg
Locke 0.1 ISO I ISO 5
-a rji
ISO 50 )jg
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The corresponding data for tests carried out during infusion of
NA in the same experiments show, in both cases, an initial depressant
effect of infusing the drug (1-10 pg min-1). In the first experiment
(Fig.4.15(3)) the 10# 02-hypoxia response was marginally potentiated
during NA infusion (10 pg min-1) and the peak response evoked by 100#
N2-ventilation was slightly reduced. Both parts of the hypoxia
response were reduced during NA infusion (1 or 5 pg min-1) in the
second experiment (Fig.4.l5(4)).
Figure 4.16 shows results of hypoxia tests performed during infus-
*
ions of NA before and after cutting the ganglioglomerular nerves.
Excitatory responses to high levels of NA infusion (10-50 pg min-1)
were more apparent with the sympathetic nerves intact than in any
other experiment. After sectioning the sympathetic supply a depres¬
sant effect of NA infusion was much more obvious. There was marked
variability in the discharge measured in the successive hypoxia tests
within the experiment. NA infusion appeared to potentiate the hypoxia
response before sympathectomy although there was little correlation
with the amount of drug infused. After cutting the sympathetic nerves
the response to hypoxia was generally attenuated during infusion of
NA.
4.4 Effects of g-selective antagonists upon the response of chemo-
receptors to hypoxia.
Hypoxia tests were performed before and after administration of
the g-selective antagonists PROP (61/g2), MET and BET (6i), or ICI
118551 (S2)» in order to determine whether the integrity of a g-adreno-
ceptor mediated mechanism is required for maintainance of the
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Figure 4.16. Chemoreceptor discharge during pre-infusion control
(C), steady-state during infusion, prior to hypoxia (I), plateau
discharge during 10? 02-hypoxia (10? 02), and peak discharge whilst
ventilating with nitrogen (100? N2). To standardise results between
individual tests the plateau discharge evoked by 10? 02-ventilation
during Locke infusion was arbitrarily taken as 100? and discharge
frequency during the other tests has been related to this level of
discharge.
In (A), the analysis of hypoxia tests carried out during infusion of
Locke (0.1 ml min-1), and NA 1, 5, 10 and 50 pg min-1 before
sectioning the sympathetic innervation (ganglioglomerular nerves) of
the carotid body is shown.
Results presented in (B) were obtained after sectioning the sympathet¬
ic nerves. Before neurotomy high rates of NA infusion tended to
increase the rate of chemoreceptor discharge, but afterwards a more
prominent chemodepressant effect of NA infusion was apparent, though
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chemoreceptor response to hypoxia, as suggested by Folgering et al
(1982). In some experiments the effects of a-selective antagonists
were also studied.
4.4.1 Results with propranolol (Bi/B2~antagonist).
Large single doses of PROP (n=4) decreased the basal rate of
chemoreceptor discharge and reduced blood pressure and resting heart
rate. The responsiveness of chemoreceptors to hypoxia was attenuated,
as shown by the reduced level of plateau discharge during ventilation
with 10% 02 (Fig. 4.17). However, the failure of chemoreceptors to
respond to hypoxic stimulation was never observed. The degree of
hypoxia (Pa02) attained during ventilation with 10% 02 was signific¬
antly reduced (table 4.3) after PROP.
Discharge on air, plateau discharge during ventilation with 10%
02, time to plateau, and the rate of increase in discharge in response
to hypoxia (slope - cf. Fig. 4.17) were not significantly altered by
the antagonist; these parameters are tabulated in table 4.4, which
may be compared with Fig. 4.18.
4.4.2 Effects of the g^selective antagonist metoprolol.
The effects of MET (n=5) were qualitatively similar to those of
PROP, but no marked depression of basal discharge occurred, unlike
after PROP. Blood gas analyses performed before and after the antag-'
onist (table 4.5) were not statistically significantly different.
In three of the five experiments there was a reduction in the
rate of discharge during air- and 10% 02- breathing, and in two of
these experiments the plateau achieved during ventilation with 10% 02
was not sustained and discharge continued to decrease even when
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i
Figure 4.17. Response of chemoreceptors in a single experiment to
10% 02 hypoxia (solid bar) before (open symbols) and after (closed
symbols) injection of PROP (5.8 mg kg-1 i.v.). A straight line was












Figure 4.18. Responses of chemoreceptors to hypoxia in three
separate experiments before (open symbols) and after (closed symbols)
single doses of PROP. Discharge during 10% 02-hypoxia, before the
antagonist, was taken as 100%, and air-breathing discharge (Air) and
peak discharge on 100% N2 were expressed relative to this value, both
before and after injecting the antagonist. Doses of PROP used were
(left to right) 1.6, 1.7, and 5.8 mg kg-1 i.v.
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Table 4.3: Results of blood gas analyses carried out before and
after propranolol, (A) during air-breathing, and (B) during 10$ 02 .
Pa02 PaC02 pHa
(mm Hg) (mm Hg)
Before After Before After Before After
CA) [n=2]
x 81.0 96.5 33.5 25.0 7.19 7.23
s.e.m. 1.0 3-5 1.5 2.0 0.02 0.03
IB) [n=2]
x 41.0 54.0* 29.5 24.0 7.29 7.22
s.e.m. 1.0 0 1.5 2.0 0.02 0.02
*=P<0.05 with respect to pre-drug value (paired t-test)
Table 4.4: Effects of propranolol upon chemoreceptor response to 10%
02 hypoxia.
CONTROL PROPRANOLOL n
Discharge (air) 6.7 + 2.9 3.8 + 0.8 3
(c.p.s. ± s.e.m.)
Discharge (10$ 02) 26.8 + 12.1 12.1 + 2.9 3
(c.p.s. ± s.e.m.)
Discharge (100$ N2) 68.3 + 32.8 26.1 + 11.3 3
(c.p.s. ± s.e.m.)
Rate of Increase 0.62 + 0.12 0.36 + 0.92 3
($max s-1 ± s.e.m.)
Time to plateau 148 + 24 118 4- 21 3
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Table 4.5: Results of blood gas analyses carried out before and
after metoprolol, (A) during air-breathing, and (B) during 10% 02 .
Pa02 PaC02 pHa
(mm Hg) (mm Hg)
Before After Before After Before After
(A) [n=4]
x 89.5 97.5 38.0 36.8 7.22 7.14
s.e.m. 7.4 7.3 4.9 6.3 0.07 0.05
03) [n=2]
x 43.0 43.0 28.5 29.5 7.34 7.23
s.e.m. 4.0 1.0 2.5 3.5 0.03 0.09
(No statistically significant differences)
Table 4.6: Effects of metoprolol upon chemoreceptor response to 10$
02 hypoxia.
CONTROL MET0PR0L0L1I n
Discharge (air) 5.1 ± 0.3 5.0 ± 1.2 3
(c.p.s. ± s.e.m.)
Discharge (10$ 02) 16.5 ± 1 .9 8.7 ± 1.4* 3
(c.p.s. ± s.e.m.)
Discharge (100$ N2) 29.0 36.4 1
(c.p.s. ± s.e.m.)
Rate of Increase 0.68 ± 0.12 0.44 ± 0.06 3
($max s-1 ± s.e.m.)




Discharge (air) 4.1 ± 2.7 5.1 ±1.6 (4)
(c.p.s. ± s.e.m.)
Discharge (10$ 02) 19.6 ± 7.9 21.3 ± 5.8 (4)
(c.p.s. ± s.e.m.)
Discharge (100$ N2) 36.7 ± 14.0 33.2 ± 9.5 (4) .
(c.p.s. ± s.e.m.)
Rate of Increase 0.87 ±0.09 1.05 ± 0.17 (4)
($max s~1 ± s.e.m.)
Time to plateau 116 ± 3 110 ± 16 (4)
(s)
11 MET 0.9 mg kg"1 (n=1), 2.9 mg kg- 1 (n=1), & 3 mg kg-1 (n=1)
t MET 1 mg kg-1 + 3-5 mg kg-1 (n=1) & 1 mg kg- 1 + 1.5 mg kg-1 (n=1)
* P<0.05 with respect to control (paired t-■tes t).
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ventilating with 100$ N2 (Fig. 4.19).
In the other two experiments, where domperidone (100 yg kg-1) had
been previously injected, no obvious changes occured (Fig. 4.19),
even with relatively high doses of MET.
Statistical analysis of the parameters quantifying the chemo-
receptor response to hypoxia before and after MET are shown in
table 4.6; discharge during hypoxia, after MET, was significantly
lower than control, but this effect was not seen in the presence of
domperidone.
4.4.3 Effects of the gt-selective antagonist betaxolol.
The effects of this antagonist upon heart rate and blood pressure
have been described in section 3. There was no marked change in the
response of chemoreceptors to 10$ 02-hypoxia after BET in five cats
(cf. Figs 4.20 and 4.21), and the discharge elicited by 100$ N2-
ventilation was sometimes increased, sometimes reduced (Fig. 4.21).
Doses of BET were sufficient to alter resting heart rate and blood
pressure and to modify the responses to injected NA, as described in
section 3.
Blood gas analyses compared before and after injection of the
antagonist (table 4.7) were not significantly different, and
comparison of the increased frequency of discharge and rate of
increase of discharge in response to hypoxia before and after BET
(table 4.8) showed no significant differences. Examination of Fig.
4.22 shows that there were no obvious effects of BET in the presence













Figure 4.19. (A): Responses of cheraoreceptors to hypoxia before
(open symbols) and after (closed symbols) MET in three separate
experiments. Discharge during 10$ 02-hypoxia, before the antagonist,
was taken as 100$, and air-breathing discharge (Air) and peak discharge
on 100$ N2 were expressed relative to this value, both before and
after injecting the antagonist. Doses of MET used were (left to
right) 0.88, 2.9 (twice) and 3.0 mg kg-1 i.e.
(B): Effect upon the response to hypoxia of injecting MET 1 mg kg-1
(•), and MET 3.5 (A - left) or 1.5 (A - right) mg kg-1 in the presence
of domperidone, 100 pg kg-1 in two separate experiments. Hypoxia
responses before MET but after DP are shown by open symbols.
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Figure 4.20. Response of chemoreceptors in a single experiment to
10% 02-hypoxia (solid bar) before (open symbols) and after (closed
symbols) injection of BET (1.0 mg kg-1 i.e.). A straight line was
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Figure 4.21. Responses of chemoreceptors in five different
experiments to hypoxia before (open symbols) and after (closed
symbols) BET. Discharge during 10% 02-hypoxia, before the antagonist,
was taken as 100*, and air-breathing discharge (Air) and peak
discharge on 100$ N2 were expressed relative to this value, both
before and after injecting the antagonist.
Doses of BET used were (A) 10 pg kg-1, (3) 0.1 mg kg-1 and (C) 1 mg
kg-1 i.e. In the last two examples illustrated, data are included for
the responses to hypoxia after injecting further doses of BET (♦): 5
mg kg-1 (C4) and 2 mg kg-1 (C5).
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Table 4.7: Results of blood gas analyses carried out before and
after betaxolol, (A) during air-breathing, and (B) during 10? 02.
Pa02 PaC02 pHa
(mm Hg) (mm Hg)
Before After Before After Before After
(A)
100 yg kg"1 [n=5]
x 102.6 97.600 31 .0 31 .4 7.24 7.24
s.e.m. 10.5 10.2 0.7 0.2 8.4x10"3 0.01
1.0 mg kg-1 [n=4]
x 88.8 88.8 31.9 29.0 7.24 7.21
s.e.m. 11.2 9.2 0.4 2.1 0.02 0.02
>1.0 mg kg-1 [n=2]t
x 73-5 79.5 26.5 27.3 7.25 7.27
s.e.m. 9.5 2.5 3.5 4.8 0.03 0.03
(B)
100 yg kg"1 [n=5]
x 39.8 42.8 29.1 28.7 7.29 '7.28
s.e.m. 4.5 2.5 0.3 0.7 0.01 0.13
1.0 mg kg-1 [n=4]
x 41.3 40.8 28.6 26.6 7.28 7-30
s.e.m. 2.5 4.3 0.9 1.3 0.02 0.01
>1.0 mg kg-1 [n=2]t
x 35.0 36.0 24.5 25.5 7.31 7.30
s.e.m. 1.0 1.0 0.5 1.5 0.01 5x10"3
t = 2 mg kg-1 (n=1) and 5 mg kg-1 (n=1 )
0°=P<0.1 with respect to pre-drug value (paired t-test)
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Table 4.8: Effects upon chemoreceptor response to 10$ 02 hypoxia of in¬
jecting betaxolol (A) 0.01, (B) 0.1, (C) 1, and (D) >1 mg kg-1.
CONTROL BETAXOLOL
5.8 + 4.2 5.2 + 3.6 2
29.3 + 22.7 20.5 + 3.6 2
72,.0 65..9 1
0.66 + 0.13 0.68 + 0.11 2
1 43 + 23 112 + 23 2
6.9 + 1 .6 11 .2 + 4.5 5
29 .8 + 9.2 37.2 + 13.7 5
55.5 + 14.2 39.2 + 16.2 4
0.57 + 0.06 0.54 + 0.16 5
153 4. 17 169 ± 17 5
6.9 + 1.6 7.3 ± 2.2 5
29.8 + 9.2 29.5 ± 9.5 5
56.6 + 14.6 46.8 ± 15.0 4
0.57 + 0.06 0.57 ± 0.06 5
153 + 17 162 ± 15 5
8.1 + 1 .9 7.6 ± 4.9 2
32.6 + 17.4 26 .1 ± 17.9 2
52.0 + 33.5 71 .0 ± 17.0 2
0.55 + 0.08 0.59 ± 0.05 2
150 + 45 102 ± 19 2
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+ BET 5 mg kg""1" (n=1) & 2 mg kg-1 (n=1), after the lower doses,
- 173 -
Figure 4.22. Results obtained in a single experiment showing steady-
state discharge during air-breathing (C), 10$ 02-hypoxia (10$ 02) and
peak discharge during ventilation with 100$ nitrogen (100$ N2), before
(0), and after
i) ICI 118551 100 ug kg-1 (•)
ii) Rauwolscine 1 mg kg-1 (A)
iii) BET 100 ug kg-1 (a)
iv) BET 1 mg kg-1 (■)
v) PROP 5.8 mg kg-1 (♦)
Discharge on 10$ 02 before antagonists has been taken as 100$, and the
other levels of discharge related to this.
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4.4.4 Effects of the B2~selectlve antagonist ICI 118551.
When injected i.e. (0.1-1 rag kg-1; n=2) this antagonist caused a
reduction of the hypoxia response in one experiment and a potentiation
in the other (Fig. 4.23). In a third experiment, when injected i.v.,
the antagonist caused no change in the hypoxia response other than a
slight reduction of the response to 100? N2-ventilation (Figs 4.23,
4.24). When ICI 118551 (1 mg kg-1 i.e.) was injected after the 6X-
selective antagonist BET (6 mg kg-1 in cumulative doses) there was a
further reduction in the response to hypoxia, already attenuated by
the 8x-antagonist (Fig. 4.23). In the remaining experiment, where ICI
118551 was injected i.e., there was a rapid deterioration in the
quality of the recording, implying damage to the carotid body. Blood
gas analyses performed before and after the antagonist are shown in
table 4.9.
Parameters quantifying the response to hypoxia before and after
the antagonist are shown in table 4.10. The two sets of data did not
differ significantly.
4.5 Summary of results presented in Section 4.
1. Infusions of catecholamine agonists provided qualitatively the same
results as injection of these drugs. PHEN (ax) was inactive, but OXM
(a2) caused chemoexcitation. SAL (fj2) and ISO (Bi/f32) both caused
excitation, and DA depressed chemoreceptor activity. NA caused
depression of discharge but an excitatory effect was also observed at
higher rates of infusion. OXM effects may have been subject to
desensitisation.
2. DP blocked depression of discharge caused by NA infusion, and MET
enhanced chemodepression evoked during infusion of NA.
- 175 -
Figure U.23. (A): Hypoxia responses before (0) and after (■) the
injection of ICI 118551 0.1 mg kg-1 i.e. in two separate experiments.
(B): Hypoxia responses before (0) and after injecting ICI 118551 0.1
(■) and 1 (a) mg kg-1 i.v. in a single experiment.
(C): Hypoxia responses before (0) and after injecting ICI 118551 1 mg
kg-1 i.v., (□) followed by BET, 1 mg kg-1 i.e. (•) - left, and before
(0) and after injecting ICI 118551 (■) 1 mg kg-1 i.e., following
cumulative doses of BET to a total of 6 mg kg_1(») -right.
Discharge on 10? 02 before antagonists has been taken as 100?, and the
other levels of discharge related to this.
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Figure 4.24. Response of chemoreceptors in a single experiment to
10% 02-hypoxia (solid bar) before (open symbols) and after (closed
symbols) injection of ICI 118551 (1 mg kg-1 i.v.). A straight line
was fitted to the data in the ranges shown, using the method of least
squares.
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Table 4.9: Results of blood gas analyses carried out before and
after ICI 118,551, (A) during air-breathing, and (B) during 1055 02.
Pa02 PaC07 pHa
(mm Hg) (mm Hg)
Before After Before After Before After
QO [n=5]
x 86.4 98.0** 32.8 33.0 7.21 7.23
s.e.m. 9.7 10.0 1.2 1.3 0.02 0.02
IB) [n=5]
x 43.2 43.2 30.8 30.4 7.28 7.29
s.e.m. 1.3 2.0 1.6 1.7 0.02 0.03
**=P<0.05 with respect to pre-drug value (paired t-test).
Table 4.10: Effects of ICI 118,551 upon chemoreceptor response to
10? 02 hypoxia.
CONTROL ICI 118551 n
(100 pg kg-1)
Discharge (air) 8.0 ± 2.6 6.9 + 1 .9 3
(c.p.s. ± s.e.m.)
Discharge (1055 02) 32.8 ± 7.8 29.5 + 13.0 3
(c.p.s. ± s.e.m.)
Discharge ( 10055 N2) 57.7 ± 5.2 44.5 + 12.1 3
(c.p.s. ± s.e.m.)
Rate of Increase 0.59 0.08 0.51 + 0.10 3
(55max s_1 ± s.e.m.)
Time to plateau 162 ± 26 159 + 30 3
(s)
CONTROL ICI 118551 n
(1.0 mg kg-1)
Discharge (air) 7.0 + 3.0 7.3 + 2.8 2
(c.p.s. ± s.e.m.)
Discharge ( 1 055 02 ) 37.4 + 12.6 25.6 + 1 .5 2
(c.p.s. ± s.e.m.)
Discharge (100? N2 ) 70.1 + 15.2 44.2 + 4.8 2
(c.p.s. ± s.e.m.)
Rate of Increase 0.52 + 0.05 0.34 + 0.13 2
(55max s-1 ± s.e.m.)
Time to plateau 182 + 15 176 + 5 2
(s)
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3. Infusions of agonists were associated with the same changes in
cardiovascular activity as seen after injections of these drugs.
Chemoreceptor activity during infusions was occasionally modified by
the transient fluctuations in blood pressure caused by the removal of
arterial blood samples.
4. ISO increased chemoreceptor discharge concomitant with a reduction
in Pa02. The increase in discharge elicited by increasing inspired
C02 was additive to the increase in chemoreceptor activity elicited by
ISO.
5. Normoxic PaO^ suppressed the response of chemoreceptcrs to an
increase in inspired C02 concentration. NA also suppressed this
response (even though it caused a simultaneous fall in Pa02); this
effect was even more marked after the 6i-antagonist BET.
6. ISO infusion enhanced the response to hypoxia in a dose-dependent
manner and excited chemoreceptors during ventilation with 100$ 02 ,
but there was no obvious correlation with dose. 'Peak' chemoexcitat-
ion during ventilation with 100$ N2 was not obviously enhanced during
ISO infusion. NA infusion suppressed chemoreceptor discharge but did
not attenuate the response to hypoxia, except after administration of
the gj-antagonist BET. Variability in the chemoreceptor response to
hypoxia during infusion did not allow any meaningful quantitative
comparison between experiments, or in some cases within a single
experiment. Sectioning the ganglioglomerular nerves appeared to
potentiate the chemodepressant effects of NA infusion.
7. PROP decreased resting discharge and the maximal discharge rate
during 10$ 02-hypoxia; differences were not statistically significant,
but the degree of hypoxia (Pa02) achieved during ventilation with the
same hypoxic gas mixture was significantly reduced after PROP. MET
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(3X) reduced the cheraoreceptor response to hypoxia, except in the
presence of DP, when no change in the response was apparent. BET (6!)
did not attenuate chemoreceptor responses to hypoxia although there
was a marked attenuation of cardiovascular responses to NA. The g2-
selective antagonist ICI 118551 sometimes reduced the response of
chemoreceptors to hypoxia but could also cause a potentiation of or
have no effect upon activity (but damage to the carotid body by close-
arterial injection of the drug in an acid vehicle cannot be ruled out).
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SECTION 5
STUDIES ON THE EFFECTS OF NORADRENALINE AND ISOPRENALINE
IN THE RABBIT
SECTION 5.
STUDIES OF THE EFFECTS OF NORADRENALINE & ISOPRENALINE IN THE RABBIT.
5.1 Introduction.
Compared with the cat and the dog, relatively few studies of the
actions of injected neuromodulatory drugs upon chemoreceptor discharge
in the rabbit have been presented (cf. Section 1). Since there are
indications that the effects of DA and 5-HT upon chemosensory
discharge in the cat and the dog are species-specific (Section 1), it
is desirable that further studies of the effects of catecholamines and
other substances should be carried out in the rabbit. It has already
been shown (Docherty & McQueen, 1979) that the effects of injected ACh
are quite different in cats and rabbits, the potent chemoexcitatory
effects (via nicotinic receptors) in the cat contrasting with the
depressant effects (via muscarinic receptors) in the rabbit.
Docherty (1980) studied chemoreceptor activity in 86 rabbits, but
obtained only a 30$ success rate (compared with a more than 90$
success rate in 37 cats). Chemoreceptor afferent activity in the
rabbit is conveyed by slowly-conducting, small diameter (<2 pm)
myelinated fibres (Laurent & Jdger-Barrks, 1964), which could very
easily be damaged during dissection. Chemoafferent fibres in the cat
(cf. Section 1) are predominantly fast-conducting A fibres -3.5 ym
diameter - Fidone & Sato, 1969). This low level of success has
limited, and continues to limit the amount of information obtained
from studies in the rabbit.
Experimental procedures (Section 2) were identical with those
used in the experiments on cats.
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5.2 Results.
In this study recordings were obtained in nine out of thirteen
rabbits (6956 ), but the quality of recordings was vastly inferior to
those obtained in cats (cf. Fig. 5.1); only multiple units were
recorded, and almost invariably a large number of baroreceptor action
potentials were also recorded, which were often of similar amplitude
to the chemoreceptor units.
5.2.1 Dose response data to noradrenaline and isoprenaline.
NA was injected i.e. in five rabbits, over the dose-range 0.01-10
yg (n=3); the range of doses was extended to 100 yg in two rabbits.
The chemoreceptor response was qualitatively similar to that seen in
cats, although a separate 'E,'-type excitatory component was not
distinguishable.
5.2.1.1 Chemodepression.
In the two experiments where the range of doses was extended to
100 yg, dose-dependent chemodepression was observed in response to
NA, with a threshold of about 1 qg (cf. Fig. 5.2).
Domperidone (10 yg kg-1), applied in three experiments, complet¬
ely blocked NA-evoked chemodepression (e.g. Figs 5.1 and 5.2). In
three experiments where the DA D2-agonist LY 141865* had been
injected previously, there was no chemodepression (n=1), slight but •
dose-related chemodepression (n=1), or chemodepression not obviously




Figure 5.1. Neurograms (with ramped counter outputs beneath showing
the number of action potentials counted in successive 1 s intervals)
of chemoreceptor activity in the rabbit.
A. Effect upon discharge of injecting Locke solution 0.3 ml i.e. (at
arrow).
B. Neurogram of chemosensory activity displayed at a faster sweep
speed, showing the typical quality of recording in the rabbit;
frequency of discharge was high, reflecting the presence of M-5 units,
some of which are of similar amplitude.
C. Effects of injecting DA 1 pg i.e. (at arrow) before and after DP
10 pg kg-1.
D. Effects of injecting NA 10 pg i.e. (at arrow) and E, NA 50 pg i.e.
(at arrow) before and after DP 10 pg kg-1,
F. Effects of injecting ISO 10 pg i.e. (at arrow) before and after
DP 10 pg kg-1.
Note the increase in basal discharge frequency after the antagonist.
 
Figure 5.2. Dose-response data for the effects upon chemoreceptor
discharge of injections of NA (0.1-100 yg i.e.) and ISO (0.1-100),
before (open symbols) and after (closed symbols) DP 10 yg kg-1.
Dose-related chemodepression (O) was evoked by doses of NA > 10 yg,
and this effect was abolished by DP. Only slight, non-dose-dependent
chemoexcitation (0) followed chemodepression, but became greater and
more dose-dependent after DP (•).
ISO did not cause chemodepression, but did elicit dose-dependent
chemoexcitation before DP; Amax was less clearly related to dose after
the antagonist, although the chemoexcitatory effect (AEx) was not
obviously altered.
Data are presented as integrated responses (AEx counts), Ax)&, and Amax.
NA ISO
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Chemodepression was not seen in response to the injection of ISO
(0.1-100 pg i.e., n=1; figures 5.1 and 5.2).
5.2.1.2 Chemoexcitation.
Dose-related chemoexoitation was seen in all five experiments in
response to the injection of NA. When quantified in terms of AZx the
magnitude of the chemoexcitation evoked by NA was not particularly
great (cf. figures 5.1 and 5.2), and the parameters Ax? and Amax were
only vaguely related, if at all, to dose, and then, more particularly
in those experiments where the higher doses of NA were used. The
threshold for NA-evoked chemoexcitation appeared to be in the order of
10 pg. After domperidone (see above), the chemoexcitation evoked by
NA was potentiated, and became more obviously dependent upon dose (see
Fig. 5.2), whether considering AZx, Ax?, or Amax.
ISO (0.1-100 pg i.e., n=1) caused a purely excitatory response
when injected; AZx, Ax?, and Amax were approximately log-linearly
related to dose before domperidone (Fig. 5.2). After domperidone
there was a slight increase in background rate of discharge, and AZx
for the response to ISO was slightly potentiated, whilst Ax? and
Amax became less obviously dependent upon dose (Fig. 5.2).
Effects of catecholamines upon blood pressure were qualitatively
the same as those seen in cats, although generally less substantial.
5.2.2 Studies of the effects of infusions of noradrenaline and
isoprenaline, and their interactions with the response to hypoxia.
5.2.2.1 Infusions of noradrenaline.
NA (1-50 pg min-1) was infused in five rabbits, in all but one of
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which LY 141865 had been previously injected in an independent
experiment. Results fell broadly into two categories: those in which
the effect of the amine was excitatory, and those in which it depres¬
sed chemoreceptor discharge (see table 5.1).
The experiment illustrated in Fig. 5.3 shows an apparent dose-
dependency of the net effect upon chemoreceptor discharge of infusing
NA; discharge in the steady-state correlated well with log10 dose
when
(Fig. 5.4A), suggesting that chemodepression predominated^low amounts
of the drug were infused, with the excitatory component becoming more
apparent as the amount of NA infusion per unit time was increased.
In the presence of the highest doses of LY 141865, only excitat¬
ory responses to infusion of NA were seen (the compound may act as a
partial agonist - McQueen et al, 1984). Where tested, chemodepressant
effects of NA infusion were 'converted' to excitatory responses after
injection of domperidone (10 yg kg-1, n=2 - although in one of the
experiments (number 3 in table 5.2) excitatory responses to infusions
of low doses of NA were not well sustained, and in response to a high
dose of NA, no change in discharge was seen), or L-sulpiride (100 yg
kg-1, n=1).
One experiment (number 4 in table 5.2) was anomalous in so far as
no steady-state was apparent: soon after onset of infusion there was a
rapid rise in chemoreceptor discharge, which then declined to a near
constant level of firing which was variously greater than, or less
than in the pre-injection control. Domperidone (two doses of 10 yg
kg-1) did not alter this pattern of response, whilst the dextro-rotat¬
ory isomer of propranolol (10 mg kg-1) caused a prolongation of the
'peak' increase in discharge during infusion of NA (50 yg min-1), and
after injecting the racemic preparation of propranolol (1.4 mg kg-1,
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Table 5.1. Mean steady-state discharge (x c.p.s.) during air-
breathing before and after onset of infusion of NA or ISO, discharge
during 10? 02-hypoxia, and peak discharge during ventilation with
100 ? N2 in a rabbit. Data are tabulated in the order in which
infusions were carried out.
No. Infusion Control Infusion Infusion Infusion
(ml or yg (air) (air) +10? 02 +100? N2
min~1)
1 ISO 10 12.5 16.0 28.0 54.0
2 Locke 0.1 1 .9 1 .3 5.6 8.5
3 ISO 1 2.7 3.0 8.0 10.1
4 ISO 50 3.0 5.5 10.5 25.0
5 NA 10 2.8 1 .4 9.0 15.7
6 NA 50 2.6 0.6 7.1 11 .3
7 Locke 0.1 1 .6 2.0 7.7 14.2
After MET 1 mg kg". i
8 Locke 0.1 1.5 1 .4 4.8 10.9
9 ISO 50 4.0 5.0 15.0 23.0
10 NA 50 11 .0 2.5 19.0 30.0
After L-sulpiride 100 yg kg-1
11 NA 50 2.1 3.3 5.3 6.7
12 NA 50 0.6 1 .2 6.4 12.4
After PROP 1.1 mg kg-1
13 ISO 50 5.4 6.0 9.4 11.4
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Figure 5.3. Responses of chemoreceptors to infusions (solid bar) of
Locke solution (0.1 ml min-1) and NA (1-50 pg min-1). Discharge was
averaged in successive 30 5 intervals, and plotted against time. The
lower concentrations of NA infused caused a reduction in discharge
frequency from pre-infusion control levels (solid blocks); infusion of
NA 10 |ig min-1 resulted in an initial excitation, which gave way to a
pronounced, if poorly-sustained depression of discharge. Infusion
of NA 50 pg min-1 was associated with only an excitatory effect.
NA 50 pg
NA 10 pg
14, NA 5 pg
NA 1 pg
14
i 1 1 1 1 i i r
Locke
0.1 ml
i I r » 1
12 min
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Figure 5.4. A. From the same experiment as shown in Fig. 5.3
average discharge in the steady-state achieved during infusion of NA
has been expressed as a percentage change from the average rate of
discharge in the respective pre-infusion control, and plotted against
the amount of NA infused (pg min-1) on a log10 scale. A straight line
was fitted to the data points by the method of least squares.
B. Infusion data from a separate experiment treated as above (A).
Infusion of NA (0) 1 or 50 pg rain-1 caused a dose-related depression
of discharge. After MET (3.5 mg kg-1) the chemodepressant effect of
infusing NA at the higher rate was unaltered (■). Two infusions of NA
at the higher concentration caused increases of -50? and nearly 100?
above pre-infusion control discharge after L-sulpiride 100 pg kg-1
(□). Also shown are the steady-state effects of infusing Locke
solution (0.1 ml min~l). Before antagonists, Locke-infusion (0)
caused either a slight depression of discharge (cf. Fig. 5.5 1A), or,
during a separate infusion, a slight increase in chemoreceptor
discharge. After MET (♦) the same infusion caused a much smaller
depression of discharge (cf. Fig. 5.5 1B).
Infusion of ISO (1-50 pg min-1) in this experiment caused a dose-
related increase in discharge, at steady-state. After MET (3.5 rag
kg-1) the increase in discharge elicited by infusion of ISO (50 pg
min-1; ■) was greatly attenuated, and even more so after administ¬
ration of L-sulpiride (100 pg kg-1) and PROP (1.4 mg kg-1; •).
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Table 5.2. Steady-state discharge during NA infusion, expressed as a
percentage change from pre-infusion discharge, before and after dom-
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* Domperidone, 10 yg kg-1
t Maximum dose
+ Implies transition from a 'peak' discharge to a lower rate of discharge,
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i.v.), the same level of NA infusion caused sustained excitation
of the chemoreceptors.
The 8i-antagonist MET (1 mg kg-1, n=1) did not alter the chemo-
depressant effect of infusing NA (50 yg min-1; cf. Figs 5.4B and
5.5).
5.2.2.2 Infusions of isoprenaline.
ISO, infused in two experimentSjcaused only chemoexcitation. In
one experiment infusion of 10 yg min-1 caused an excitation of 20?
over pre-infusion control discharge (domperidone had been injected
earlier in the experiment); in the other experiment there was a dose-
related increase in discharge in the steady-state (Figs 5.4B and
5.6), and excitation in response to the highest rate of infusion (50
yg min-1) was reduced by MET (1 mg kg-1), and, again, by PROP (1.4 mg
kg-1, after L-sulpiride, 100 yg kg-1).
5.2.2.3 Interaction of catecholamine infusion and the response to
hypoxia.
Hypoxia tests were performed during infusions of NA or ISO,
before and after various antagonists, in one rabbit (Figs 5.5 and
5.6). Values for mean discharge in the steady-state during air-
breathing before and after commencing infusion, during 10%02-hypoxia
(whilst infusing drugs), and peak discharge during 100? N2-ventilatiori
are shown in table 5.2, where data are presented in the sequence in
which the experiments were carried out. Variability between tests was
such that no meaningful comparisons could be made between the
quantitative analyses of these tests, whether comparing discharge (x











Figure 5.5. Chemoreceptor responses to ventilation with 10$ 02-
90$ N2 (4 min; open bar), 100$ N2 (1 min; solid bar), and 100$ 02 (2
min; stippled bar), during infusion of Locke solution (0.1 ml min-1)
or NA 10 and 50 pg min-1, (A) before, (B) after MET (3.5 mg kg-1) and
(C) after L-sulpiride (100 pg kg-1). Discharge was averaged in 30 s
blocks before onset of hypoxia, and in 15 s blocks thereafter.
The variability in discharge (note changes in calibration of the
ordinate) did not permit meaningful quantitative comparison between
tests.
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Figure 5.6. Chemoreceptor responses to ventilation with 10% 02-
90% N2 (4 min; open bar), 100% N2 (1 min; solid bar), and 100% 02 (2
min; stippled bar), during infusion of Locke solution (0.1 ml min-1)
or ISO 1 and 50 ug min"1, (A) before, (B) after MET (3.5 mg kg-1) and
(C) after L-sulpiride (100 ug kg-1) and PROP (1.4 mg kg-1). Discharge
was averaged in 30 s blocks before onset of hypoxia, and in 15 s
blocks thereafter.
Variability in discharge did not permit any meaningful quantitative
comparison between tests.
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change from each pre-infusion control, changes in discharge expressed
as a percentage change from either the plateau discharge during 10$ 02-
hypoxia in each test, or the plateau discharge on 10$ 02 during Locke
infusion (compare with the analysis of similar experiments in the cat -
Section 4). Qualitatively, ISO infusion enhanced discharge during
ventilating with room air and tended to potentiate discharge during
the hypoxia test. The rise in discharge elicited by infusion of ISO
was reduced following MET (1 mg kg-1), and also after PROP (1.4 mg
kg-1 cf. Figs 5.4B and 5.6). NA infusion caused an initial reduction
in discharge frequency, but did not alter the ability of chemorecep-
tors to increase their rate of firing in response to reduced arterial
oxygen tension. The initial depressant effect of NA (whilst breathing
air) was abolished by L-sulpiride (100 yg kg-1), after which the
effect of NA infusion was a slight excitation (Figs 5.4B and 5.5), as
previously described.
The response of chemoreceptors to hypoxia was not obviously affec¬
ted by MET or L-sulpiride (Figs 5.5 and 5.6), and after PROP only the
peak discharge during ventilation with 100$ nitrogen was diminished,
albeit during an infusion of ISO (50 yg min-1). Thus, the hypoxia
response persisted after the excitatory effect of ISO was reduced,
following the administration of PROP (in the presence of L-sulpiride).
5.3 Summary of results presented in section 5.
1 . NA injection caused dose-related chemodepression followed by
chemoexcitation. Chemodepression was blocked by the DA D2-antagonist
domperidone, after which chemoexcitation became more prominent.
Chemodepression was also partially blocked by the D2-agonist LY
141865, which may have partial agonist activity. ISO injection
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caused only ehemoexcitation, which was broadly dose-related.
2. Infusions of NA caused dose-related depression of chemoreceptor
discharge; when large amounts of NA were infused, chemoexcitation
was observed. The chemodepressant effect was abolished by L-sulpiride,
a DA D2-antagonist. In about half the experiments, only excitatory
effects of infusion of NA were seen, but these infusions were carried out
after prior injection of LY 141865.
3. ISO infusion caused only excitation of the chemoreceptors, and
the effect was apparently reduced after MET and PROP.
4. The response to hypoxia was not obviously changed by concomitant
infusion of NA or ISO, nor was the response to hypoxia markedly dif¬
ferent after administration of 8-antagonists MET or PROP, although




DISCUSSION OF THE EFFECTS OF CATECHOLAMINES AND SELECTIVE
ADRENOCEPTOR AGONISTS OR ANTAGONISTS UPON CHEMORECEPTOR ACTIVITY
SECTION 6.
DISCUSSION OF THE EFFECTS OF CATECHOLAMINES AND SELECTIVE
ADRENOCEPTOR AGONISTS OR ANTAGONISTS UPON CHEMORECEPTOR ACTIVITY.
This series of experiments was performed to investigate the
actions of catecholamines, particularly NA, upon carotid chemoreceptor
afferent activity. It was anticipated that the use of a series of
selective agonists and antagonists would allow a classification of the
sub-types of receptors mediating these effects. The effects upon
chemoreceptor activity of DA have been extensively reported, and it
was used in these experiments as a 'marker', together with responses
to cyanide or hypoxia, to confirm that a particular preparation
exhibited 'typical' chemoreceptor activity, justifying the results
obtained with less well-documented drugs.
Results obtained in cats and in rabbits do not suggest any marked
differences, unlike the early studies of the effects of ACh in these
two species (cf. Docherty & McQueen, 1979), and there appears to be no
reason to treat the data obtained independently.
The response to injections of drugs is likely to resemble that
evoked by transient or discrete release of neurotransmitters, an event
which has not been shown definitely to occur within the carotid body.
The second approach, where drugs were infused, might be taken to
represent a situation where high levels of circulating catecholamines
influence chemoreceptor activity. This could occur as a result of
increased sympathetic and adrenal-medullary activity during exercise-
stress (e.g. Galbo et al, 1975), or during altitude hypoxia in
unacclimatised subjects (cf. Cunningham et al, 1965; Sharma etal,
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1978).
6.1 The response of carotid chemoreceptors to NA and related drugs.
The response to injected NA was typically biphasic, chemodepres-
sion being succeeded by excitation, which could itself be divided into
two distinct components. Infusions of NA caused a less complex
pattern of response, which generally was a chemodepressant effect.
6.1.1 Chemodepression.
Initial chemodepression, which was dose-related, followed
injection of NA at doses of 1 yg or more. This phase of the response
was consistent, and has been reported earlier in a number of species
(e.g. cat - Sampson, 1972; Black et al, 1972; Llados & Zapata, 1978b;
Folgering et al, 1982; dog - Bisgard et al, 1979; rabbit - Folgering
et al, 1982), although few attempts appear to have been made to
quantify the response - which has been described as 'transient', or
even 'uncommon' (Llados & Zapata, 1978b). Much of the discrepancy in
the literature results, in part, from the wide range of doses used.
Thus, Folgering's group reported responses to 0.5-2.0 yg NA, Llados
and Zapata, -2-7.5 yg, Bisgard and co-workers, 0.5-40 yg, and Black's
group, 0.1-20 yg. From the results described in this thesis it would
seem that little meaningful comparison can be made with the chemodep-
ressor responses to NA reported by Folgering et al (1982) or Llados
and Zapata (1978b), since the doses they used could be considered
unlikely to cause a pronounced chemodepressant effect. Qualitatively,
there is no disagreement with the proposition that the effect is mediat¬
ed through activation of DA receptors by NA (cf. Folgering et al, 1982).
DA-receptors in the carotid body that mediate chemodepression
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appear to be of the D2-subtype (e.g. McQueen, 1984; Mir et al, 1984b)
which are unlinked (Ke'oabian & Calne, 1979) or negatively linked
(Creese et al, 1982) to adenylate cyclase. The D2-receptor has been
characterised from studies of DA activity in anterior pituitary
mamotrophs (see Kebabian & Calne, 1979) where DA mediates inhibition
of prolactin secretion independently of the stimulation of adenylate
cyclase and cAMP formation. DA, apomorphine, and dopaminergic
ergots are potent agonists at this receptor, and ligand binding
profiles are markedly different from those of the adenylate cyclase-
linked Dj-receptor typified by the bovine parathyroid gland (Kebabian
& Calne, 1979) -
L-sulpiride, which is selective for D2-receptors in the pituitary
(Stoof & Kebabian, 1981), abolishes DA-evoked chemodepression in the
cat (McQueen, 1984) and in the rabbit (Mir et al, 1984b), where the
pharmacological profile, as well as in vitro ligand binding studies,
has confirmed that the receptor mediating DA-evoked chemodepression
is of the D2-subtype. In the experiments described here, L-sulpiride
again abolished chemodepression evoked during infusion of NA in the
rabbit (see section 5). Similarly, domperidone (DP), a selective
antagonist at D2-receptors blocks DA-evoked chemodepression in both
cats and rabbits (McQueen, 1984), and in this set of experiments DP
was equally effective in blocking NA-evoked chemodepression in cats
and in rabbits (see Sections 3, 4, and 5). It is reasonable to cone-'
lude that NA depresses chemoreceptor activity through direct actions
(or via the action of endogenously released DA) at D2-receptors.
The possibility that chemodepression is a consequence of NA-
evoked release of DA (cf. Krammer, 1978) cannot be ruled out in these
experiments. Although the affinity of NA for a-receptors is some
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four times its affinity for g-recepors (see Kenakin, 1981), the
possible release of DA is unlikely to be the result of an a-adreno-
ceptor-mediated effect, since the a2-agonist OXM caused virtually no
chemodepression, and PHEN (ax) was a weaker chemodepressant than NA,
at doses equipotent in eliciting pressor responses. Similarly,
although the a2-selective antagonist RAU blocked chemodepressor res¬
ponses to NA, it had a comparable effect upon depression of discharge
evoked by exogenous DA. Mediation of DA release through a gt-
receptor can be ruled out simply by the fact that both NA- and DA-
evoked chemodepression were markedly potentiated after the antagon¬
ists MET and BET, and the depressant effects of ISO or SAL did not
differ from those of the drug vehicle.
The hydroxylated aryl-alkyl DA-derivative DOB (Tuttie & Mills,
1975) has been said not to have effects upon DA receptors (Holloway &
Fredrickson, 197-4) , but did cause chemodepression in the experiments
reported here. Minneman et al (1979a,b) showed that this drug stimul¬
ates cAMP formation, and is equipotent in inhibiting radioligand
binding to gj- and g2- receptors. Kenakin (1981) reported DOB to be a
partial agonist at a-receptors (its affinity being some twenty five
times that of NA, but its efficacy only one-fortieth), with no
selectivity for either g-receptor subtype ; its apparent gx-selectiv-
ity in clinical usage stems from a net predominance of actions
mediated via gj-receptors, when opposing actions at a-and g2-receptors
mutually cancel.
Chemodepression caused by DOB could represent a non-specific
action on the grounds that it is a short-lasting effect unrelated to
dose. It would appear necessary to confirm whether DOB truly has no
effect at DA-receptors, or whether it may be rapidly broken down with
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the release of DA or DA-like metabolites. Its ability to stimulate £5-
receptors and adenylate cyclase does not rule out the possibility of
activity at non-adenylate cyclase linked D2-receptors, since DA
itself can activate 8-receptors (e.g. Goldberg, 1972), which are
presumably linked to adenylate cyclase.
The full potential of the depressor response to NA is rarely
achieved since, particularly with' higher doses of NA, the effect
appears to be cut short by the onset of marked chemoexcitation. With
DA, where is no attenuation of chemodepression by an excitatory res¬
ponse, but a graded increase in discharge back to control frequency,
with an occasional 'overshoot' that appears as a transient excitation
following return of discharge to normal levels. This gradual decline
of the depressant effect is only seen with NA following treatment with
the antagonists MET and BET which attenuates much of the cardiovascul¬
ar response to injected NA as well as the associated increase in
chemoreceptor discharge.
DA is about twelve times more potent than NA in inhibiting the
specific binding of [3H]-apomorphine to homogenates of calf caudate
tissue (Seeman et al, 1978), but given that doses of DA as low as 0.1
pg will markedly attenuate chemoreceptor discharge, whereas the
threshold for the similar effect of NA is some 1-5 qg, the depressant
effect of NA upon chemoreceptors is some ten to fifty times less than
that of DA. Despite the differences in experimental techniques, this •
is perhaps not too disimilar from reports that NA is eighteen (Struy-
ker Boudier et al, 1974) to twenty five (Woodruff, 1971) times less
potent than DA in inhibiting firing of neurones from the parietal
ganglion of the mollusc Helix aspersa. Caution might be advised in
drawing too close a comparison, since apomorphine appears to be a DA-
- 202 -
antagonist in this preparation (Woodruff, 1971), contrary to its
agonist activity upon mammalian chemoreceptors - cf. Docherty and
McQueen (1978). At the same time, it is highly relevant that PHEN, in
the molluscan preparation,does not activate DA-receptor mediated
events at 2000 times the effective concentration of DA (Woodruff,
1978), and in the present study did not show any marked capacity to
alter chemoreceptor activity.
Since D2-receptor activation may actually inhibit adenylate
cyclase activity (Creese et al, 1982), the reduction of chemodepres-
sion by the a2-antagonist RAU may be a non-specific action, since the
drug was applied in high doses and a-receptors involved in inhibiting
adenylate cyclase activity appear to be of the a2-subtype, whilst
those that alter phophatidylinositol turnover or calcium ion levels
are of the -subtype (Fain & Garcia-Sainz, 1980). It is by no means
certain that RAU does not affect DA receptors (cf. earlier reports of
blockade of DA-chemodepression by a-antagonists - Section 1).
Two possible explanations of the potentiation of NA- or DA- evok¬
ed chemodepression by the (^-selective antagonists MET and BET may be
considered; first, a reduction in heart rate, and the possibility of
enhanced g2-mediated vasodilatation after gj-blockade in vivo,
could prolong the time during which injected substances remain within
the carotid body and capable of reacting with other receptors unaffec¬
ted by these selective antagonists. Secondly, g-antagonists are able'
to reduce neuronal and extraneuronal catecholamine uptake (e.g.
Farrant et al, 1964; Foo et al, 1968; Iversen, 1965) independently of
their blocking effects upon g-receptors. At concentrations as low as
50 pM pronethalol and PROP reduced NA uptake in the isolated rabbit
heart by some twenty and forty-five percent respectively (Foo et al,
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1968). The failure of an intrinsic mechanism to remove catecholamines
from the environment of the chemoreceptors in the carotid body treated
with g-antagonists could mean that proportionally more of the
injected dose is available (also for longer) to bind with receptors
mediating depressant effects.
6.1.2 Chemoexcitation.
Chemoexcitation followed the depression of discharge evoked by
injections of NA, and occured also in response to injections or
infusions of the agonists OXM (a2), ISO (gj/gj), and SAL (g2). When
infusing NA an excitatory effect was only obtained when large amounts
were infused per unit time.
Chemoexcitation appeared to be correlated with cardiovascular
effects of a particular drug, with respect to latency of onset,
magnitude, and duration. In the case of NA and SAL there was a
separate excitatory component that appeared not to be dependent upon
changes in cardiovascular activity.
6.1.2.1 Chemoexcitation associated with cardiovascular effects.
As with chemodepression, an excitatory response of chemoreceptors
in situ to exogenous NA has been widely reported (e.g. Joels &
White, 1968; Sampson, 1972; Llados & Zapata, 1978b; Bisgard et al,
1979; Folgering et al, 1982). Llados and Zapata (1978b) reported that
the effect is blocked by the a-adrenoceptor antagonists dibenamine and
phenoxybenzamine (as is the reflex hyperpnoea [Joels & White, 1968;
Matsumoto et al, 1980a] caused by exogenous NA - Matsumoto et al,
1981; Yasuhara et al, 1980). Although this is consistent with the
greater affinity of NA for a-receptors, in comparison with g-receptors,
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the situation becomes somewhat confused in the light of reports that
ADR and ISO (potent g-receptor stimulants) also cause chemoexcitation
in the in vitro preparation of the cat carotid body (Biscoe, 1965),
where, it is said, excitation is not due to vascularly-mediated vaso¬
constriction. Besides, the usual vascular response to ISO is
vasodilatation.
Others studying the in vitro preparation have failed to show
any immediate excitatory effect of NA or ADR upon the chemoreceptors
(Eyzaguirre & Koyano, 1965). Zapata (1975, 1977) did report a
slight but late potentiation of discharge in 'a few' preparations.
ISO is a chemoreceptor stimulant of the cat chemoreceptors in situ
(Llados & Zapata, 1978b; Lahiri et al, 198la; Gonsalves et al, 1 983),
and again the effect has been attributed to vascular changes (e.g.
Llados & Zapata, 1978b).
In addition to the in vitro excitatory effects of catechol¬
amines reported by Biscoe (1965), Folgering et al (1982) have reported
similar findings in the cat and rabbit after studying chemoreceptor
responses in situ. These authors observed the blockade of the
response to exogenous catecholamines and hypoxia by the g-antagonist
PROP. Zapata et al (1969) attributed the effect reported by Biscoe
(1965) to nerve-blockade caused by the g-antagonist DCI, rather than a
consequence of g-receptor blockade. Perhaps similar explanations
might be offered for the effects observed by Folgering's group (1982) •
since PROP has pronounced membrane stabilising activity, and has been
shown to exert local anaesthetic actions upon the dog carotid body
chemoreceptors (Silva-Carvalho et al, 1981) and carotid baroreceptors
(Schultz & Zehr, 1981) in situ. PROP has been reported not to
affect reflex responses to hypoxia in conscious man (Heistad et al,
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1972; Patrick & Pearson, 1978) and in the dog (Kontos & Lower, 1969),
nor to affect chemoreceptor responses to hypoxia or hypercapnia in the
cat (Lahiri et al, 1981a).
The onset and duration of the consistent and large excitatory
effect of NA, OXM, ISO and SAL reported in the present series of
experiments could not be dissociated temporally from the onset and
duration of the observed cardiovascular changes elicited by the
drugs. Of major significance is the fact that PHEN (at), whilst
causing hypertension as great as that evoked by NA, was virtually
devoid of any effect, especially excitatory, upon the chemoreceptors.
The lack of a response to PHEN suggests that there are no functional
aj-receptors in the carotid body of the cat, or that they are
inaccessible to or are not activated by exogenous ctj-agonists.
It would appear, however, that c^-mediated systemic vasoconstric¬
tion does not adequately explain the excitatory response to NA. A
rise in systemic arterial pressure can contribute to an increased
venous return, but also increases peripheral resistance. Although
these changes contribute to an increased cardiac output (the product
of heart rate and stroke volume), in the absence of changes in heart
rate cardiac output will not increase. PHEN increases arterial blood
pressure solely by peripheral vasoconstriction, and the drug is
considered to be devoid of cardiac activity and does not increase
cardiac output (e.g. Aviado, 1959). NA also increases arterial pres- •
sure by peripheral vasoconstriction (Green & Kepchar, 1959), but
markedly increases cardiac output due to B-receptor mediated increases
in heart rate. Chemoexcitatory responses related to an elevation of
blood pressure would appear to occur only when there is a simultaneous
increase in cardiac output.
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The a2-selective agonist OXM caused chemoexcitation (albeit the
effect was smaller than that evoked by doses of NA equipotent in
causing an increase in blood pressure), suggesting that there is some
involvement of ct2-receptors in the excitatory response to catechol¬
amines. Systemic blood pressure changes were comparable to those seen
in response to PHEN or NA, but there was no obvious effect of OXM upon
heart rate. It is not possible from these experiments to determine
whether these ct2-receptors are a part of the sensory complex, or
whether they might mediate localised vasoconstriction causing a
reduced flow within some part of the carotid body.
From the limited number of measurements made (cf. Table 3-7;
legends to Fig. 4.1) it appears that purely a-agonistic effects upon
systemic arterial blood pressure do not result in changes in arterial
gas tensions (i.e. decreased P02 or increased PC02) that will
stimulate the chemoreceptors. If cardiovascular changes in response to
a-adrenoceptor stimulation by exogenous catecholamines (particularly
NA) are to explain the concomitant chemoexcitatory effects then it is
likely that these must be mediated solely by vasoconstriction at
specific localities within the carotid body causing a highly localised
reduction of blood flow at some point critical for chemosensory
transduction. It seems improbable that such an effect would result
in chemoreceptor discharge reflecting the levels of gas tensions
in the systemic circulation in any meaningful way.
Total blood flow through the carotid body may be markedly reduced
by stimulating the sympathetic nerves, without altering tissue P02
'deep' within the carotid body, and pressumably close to the sensory
complex (Acker & 0'Regan, 1981). Because of this independence of
capillary blood flow and local tissue P02 from total blood flow
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through the carotid body, and considering the high threshold for OXM-
evoked cheraoexcitation, it seems reasonable to conclude that S-recep-
tor activation is of some importance in evoking the large excitatory
response to NA.
In the experiments described in this thesis the contribution of
f^-receptor stimulation alone determined by the use of 'selective'
agonists is unresolved, given the difficulties in determining at which
receptor types DOB is active, and the lack of excitatory responses to
PREN, which, like DOB, cannot really be classed as a Si-selective
agonist (see later). The fact that both drugs are marketed for
clinical use forms the only basis for assuming that they were
biologically active. Majcherczyk (1984) also failed to detect any
stimulation of chemoreceptor activity using a selective Si-agonist,
although ISO did increase discharge. Unfortunately it is not stated
which agonist he used, or the experimental conditions.
The cause of vascularly-mediated chemoexcitation seen with NA
would appear to be due to simultaneous a- and S~ receptor stimulation;
the a-receptor component causes vasoconstriction, reduced vascular
capacitance and an increased venous return whereas B-receptor
stimulation by NA will result in increased cardiac inotropy and, more
importantly, an increase in heart rate. All these factors will
contribute to a marked increase in cardiac output, which may cause an
increased rate of blood flow (but possibly a decreased volume) through
the carotid body. If S2-adrenoceptors mediating vasodilatation are
also stimulated the increase in rate of blood flow could be accompan¬
ied by an increased volume of flow. Also of importance during intense
vasoconstriction is the increase in total peripheral resistance
against which the heart must pump; this can attenuate the potential
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increase in cardiac output, which may thus be a very inconstant factor
between experiments. Myocardial oxygen consumption can increase after
injecting NA even in the absence of an increased cardiac output
because the work-load involved in maintaining blood flow in the
pressence of an increased total peripheral resistance is substantially
increased. The capacity of B-agonists to increase general oxygen
consumption is almost certainly irrelevant, since 'oxygen consumption'
reflects the metabolic activity of the whole body. Metabolic acidosis
might ultimately cause stimulation of the chemoreceptors, but there
was no evidence of such an effect in the acute experiments considered
here.
Although the pulmonary circulation is characteristically a low
resistance-high capacity circuit, intense vasoconstriction following
high doses of MA is likely to occur, causing a perturbation of the
normal balance of ventilation and perfusion in the lungs. Although
the pulmonary arteries are less well endowed with smooth muscle than
are the arteries of other beds, vasoconstriction can occur (most
particularly during hypoxia - Duke et al, 1961), presumably to shift
perfusion away from areas of poor ventilation. Reduced alveolar
perfusion is suggested by the decrease in Pa02 and the increase in
PaC02 measured after injection or infusion of NA in these experiments.
Systemic hypertension is also likely to increase small airways
resistance, further reducing the capacity for gaseous exchange (Bucca '
et al, 1980). If the velocity of blood flow through an organ (e.g.
lungs or carotid body) increases, then the equilibrium of blood gases
(e.g. P02) is likely to be reduced (cf. Murray, 1981). These changes
in blood gas tension might well be an important link between the
cardiovascular changes and chemoexcitation evoked by NA.
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The chemoexeitatory effects observed when blood pressure and
heart rate have been increased by NA may be compared with the
stimulation of chemoreceptors evoked by the g2-agonist SAL and the
mixed Bx/62 agonist ISO, which in these experiments both caused
systemic hypotension, but an increase in heart rate. Llados and Zapata
(1978b) reported that after i.v. injection of ISO in the cat chemoex-
citation was correlated in amplitude and time course with the systemic
hypotensive effects of the drug (a finding which is in agreement with
the effects described here); these authors also observed concomitant
blockade of chemoexcitation and vascular effects following PROP or
DCI.
Venous return falls as vascular capacitance is increased, but the
doses of B(2)-agonists used in the present study also caused a simul¬
taneous increase in heart rate, so the net effect is likely to be an
increase in cardiac output. Cardiac acceleration in response to SAL
may be due to activation of gx-receptors by high doses of the drug or
by partial mediation of cardiac chronotropy by g2-receptors. A reflex
response to systemic hypotension seems unlikely (parasympathetic act¬
ivity is reduced in pentobarbitone-anaesthetised dogs, where i.v.
injection of ADR and NA causes an increase in heart rate - Shanks
1966).
The absence of a vascularly-mediated chemoexcitatory response to
catecholamine agonists after administration of selective antagonists •
correlates with their ability to alter part of the cardiovascular
response that may contribute to an increase in cardiac output. Thus a-
antagonists reduce the pressor effects that lead to an increase in
venous return, gj-antagonists reduce the evoked increase in heart
rate, and g2-antagonists reduce the hypotensive effects which may
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reduce peripheral resistance.
The primary difference between NA- and SAL- mediated increases in
cardiac output may be that the former increases heart rate more, and
at lower doses than the g2-agonist; ISO is a well established and
potent agonist at g-receptors mediating increases in heart rate. In
addition NA might cause pulmonary vasoconstriction thereby reducing
the potential for gaseous exchange in the lungs. Despite the fact
that PaC02 appeared to increase after both SAL and NA, Pa02 was
commonly reduced after ISO, but tended to increase after SAL. It
might be concluded that changes in arterial gas tensions caused by
adrenoceptor agonists contribute to the chemoexcitatory response. What
remains to be clarified is the effect of flow through the carotid
body, and the precise regulation of the access of blood to the
chemosensory complex. The independence of glomeral tissue P02 from
total flow (Acker & 0'Regan, 1981) remains enigmatic. If 62~recePtors
mediate vasodilatation within the carotid body then, especially when
there is also an increase in cardiac output, the vol-urn e of blood
flowing through the carotid body at a certain rate, which is also
susceptible to change, may be of some importance. It is significant
that Mir et al (1983) demonstrated the probable existance of g2- (but
not 8i") adrenoceptors in the rat carotid body.
6.1.2.2 Excitatory responses to catecholamines not associated with
cardiovascular changes.
This type of excitation occured in response to NA in 67? of
experiments. Again, the full effect may net always be seen because it
can be obscured either by the marked chemodepression evoked by NA, or
by the larger secondary or delayed excitation discussed above. The
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increase in magnitude of this early excitatory response after gt-
antagonists may be due to a longer period of access of the injected
drug to its sites of action, presumed to result from a reduction in
rate of blood flow after these antagonists. The effect could also be
due to blockade of NA-uptake mechanisms by g-blocking drugs (see
above). Early transient excitation was not blocked by any of the
antagonists which alone or in combination initially attenuated and
then, at higher doses, blocked the delayed excitatory response to NA.
It might be argued that the effect is nothing more than an
injection artefact since it is not always seen, but when present, and
particularly after injection of g-antagonists, it is not markedly
dependent upon dose. Although the same type of excitation was some¬
times seen with SAL (especially after g-blockade) and to a much lesser
extent with DA (in particular after the chemodepressant effect had
been blocked) or Locke injections, it was never so intense in the
latter two cases as the response to NA or even SAL. In one experiment
it was actually shown that the transient excitation associated with
injection of Locke solution was diminished by making several injections
in succession, suggesting that the effect was due to contamination of
the injection cannula with residual NA. This form of excitation was
not observed after injections of PHEN or OXM, and so it appears that
it may be associated with g-receptor-stimulating properties. The
effect was, however, not abolished by g-antagonists, whether evoked by
NA or by SAL.
Bisgard et al (1979) reported an intense transient excitation in
dogs following injection of DA, and preceding the chemodepressant
effect of the drug. A similar effect was observed after about 45% of
i.e. injections of NA in the same animals. Excitation in response to
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DA was dose-dependent in this species. Although succinyldicholine and
gallamine did not affect the excitatory response, D-tubocurarine (D-TC
- at doses less than those required for neuromuscular block) was a
potent antagonist of initial excitatory responses to DA and also 5-
HT. The recovery of an excitatory response to 5-HT was more rapid
than recovery of DA-evoked excitation, and it is not possible to say
whether the effect is mediated by a single type of receptor sensitive
to indole- and catechol- amines, or whether D-TC was acting non-selec-
tively. D-TC did not antagonise the delayed ('vascularly-mediated*)
excitatory responses to NA. It is an attractive speculation that this
early excitatory response to NA or DA in dogs is the same as the Ex-
type excitatory effect of NA which, in the present study, was seen to
occur after or towards the end of the depression of chemoreceptor
discharge evoked by NA in the cat.
The E!-excitation evoked by NA might be related to the excitatory
response to DA seen after selective blockade of the depressant effects
of this agonist (e.g. Llados & Zapata, 1978b; Zapata & Zuazo, 1982;
Lahiri & Nishino, 1980; Nishi, 1977), or after blockade of a-receptors
with dibenamine (Zapata & Zuazo, 1982). It has yet to be determined
whether the excitatory effect of LSD (Nishi, 1975) is also related to
this transient type of excitation, since LSD is a specific ligand for
DA receptors which mediate depolarisation in some molluscan preparat¬
ions (Drummond et al, 1978); the blockade by D-TC of DA-receptors
mediating depolarisation in the molluscan nervous system has also been
reported (Ascher, 1972).
Eyzaguirre and Monti-Bloch (1980) reported that DA-evoked chemoex-
citation in the rabbit carotid body superfused in vitro was blocked
by haloperidol, as was the chemodepressor response. Nishi (1977) and
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Lahiri and Nishino (1980) found that the excitatory response to DA in
the cat carotid body in situ emerged after treatment with haloperidol.
Both Llados and Zapata (1978a) and Zapata and Zuazo (1982) found that
the excitatory response to DA was not blocked by haloperidol.
It is possible that this excitatory effect of DA reported else¬
where is mediated by non-specific activity at an adrenoceptor, since
the effect persisted after depressant effects of DA had been blocked,
using specific antagonists. This must remain unresolved until further
studies determine the nature of specific excitatory DA-receptors in
the carotid body, if such exist. It is unknown whether Dj-receptors
are located in the carotid body or would be activated by DA. DA Dx-
receptors are held to be linked to adenylate cyclase and an excitatory
response to cAMP has been reported in cats (Joels & Neil, 1968).
However, a-flupenthixol, which blocks the Di-receptor in the CNS (cf.
Kebabian & Calne, 1979) does not block the excitatory response to DA
in the cat (Docherty & McQueen, 1978).
DA can stimulate a-receptors directly (independently of the
release of NA - e.g. Mark et al, 1970), but its potency relative
to that of NA varies in different vascular beds (Waller, 1961;
McNay et al, 1965; Mark et al, 1970). Stimulation of g-receptors by
DA is a much weaker phenomenon; the potency of DA in the femoral
vascular bed of the dog being one thousandth that of ISO, and sixty-
five times less than that of NA (McNay & Goldberg, 1966).
The question of whether the chemoexcitatory effect could repres¬
ent a common action of NA and DA at DA-receptors or at adrenergic
receptors remains to be clarified, as does the relative importance of
DgH activity which might convert DA to NA under certain circumstances.
Another finding which might be said to bear comparison with the Ex-
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excitatory effect described in this thesis is the 'type I' excitation
occuring in response to stimulation of the carotid body sympathetic
nerves, reported by 0'Regan (1981). This effect was rapid in onset,
occuring 10-20 s after stimulation, and was resistant to blockade with
the a-antagonists phentolamine and phenoxybenzamine; the effect was
potentiated after haloperidol. Some 66$ of the excitatory responses
recorded were described as being of this type, which is virtually the
same as the frequency of occurance of 'Ej-excitation' in response to
injected NA reported here.
Conventional adrenoceptor and cholinoceptor antagonists do not
appear to alter either Ej-excitation in response to exogenous NA, nor
'type I' excitation in response to sympathetic stimulation. This led
0'Regan (1983) to suggest the involvement of other transmitters such
as SP or VIP in the response to sympathetic stimulation. Assuming
that exogenously administered drugs reach the same sites of action in
the carotid body as endogenously released transmitters, it seems from
the results to be presented later (Section 9) that SP itself is an
unlikely candidate as the endogenous transmitter mediating sympath¬
etic effects since it causes neither consistent nor potent excitatory
effects in the carotid body. Whether it facilitates excitation in
response to other transmitters in the carotid body remains uncertain
(see Section 9). In addition, the response to exogenous NA is
sufficiently intense that it appears unneccesary to invoke mediation
of the effect by release of endogenous substances. It remains possible
that adrenoceptors mediating the effect are atypical.
Others have also suggested the existence of 'atypical' adrenocep¬
tors, for example, the Y-adrenoceptor proposed by Hirst & Neild (1980).
In studies of the responses of the rat basilar artery to NA in vitro
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(Hirst et al, 1982) a depolarising response to bath-application of
NA was noted; cocaine potentiated the effect, and in common with
depolarisations obtained by nerve stimulation, the response was not
blocked by prazosin (c^), phentolamine (a1/a2), or PROP (g1/B2). The
receptors presumed to mediate the effect were activated equally well
by DA, ADR, and both optical isomers of NA, but not by PHEN. Flavahan
and McGrath (1980) have also shown a part of the pressor response to
ADR in the pithed rat to be resistant to combined a- and g- blockade.
Bevan (1984) has criticised the proposition of a novel type of
adrenoceptor by Hirst et al on the grounds that the threshold for
activation by NA is generally as high as 10-1*M (but evoked release of
NA from arteriolar nerves has been estimated to be from 0.4x10~3M -
Bell & Vogt, 1971 - to 10~2M - Bevan et al, 1980), and the capacity of
this 'receptor' to respond equally to several different catecholamines
is not typical of 'conventional' receptors, which are generally held
to be activated by 'selective' agonists.
What cannot be denied is that in two differing experimental
approaches to the study of chemoexcitation by catecholamines, an
excitatory response has been shown to resist blockade with potent
conventional adrenoceptor antagonists. In one case (the results
reported here) the response was evoked by exogenous NA, and in the
other (e.g. O'Regan, 1981) the response was probably caused by
activation of a noradrenergic pathway. The parallel with antagonist-
resistant pressor responses (e.g. Flavahan & McGrath, 1980) or
arteriolar depolarisation (e.g. Hirst et al, 1982) may be fortuitous,
or may suggest that a more complex aspect of catecholaminergic
mechanisms has yet to be fully studied and appreciated.
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6.1.3 Comparison of responses evoked by injections and infusions.
Except in the case of NA (the excitatory effects of which were
more marked and more consistent when the drug was injected) the
response to injections of adrenoceptor agonists was much the same as
the effect of infusion. Injections were normally completed within two
seconds so that the amount of drug reaching the carotid body when 10
pg NA were injected is roughly equivalent to an infusion of some
300 qg min-1. The doses of NA injected might be criticised as being
higher than those normally used in physiological studies, and were
generally greater than those employed by many other groups studying the
chemoreceptors. The first few seconds of an infusion of NA might be
taken to be similar to the injection of very small doses of NA; as
when low doses (<1-5 pg) of NA were injected, no obvious effect upon
chemoreceptor discharge could be detected. After infusions of NA
which resulted in chemodepression it was noted that chemoreceptor
discharge increased almost instantaneously upon stopping the infusion.
The onset of chemodepression during infusions was generally not so
rapid, taking a several seconds to occur, whereas with injections the
depression of discharge usually commenced during the injection. The
driving pressure whereby the drug is delivered to the carotid body is
obviously greater during injection than during infusion, and a single,
low rate of infusion (0.1 ml min-1) was used so as not to bias results
by applying a significant or variable pressure that could enhance flow
through the carotid body.
The predominant effect of infusing NA in both cats and rabbits
was a sustained depression of discharge. NA-evoked depression of the
response to hypoxia or hypercapnia (which are far more intense stimuli
than the more subtle changes in arterial gas tensions caused by cardio-
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vascular changes evoked by infused or injected drugs ) was evident
after Bi-blockade had reduced cardiovascular changes in response to
NA.
The profile of receptors involved in the response to infused cat¬
echolamines was similar to that deduced from the responses to
injections. PHEN (a:) was virtually inactive and OXM (ct2) was not
associated with chemodepression, but with an excitatory response. The
B-agonists ISO and SAL consistently caused chemoexcitation when infus¬
ed, and there is no obvious explanation for the unexpected depressant
effects which were occasionally observed. The excitatory effect could
again have resulted from cardiovascular changes; the increase in pulse
pressure usually persisted long after cessation of infusion, and
background discharge was usually slightly elevated following administ¬
ration of these drugs.
There is a fundamental disagreement between the present findings
and the reports of Folgering et al (1982) that infusion of ADR, NA and
ISO was accompanied by pronounced excitation of the chemoreceptors.
These authors reported that MET (Bi) and PROP (Bi/32) were equally
effective in shifting the dose-response curve for ISO-evoked excitation,
consistent with blockade of the excitatory effect. This does not
appear to allow for any S2-effect °f ISO v/hich would be expected to
remain after Bi-blockade with MET; in the present experiments SAL (B2)
was a relatively potent chemoexcitant, and Mir et al (1984a) have
described B2-binding sites in the rat carotid body, sensitive to ISO.
According to the report of Folgering et al the excitatory effects
of ADR, NA and ISO were identical when infused at rates of 1 or 1.5 pg
min-1. In the light of the present experiments such infusions of NA
would be expected depress chemoreceptor activity. These authors made
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no comment of the fact that NA has predominantly a-agonist properties,
or that both ADR and ISO would be expected to stimulate B2-receptors,
which NA, at these low doses possibly would not. One of their
findings that is consistent with the results discussed here is that
the response of chemoreceptors to NA infusion was similar to the
effect of elevating PaC02. Much of the evidence drawn from the
present series of experiments suggests that the enhancement of
chemoreceptor discharge by catecholamines is concomitant with
increases in PaC02 (and in the case of NA and ISO to a reduction of
Pa02 also). The contribution made by increased flow (during systemic
hypertension) or decreased flow (hypotensive effect) is unknown.
The observation in the present experiments that reponses to
catecholamine infusions could be 'reversed' when taking arterial
blood samples (e.g. Fig. 4.2, where the initial depression of
discharge during infusion of NA 25 or 50 pg min-1 is lost after the
blood sample at three minutes) further suggests that there is some
correlation between vascular responses and chemoexcitation evoked by
catecholamines.
6.2 Interactions of catecholamines with hypoxia or hypercapnia.
The hypoxia test performed in these experiments was reproducible
in cats. When discharge is plotted against time a distinctive pattern
of response emerges, and these 'curves', in the absence of marked
changes in background discharge, may be superimposed. If the pattern
of the response is altered as a consequence of drug-administration
then comparisons can be made between differing levels of discharge at
each stage of the test, or of the dynamic component of the test, where
chemoreceptor discharge increases in response to hypoxia.
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In the rabbit the situation was less clear, since there was far
less consistancy in the response to hypoxia within a single experiment
- background rate of discharge tended to vary between tests performed
in an experiment, and the peak discharge elicited by ventilation with
100/6 N2 did not occur in all tests (but could occur in a subsequent
test, which may imply that chemoreceptors are more readily exhausted
than in the cat). The variation in discharge did not necessarily
correlate with concomitant infusion of NA or ISO.
Ventilating cats with 10/6 02 caused a reproducible and consistent
reduction in Pa02 to -35-40 mm Hg. Discharge during air-breathing,
compared to the hypoxia steady-state level of discharge (100)6),
generally represented some 20-25? of that elicited during the
'maximal' response to 10? 02, suggesting that arterial gas tensions
during air-breathing and basal discharge rates were broadly comparable
in different animals. During 10? 02-hypoxia and 100? N2-ventilation
blood pressure usually decreased. At onset of ventilation with 100?
02 blood pressure rose rapidly to -150-200 mm Hg and heart rate
increased; during this phase a transient chemoexcitation was only
occasionally observed. Hyperoxia depresses chemoreceptor activity and
this excitatory effect is therefore related to increased blood flow
during this rapid increase in blood pressure. Whether the blood flow¬
ing through the carotid body at this time is enriched with substances
or metabolites released during hypoxia remains to be established.
Changes in the pattern of response to the hypoxia test during
drug infusions may be due to three factors. Firstly, direct effects
of drugs upon the chemoreceptors, secondly, subtle changes in gas
tensions (but the application of 10? 02-hypoxia is likely to outweigh
these), or thirdly, changes in cardiac output resulting in an increased
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blood flow. Direct excitatory effects of catecholamine agonists upon
chemoreceptor discharge might appear unlikely since only when
relatively high amounts of ISO were infused was there evidence of an
increase in the chemoreceptor response to hypoxia, even though obvious
cardiovascular changes occured with the lower levels of infusion.
Also, the clear depression of discharge during NA infusion at the
onset of hypoxia did not appear to markedly attenuate the chemorecep¬
tor response to hypoxia, exept after blockade of gj-receptors.
In the present experiments it was observed that discharge
increased during the infusion of ISO and when inspired C02 was raised.
When the percentage increase in discharge evoked by C02 was compared
to the respective air-breathing (0% C02) discharge, the relative
effect of C02 was seen to be the same whether ISO was infused or not
(Fig. 4.9). It is not possible to ascribe the increased level of
discharge during ISO infusion solely to a direct effect of the drug
upon the chemoreceptors, since not only would there have been changes
in blood flow, but Pa02 commonly fell during the infusion. The
increase in chemoreceptor discharge appeared always to be concomitant
with this effect.
The interaction of ISO with hypoxia remains a vexing problem.
Heistad et al (1972) showed an enhancement of ventilation in response
to NA or ISO infusion in man, which was abolished by PROP (in passing,
it is perhaps significant that these authors saw only a small
suppression, and no enhancement of ventilation during infusion of
PHEN). The effect of hypoxia itself was unaltered by g-blockade, a
conclusion also reached by Patrick & Pearson (1978). Wasserman et al
(1979) confirmed indirectly the excitatory effect of ISO upon cat
chemoreceptors; according to this report 1 0056 02 attenuated hyperpnoea
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in response to CN~, but had little effect upon the ventilatory
response to ISO. The authors concluded that in the absence of
peripheral chemoreceptor activity central cheraoreceptors respond to
increased PaC02 induced by the elevated cardiac output caused by ISO,
thus stimulating ventilation.
Lahiri et al (1981a) observed that injection of ISO into the
femoral artery of cats caused an increase in chemoreceptor discharge
within 2.5 s, peaking at 5 s (perhaps a surprisingly short latency for
a direct action upon the carotid body). The chemoreceptor response to
ISO was shown by these authors to be reduced by hyperoxia and
augmented by hypoxia, suggesting that the response to ISO is related
to intrinsic activity of the chemoreceptors at the time of injection.
Evidence supplied in the report of Lahiri et al also suggests that
the chemoreceptor response to ISO precedes, and is independent of
cardiovascular changes. It was allowed that 'a local constrictor
effect on carotid body blood vessels, which may respond to
isoprenaline in a manner different from that of the rest of the
circulation, cannot be ruled out'. ISO can indeed cause even systemic
vasoconstriction (Butterworth, 1963) but at doses (mg) higher than
those injected i.e. in the present series of experiments, and far
greater than those used by Lahiri et al (1981a).
Although the addition of C02 to inspired air to maintain alveolar
PC02 constant during infusion of NA in man (Barcroft et al, 1957) is
required to maintain hyperpnoea in response to infusion, stimulation
of ventilation by ISO is both more powerful and sustained during i.v.
infusion (Cobbold et al, 1960), and is not reduced by the concomitant
fall in alveolar PC02. It is of course impossible here to separate
peripheral and central stimulatory effects upon ventilation, for even
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if peripheral drive decreased with the hyperpnoeic reduction in PaC02,
a central drive from stimulation of ^-receptors - but probably not
B2-receptors - by ISO (Folgering, 1980) might compensate. Hence,
evidence suggests that the ventilatory response to NA mediated by
the peripheral chemoreceptors is 'self-limiting' because of the
resultant fall in PaC02, but direct activation of B(x)-receptors
would appear also to mediate an increase in ventilation. It must be
conceded that this effect, which is largely a property of the drug
ISO, could be mediated at central rather than peripheral sites.
Folgering et al (1982) showed a reduced chemoreceptor response to
hypoxia following g-receptor blockade. In the present experiments
such an effect was seen only after relatively large doses of PROP, and
even then chemoreceptor discharge never failed to increase in response
to 10$ 02-hypoxia. In their experiments Folgering's group also used
the g!-antagonist MET, and found it to be as effective as PROP in
attenuating the hypoxia response. Of the antagonists used in the
present study, PROP, MET and ICI 118551 may be problematic because of
their membrane-stabilising actions (e.g. Dohadwalla et al, 1969; i?blad
et al, 1975; Bilski et al, 1979; Evangellsta et al, 1981). The dose
of PROP expected to exert this effect has been estimated to be 10-30
pM (Rand et al, 1976) or approximately 3~9 mg, well within the range
of doses used in these experiments (PROP may also function as a 5-HT
antagonist - e.g. Green et al, 1981 - which could further complicate
interpretation of results obtained using it). The relatively weaker
membrane-stabilising properties of MET ($blad et al, 1975) may explain
why the chemoreceptor response to hypoxia was less attenuated after
this antagonist than after PROP in the present experiments.
BET has at least ten times the 8i-blocking capacity of PROP or
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MET, and a longer duration of action, but it has more than twenty-
times less membrane-stabilising capacity as PROP (Boudot etal,
1979). This antagonist (at doses which altered cardiovascular
activity and the responses to exogenous NA) caused no significant
change in the response to hypoxia, and the failure of this antagonist
to attenuate the effects of hypoxia can be confidently accepted as
evidence that gx-adrenoceptors are not involved in the carotid
chemoreceptor response to hypoxia in the anaesthetised cat.
It is uncertain whether the attenuation of the hypoxia response
after ICI 118551 resulted from damage to the carotid body caused by
the acid vehicle, membrane-stabilising properties of the antagonist
(which are comparable to those of PROP - Bilski et al, 1979), or to
other effects.
Further experiments are necessary to determine whether an en¬
hanced chemodepressant effect of endogenous NA after gj-receptor
blockade could account for any reduction in the response to hypoxia.
Tentative evidence for such an effect is to be found in the
observation that little reduction in the response to hypoxia was
observed after MET when the D2-antagonist domperidone had been
previously administered. This would require that a significant
ammount of NA or ADR would reach the chemosensory complex during
from type I cells,
hypoxia. Whether this would be derived^from sympathetic terminals, or
from the adrenal medulla remains to be shown.
Other reports also disagree with the findings reported by
Folgering et al (1982). Mills and Smith (1983) reported a sustained
increase in chemoreceptor discharge with low rates of i.v. infusion of
NA (0.02- 0.04 mg kg-1hr-1) in cats, prevented by atenolol (5 mg kg-1);
the response to hypoxia or asphyxia was retained after the antagonist.
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Gonsalves et al (1983, 1984) showed that ISO infusion shifted the
line relating chemoreceptor discharge to arterial 02-saturation
slightly to the right, and that the g-antagonists PROP, atenolol and
ICI 118551 all caused a similar left-wards shift of the curve (as
well as blocking the effects of ISO infusion). In no case was there
any change in the slope of this line, and it was concluded that ISO
did not interact with the hypoxic stimulus, but exerted actions at a
site different from the 02-sensor. The authors commented that
chemoreceptor discharge declined abruptly after PROP, with a recovery
to near control levels within 5 minutes, suggesting that the time
interval for retesting the hypoxia response after PROP is critical.
It seems unlikely that Folgering's group would have fallen into such a
trap. An additional observation in the present experiments was that
occasionally after PROP systemic blood pressure fell rapidly and was
accompanied by a very large sustained increase in chemoreceptor
discharge. This in itself suggests that the normal mechanism of
chemotransduction was not compromised by the g-blocker.
6.3 Comments on the drugs used.
In an in vitro preparation of an isolated tissue it is some¬
times possible to block activity selectively at specified receptors
allowing the study of actions at another receptor, independently.
This is not possible in the whole animal since the sensitivity of
differing tissues to selective antagonists is highly variable (because
of differing receptor densities, accessibilities, etc.), and marked
changes in homeostasis can occur without necessarily involving the
blockade of receptors whose activation interferes with the response
under examination. Concentrations of drugs at different sites are
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unknown and may be non-uniform in the whole animal, and reflex mechan¬
isms or physiological antagonism can have important effects upon a
particular agonist-receptor response (cf. Furchgott, 1972). Hence,
the blockade of ISO-evoked hypotension may occur with lower doses of
antagonists (PROP) than are required to block its cardiac actions
(Shanks, 1966).
The rationale for using the 'selective' gj-agonists DOB and PREN
was to assess the effects mediated by g1-receptors that could con¬
tribute to the complex response to NA. The effects of both drugs were
markedly different, and neither can be considered to be truly
selective for gj-adrenoceptors. The actions of DOB have been discus¬
sed above; Kenakin and Beek (1980) showed the affinities of ISO and
to be equal
PREN for gt- and g2- receptors^ It was determined that there were
strong differences in the stimulus-response mechanisms of different
tissues leading to a 'functional organ selectivity' of PREN rather
than a 'receptor selectivity'. It is evident that occupation of
carotid body g-receptors, (whether they be gt or g2) by PREN does not
lead to any marked changes in chemoreceptor activity, and g-receptor
occupation by ISO, NA or SAL is either accompanied by more efficient
stimulus-response coupling (adenylate cyclase activation?) at sites
within the carotid body, or is more important at sites outwith the
carotid body.
Results obtained with the agonist SAL may ultimately cause some
problems for interpretation for, although the drug is held to be
selective for g2-receptors, it has similar binding affinities for gj-
and g2- receptors in vitro, it is an antagonist at gx-receptors, and it
may exhibit partial agonist activity at g2-receptors (Minneman et al,
1979a) which could cause 'desensitisation' of the preparation.
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The somewhat low potency as a chemoexcitant of the a2-selective
agonist OXM may not necessarily argue against a possible involvement
of a2-receptors in the response to NA because, although the drug has
five times the affinity of NA for the same binding sites, it has only
0.2-0.3 times the efficacy of NaT Consequently, occupation by NA of a
smaller proportion of the available binding sites is adequate for the
generation of a response, in contrast with OXM.
Letts et al (1983) studied the blocking effects of PROP and MET
in the cat and concluded that MET, particularly at high doses, showed
no clear organ selectivity in vivo, and was 'cardioselective' (i.e.
selective for (^-receptors) at low doses only (0.1-0.5 ymol kg-1, -69-
345 yg kg-1). Low doses of ICI 118551 are selective for g2-receptors,
but Johns (1981) has determined that there was a significant reduction
in the cardiac accelerating effect of ISO after administration of 2.9
yM of the antagonist in cats. Thus, in the present experiments the
low doses of ICI 118551 (100 yg or 0.3 yM kg-1) may be considered to
have blocked g2-receptors, whilst higher doses (1 mg or 3yM kg-1) may
have resulted in a more complete and non-selective g-receptor
blockade, which, none-the-less, did not necessarily result in a loss
of normal chemoreceptor responsiveness.
The antagonist yohimbine, of which COR (a,) and RAU (a2) are
stereoisomers (cf. Weitzell et al, 1979) has been shown to have local
anaesthetic properties (e.g. Lipicky et al, 1976, 1977) particularly
in the heart (Azuma et al, 1978). This means that it might be
necessary to apply similar reservations to data obtained after a-
blockers as with g-antagonists. The selectivity of these drugs must
also be treated with caution, since Langer et al (1981) demonstrated




adrenoceptor sites, but less obviously so at ax-adrenoceptors.
A final aspect which has only recently been suggested to be of
importance to adrenoceptor activity is the effect of pHa. In rats
the mediation of pressor responses by a-adrenoceptors is highly
susceptible to modulation by changes in acid-base balance; ADR acts
predominantly through cii-receptors at high pH, but the significance
of a2-activity increases as pHa falls (e.g. McGrath et al, 1982).
These authors also demonstrated that the pressor effects of PHEN and
the a2-selective agonist xylazine decrease and increase respectively
with a reduction in pHa; effects upon antagonist properties are
similar.
The question to be asked in conclusion is which component of the
chemoreceptor response to NA is the more important? The evidence
provided by these experiments suggests that high local concentrations
of NA would depress chemoreceptor activity. It is doubtful whether
endogenous levels of NA would ever be sufficient to replicate the
potent effects of exogenous ISO, particularly if chemoexcitation is
also mediated by g2-receptors, as suggested by the results obtained
with SAL. a2-receptors, but almost certainly not a1-receptors, might
also be involved in the excitatory response (though it is but speculat¬
ive whether these are a part of the chemosensory mechanism or mediate
local vasomotor activity). Even-so, in the case of NA these effects
would appear to be secondary to the chemodepressant effects. Much of'
the excitatory response to NA can be attributed to cardiovascular
changes, but general vasoconstriction with no increase in cardiac
output does not appear to compromise the chemoreceptors, as evidenced
by the lack of excitatory responses to PHEN (ax).
The inability of g-antagonists to attenuate the response of
- 228 -
chemoreceptors to hypoxia, in disagreement with the data of Folgering
et al (1982) also suggests that functional S-receptors are not
important for normal chemotransduction. A phase of chemoexcitation
that appears not to be dependent upon cardiovascular changes, and to
be resistant to blockade by adrenoceptor antagonists raises the
possibility that the carotid body contains atypical adrenoceptors
which might enable the chemoreceptors to respond in a manner that




STUDIES ON THE EFFECTS OF 5-HYDROXYTRYPTAMINE
SECTION 7.
STUDIES ON THE EFFECTS OF 5-HYDROXYTRYPTAMINE.
7.1 Introduction.
5-HT is present in the cat carotid body (see Section 1) but its
physiological role there remains to be determined. Intracarotid
injection of 5-HT in anaesthetised cats produces a complex response
(e.g. Black et al, 1972; Nishi, 1975; Docherty & McQueen, 1978),
whilst in the in vitro preparation, no significant effect of 5-HT has
been shown (Eyzaguirre & Koyano, 1965). Nishi (1975) found the
response of chemoreceptors in situ to 5-HT to be unaltered by atropine
or hexamethonium, thus precluding the involvement of ACh receptors,
but the putative (and non-selective) 5-HT antagonists (+)-lysergic
acid (LSD, which can also act as a partial agonist), methysergide, and
gramine were also without effect upon the response; consequently, the
receptors that might be associated with the chemoreceptor response to
5-HT remain, to date, unclassified. With the advent of more selective
agonists and antagonists, a further attempt has been made to character¬
ise the types of 5-HT receptors that might mediate the response of
chemoreceptors to exogenous (and, by inference, to endogenous) 5-HT.
Fozard and Gittos (1983) and Fozard (1983, 1984a) described a new
antagonist, MDL 72222 (MDL; 1aH,3aH,5aH,-tropan-3-yl-3,5-di-chloro-
benzoate), which is a potent and highly selective antagonist at
certain 5-HT receptors on mammalian peripheral neurones, for example,
the fibres mediating the von Bezold-Jarisch reflex in the rat heart.
5-methoxytryptamine (5-MOT) is an active stimulant at a variety of
5-HT receptors (see Fozard & Mobarok Ali, 1978), but devoid of
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activity, at 5-HT excitatory sites on the cat inferior mesenteric
(Gyermek & Bindler, 1962) and rabbit superior cervical (Wallis & Nash,
1981) ganglia, and sympathetic nerve terminals of the rabbit heart
(Fozard & Mobarok Ali, 1978). It can thus be considered to be devoid
of agonist activity at MDL-sensitive 5-HT receptor sites. In contrast
to 5-MOT, the 2-methyl substituted form of 5-HT (2-Me 5-HT) is said to
be a potent stimulant of MDL-sensitive 5-HT receptors (Humphrey,
1984).
The classification of 5-HT receptors as 5-HT! or 5-HT2, on the
basis of radioligand binding studies has been proposed by Peroutka and
Schneider (1979). According to this classification ketanserin is a 5-
HT antagonist with high selectivity for 5-HT2 receptors, and no
activity at 5-HTj receptors (Leysen et al, 1981). 5-HTx receptors
have been further subdivided, and 8-Hydroxy-2-(di-n-propylamino)
tetralin (8-OH DPAT) is a selective agonist at 5-HT-|^ receptors
(Middlemiss & Fozard, 1983), and 5-methoxy-3~(1,2,3,6- tetrahydro-
pyridin-4-yl)1H indole (RU 24969) is a selective agonist at 5-HT-]g
receptors (Cortes et al, 1984).
Dopamine is a potent depressant of spontaneous chemoreceptor
activity in the cat (Docherty & McQueen, 1978); a-flupenthixol (0.2 mg
kg-1) blocks this action of DA, and higher doses (0.5-1.0 mg kg-1)
also block the depressant effects of 5-HT (Docherty & McQueen, 1978).
It was considered that the effects upon 5-HT evoked chemodepression
of domperidone, which antagonises the chemodepressor effects of DA in
vivo (cf. McQueen, 1984, and Sections 3-6 of this thesis), should be
examined.
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7 . 2 Results.
Experiments were performed on twenty cats, of which seven were
anaesthetised with pentobarbitone, and the remainder with ct-chloral-
ose. No obvious differences were seen in the results obtained using
these two different anaesthetics, and data from the two groups were
pooled.
7.2.1 Effects of injected 5-HT.
Dose-response data for the effects of 5-HT were obtained from
sixteen recordings, and 5-HT (1-100 pg, injected i.e.) consistently
caused a depression of spontaneous discharge, which lasted for some
3-15 s (Fig. 7.1). This chemodepression was rarely 'absolute', as
occurs in response to dopamine when discharge is 'silenced' for a
significant period of time. The effect was clearly dose-related in
twelve (75%) of the recordings, as shown in Fig. 7.2 where the
change in chemoreceptor discharge frequency in the first five seconds
after injection (expressed as a percentage of the frequency during the
pre-injection control period) is plotted against log10 dose of 5-HT.
This method of expressing results was used so that a comparison could
be made of data obtained from experiments with differing rates of
basal discharge. In the remaining four experiments (25%), chemodepres¬
sion, although present, was not obviously related to dose, and it
should be noted that tachyphylaxis or desensitisation is a problem
commonly encountered in studies with 5-HT; the presence or absence of
such .an effect in these experiments largely depends upon the interval
allowed between successive injections (cf. Nishi, 1975).
The threshold for chemodepression was about 1 pg, with lesser
doses producing only slight changes in discharge which were not
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Figure 7.1. Neurogram showing the response of 2-3 chemoreceptors to
the injection of 5-HT (100 qg i.e., at arrow). The ramped counter
output below the neurogram shows the number of action potentials
counted in successive 1 s intervals. Clearly shown in this figure are
all three phases of the response to 5-HT - initial transient chemoexcit-
tion, chemodepression, and subsequent (delayed) excitation.
Figure 7.2. Dose-response data showing the relationship between
dose of 5-HT (log10 scale) and the percentage change in chemoreceptor
discharge (from pre-injection control levels) that occured in the
first 5 seconds after injecting the drug, and precluding the initial
transient excitation. A straight line was fitted to the data by the
method of least squares, and the ID50 determined (see broken lines).
(♦) denotes the effect of injecting Locke solution (drug vehicle).
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significantly different from the effects of injecting Locke solution
as a vehicle control.
From dose response curves such as that shown in Fig. 7.2, the
parameter *ID50' (the dose of 5-HT causing a 50? depression of spont¬
aneous discharge in the first five seconds of response) was deter¬
mined, and the mean ID50 (± S.E.M.) for the twelve experiments where
the response was dose related was 5.8 ± 1.9 yg.
In nine of these recordings (56?), chemodepression was preceded
by a transient burst of action potentials (Fig. 7.3). Both latency
of onset and duration of this effect were very short, the burst
usually taking place, or at least commencing, within the period of the
injection. The threshold for this excitatory effect was rather great¬
er than that of chemodepression, since transient chemoexcitation was
not obvious at doses below 10 yg 5-HT. This brief phase of excitation
represented an increase of up to 1000? of the pre-injection control
discharge, but a clear dose-response relationship was seen in only
three experiments (33? - Fig. 7.11), perhaps because of tachyphylaxis.
In those experiments (25?) where transient chemoexcitation was
not observed, chemodepression was still obtained. This suggests that
chemodepression does not represent a state of refractoriness after
injection of 5-HT, since chemodepression also occured in the absence
of any obvious initial excitatory response to 5-HT, a conclusion which
is supported by the observation that a second 'burst' of action
potentials sometimes occured during the 'wash' phase of i.e. injec¬
tions of 5-HT, before the onset of chemodepression (Fig. 7.4).
In most experiments chemodepression was succeeded by a delayed
chemoexcitation (Figs 7.1, 7.3), where the discharge frequency first














Figure 7.3- Neurograms showing the effects of the injection of 5-HT .
(10 ng i.e., at arrow) upon chemoreceptor discharge (3 units), and
illustrating in (A) an initial burst of action potentials, followed by
a period of relative depression of discharge. The same test is
displayed at a slower sweep speed in (B), where a delayed phase of
chemoexcitation can be seen, following chemodepression. The ramped
counter output below each neurogram shows the number of action
potentials counted in successive 1 s intervals.
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Figure 7.4. Neurogram showing the immediate response of chemo-
receptors to the injection (i) of 5-HT, 25 yg i.e. A second (larger)
burst of action potentials occured when the injected drug was washed
in with Locke solution (w). The ramped counter output below the
neurogram shows the number of action potentials counted in successive
1 s intervals.
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Where present, the effect was rather prolonged, lasting some 10-60
seconds, but no consistent dose-response relationship was apparent.
The onset and the duration of this effect appeared to be coincident
with the systemic hypotensive response to the injection of 5-HT (see
Fig. 7.14).
7.2.2 Effects of selective 5-HT agonists.
7.2.2.1 Effects of 5-methoxytryptamine.
When injected i.e., 5-MOT (1-100 pg; n=3) caused no initial
transient chemoexcitation, and either no chemodepression (in one
experiment), or (in two experiments) chemodepression no greater than
that caused by the injection of Locke solution as a control (Figs
7.5 and 7.7). No clear secondary excitatory effect was observed, and
the agonist thus appeared to have only minimal effects upon chemo-
receptor discharge.
7.2.2.2 Effects of 2-methyl 5-hydroxytryptamine.
This compound was used in four experiments. In only one out of
the four experiments (25?) did 2-Me 5-HT (1-50 pg, i.e.) cause an
initial transient chemoexcitation; chemodepression similar to that
caused by 5-HT was seen in all four experiments, although the effect
was usually no greater than caused by 5-HT itself (Figs 7.5, 7.6, and'
7.7). No obvious delayed chemoexcitation was observed although the
agonist caused systemic hypotension comparable to that evoked by 5-HT.
7.2.2.3 Effects of the selective 5~HTt agonists, 8-OH DPAT & RU24969.
Both these agonists were applied in the same two experiments, and
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Figure 7.5. Neurograms showing responses to i.e. injection (at
arrows) of 5-HT (10 yg), 2Me 5-HT (25 yg) , 5-M0T (10 yg), 8-0H DPAT
(10 yg) and RU 24969 (25 yg). Responses to the same doses of 5-HT and
2Me 5-HT after MDL, 1 mg kg-1 are also shown. The typical triphasic
response to 5-HT is clearly demonstrated, and the usual changes are
seen after the antagonist; the response to 2Me 5-HT is similar,-but
the initial transient excitation appears to be absent. 5-M0T was
devoid of significant influence upon chemoreceptor activity, and 8-0H
DPAT and RU 24969 were potent depressors and excitors respectively of
chemoreceptor activity. A ramped counter output beneath each neuro-
gram shows the number of action potentials counted in successive 1 s
intervals.
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Figure 7.6. Neurograms showing responses to i.e. injection (at
arrows) of 5-HT (10 yg), 2Me 5-HT (10 yg), RU 24969 (25 yg) and 8-0H
DPAT (25 yg). Responses to the same doses of agonists, with the
exception of 2Me 5-HT, are shown after MDL 100 yg kg-1. The typical
triphasic response to 5-HT is clearly demonstrated, and the usual
changes are seen after the antagonist; the response to 2Me 5-HT is
similar, but the initial transient excitation appears to be much
smaller. 8-OH DPAT and RU 24969 were potent depressors and excitors
respectively of chemoreceptor activity, and their affects were not
markedly altered after the 'neuronal' antagonist. A ramped counter
output beneath each neurogram shows the number of action potentials
counted in successive 1 s intervals.
Control MDL 100 yg










Figure 7.7. Dose-reponse data from a single experiment showing the
chemodepressant effects (•) and excitatory effects (■) of injecting
(A) 5-HT, (B) 5-MOT, (C) 2Me 5-HT, (D) RU 24969, and (E) 8-OH DPAT.
Changes in chemoreceptor discharge were integrated with respect to pre-
injection control discharge, (AEx), and plotted against dose, using the
same log-molar scale. Lines were fitted to the data using the method
of least squares.
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their effects were markedly different.
RU24969 had no effect upon systemic blood pressure, but caused a
marked, dose-related chemoexcitation (Figs 7.5, 7.6, and 7.7),
following a transient depression of chemoreceptor discharge not
markedly different from that caused by injection of the drug vehicle.
The latency of onset of the excitatory effect was only a few seconds,
but the duration of the effect was much longer than that of other
excitatory responses evoked by any of the 5-HT agonists studied.
8-OH DPAT caused neither initial transient nor delayed chemoex¬
citation, but did evoke chemodepression similar to or greater than
that observed with 5-HT (Figs 7.5, 7.6, and 7.7). This agonist
caused a prolonged and progressively larger 'step-wise' decrease in
blood pressure as the dose was increased.
7.2.3 Experiments with novel 5-HT antagonists.
t
7.2.3.1 Effects of MDL 72222.
Intracarotid injection of MDL (10-100 yg kg-1) caused a depres¬
sion of chemoreceptor discharge which was followed by a delayed
increase'in frequency (Fig. 7.8); transient chemoexcitation during the
injection MDL was never observed, and systemic blood pressure was not
noticeably affected by the antagonist.
In seven recordings MDL (10 yg kg-1 i.e.) caused the dose res¬
ponse curve for 5-HT-induced chemodepression (first five seconds
after injection) to shift upwards, and to the right (Fig. 7.9), and
the mean IDS0 was increased to 49.4 ± 33.6 yg (n=7; P < 0.05 with
respect to controls [see above], Wilcoxon two sample test, two-tailed).
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Figure 7.8. Neurograms of chemoreceptor discharge illustrating the
response to the injection, (at arrow) of (A) MDL 72222 (100 yg kg-1,
i.e.), and, from a separate experiment, (B) ketanserin (100 yg kg-1,
i.e.). The ramped counter output below each neurogram shows the
number of action potentials counted in successive 1 s intervals.
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Figure 7.9. Cheraodepressant effect of 5-HT (expressed as a percen¬
tage change from pre-injection control discharge) injected before
(O—O) and after MDL 72222, 1 (♦--♦), 10 (•-—•), and 100
(■--■) yg kg-1. Although the low dose of antagonist appeared to
potentiate the chemodepression evoked by 5-HT, higher doses caused
progressive rightward shifts in the dose-response curve, increasing
the IDsa.
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which it followed the lower dose) there was a further upwards, and
rightwards shift of the dose-response curve, and the IDS0 was increas¬
ed to 638 ± 408 yg in five of the recordings (63? - Figs 7.9, 7.10).
This increase was, again, significant at the 0.05 level. In the
remaining three recordings (37?) a dose-dependent chemoexcitation
was obtained in the first five seconds after the injection of 5-HT
(e.g. Fig. 7.10), and no chemodepression occured unless very high
doses of 5-HT (250-1000 yg) were injected. This chemoexcitation never
attained a 50? increase above control and it appeared more valid to
calculate an ED30 (dose of 5-HT causing a 30? increase in discharge
frequency above control), which was 103.1 ± 9.0 yg (n=3).
In the nine experiments where transient chemoexcitation was
evoked by 5-HT, this part of the response was substantially reduced
(totally abolished in two recordings - 22?) by MDL, 10 yg kg-1 (Fig.
7.11). Increasing the dose of antagonist to 100yg kg-1 further reduced
or abolished this part of the response (Figs 7.11 and 7.12).
The delayed or secondary chemoexcitation generally increased in
magnitude, and became more rapid in its onset after MDL (10-100 yg
kg-1; Fig. 7.13). This phase of increased chemoreceptor discharge
thus no longer appeared to be correlated with systemic hypotension.
The magnitude and latency of onset of the hypotensive response to
5-HT was not obviously altered by the antagonist.
Chemodepression evoked by 2Me 5-HT was slightly reduced after
MDL in the one experiment where studied, although the depressant
effect of 5-HT itself was more obviously attenuated (Fig. 7.5)
The effects of 8-0H DPAT after MDL (100 yg kg-1) were studied in
only one experiment, where it appeared (Fig. 7.6) that chemodepression
evoked by 8-0H DPAT resisted blockade by MDL, even though the
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Figure 7.10. (A) Chemodepressant effect of 5-HT injected before
(0—KD) and after (»--•) MDL 72222, 10 ug kg-1, i.e. An
'additional dose of antagonist (100 ug kg-1, i.e.) caused a further
shift of the dose-response curve upwards and to the right (■). In a
separate experiment (B) the higher dose of antagonist (100 ug kg-1)
completely abolished 5-HT-evoked chemodepression (■ ■), and slight
chemoexcitation was obtained in response to the lower doses of 5-HT
Lines were fitted to the data using the method of least squares.
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Figure 7.11. Discharge during the initial transient cheraoexcitation
('burst') expressed as a percentage change from pre-injection control
discharge, and plotted as a function of dose of 5-HT , before (0 0)
and after MDL 72222, 1 (♦--♦), 10 (• •) and 100 (■) ug kg-1, i.e.
Lines were fitted to the data using the method of least squares.
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Figure 7.12. Responses of chemoreceptors (multiple-unit recording) to
i.e. injections at arrows of 5-HT 5 pg (A), and 25 pg (3), before
and after injecting MDL 72222 100 pg kg-1, i.e. The initial transient
chemoexcitation and the subsequent depression of discharge were both
virtually abolished by the antagonist, after which chemoexcitation
became more evident in the first five seconds of the response to 5-HT
injection. Each ramped counter output shows the
number of action potentials counted in successive 1 s intervals.
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Figure 7.13» Delayed chemoexcitation expressed as a percentage
change from pre-injection control discharge, and plotted against
dose of 5-HT before (0 0) and after MDL 72222, 1 (♦---♦),
10 (•- - -•), and 100 (■ ■) yg kg-1, i.e. Delayed excitation
became prominent, and more clearly dose-related, after the high dose
of antagonist. Lines were fitted to the data, as appropriate, using
the method of least squares.
- 249 -
chemodepressant effect of 5-HT was attenuated.
7.2.3.2 Effects of the antagonist ketanserin.
The effects of ketanserin alone were studied in five experiments.
Intracarotid injection of ketanserin (100yg kg-1) caused an increase
in chemoreceptor discharge lasting some 10-30 s (Fig. 7.8), accompan¬
ied by a much more prolonged fall in systemic arterial blood pressure,
which may indicate a change in tonic vascular tone. The injection of
this antagonist caused neither chemodepression nor any bursting
pattern of chemoexcitation.
5-HT was the only agonist studied after injection of ketanserin.
In three of these recordings where there was an initial transient
excitation in response to 5-HT, the effect was unaltered by ketanserin
(e.g. Fig. 7.14). The marked chemodepression appeared also to be
unchanged after administration of the 5-HT2 antagonist, but there was
mean
a small increase in the^ID50 for the 5-HT-induced chemodepression, to
14.2 ± 5.0 yg (n=4; P < 0.05). This represents a small but statis¬
tically significant decrease in the average response after ketanserin,
although substantially less marked than the antagonism of
chemodepression caused by even 10 yg kg-1 MDL, and in some tests
ketanserin showed little or no antagonism of 5-HT-evoked chemodepres¬
sion, as can be seen from inspection of Fig. 7.14.
In all five recordings where tested both the delayed increase in
chemoreceptor discharge and the hypotensive effect of 5-HT were
substantially reduced, or abolished by ketanserin (Fig. 7.14).
In five experiments where ketanserin (100 yg kg-1) was injected
after MDL (100 yg kg-1), any chemoexcitatory response to injected 5-HT
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Figure 7.m. (A) Injection of 5-HT (10 yg i.e. at arrow) caused
typical changes in chemosensory discharge (lower trace - count of
action potentials in successive 1 second intervals), and also caused
systemic hypotension (upper trace).
(3) After ketanserin (100 yg kg-1, i.e.) the same dose of 5-HT had
much less effect upon blood pressure, and there was less delayed
chemoexcitation (-10-15 5 after injecting 5-HT). Both initial
transient excitation and chemodepression were relatively unaffected
by this antagonist.
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seconds after injection against log10 dose produced a line of such
shallow slope that values for ID50 or ED30 could be obtained only by
extrapolation far beyond the range of doses that could feasibly be
used in these experiments, and were therefore not considered to be
meaningful. Similarly, when MDL (100 pg kg-1) was administered after
ketanserin, in five experiments, there was no longer any obvious
chemoreceptor response to injected 5-HT.
7.2.4 Effects of the dopamine D?-antagonist domperidone.
This antagonist had no effect upon 5-HT-evoked chemodepression,
or any other part of the response to 5-HT (Fig. 7.15). The doses
applied (10-100 pg kg-1, i.e.) were adequate to block the chemodep¬
ression evoked by injection of DA (0.1-10 pg i.e.). No effect of
domperidone upon the 5-HT response was observed whether the injection
was made before (n=4) or after (n=4) the application of the 5-HT
antagonists reported above. IDS0 values for 5-HT-induced chemodep¬
ression obtained after domperidone in the absence of other antagonists
were 10.8 ± 2.5 pg (n=4) and 8.1 ± 3.1 pg (n=2) for the 10 and 100 pg
kg-1 doses respectively (P > 0.05 when compared with controls).
Conversely, the chemodepressant effect of DA (0.1-10 pg i.e.), which
was obtained in all recordings, was unaffected by either ketanserin or
.MDL (Fig. 7.16).
7.2.5 Effects of antagonists upon the responses to physiological
(hypoxic) stimulation.
The effect of hypoxic stimulation (4 minutes ventilation with
10$ 02:90$ N2) was studied in fourteen experiments. Figure 7.17 shows
the responses to hypoxia obtained before and after the injection of
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Figure 7.15. Neurograras showing the responses of chemoreceptors to
injections (at arrows) of (A) 5-HT (10 pg i.e.) and (B) DA (1 pg i.e.)
before and after administering the antagonist domperidone (10 pg kg-1
i.e.). The antagonist greatly reduced DA-evoked chemodepression,
without appreciably altering the response of chemoreceptors to 5-HT.
A ramped counter output below the neurograms shows the number of
action potentials counted in successive 1 s intervals.
Figure 7.16. Neurograms showing the responses of chemoreceptors to
injections (at arrows) of (A) 5-HT (25 pg i.e.) and (B) DA (1 pg i.e.)
before and after administering the antagonist MDL 72222 (100 pg kg-1
i.e.). The antagonist virtually abolished 5-HT-evoked chemodepres¬
sion, whilst that caused by injection of DA was hardly altered. A
ramped counter output below each neurogram shows the number of action
potentials counted in successive 1 s intervals.
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Figure 7.17. The increase in chemoreceptor discharge caused by .
ventilating with 10$ 02:90$ N2 for 4 minutes (solid bar), commencing
at 0 s. Discharge was averaged in consecutive 15 5 intervals before
(0- -o) and after (•--•) injecting (A) MDL 72222 (100 yg kg-1,
i.e.) or (3), in a separate experiment, ketanserin (100 yg kg-1,
i.e.). Lines were fitted to the data in the ranges shown using the
method of least squares. Neither antagonist had any significant
effect upon the response of chemoreceptors to hypoxia.
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MDL (100 pg kg-1; A), or ketanserin, (100 pg kg-1; B).
The mean control (air-breathing), and plateau hypoxic discharge
frequencies, mean slope (rate) of the dynamic phase of the response to
hypoxia, and the time taken from application of hypoxia to steady
state are shown in table 7.1 for data obtained before and after MDL,
10 pg kg-1 (n=6), MDL, 100 pg kg-1, (n=12, in three of which MDL was
injected after ketanserin), and ketanserin, 100 pg kg-1, (n=5). Table
7.2 shows the mean values for Pa02, PaC02, and pHa in the control and
hypoxic states, before and after the injection of antagonists. No
significant differences were detected (Wilcoxon two-sample test, two-
tailed) in either the pre- and post- antagonist chemoreceptor
responses, or blood gas analyses.
7.2.6 Effect of 5-HT in the rabbit.
5-HT (0.01-100 pg i.e.) was studied in one rabbit only, where it
caused chemodepression, but no clear chemoexcitation, whether in the
form of an initial transient, or as a delayed effect. Chemodepres¬
sion was dose-related (Fig. 7.18), and the duration was from 6 to
20s. The IDS0 for 5-HT evoked chemodepression was 10 pg, slightly
higher than the mean value calculated for the same effect in cats.
The effect of 5-HT injection upon blood pressure was a small transient
fall, with the 50 and 100 pg doses only.
7.3 Summary of results presented in section 7.
1. Three separate components were identified in the complex response
of carotid chemoreceptors to injected 5-HT. First, a transient burst
of action potentials was obtained during the injection period in 56$
of the recordings. Second, a period of dose-related chemodepression
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Table 7.1: Effects of MDL 72222 and ketanserin on background (air-
breathing) and hypoxic (10? 02) discharge, time to plateau ('max')
and rate of response to hypoxia.
DISCHARGE PLATEAU TIME TO 'MAX' RATE
(air; c.p.s.) (10? 02; c.p.s.) (s) (?max s_1)
Control 6.8 ± 1.5 26.8 ± 5-3 112 ± 6 1.08 ± 0.11
(n=6)
MDL 72222 10.8 ± 3-2 27.3 ± 5.8 109 ± 11 1.OA ± 0.12
(10 ug kg-1)
(n=6)
Control 5.3 ±1.0 21.9 ± 3-2 114 ±4 1.02 ± 0.07
(n-12)
MDL 72222 7-7 ± 1.8 26.3 ± 5.5 116 ±7 1.08 ± 0.11
(100 pg kg"1)
(n-12)
Control 6.9 ± 2.0 25.6 ± 6.5 112 ± 6 0.99 ± 0.06
(n=6)




Table 7.2: Results of arterial blood gas analyses during normoxia
(air-breathing) and hypoxia (10% 02) before, and after the applicat¬





















95.3 + 2.4 36.2 + 1 .5
31 .9 + 1 .1 31 .1 + 1 .1
7.30 + 0.01 7.32 + 0.01
92.0 + 7.0 35.5 + 0.5
31 .5 + 0.5 30.5 + 1 .5
7.29 + 0.04 7.32 + 0.02
87.8 + 1 .7 39.5 ± 2.6
33-1 + 0.9 31 .5 + 0.5
7.28 + 0.02 7.33 + 0.02
83.8 + 7.7 34.1 ± 1.6
32.3 + 2.3 33-3 ± 2.0




Figure 7.18. Dose-response data for the cheraodepression evoked by
5-HT in a rabbit. (Transient cheraoexcitation was not observed, and
there was no clear secondary excitation). (A) AIx plotted against
dose, and (3) Ax$ for the response occuring in the first five
seconds after drug injections, plotted against dose. Lines were fitted
to the data by the method of least squares.
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commenced within a few seconds of completing the injection in all
recordings,even in the absence of an initial transient excitation.
Finally, a delayed non-dose-related but longer-lasting chemoexcitation
occured in most experiments, simultaneous with a fall in systemic
blood pressure.
2. The initial transient chemoexcitation was evoked by only one
other 5-HT agonist, 2-Me 5-HT, which mimicked 5-HT in evoking all
three components of the response, although the intensity of chemodep-
ression alone was comparable to the effect seen with 5-HT itself.
5-MOT had virtually no effect upon chemoreceptor discharge. The
5-HTi agonists 8-OH DPAT and RU 24969, selective for the A and B
sub-types respectively of this receptor had divergent effects, the
former being a potent depressant of chemosensory discharge, and
evoking little or no secondary excitation, whilst the latter was a
weak depressor of chemoreceptors, but had potent excitatory effects.
3. The novel 'neuronal' 5-HT antagonist MDL 72222 virtually
abolished the transient chemoexcitation evoked by 5-HT, and also
significantly increased the mean IDS0 for 5-HT-induced chemodepres-
sion, in a dose-related manner. In 37$ of the recordings 5-HT caused
dose-related chemoexcitation after the highest doses of the antagonist
applied. Neither delayed chemoexcitation nor hypotension were
obviously affected by the antagonist.
4. The 5-HT2-selective antagonist ketanserin had no appreciable
effect upon initial transient excitation in response to injected 5-HT,
but there was a slight increase in the mean IDS0 for 5-HT-evoked
chemodepression. The delayed chemoexcitation and hypotension were
both either abolished or substantially reduced by ketanserin.
5. All the effects of injected 5-HT upon chemoreceptor discharge
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could be abolished by the combination of MDL and ketanserin, without
the antagonists having any appreciable effect upon the capacity of
chemoreceptors to increase their discharge frequency in response to
hypoxic stimulation.
7.4 Discussion.
The present results show that 5-HT has complex, if somewhat
variable, effects upon chemosensory discharge in anaesthetised cats.
The limited data obtained in one rabbit do not suggest any marked
difference from results in the cat, save that chemoexcitation was
apparently lacking. Three separate components in the response to 5-HT
were identified, and the antagonists MDL and ketanserin selectively
affected different parts of the response. Earlier studies using
respiratory reflexes as an index have provided evidence for both
inhibitory and excitatory effects of 5-HT upon the carotid body
chemoreceptors in various species, including the cat (Page, 1952;
Douglas & Toh, 1953; Ginzel & Kottegoda, 1954), but 5-HT also induces
complex and marked neurogenic and circulatory effects which are able
to exert influences upon respiration independently of the chemorec¬
eptors (Mott & Paintal, 1953; Comroe et al, 1953). making
respiratory effects a rather poor index of chemoreceptor activity.
7.4.1 Transient chemoexcitation.
Transient chemoexcitation occured during the injection period in
about half the recordings, and this effect has previously been
described by Black et al (1972), Nishi (1975), and Docherty and
McQueen (1978). The increase was only occasionally dose-related,
which may be a consequence of tachyphylaxis. When identical doses of
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5-HT are applied in close succession (e.g. less than 5 rain appart -
Nishi, 1975) either no response, or a much reduced effect is seen in
response to the later doses; it should be noted that the effect more
closely studied by Nishi, prone to tachyphylaxis, and considered by
him to be the response to 5-HT is apparently the same as the
transient chemoexcitation described here.
The rapid onset (i.e. during injection of 5-HT) suggests a direct
action on the sensory nerve fibres (Eyzaguirre & Nishi, 1974). Whilst
it cannot be denied that 5-HT could be acting indirectly, by release
of endogenous substance(s) from, presumably, type I cells, to act
upon the nerve endings, the time course of the response seems to prec¬
lude it from being secondary to 5-HT-induced vascular changes. The
possible influences upon the chemoreceptors of increased sympathetic
activity arising from the ganglion-stimulating action of 5-HT (e.g.
Trendelenburg, 1958, 1959) were prevented by sectioning the ganglio-
glomerular nerves. This cannot exclude the possibility that 5-HT may
release stored NA from the terminals of sympathetic nerves that
remain in situ in the carotid body, after transection of the nerve
trunks. The finding that transient excitation was not obtained in
all recordings, in agreement with Black et al (1972), could be due to
differing sensitivities of myelinated and unmyelinated fibres to 5-
HT, or perhaps to differences in the amount of 5-HT delivered by
injection to the chemoreceptors whose activity is being recorded in
any particular experiment. Tachyphylaxis cannot explain the absence
of an excitatory response to the initial doses of 5-HT applied in an
experiment, although in recordings where excitation did occur
repeated administration could attenuate the response, possibly
explaining the poor dose-dependency of the effect in some experiments.
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Nishi (1975) considered this transient excitation to be the most
consistent part of the response to 5-HT, and found it to occur with
doses as low as 2 yg (i.e.); in the present experiments the effect
was not clearly discernable at doses of less than 10 yg.
At the time of Nishi's studies LSD, methysergide, and gramine
were widely used antagonists in the investigation of the effects of
5-HT upon peripheral and muscle 5-HT receptors (cf. Gyermek, 1966). LSD
appeared to act as a partial agonist, since it caused chemoexcitation
similar to 5-HT, but blocked only the vascular, and not the chemorec-
eptor effects of injected 5-HT (Nishi, 1975). In the same experiments
gramine and methysergide also blocked the vascular effects of 5-HT,
but not the chemoreceptor responses, nor did they themselves cause any
chemoexcitation. This was taken as evidence that the 5-HT-evoked
changes in chemoreceptor discharge are direct, rather than a consequence
of vascular changes. Nishi was not able to classify the type of
receptor responsible for excitation, although he did exclude direct or
(
indirect involvement of nicotine or muscarinic ACh receptors. Docherty
and McQueen (1978) found that the DA antagonist a-flupenthixol at
high doses could reduce the responses to 5-HT, but inconsistently. The
5-HT2 antagonist ketanserin had no appreciable effect upon transient
chemoexcitation, but the 'neuronal' antagonist MDL inhibited the effect.
MDL has been shown to have potent and selective blocking actions
at excitatory 5-HT receptors located upon peripheral neurones (Fozard,'
1984a). In particular, it antagonises responses to 5-HT mediated by
receptors present upon the terminals of sympathetic fibres of the
rabbit heart, at nanomolar concentrations; the actions of nicotinic
agonists require much greater concentrations of the antagonist before
they are inhibited. This compound also blocks the von Bezold-Jarisch
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reflex evoked by 5-HT in the rat. It is only weakly active against
responses mediated by the classic 'Mf receptor (Gaddum & Picarelli,
1957) present upon cholinergic nerves of the guinea-pig ileum, nor
does it block smooth muscle contractile responses mediated through
5-HT 'D' receptors, muscarinic or nicotinic ACh receptors, or
histamine Hi-receptors, except at high concentrations. It appears
that the bulk of the evidence points to the initial excitatory action
of 5-HT upon chemoafferent fibres being the result of actions at a
receptor, presumably within the carotid body, very closely associated
with, or located upon the sensory nerve endings. Recent studies
showing that MDL blocks the excitatory actions of 5-HT upon the cell
bodies of rabbit vagal primary afferents (Azami et al, 1984) might be
taken to support the hypothesis that 5-HT acts upon neuronal or sen¬
sory receptors in the carotid body.
The fact that MDL itself had certain 5-HT-like effects upon
chemoreceptors could mean that the drug is a partial agonist. Of the
other agonists studied, only 2Me 5-HT caused any transient chemoexcit-
ation, but rather less potently than 5-HT itself.
7.4.2 Chemodepression.
5-HT caused a short-lasting chemodepression which commenced
almost immediately upon completion of the injection, and which was
dose-related in most experiments. Again, the rapid onset of the
effect suggests that is not secondary to vascular changes caused by 5-
HT. It was the most consistent component of the response, and occured
regardless of whether or not the initial transient excitation was
present. Depression of chemoreceptor discharge has also been previous¬
ly reported (Black et al, 1972; Nishi, 1975; Docherty & McQueen,
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1978). Earlier studies showed that very high doses of a-flupenthixol
reduced the effect (Docherty and McQueen, 1978), but that a range of
putative 5-HT antagonists did not alter this component of the
response to 5-HT (Nishi, 1975). Nishi (1975) proposed that exogenous
5-HT induces depolarisation of the nerve endings, with very rapid
onset, initiating nerve impulses at the non-myelinated portion of the
sensory fibre, or at the first node; once depolarisation reaches a
certain level, a cathodal block of the nerve occurs lasting several
seconds. When depolarisation subsides, discharge reappears. This
suggestion seems unlikely, for if this were the case, chemodepres-
sion should not occur in the absence of an initial depolarisation or
excitatory effect, which is inconsistent with the present results. It
is, of course, not impossible that 5-HT-induced depolarisation can be
subthreshold, so far as generation of nerve impulses is concerned, but
at the same time, sufficient to activate a hyperpolarising current, res¬
ulting in chemodepression in the absence of an obvious depolarisation.
Ketanserin had a rather variable effect upon 5-HT-induced
chemodepression, usually causing a slight reduction, but sometimes a
potentiation of the effect. In contrast, MDL caused a substantial
dose-related antagonism of chemodepression, as shown by the increase
in IDS0 values, and higher doses could completely abolish the response
- either unmasking an excitatory component, or potentiating the
delayed secondary excitation.
The chemodepressant responses to 5-HT and to DA were compared
before and after the antagonists domperidone, ketanserin, and MDL.
Domperidone had no significant effect effect upon any phase of the
chemoreceptor response to 5-HT when given in doses that substantially
reduced DA-evoked chemodepression, and responses to DA were
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unnaffected by either MDL or ketanserin. It may be concluded that
chemodepression evoked by 5-HT does not involve a DA D2-receptor, and
is mainly mediated by mechanisms sensitive to the neuronal 5-HT
antagonist MDL. The results with ketanserin might suggest that a
small part of the chemodepression is attributable to actions upon
5-HT2-receptors, assuming the antagonist is selective, and does not
affect MDL-sensitive sites at the doses used. The possibility that
depression of discharge results not from direct actions of 5-HT, but
rather from the release of inhibitory substances (other than DA)
cannot be ruled out, but the persistance of 5-HT-evoked chemodepres¬
sion during naloxone infusion (see Section 8) tends to preclude the
involvement of opioids, which are potent chemodepressant substances
and are present in the carotid body.
Chemodepression was also elicited by 2Me 5-HT (an agonist at MDL-
sensitive sites), but not by 5-MOT (which is relatively inactive at
such sites). Of the 5-HTj agonists examined, a particularly
marked chemodepressant effect was elicited by 8-OH DPAT, which is said
to be selective for the A sub-type of 5-HTx-receptors.
7.4.3 Delayed excitation.
The final component of the response to injected 5-HT was a
delayed (10-30 s) phase of secondary excitation that lasted longer
than any of the other components. It was rather variable, and, where'
present, its onset appeared to coincide with that of the fall in blood
pressure caused by 5-HT. The antagonist MDL had no effect upon
blood pressure, nor did it reduce the delayed chemoexcitation.
Ketanserin inhibited both effects, and the reponses to injection of
ketanserin itself may reflect some partial agonist properties of the
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drug. It is not possible to say whether the delayed chemoexcitation
was caused by the hypotensive effect, or resulted from actions upon
5-HT..-receptors in the carotid body, more especially since onset of
secondary excitation was much faster after the antagonist MDL, which
did not alter the latency of the hypotensive effect.. It is question¬
able how accurately changes in systemic blood pressure reflect
vascular effects in the carotid body.
RU 24969 was a potent stimulant of chemoexcitation similar to the
delayed effect seen after injection of 5-HT; other agonists tested
caused little or no secondary excitation. It is perhaps a little
anomalous that one of the 5-HT! agonists should cause an effect similar
to that of 5-HT, apparently mediated through a 5-HT2-receptor. More
information concerning the biochemical events mediated by different
5-HT agonists at varying receptor sites is needed, and also the
effects of this agonist after ketanserin must be studied, before any
conclusions can be reached on this finding.
7.4.4 Classification of 5-HT receptors.
In the peripheral nervous system classification of 5-HT receptors
is a complex problem. Amongst the effects mediated by these recep¬
tors are depolarisation, hyperpolarisation, and facilitation or
depression of transmission. The net effect of 5-HT in the system
under investigation may be excitatory or inhibitory, with little
obvious relationship to the immediate effects of 5-HT/receptor
interactions. With respect to sensory neurones, 5-HT may cause
excitation or depolarisation of the cell body (Sampson & Jaffe, 1974;
Higashi, 1977, Simonds & de Groat, 1980, Stansfeld & Wallis, 1981), or
hyperpolarisation of the cell body (Higashi, 1977). Sensory axons may
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be depolarised (Neto, 1978), whilst the nerve endings of various
sensory fibres have been shown to be excited by 5-HT (e.g. Paintal,
1954 [gastric, but not pulmonary stretch fibres]; FjSllbrant & Iggo,
1961; Nishi, 1975) .
In some respects, the effects of 5-HT upon sensory somata in the
rabbit nodose ganglion (Higashi 1977) bear close resemblance to the
chemoreceptor responses observed in these experiments, and the ionic
currents that he determined could perhaps also underly the effects of
5-HT upon the chemcreceptors. In 8% of the neurones Higashi studied
there was no response to 5-HT; 86$ were, however, depolarised rapidly,
and in a concentration-dependent manner by 5-HT, with concomitant
repeated firing. Depolarisation was followed by an equally rapid
repolarisation, and then an 'after'-hyperpolarisation of approximately
5 mV. This after-hyperpolarisation was in turn followed by a long-
lasting depolarisation of a few millivolts. It was suggested that
during the initial depolarisation response to 5-HT there is a
simultaneous increase in the conductance of sodium and potassium ions,
and during the after-hyperpolarisation only potassium ion-conductance
remains increased. Both initial depolarisation and the after-hyperpol¬
arisation were abolished in a sodium-free medium, which could mean
that the hyperpolarising effect may be triggered by influx of sodium
ions. There were indications that the residual depolarisation, which
follows hyperpolarisation, is associated with a small increase in
permeability to sodium ions. In about 6$ of his recordings Higashi
observed a simple hyperpolarisation (with neither initial, nor
subsequent depolarisation), which was associated with a reduction in
membrane resistance. Hyperpolarisation appeared to be caused by an
increased potassium ion conductance, since it was enhanced by
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removal of external potassium ions, and the polarity was reversed by
displacing membrane potential beyond -90 mV.
Increased potassium and sodium ion conductances mediating the
depolarisation of rabbit sympathetic ganglion cells has
similarly been shown by Wallis and Woodward (1975) and Wallis and
North (1978); after-hyperpolarisation, also observed by these
authors, was attributed to activity of an electrogenic pump (cf.
Lees & Wallis, 1975), activated by the influx of sodium ions.
Presumptive sensory myenteric neurones are usually hyperpolarised
by 5-HT; the response is not subject to tachyphylaxis, and is accomp¬
anied by a fall in input resistance, possibly generated by an increase
in potassium ion conductance (Johnson et al, 1980b).
In the light of these findings in other systems, it would be
possible to ascribe all three components of the chemoreceptor response
to injected 5-HT to sequential events following the activation of just
one type of receptor, and this is empirically supported by the common
blockade of transient chemoexcitation and chemodepression by the
neuronal antagonist MDL.
Such a simplistic analysis may, however, not apply, since
pronounced chemoexcitation, blocked by ketanserin, often appears
after the application of MDL. The lack of effect of 5-MOT in
causing any part of the typical response seen with 5-HT is encourag¬
ing, since the agonist is virtually inactive at MDL-sensitive sites
(Fozard, 1984b). In contrast, 5-MOT is almost as effective an agonist
as 5-HT at the classical 'M'-receptor. Since 5-MOT causes no marked
changes in chemoreceptor activity, this may exclude 'M'-receptors
from the mediation of the 5-HT response, hence, perhaps, Nishi's
failure to classify the 'chemoreceptor' 5-HT-receptors, using
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conventional 5-HT antagonists.
The basis of classifying certain 5-HT receptors as 5-HT! or 5-HT2
derives from the differential binding of tritiated ([3H]—) 5-HT and
spiroperidol (SPIR) to two different populations of post-synaptic
receptors located on membranes of brain tissue obtained from different
locations. [3H]-LSD appears to bind to both types of receptor with
equal affinity (Peroutka & Snyder, 1979). Morphine is inactive at
both receptor subtypes, and phenoxybenzamine only weakly so. Thus,
neither fits the scheme of ' M' (morphine sensitive) or ' D' (sensitive
to phenoxybenzamine-like drugs) proposed by Gaddum and Picarelli
(1957). The potencies of various agonists and antagonists differ
widely in competing for [3H]-5-HT (5-HT!) and [3H]-SPIR (5~HT2)
binding. [3H]-5-HT binding has been shown to be inhibited by guanine
nucleotides, in a manner comparable to the regulation of receptor
binding of neurotransmitters whose effects are linked to an adenylate
cyclase (Peroutka et al, 1979). This suggests, at least indirectly,
that 5-HTi receptors may exert their effects via cAMP. 5-HT-sensitive
adenylate and guanylate cyclases have been identified in the CNS
(Pagel et al, 1975; Quayle et al, 1978), but not in the peripheral
nervous system (Wallis, 1981).
There is ample evidence (Bennett & Snyder, 1975; Fillion et al,
1976; Leysen & Laduron, 1977; Leysen et al, 1978; Nelson et al,
1978) that 5-HTi and 5~HT2 receptors are different molecular entities.
Ketanserin has a high affinity for 5-HT2-receptors (Leysen et al, 1981;
Leysen et al, 1984), and ketanserin-sensitive sites appear to be
involved in central mediation of certain behavioural activities. In
isolated tissues they can mediate vasoconstriction, tracheal smooth
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muscle contraction, as well as bronchoconstriction in vivo (Leysen
et al, 1984). Activation of platelets by 5-HT, particularly in the
cat, appears to be mediated via 5-HT2-receptors (de Clerck et al,
1984, de Clerck & Herman, 1983; Leysen et al, 1983). It is thought
that binding to 5-HT2 receptors activates phoshpolipase C, causing
formation of diacylglycerol (Leysen et al, 1984). Signal
transmission through increased turnover of phospholipid involves
release of calcium ions from membrane-chelated stores to activate
phospholipase C (Erne et al, 1983), leading to generation of
diacylglycerol - which is a potent activator of protein kinase C.
Activation of protein kinase C has been proposed as the key event in
the transmission of receptor stimuli (Nishizuka, 1983), and has an
absolute requirement for calcium ions and phospholipid, although its
target proteins in most tissues remain to be clarified. Such
mechanisms presumably require a finite amount of time in which to
become active, ana the 5-HT2-receptor may be capable of subserving the
secondary excitation of chemoreceptors that can be blocked by
ketanserin. It may be fortuitous that, in the absence of MDL, this
part of the response appears to coincide with the hypotensive response
to 5-HT, for ketanserin is inactive at receptors mediating relaxation
of contracted vessels (van Nueten et al, 1984). Blockade of
MDL-sensitive receptors may result in a significantly larger quantity
of the injected 5-HT being available for binding with chemoreceptor 5-
HT2-receptors (if such exist) than when the MDL-sensitive sites are
free to bind the drug. The possibility that there is a balance
between the effects mediated by MDL- and ketanserin- sensitive sites
needs to be resolved.
The effects of 5-MOT and 2Me 5-HT upon chemoreceptors are
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consistent with the hypothesis that transient chemoexcitation and
chemodepression are the major effects of exogenous 5-HT, and that they
are both mediated via MDL-sensitive sites. Since only slight
secondary excitation was evoked by 2Me 5-HT, there is still the
possibility that this part of the response is mediated by a receptor
different to that or those mediating the earlier parts of the
response. Although 5-HT2-receptors are implicated in the mediation of
delayed excitation, RU 24969-sensitive 5-HT-j g-receptors may also be
involved, because of the potent effects of this agonist. It is not
possible to say whether or not this excitation involves the same
receptors as those activated by 5-HT.
Controversy still surrounds the classification of 5-HT receptors
(cf. Wallis, 1981; Fozard, 1984b; Humphrey, 1984), and the rather
perplexing array of effects of 'selective' 5-HT agonists upon
chemoreceptor activity will only be resolved when further information,
in particular concerning the biochemical events mediated by these
agonists at different receptors, is forthcoming.
7.4.5 Physiological Stimulation.
Although the combination of MDL and ketanserin effectively
blocked the actions of injected 5-HT upon chemosensory discharge, the
response of chemoreceptors to physiological stimulation by hypoxia was
unaltered. Assuming the antagonists reached effective concentrations'
at sites within the carotid body where locally-released 5-HT might
act, the implication is that endogenous 5-HT has no vital role in the
mechanism of chemoreception. However, the possibility that 5-HT might
exert more subtle influences must be borne in mind, especially in view
of its reported co-storage with substance P in neurones (see, for
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example, HOkfelt et al, 1980), and the potentiation of its effects
during SP infusion (see Section 9).
Reports of the conditions under which 5-HT is released in the
carotid body, if indeed it is, are still awaited. Histochemical
demonstration of 5-HT in type I cells clustered around blood vessels
in the carotid body of the rat might point to some function as a
vasoactive agent, and in this respect it is interesting that increased
levels of 5-HT have been reported in the carotid bodies of hyperten¬
sive subjects, where an abnormal blood flow might necessitate some
compensatory mechanism to maintain normal chemoreception.
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SECTION 8.
THE EFFECTS OF OPIOID PEPTIDES UPON CHEMOSENSORY ACTIVITY IN THE CAT.
8.1 Introduot-ion.
Interest in the enkephalins as possible transmitters or neuro¬
modulators in the carotid body stems from the discovery that [Met]enk
and [Leu]enk are present in the carotid body (e.g. Wharton et al,
1980), and are possibly stored with NA in type I cells (Hansen
et al
, 1982). When applied in vivo or in vitro they are able
to alter chemoreceptor activity. Monti-Bloch and Eyzaguirre (1980b)
reported that [Met]enk increases chemoreceptor discharge in vitro,
but McQueen and Ribeiro (1980) showed that it is a potent depressant
of chemosensory activity in the cat in vivo, the effect being at
least partially blocked by the opioid antagonist naloxone (NAL -
McQueen & Ribeiro, 1980, 1981b). NAL itself appears to have only
slight effects upon chemoreceptor discharge in vivo (McQueen & Rib¬
eiro, 1980), but the fact that the response to hypoxia may be enhanced
after NAL (Pokorski & Lahiri, 1981) does suggest that opioids (i.e.
enkephalins) may exert some tonic inhibitory action.
Related substances such as morphine and g-endorphin (g-END) have
only weak (excitatory or depressant) effects upon chemoreceptor
discharge in vivo, and these are blocked by NAL (McQueen & Ribeiro,
1980, 1981b). ENK-mediated chemodepression is likely to be mediated
through specific activation of opioid receptors because of the
antagonism by NAL, and also the failure of a-flupenthixol to block the
effect at doses which abolish DA-evoked chemodepression (McQueen,
1981); similarly, the effect of DA is unaltered by NAL (McQueen &
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Ribeiro, 1980).
In contrast, the antinociceptive effects of enkephalins are
weaker than those of morphine; although both the enkephalins and
morphine display similar potencies in receptor binding assays, the
doses of ENK required for an analgesic effect are generally 50-100
times greater than those of morphine, and must be administered
specifically to the cerebral ventricles, cisterna magna or periaque¬
ductal grey matter. Even then the effect is weak and short-lived (cf.
Schwartz et al, 1981). The in vivo potency of enkephalins is greatly
increased in analogues rendered less susceptible to degradation by
peptidases (see Schwartz et al, 1981). Replacement of the L-Gly2
residue by a D-amino acid (e.g. D-Ala, D-Met or D-Thr) and/or N-methyl-
ation of the Tyr1 residue increases potency in vivo (but does not
alter in vitro receptor binding properties). An increase in potency
is also achieved in compounds containing an N-methyl-Phe1* residue, a
D-amino acid in position 5, or in which the terminal carboxyl group is
acidified, esterified or replaced by an alcohol (Morley, 1980).
Differing pharmacological profiles of a number of opiate drugs
and neuropharmacological or behavioural tests in spinal dogs led to
the proposal of three different receptor sub-types - p (morphine-sen¬
sitive), k (_ketazocine-sensi tive), and a (N-allylnormetazocine (SK&F
10047)-sensitive - see Gilbert & Martin, 1976; Martin et al, 1976).
Another receptor type was identified and designated 5 in the mouse vas
_deferens, this receptor being different from the p- and <- sites,
and with which the enkephalins appear to interact preferentially (Lord
et al, 1977); the antagonistic effects of NAL at this receptor were
also observed to be less potent than its actions at p-receptors.
Most of the opioid or related drugs used in this study (see
- 275 -
Appendix 2) were chosen because of their increased resistance to
peptidase degradation (which enhances their potency) and because of
their reported greater (though by no means absolute) selectivity at
differing receptor sub-types. This study was performed to determine
which opioid receptor sub-types might mediate the ENK effects upon
chemoreceptor activity, and to determine whether any particular opioid
would be more appropriate for use in the investigation of the
interaction of opioids and substances such as NA (with which there
appears to be co-storage in the carotid body - see above - and in the
adrenal medulla - cf. Viveros et al 1980), DA, ACh or 5-HT. [Met]enk
and [Leujenk are typically 5-receptor ligands; [D-Ala2, D- Leus]enk
(DADL) is a commonly employed 6-'selective' agonist, although it is
only twelve times more active at the 6-site than at y-receptors
(Paterson et al, 1983). [D-Ala2, MePhe", Gly- ol5]enk (DAGO) is
some 220 times more active at y- than at 6- binding sites (Kosterlitz
& Paterson, 1981); the casein-derivative morphiceptin (MCPT; Chang £t
al, 1981) is also selective for y- receptors, but less potent. Benzo-
morphans, ketazocine-like compounds and dynorphins have been shown to
exhibit preferential activity at <- receptors (e.g. Gilbert & Martin
1976; Martin et al, 1976; Corbett et al, 1982), and the compounds
ethylketocyclazocine (ETZ) and dynorphin octapeptide (dynorphin (i-e)
- DYN) were used in this study to determine the possible contribution of
K-receptor activation to the response of chemoreceptors to opioids.
NAL-blockade of the chemodepressant effect of enkephalins is
incomplete (see above) and its specificity, particularly at high doses
has been questioned (Sawynok et al, 1979). The antagonists used in
this study (see Appendix 2) were the more recently developed substit¬
uted enkephalins ICI 154,129, which is more selective for 6-receptors
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(Shaw et al, 1982) and ICI 174,864 which is also selective for 5-rec-
eptors, but more potent than the former antagonist (Cotton et al, 1984).
8.2 Methods.
The effects of i.e. injection of a range of doses of agonists
were studied before and after different doses of antagonists. In
three experiments hypoxia tests (see Sections 2 and 4) were carried
out during infusions of [Metjenk and the effects of raising the
inspired C02 to 5% were studied in the same experiments. Comparison
was made with the same tests performed during infusion of C02-air-
equilibrated Locke solution. To study the interactions of monoamines
and ACh with enkephalins these drugs were injected at 90 seconds of a
two-minute infusion of [Metjenk, the amount of opioid infused being 2
or 10 pg min-1, sufficient to cause an obvious depression of
chemoreceptor discharge, the dose varying in different experiments
depending upon the sensitivity to [Metjenk. Short infusions were
prefered so as not to desensitise the preparation. Because of the
lack of material the more selective antagonists could not be used in
the 'interactions' experiments; instead NAL was infused at a level of
600 pg min-1 (determined by experiment) for two minutes, with
injections of monoamines being made at 90 seconds of the infusion. In
all experiments controls were carried out by making injections of
monoamines during infusion of Locke solution (0.1 ml min-1), and in
the case of NAL-infusions single injections of [Metjenk (e.g. 1 pg




[Met]enk is the most abundant opioid peptide found in the carotid
body of the cat (Wharton etal, 1980), and was used as the 'reference'
compound. When injected i.e. [Metjenk caused chemodepression in all
experiments (cf. Figs. 8.3, 8.6). Dose response data were obtained in
thirteen cats; depression of discharge (which was usually 'absolute'
for 5-15 s) was dose-related in all cases (e.g. Fig. 8.1). Following
the initial depression of discharge, with doses of 1 pg or greater, the
rate of discharge gradually increased back to control levels, with the
total period during which discharge frequency was reduced lasting for
a minute or more. It was determined that the optimum method of
quantifying this effect was to calculate the mean discharge frequency
in the first 30 s after injection and to express this as a percentage
change from the appropriate pre-injection control (Ax$ - see Fig.
8.1). If a shorter time interval was chosen (e.g. 5 s, cf. analysis of
5-HT effects, Section 7), a 'maximum' response could be demonstrated
with very low doses of agonist; the effects of control injections of
Locke solution appeared to be inordinately large when compared to the
effects of the peptide on this time scale. When mean discharge was
calculated in a longer time period (e.g. 1-2 mins) the effects of low
doses of the drug were largely nullified. Subsequently, this method '
of analysis was applied for all opioid-like drugs used, to enable
comparison of dose-response data. From dose-response curves such as
that illustrated in Fig. 8.1 the ID50 (dose causing a 50% decrease in
discharge from pre-injection control discharge, in the first 30 s
after injection) values were determined, and are presented in table
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Figure 8.1. Dose-response curve for [Met]enk-evoked chemodepression
(in a single experiment) showing the relationship between dose and
the average discharge in the first thirty seconds after injection
expressed as a percentage change from pre-injection control. The
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8.1. An example of dose-response curves, obtained in the same
experiment, for a 6-agonist ([Met]enk) and for a x-agonist (DYN) is
shown in Fig. 8.2. From the pooled data it was determined that the
rank order of potency as depressors of chemoreceptor activity (cf.
table 8.1) was: [Met]enk i [Leu]enk = DADL > DAGO >> DYN >> EKZ >>>
MCPT = 0.
IDS0 values calculated for 6-'selective' agonists were
significantly lower (Student's t-test) than those calculated for the
other agonists. MCPT did not cause any appreciable depression of
discharge but, instead, an approximately 20% increase in discharge at
all doses in the single experiment where studied.
All agonists caused some degree of change in systemic arterial
blood pressure, the observed effect being hypotension at high doses
(greater, generally, than the value of ID50).
8.3.2 Effects of novel selective antagonists.
ICI 154129 (0.1-10 mg kg-1 i.e.) was studied in seven experiments.
The antagonist blocked [Met]enk-evoked chemodepression (Fig. 8.3) and
caused the dose-response curve for chemodepression to shift upwards
and to the right (Fig. 8.4); the mean IDS0 was significantly
increased (P<0.05 - Student's t-test) in a dose-related manner (Table
8.2) after 1 and 10 mg kg-1 doses of the antagonist. Fig. 8.5
shows the effect of the antagonist upon IDS0; despite variability,
ID s 0 was clearly increased by the lowest dose used (inall but one of three
where tested
experiments^),and increasing the dose of antagonist caused the IDS0
value to be raised still further.
The effects of ICI 174864 were examined in four experiments,
where the chemodepressant effects of [Met]enk were blocked by
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F1gure 8.2. Comparison of the dose-response curves for chemodepres-
sion evoked by the '5'-agonist [Met]enk and the '<'-agonist DYN in the
same experiment. Average discharge in the first thirty seconds after
injection, expressed as a percentage change from pre-injection
control, has been plotted against dose. The straight lines were fitted
to the data using the method of least squares.
Data for responses to [Metlenk and DYN are denoted by open and closed
symbols respectively-
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Figure 8.3. Neurogram showing the response of 3-4 chemoreceptor
units to the injection of [Met]enk (0.1 pg i.e. at arrows) before
(A) and after (B) injection of the antagonist ICI 154129, 10 mg kg-1
i.e. The discriminator was set to count just two units, and the
ramped counter output beneath each neurogram shows the number of
action potentials counted in successive 1 s intervals. The depres¬
sion of discharge by [Metjenk and antagonism of the effect by ICI
154129 are both clearly displayed.
- 283 -
0-01 0-1 1 10 100 yg
i i ■ ■ 1
Figure 8.4. Comparison of the dose-response curves for chemodepres-
sion evoked by [Metjenk before and after ICI 15^129, 10 mg kg-1 i.e.
in one experiment. Average discharge in the first thirty seconds
after injection, expressed as a percentage change from pre-injection
control, has been plotted against dose. The straight lines were fitted
to the data using the method of least squares.
Data for responses to [Metlenk obtained before and after ICI 154129






Figure 8.5. Comparison of IDS0 values for [Met]enk-evoked chemodep-
ression obtained before (control) and after increasing doses of the
antagonist ICI 15^129 in seven different experiments, plotted on the
same axes. The increase in IDS0, reflecting antagonism of the chemo-
depressant effect of [Metjenk, is clearly dose-related in all
experiments. Note that the scales of both axes are logarithmic.
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*P<0.05withrespecttoc n rol(Student's-t s ).
comparatively low doses of the antagonist (Figs 8.6, 8.7). The mean
IDS0 for [Met]enk-evoked cheraodepression in these four experiments was
0.35 ± 0.1 pg (0.62 ± 0.2 nmol). After ICI 174864 0.1 mg kg-1 (n=2)
the ID50 was 3.75 ± 0.05 pg (6.5 ± 0.1 nmol), and after the higher
dose of antagonist, 0.2 mg kg-1 (n=3) , the IDS0 increased still more
to 132 ± 67.3 pg (231 ±117 nmol). These differences were significant
(Wilcoxon ranked test), and when presented as in Fig. 8.8 it is clear
that there was a marked and potent antagonism of the effect of
[Met]enk in all experiments. It should be noted that the highest dose
of this antagonist was approximately fifty times smaller than that of
ICI 154129.
Chemodepression evoked by [Leu]enk was markedly reduced after ICI
174864; after the lower dose of antagonist IDS0 increased two
thousand-fold in one experiment, and in a separate experiment the
increase in ID50 after the higher dose of antagonist was increased by
a factor of ten thousand. DADL and DAGO were also studied after ICI
174864, although data for full dose-response curves after the
antagonist were not obtained. Chemodepression evoked by single or a
few doses of these agonists was markedly attenuated in all four
experiments, and there was some evidence of an excitatory effect
replacing chemodepression, after the antagonist.
Both ICI 154129 and ICI 174864 had only slight effects upon basal
rate of discharge; there was a slight but significant increase (P<0.05;
Wilcoxon two sample test) in one out of four experiments, after ICI
154129. After ICI 174864 (n=4) discharge was significantly increased
in one experiment (P<0.05; Wilcoxon test) and only slightly increased in
one, and decreased in the remaining two experiments.
ICI 154129 partially blocked the hypotensive effect of [Met]enk,
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Figure 8.6. Neurogram showing the response of a single ehemorecep-
tor unit to the injection of [Metjenk (0.1 yg i.e. at arrows) before
(A) and after (B) injection of the antagonist ICI 174864, 0.2 mg kg-1
i.e. The ramped counter output beneath each neurogram shows the
number of action potentials counted in successive 1 s intervals.
Opioid-evoked chemodepression and antagonism of the effect are both
clearly shown.
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Figure 8.7. Comparison of the dose-response curves for chemodepres-
sion evoked by [Metjenk before and after ICI 17^86^, 0.2 mg kg-1 i.e.,
in one experiment. Average discharge in the first thirty seconds
after injection, expressed as a percentage change from pre-injection
control^ has been plotted against dose. The straight lines were fitted
to the data using the method of least squares.
Data for responses to [Metlenk obtained before and after ICI 174864

























Figure 8.8. Comparison of ID50 values for [Met]enk-evoked chemodep-
ression obtained before (control) and after different doses of the
antagonist ICI 174864 in four different experiments, plotted on the
same axes. The increase in IDS0, reflecting antagonism of the chemo-
depressant effect of [Met]enk, is clearly dose-related in all
experiments. Note that the scales of both axes are logarithmic.
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but the antagonist ICI 17^864 had no obvious effect upon opioid-
induced changes in systemic arterial blood pressure.
Because of the apparently greater sensitivity of chemoreceptors
to [Met]enk, and to allow possible comparison with other studies (see
introduction) this opioid was used in the remaining parts of the
experiments.
8.3-3 Interactions with hypoxia or hypercapnia.
Hypoxia tests were performed during infusion of [Met]enk (2 pg
min-1, n=1 or 10 pg min-1, n=2) in three cats. Data were analysed as
described in sections 2, 4, and 5. [Met]enk infused at either
concentration depressed the basal rate of discharge (Fig. 8.9) and
markedly attenuated the response to hypoxia, without abolishing it
(Fig. 8.9). Rate of increase in chemoreceptor discharge in response
to 10? 02-hypoxia was not significantly altered (see table 8.3).
Because of the variability between experiments mean chemoreceptor
discharge frequencies were not significantly different at any stage of
the test when data obtained during [Met]enk or Locke infusion were
compared (table 8.3). When discharge on 10% 02 during Locke infusion,
in each experiment, was set as 100?, and discharge levels related to
this, then rate of discharge at all stages of the hypoxia test was
significantly reduced during infusion of [Metjenk (table 8.3).
Chemoreceptor discharge increased when animals were ventilated
with 5% C02, whilst Pa02 was maintained as near constant as
experimental conditions allowed. This test was performed in three
cats and [Met]enk infusion (2 pg min-1, n=1, or 10 pg min-1, n=2)
depressed the activity of chemoreceptors during normocapnia and during
hypercapnia (Fig. 8.10). The responsiveness of chemoreceptors to C02
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Figure 8.9. (A) Responses to hypoxia (hatched bar, 10$ 02; solid
bar, 100$ N2; stippled bar, 100$ 02) during infusion (horizontal bar)
of Locke solution (0.1 ml min-1) and (B) [Met]enk 2 yg min-1 in a
single experiment.
(C,D,E): hypoxia responses in three different experiments during
infusion of Locke solution (0.1 ml min-1; open symbols) and [Met]enk
(2 or 10ygmin-1; closed symbols). 'Plateau' discharge during 10$ 02-
hypoxia whilst infusing Locke solution has been set at 100$ in each
experiment, and the levels of discharge during ventilation with air,
10$ 02, and 100$ N2 have been related to this degree of chemoreceptor
activity. The opioid depressed chemoreceptor discharge at all stages
of the test, in each experiment.
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Figure 8.10. Chemoreceptor responses to hypercapnia. Results
presented are pooled data from three separate experiments. Discharge
(mean c.p.s. during steady state) has been plotted against PaC02.
Results were obtained during infusion of Locke infusion (open symbols,
± s.e.m.) and during infusion of [Met]enk (2 yg min-1, n=l, and 10 yg
min-1, n=2 - closed symbols, ± s.e.m.). [Met]enk infusion depressed
rate of discharge during both normo- and hyper- capnia.
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might be judged to have increased during infusion of [Metjenk since
the increase in discharge caused by hypercapnia during infusion of the
opioid was twelve-fold (1383 ± 864$), but only three-fold (244 ± 63$)
during Locke infusion. PaC02 values during normocapnia and hypercap¬
nia were unaltered by the infusion of [Metjenk.
The antagonist ICI 154129 had no appreciable effect upon the
response to hypoxia in three experiments (e.g. Fig. 8.11), and none of
the parameters used to assess the response to hypoxia was significan¬
tly different after the antagonist (table 8.4A).
The response to hypoxia was increased after ICI 174864 (0.1 or
0.2 mg kg-1) in three out of four experiments (e.g. Fig. 8.12). There
was a consistent tendency for 'plateau' level of discharge to
increase, and there was an increase in the slope of the line represen¬
ting the dynamic phase of the chemoreceptor response to hypoxia (table
8.4B). The low number of results and variability in magnitude of
discharge (but not in overall pattern of altered response) meant that
only control (pre-hypoxia) discharge was significantly altered after
the antagonist.
Both antagonists affected the chemoreceptor response to three
levels of hypercapnia at normal Pa02. When plotted against PaC02,
mean discharge frequency during steady-state was lower at all levels
of PaC02 after ICI 154129 (10 mg kg-1, n=2) or ICI 174864 (0.2 mg
kg-1, n=2)- see Figs 8.11 & 8.12.
8.3.4 Interactions of monoamines and [Metjenkephalin.
In this series of experiments monoamines were injected during
infusion of [Metjenk, and the effects of each injection were analysed






















Figure 8.11. (A) Chemoreceptor responses to 10$ 02-hypoxia in a
single experiment, before (open symbols) and after (closed symbols)
administration of the antagonist ICI 154129, 10 mg kg-1. Basal and
plateau levels of discharge were not significantly altered, nor was
the slope of the dynamic part of the response to hypoxia, shown here.
Discharge (c.p.s.), averaged in successive 15 s intervals, has been
plotted against time, 0 s indicating the onset of hypoxia; the mean
pre-hypoxia control discharge is also indicated.
(B) The response of chemoreceptors, in the same experiment, to three
levels of C02 at the same level of Pa02. Mean discharge during steady-
state at each level of C02 has been plotted against PaC02, Open
symbols represent data obtained before, and closed symbols data
obtained after injecting the antagonist ICI 154129, 10 mg kg-1.
Lines were fitted to the data using the method of least squares.
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Figure 8.12. Chemoreceptor response^ to 10$ 02-hypoxia in a single
experiment, before (open symbols) and after (closed symbols) adminis¬
tration of the antagonist ICI 174864, 0.2 mg kg-1. Basal and plateau
levels of discharge were significantly increased, as was the slope of
the dynamic part of the response to hypoxia. Discharge (c.p.s.),
averaged in successive 15 s intervals, has been plotted against time,
0 s indicating the onset of hypoxia.
(B) The response of chemoreceptors, in the same experiment, to three
levels of CO2 at the same level of Pa02. Mean discharge during steady-
state at each level of C02 has been plotted against PaC02. Open
symbols represent data obtained before, and closed symbols, data
obtained after injecting the antagonist ICI 174864, 0.2 mg kg-1.
Lines were fitted to the data using the method of least squares.
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Table 8.4: Effects of opioid antagonists upon parameters defining the
responsiveness of chemoreceptors to hypoxia; (A) measurements before and
after the antagonist ICI 154129 (10 mg kg-1) and (B) in a separate set of
experiments, before and after ICI 174864 (0.2 mg kg-1)
A Control After mean difference n
ICI 154129 (± £i .e.m.)
Control x c.p.s. 5.4 4.8 0.6 + 1 .8 3
Plateau x c.p.s. 27.7 20.7 7.0 + 10.1 3
N2 peak x c.p.s. 39.7 35.2 4.4 + 12.7 3
Slope (% max s-1) 0.96 0.82 0.15 + 0.30 3
Time to plateau (s) 103 102 1 .0 + 1 .0 3
Control c.p.s. % 20 22 2.1 + 7.0 3
Plateau c.p.s. % 100 93 7.0 + 30.6 3
N2 peak c.p.s. % 165 166 1 .7 + 35.6 3
Pa02 (10% 02; mm Hg) 33.7 34.3 0.67 + 2.6 6
PaC02 (mm Hg) 32.0 28.6 3.4 + 2.4 6
pHa 7.33 7.34 0.007 + 0.018 6
B Control After mean di.f ference n
ICI 174864 (± £i.e.m.)
Control x c.p.s. 1 .7 2.7 1 .1 + 0.3 3
Plateau x c.p.s. 8.9 12.4 3.4 + 1 .6 3
N2 peak x c.p.s. 18.5 18.7 0.2 + 4.1 3
Slope (% max s-1) 0.58 0.91 0.33 4. 0.3 3
Time to plateau (s) 166 186 19.7 ± 51 .5 3
Control c.p.s. % 19.7 32.3 12.7 ± 1 .8 * 3
Plateau c.p.s. % 100 163 63-3 ± 29.2 3
N2 peak c.p.s. % 216 254 38.0 ± 58.0 3
Pa02 (10% 02; mm Hg) 43.8 41 .8 2.0 ± 5.8 3
PaC02 (mm Hg) 27.8 29.7 1 .8 ± 1 .9 3
pHa 7.34 7.34 0.002 ± 0.023 3
* P<0.05 (Student's paired t-test.)
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background discharge at the time of injection was decreased during
infusion of the opioid, and raised during infusion of NAL, relative to
control discharge during infusion of Locke solution.
Dose response data were obtained during Locke, [Met]enk or NAL
infusion, and the integrated reponses plotted as sets of dose response
curves; it was noted from the relative positions of these curves
whether the integrated response was unaltered, increased or reduced
during [Met]enk or NAL infusion, relative to the curve obtained during
Locke infusion. The mean pre-injection control discharge of all tests
included in each dose-response curve was calculated and the effects of
drug infusions were compared with the control discharge during Locke
infusion by expressing this mean value as a percentage change (xA?)
from the corresponding control mean. The standard error of any set of
pre-injection control data was generally small, and the change in back¬
ground discharge against which injections of monoamines was tested for
statistical significance.
For each set of dose response curves the magnitude of the shift
in response was assessed by expressing the response to each injection
of a monoamine as a percentage change from the effect elicited by the
same dose of drug during Locke infusion (average change - avA$). This
gave a set of three to four values for each dose-response curve which
were highly variable in every case; the average of these values,
discarding any obvious anomalies, was taken as an index of the change'
in responsiveness of the system. The parameter xA* was used to
predict the amount of change in the dose-relationship of the
integrated response that could be accounted for by the change in
background discharge caused by infusion of [Metjenk or NAL; when
compared with this, avA$ gave an indication of whether or not the
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observed changes in the magnitude of AEx were likely to result from
attenuation or potentiation of responses by the opioid or the
antagonist.
Examples of the changes in integrated responses to injections of
NA, DA, ACh and 5-HT during infusions of [Metjenk or NAL are shown in
Figs 8.13-8.16. The calulated values of xk% and avA5& for dose-
response data to these monoamines are shown in tables 8.5-8.8. There
was no clear difference in the changes in background discharge caused
by infusion of [Metjenk at a concentration of either 2 or 10 yg min-1.
Where xk% and avA$ were comparable (with a difference of less than 10-
15%) it was considered that the change in magnitude of the response to
the injected drug was due to alterations in background discharge
caused by the infused drug. If these two measurements differed it was
inferred that the change reflected some degree of interaction. Results
are summarised in table 8.9. Where DA- or 5-HT- evoked chemodepression
was altered during infusion of [Metjenk, it was generally potentiated.
No clear pattern of change in the depressant response to NA emerged.
Some 50-7555 of all depressant responses, whether evoked by NA, DA or 5-
HT were unaltered during infusion of [Metjenk. Excitatory responses
to ACh were almost equally unaltered or potentiated. Secondary
excitatory responses to NA were potentiated in over half of the tests.
Delayed excitation following 5-HT-evoked chemodepression was
unaltered in one experiment and potentiated in the other. Initial
transient excitation, where present, was still seen to occur during
[Metjenk infusion, but was not quantified as the effect is normally
variable, and was clearly small during infusion of the peptide.
During infusion of NAL responses to all monoamines were altered;




















Figure 8.13. Dose-response data (integrated responses - AZx -
plotted against dose) for the initial ohemodepressant and secondary-
excitatory effects of NA injection during infusion of Locke solution
(0.1 ml min-1, open symbols) and [Metjenk (10 yg min-1, closed
symbols). The opioid caused a mean depression of background discharge
(xA?) of -62$. Chemodepression was reduced by a factor of
approximately -42$ (avA$) , and chemoexcitation was reduced by about
87$, thus the reduction in both depression and excitation could not bd
explained solely as being due to the 62$ reduction in basal discharge,















Figure 8.14. Dose-response data (integrated responses - AEx -
plotted against dose) for the chemodepressant effects of DA injection
during infusion of Locke solution (0.1 ml min-1, open symbols) and
[Met]enk (10 yg min-1, closed symbol^). The opioid caused a mean
depression of background discharge (xA$) of -42$. Chemodepression
was reduced by a factor of approximately -30$ (avA$), and the reduction
in depression is possibly accounted forbythe 42$ reduction in basal
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Figure 8.15. Dose-response data (integrated responses - AEx -
plotted against dose) for the excitatory effects of ACh injection
during infusion of Locke solution (0.1 ml min-1; 0), [Metjenk (10 pg
min-1; •) and NAL (600 pg min-1; A)._The opioid caused a mean
depression of background discharge (xA?) of -22%. Chemoexcitation was
reduced by a factor of approximately -195? (avA5?) during opioid-
infusion, and the reduction in excitation could be explained solely as
being due to the 225? reduction in basal discharge, against which the
injections were made. During NAL infusion background discharge was
increased by some 130?, relative to Locke infusion control discharge,
but the ACh-evoked excitation was increased by some 315? when compared
to Locke infusion controls, suggesting that the effect was potentiated
during infusion of the opioid antagonist.
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Figure 8.16. Dose-response data (integrated responses - AEx -
plotted against dose) for the cheraodepressant and delayed excitatory
effects of 5-HT injection during infusion of Locke solution (0.1 ml
min-1; 0), [Metjenk (10 pg min-1; •) and NAL (600 pg min-_J_; A). The
opioid caused a mean depression of background discharge (xA?) of
-53%• Chemoexcitation was reduced by a factor of approximately -47*
(avA*) and chemodepression by a factor of some -56* during opioid-
infusion, and these reductions might be explained solely as being due
to the -50* reduction in basal discharge, against which the injections
were made. During NAL infusion background discharge was increased by,
some 117?, relative to Locke infusion control discharge;
chemodepression evoked by 5-HT was increased approximately 675?, and
chemoexcitation was reduced. The depressant effect of 5-HT during NAL
infusion was potentiated during infusion of the opioid antagonist
since the percentage change, whilst lacking precision, is none-the-
less far greater than can be accounted for solely by the shift in
background discharge.
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Table 8.9: Summary of the changes in effects upon chemoreceptor discharge
of injected monoamines caused by infusion of (A) [Met]enkephalin (2-10 pg
min-1) or (B) naloxone (600 pg min~l).
(A) Effects of [Met]enk.
no change potentiation attenuation n
NA
Depression 60$ 20$ 20$ 5
Excitation 16.5$ 67$ 16.5$ 6
DA
Depression 55$ 36$ 9$ 11
ACh
Excitation 44.5$ 44.5$ 11$ 9
5-HT
Depression 75$ 25$ 0$ 4
Delayed excitation 50$ 50$ 0$ 2
(B) Effects of NAL.
no change potentiation attenuation n
NA
Depression 0$ 100$ 0$ 4
Excitation 0$ 25$ 75$ 4
DA
Depression 0$ 67$ 33$ 3
ACh
Excitation 0$ 33$ 67$ 3
5-HT
Depression 0$ 33$ 67$ 3
Delayed excitation 0$ 0$ 100$ 2
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8.3-5 Summary of results presented in section 8.
1. Opioid peptides and related drugs caused chemodepression. The rank
order of potency as chemodepressants was [Met]enk S [Leu]enk = DADL >
DAGO >> DYN >> EKZ >>> MCPT = 0.
2. Chemodepression was reduced by the selective '6'-opioid antagonists
ICI 154129 and ICI 174864 in a dose related manner.
3. Infusion of [Met]enk suppressed the increase in discharge elicited
by ventilation with hypoxic or hypercapnic gas mixtures. The response
to hypoxia was unaltered after ICI 154129, but potentiated after ICI
174864. The response to hypercapnia was reduced after administration
of either of these two selective antagonists.
4. During infusions of [Met]enk chemodepression evoked by NA was
equally potentiated or attenuated, but was unaltered in 60$ of
experiments. Delayed excitatory effects of NA were potentiated in 67$
of recordings. DA-evoked chemodepression was potentiated in 36$ of
recordings, but unaltered in 55$, whilst chemodepression in response
to 5-HT was largely unaltered. ACh-evoked excitation was potentiated
or unaltered with equal frequency during infusion of the peptide.
5. During infusions of NAL chemodepression evoked by NA was
potentiated in all recordings and DA-evoked chemodepression was
potentiated in 67$ of recordings. Delayed excitatory effects of NA
were attenuated in 75$ of recordings. ACh-evoked excitation was
attenuated in 67$ of recordings, during infusion of the peptide.
Chemodepression in response to 5-HT was usually attenuated, as was
delayed excitation.
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8.9) and the effect of DA was potentiated in two out of three
experiments. Depression caused by 5-HT was, however, more commonly
attenuated. Excitatory effects of NA were attenuated during NAL
infusion in three out of four experiments, since the change in AEx was
less than anticipated from the increase in background discharge,
during infusion of the antagonist. ACh-evoked chemoexcitation was
attenuated in two out of three experiments, but the delayed excitatory




The pattern of response of cat carotid chemoreceptors to exogen¬
ous [Met]enk accorded well with that reported previously by McQueen
and Ribeiro (1980, 1981b). Chemodepression evoked by this peptide is
similar to the response evoked by the catecholamine DA, although at
the doses used the effect of the opioid was rather more prolonged,
discharge remaining depressed for many seconds, and up to one or two
minutes with the highest doses used in these experiments. [Met]enk is
a prototype 5-opioid agonist, and its effects are less complex than
those of 8-END or morphine (McQueen and Ribeiro, 1980, 1981b) which
are relatively weak modulators of chemoreceptor activity, even though
they appear capable of activating several different sub-types of
opioid receptor (cf. Section 1). The antagonist NAL is more potent at'
p-receptors and the only partial antagonism of [Met]enk-evoked
chemodepression by NAL, even at high doses of the antagonist (which
more effectively block the effects of 8-END), suggests a selective
action of [Met]enk at a receptor other than the p-sub-type.
The evidence provided by the experiments reported here appears to
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confirm that the chemodepressant effects of enkephalins are mediated
mainly through actions at 6-receptors. Agonists which are considered
to be relatively more selective for p- and <- receptors (but not
devoid of actions at 6-receptors - cf. Paterson et al, 1983) were less
potent (x-agonists markedly so) than either the enkephalins or the
'selective' 6-agonist DADL. Furthermore, there is the evidence
provided by the actions of the two selective 6-antagonists, ICI 154129
and ICI 174864, both of which effectively blocked the effects upon
chemoreceptor discharge of enkephalins. ICI 154129 is some thirty
times more selective for 5-receptors than for p-receptors (Shaw et al,
1982) and ICI 174864 is devoid of actions at receptors other than 6-
receptors when used at concentrations of less than 5 pM in vitro. In
the experiments reported here the maximum amount of this antagonist
total
administered in any one animal (0.1+0.2 mg or approximately 0.5
pM) was very much less than the amount likely to show non-selective
actions at other opioid receptors, but it did virtually completely
block the chemodepressant effects of 6-agonists. It is reasonable
to conclude that the predominant effects of opioids upon chemoafferent
activity are mediated through actions at 6-opioid receptors.
[Met]enk was slightly more potent (although the difference was
not significant) than [Leu]enk in these experiments, although the
latter is generally considered to be the more potent agonist in the
mouse vas deferens (e.g. Waterfield etal, 1979). Whether this
results from the differing numbers of experiments carried out with the
two pentapeptides (13 experiments with [Met]- and 5 experiments with
[Leu]- enk) or reflects some property related to the greater abundance
of the [Met] form in the carotid body (Wharton etal, 1980) cannot be
determined. It was observed that the sensitivity to [Met]- or [Leu]-
- 311 -
enk often depended upon the order in which the two drugs were
administered, so that chemoreceptors were apparently more sensitive to
the [Leu]- form if this agonist was studied first, somewhat less
sensitive if [Met]enk was the first opioid injected. Further
experiments would be required to elucidate whether there is some
partial desensitisation after the first application of an opioid.
Possibly this could involve some form of irreversible binding at some
of the 6-receptors, or an allosteric change in part of the receptor
population.
Enkephalins have been proposed as inhibitory transmitters since
they show hyperpolarising actions when applied to some peripheral and
central neurones (e.g. North et al, 1979; Pepper & Henderson, 1980).
This hyperpolarising action has not been observed in all preparations
(e.g. Zieglgdnsberger & Tulloch, 1979) and some allowance must
also be made for a possible modulatory role of enkephalins whereby
the actions of other transmitters are altered. This could represent a
change in the release of transmitters (e.g. monoamines - cf. Henderson,
1983) or changes in the effects of other transmitters at their own post¬
synaptic sites of action.
Opioids cause dose-related, NAL-reversible hyperpolarisations
when applied to locus coeruleus neurones (Pepper & Henderson, 1980);
the effect appears to represent a direct action upon the neurone since
it is unaltered by abolition of synaptic activity by perfusion with a •
Ca2+-free medium. Such hyperpolarisation is associated with an
increased Ca2+-sensitive K+ conductance (Williams et al, 1982).
Opioids have been reported to reduce ATP-dependent binding of Ca2+ to
synaptosomal membranes (Guerrero-Munoz et al, 1979), and binding of
opioids to opioid receptors could result in either displacement of
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Ca2+ from binding sites on the inner plasma membrane, or in decreased
sequestration of Ca2+ entering a neurone during activation, thus
causing an increased intracellular [Ca2+] activating an increase in
K+ conductance (see Henderson, 1983). Inhibition of K+-evoked NA
release from slices of occipital cortex and hypothalamus by [Met]enk
appears to involve a reduction in the transmembrane inward current
carried by Ca2+ ions (GOthert et al, 1979). The opioid receptors
mediating adenylate cyclase inhibition in cultured tumour cells of
neural origin are of the 5-subtype (Chang & Cuatrecasas, 1979;
McLawhon et al, 1981; Gilbert et al, 1982), and opioid inhibition of
adenylate cyclase in striatal tissue is also possibly mediated through
6-receptors (Cooper et al, 1982). This is of interest since the DA
D2-receptor may also be negatively-linked to adenylate cyclase
(Creese et al 1982), and could represent a common mechanism for
depression of chemoreceptor activity (see later). It is perhaps an
anomaly of the carotid body that a-receptors that supposedly also
inhibit adenylate cyclase activity when activated do not appear to
mediate chemodepression (see Sections 3, 4, & 6).
Delayed chemoexcitatory responses to enkephalins were not very
evident in the experiments reported here, regardless of the agonist
used; after 6-receptor blockade there was no obvious or consistent
replacement of chemodepression with an excitatory effect, and it
could be that the chemoexcitatory responses to exogenous opioids seen'
occasionally in vivo (e.g. McQueen & Ribeiro, 1980, 1981b) result from
indirect changes effected outwith the carotid body, thus explaining
their inconstancy. There is some important evidence from a recent
in vitro study (Monti-Bloch & Eyzaguirre, 1985) which very much
contrasts with this speculation. These authors reported that
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superfusion of the carotid body with [Met]enk-containing solutions
caused chemodepression followed by 'rebound' excitation; injection
of bolus doses of [Metjenk in this preparation caused chemoexcitation
at low doses and depression at high doses. The possibility exists that
both 'inhibitory' and 'excitatory' receptors are present in the cat
carotid body, as in the rat vas deferens, where morphine can cause
both inhibitory and excitatory effects. The situation then becomes
analogous to the comparable effects of DA in the carotid body, where
depressant effects predominate in the in vivo preparation (and
excitatory effects may sometimes by observed after DA-receptor
blockade - see Section 1), but excitatory effects are far more common
in the excised in vitro preparation (e.g. Zapata 1975).
One obvious inferenceis that some trophic neural activity
(ganglioglomerular or efferent fibres supplied by the sinus nerve)
is required to maintain the integrity of the systems that mediate the
depressant effects of opioids or DA, which possibly exert a tonic
'braking' effect upon chemoreceptors. As after domperidone, background
discharge increased during infusion of NALJ McQueen and Ribeiro
(1980) reported that injection of NAL had only slight effects upon
spontaneous discharge. In the present experiments infusion of NAL
virtually always caused a significant increase in the background
rate of chemoreceptor discharge. It is not possible to determine
whether this results from 'disinhibition' of the chemoreceptors, or
from the unmasking of excitatory responses to opioids at NAL-insen-
sitive receptors. Presumably the sensitivity of both opioid- and
DA- excitatory receptors is much lower than the sensitivity of
receptors mediating chemodepression. Where two 'opposing' receptor
mechanisms coexist low doses of agonist may activate both systems
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simultaneously with no net change in ongoing activity; increasing
doses of agonist may be expected to elicit greater responses through
preferential activation of the more sensitive site - if the site
mediating the greater activity is blocked then actions mediated
through the 'complimentary' site become more evident. It seems
unlikely that endogenous receptor'antagonists'could play such
a modulatory role, and the effect of interactions between differing
neurotransmitter systems or the effects of (neuro)hormones are likely
to be crucial. It is debateable whether two populations of receptors
would exist in the same effector complex (i.e. at the same post¬
synaptic site) or whether two populations of effector mechanisms would
co-exist mediating opposing effects in separate systems which would
converge upon a common integrating element.
Palmer and Hoffer (1980) found that enkephalin-induced neuronal
depression in rat frontal cortex was dependent upon the integrity of
catecholamine afferents supplying the region, and concluded that the
interaction here took the form of an augmentation of the post-synaptic
effects of ENK by catecholamines. In the carotid body in vitro the
loss of effective catecholaminergic control of the effects of opioids
could explain the greatly differing results obtained, as compared with
in vivo experiments, but it should be remembered that in most cases in situ
the sympathetic nerves supplying the carotid body are cut, and the sinus
nerve itself is cut, prior to recording; it thus remains possible that
circulating substances may also play some important trophic role, or
that they are necessary for the maintainance of activity at the
terminals of efferent nerves, which can thus be prolonged (after
axonal transection) for a longer period in the intact animal than when
the carotid body is excised.
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The scheme adopted for investigating possible interactions
between opioids (and other peptides) and monoamines was based upon the
assumption that peptides might alter the responsiveness to
'sporadically' or 'discretely' released classical transmitters, for
instance by resetting resting membrane potential, increasing or
reducing the likelihood that a given ammount of transmitter will
produce its normal effects.
When examined subjectively, dose-response curves for the effects
of monoamines drawn from data obtained during [Metjenk infusion showed
either no change in the position of the data points, relative to those
obtained during Locke infusion, or a reduction in the magnitude of the
integrated reponse (AEx) at any given dose. This was true whether
considering depressant or excitatory effects. The pattern of response
to all monoamines studied appeared not to vary, whether injections
were made during infusion of Locke solution, [Metjenk, or NAL; the time
course of the various phases of the responses was also not seen to be
altered. Much care is needed in the interpretation of such data; the
integrated response represents an absolute number of action potentials
occuring additionally, or failing to occur, in a given period of
time when a calculated number of action potentials is predicted,
supposing no alteration in mean discharge frequency. If the numerical
value of AEx remains constant (with no marked changes in the time
course of the response) yet background discharge is reduced (as during
[Metjenk infusion) then the responsiveness of the system can be said
to have increased. Where control discharge is reduced, the reduction
in the magnitude of AEx may represent no net change in responsiveness,
unless the degree of reduction in AEx exceeds the amount of decrease
in control discharge. It was considered necessary, then,
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to attempt to quantify the changes in responses to monoamines
during opioid or opioid antagonist infusions, to determine whether
the altered effects of monoamine injections reflected changes in
basal discharge frequency, or could represent some change in the
sensitivity of the chemoreceptors to these substances.
The dose-response curves compared were all linear relationships
(deviation from linearity in the case of NA excitation - cf. Section 3 -
was avoided by restricting the range of doses used), but not
parallel. In very general terms dose-response curves were shifted by a
constant factor, suggested by the fact that the percentage change from
the control curve was usually comparable at at least two doses;
anomalies frequently arose because of deviations from a best-fit line
drawn through the data points, which could occur in either or both of
the curves in each pair that were compared. Also, since only three to
four data points were obtained for each dose-response curve, even
small variations (i.e. poor correlation) led to errors in calculating
a mean factor quantifying the change in position of the curve during
[Metjenk or NAL infusion. The analysis carried out in these
experiments is limited in its precision, and may represent an underes¬
timation of the number of experiments where [Metjenk altered the
response of the chemoreceptors to the injected drugs.
Subjectively it appeared that infusion of [Metjenk caused a
reduction in the integrated responses to monoamines, and NAL infusion •
caused an increase. Where the mean change in background frequency
(mean pre-injection control discharge for all points contributing to a
dose-response curve during drug infusion expressed as a percentage
change from the mean of the same points during Locke infusion - xA?)
appeared to be close to the average percentage change of the dose-res-
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ponse data from control values, it was concluded that the change in
position of the dose-response curve during drug infusion could be
accounted for by the alterations in background rate of discharge.
Just over half of the depressant responses to DA and NA (which may be
mediated through activation of the same receptors) were considered, on
these grounds, to be unaltered during infusion of [Met]enk, although
chemoreceptor discharge was reduced by the opioid. There was greater
evidence for a potentiation of the depressant effect of DA than for
an attenuation, during opioid infusion. Given that the majority of dep¬
ressor responses to these catecholamines were unaffected, the apparent
potentiation of some responses may represent an additive effect of
opioid- and catecholamine- evoked chemodepressions. The failure of
two depressant effects to summate (in the case of experiments where
there was no obvious change in the responsiveness to catecholamines)
might also be interpreted as an interaction, since it would appear
that one form of depression is not contributing to the anticipated
net effect.
Chemodepression evoked by 5-HT was reduced during [Metjenk
infusion, but in 75$ of experiments it seemed that the shift in the
dose-response curve could be accounted for by the similar reduction in
background level of discharge at the time of injection. In one
experiment only there was evidence of a potentiation of the chemodep-
ressant effect.
Delayed or secondary excitation followed the depression of
discharge evoked by NA and 5-HT. In the case of NA there was clear
evidence for a potentiation of the effect in more than half of the
experiments performed during infusion of [Metjenk. Only two experi¬
ments with 5-HT gave consistent results showing a dose-related
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secondary cheraoexcitatory effect and it should be remembered that this
effect is more commonly observed only after blockade of depressant
effects (Section 7). Both types of excitatory responses examined here
have been more fully discussed in earlier sections of this thesis,
where it was concluded that they are largely dependent upon the
development of cardiovascular changes, particularly in the case of
NA. Since [Met]enk infusion produced a fall in systemic blood
pressure, which commenced at least a minute before injections of tlje
monoamines, it is possible that reflex mechanisms could already have
begun to alter cardiovascular activity by the time of injection, hence
the potentiation of the NA-evoked delayed excitation. The main factor
against such an interpretation is the fact that reflex activity is
generally not present during pentobarbitone-anaesthesia. The more
direct excitation caused by ACh was attenuated in one experiment only,
during infusion of [Metjenk. In all other cases it was either unal¬
tered or potentiated with equal frequency, and the events that underly
this effect cannot be certainly identified.
If NAL infusion can be considered only to have blocked the
effects of endogenously released opioids (cf. Sawynok etal, 1979), as
suggested by the increase in background discharge, then the effects of
concomitant NAL infusion upon monoamine responses may prove to be of
some interest. In all cases the dose-response curve for monoamine
effects was shifted to a degree markedly different from that predicted
by the shift in background rate of discharge. Most striking was the
potentiation of catecholamine-evoked chemodepression, which contrasted
with the more usual reduction of 5-HT evoked chemodepression during
NAL infusion. A possible interpretation of this finding is that (end¬
ogenous) opioids are normally responsible for limiting the depressant
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effects of catecholamines. This raises the possibility that exogenous
catecholamines depress chemoafferent activity through release of
another (as yet unidentified) transmitter or, perhaps more likely,
that there is an interaction at the level of the intracellular second
messenger.
The majority of excitatory responses, whether evoked by NA, 5-HT
or ACh, were attenuated during NAL infusion. This finding is again
difficult to interpret, although it seems reasonable to suggest that
if depressant effects are modulated in one direction then excitatory
effects are likely to be affected reciprocally, since the two types of
effect must surely represent complimentary biochemical mechanisms.
Less clear is the correlation between reduction in the 'direct'
effects of ACh and the reduction in the 'delayed' excitatory effects
of NA or 5-HT. It is not possible from these experiments to assess
any contribution from actions at excitatory NAL-resistant receptors
stimulated by endogenously-released opioids. To reconcile such an
effect with the results obtained is difficult, except by arguing
that 'excitation'-mediating opioid receptors facilitate the
release of transmitters, which under basal conditions are tonically
excitatory; it would be necessary to show that when DA or NA are
applied, they evoke release of inhibitory transmitters, this effect also
being enhanced when 'excitatory'-opioid receptors are active. So far
it has not appeared necessary to invoke release of second transmitters •
to explain the very rapid effects of catecholamines upon chemoreceptors,
and it seems more reasonable, partly because of the rapidity of the
effects of the injected monoamines, to suggest that interactions with
opioid peptides are more likely to occur at the level of second
messengers.
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Adenylate cyclase is activated by guanosine triphosphate (GTP;
Rodbell et al, 1971) and by non-hydrolysable analogues of GTP (Londos
et al, 1977). Koski and Klee (1981) reported that opioid petides
stimulate GTP hydrolysis, leading to inhibition of adenylate cyclase
(the effect being reversed by NAL). Some substances, such as prostag¬
landin E2, secretin, and fluoride can stimulate adenylate cyclase
activity without affecting GTP hydrolysis (see Koski & Klee, 1981);
others, notably g-agonists, stimulate both adenylate cyclase and the
hydrolysis of GTP (Cassel & Selinger, 1976; Fain & Garcfa-Sainz,
1980). Receptor-mediated inhibition of adenylate cyclase by a-adreno-
ceptor agonists, muscarinic agonists, and opioids appears to require
the presence of Na+ ions and GTP and it would most useful to confirm
whether D2-receptors are in fact negatively-linked to adenylate
cyclase, as suggested by Creese et al (1982). The depressant effects
of opioids and catecholamines might indeed share a common final path¬
way, with the addition that opioid actions could also reduce the
capacity of catecholamines to inhibit adenylate cyclase. Sabol and
Nirenberg (1979), studying mouse neuroblastoma-rat glioma hybrid cells,
showed that the inhibition of adenylate cyclase caused by activation
of a-receptors, muscarinic receptors (which mediate chemodepression in
the rabbit - Docherty & McQueen, 1979) and opiate receptors was not
additive, and they concluded that the three species of receptor can be
functionally coupled to the same adenylate cyclase molecules or mole- •
cules regulating enzyme activity. GTP, which appears to be required
for effecting responses to all three types of agent, was proposed as a
coupling factor between receptors and the enzyme, and this coupling may
result in activation or inhibition depending upon the receptor species.
If opioids are able to regulate such coupling by reducing GTP
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levels then this could form a means of controlling D2-receptors, if
these are negatively-linked with adenylate cyclase and have a require¬
ment for GTP to enable coupling, hence the enhanced chemodepression
during NAL infusion, when GTP hydrolysis by opioids is 'inoperative'.
It would appear that further investigations of the possible
interactions between monoamines and opioid peptides would prove worth¬
while, but more refined quantification is required before a firm
interpretation of the type of results obtained in this study can be
attempted. The fact that the receptor modulating opioid effects upon
the chemoreceptors has been shown probably to be of the 6-sub-type
should facilitate future research, as more improved drugs become
available for use in studies such as this.
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SECTION 9
STUDIES ON THE EFFECTS OF SUBSTANCE P AND VASOACTIVE
INTESTINAL POLYPEPTIDE IN THE CAT
SECTION 9.
STUDIES ON THE EFFECTS OF SUBSTANCE P AND VASOACTIVE
INTESTINAL POLYPEPTIDE.
9.1 Studies on the effects of Substance P.
9.1.1 Introduction.
Evidence that Substance P (SP) modulates neural activity, is
located in nerve fibres of the carotid body and can alter chemorecep-
tor activity, has been cited in Section 1. The effects of SP upon
chemosensory activity are, however, equivocal (McQueen, 1980b), and
warrant further investigation. From competitive binding studies,
Iversen et al (1982) have proposed the existence of two distinct
receptor sub-types - SP-P, which is equally sensitive to all the
tachykinins, and SP-E, which is considerably more sensitive to
eledoisin (ELD) and kassinin (KAS). The methyl ester of SP (SP-O-Me)
and other alkyl esters of the undecapeptide appear to be relatively
selective for the SP-P receptor (Iversen et al, 1982). Few potent and
selective antagonists at SP-receptors have been identified, thus
hindering the classification of SP-receptors, and the clarification of
its possible role as a neurotransmitter.
The aim of this part of the study was to attempt a classification
of the SP-receptors that might be involved in the response of chemo-
receptors to the peptide, with the possibility that one of the other
tachykinins might prove a more useful tool in further studying the
effects of this type of peptide upon chemosensory activity. The
tachykinins used were SP, SP-O-ME, ELD, KAS, physalaemin (PHY), and
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Substance K (SK; isolated by Maggio et al - 1983 - from spinal cord,
and proposed as a possible endogenous SP-E ligand; also identified as
neurokinin a - Kimura et al, 1983).
9.1.2 Results.
9.1.2.1 Effects of injections of Substance P and other tachykinins.
Experiments were carried out in eight cats. SP (n=8) , SK (n=3),
PHY (n=3), KAS (n=3), SP-O-Me (n=1) and ELD (n=1) were injected over
the dose-range 0.01 or 0.1 - 100 yg i.e. All caused a complex pattern
of response. An initial depression of discharge lasting some 10 s
was followed by a longer-lasting phase of increased chemoreceptor act¬
ivity. Neither magnitude nor duration of either part of the response
showed any marked dose-dependency, although the interval between
injections was prolonged so as to avoid the effects of tachyphylaxis.
The percentage-change from pre-injection control discharge levels was
not dependent upon dose, and rarely exceeded 50$ whether considering
depressant or excitatory effects. None of the drugs tested showed any
evidence of being more suitable than SP for use in subsequent
experiments. Tachykinins were associated with a hypotensive effect,
but this also was variable in its occurance and in its intensity.
9.1.2.2 Effects of Substance P infusions, and interactions with
monoamines, hypoxia, and hypercapnia.
Two minute infusions of SP (10 yg min_1i.c.; n=49) were made in
four experments. Short infusions were performed so as to minimise the
possibility of desensitising the preparation. Mean disharge frequency
was calculated in successive 15 s intervals; within 15 s of onset of
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SP infusion there was a small but significant decrease (P<0.05;
Student's t-test) in the mean discharge frequency, when compared
with the mean pre-infusion control discharge (Fig. 9.1). Infusion of
Locke solution (0.1 ml min-1 i.e.; n=63) was not associated with any
marked reduction in discharge frequency. The pattern of discharge
during any infusion was variable, and it was found that in the case of
Locke infusion approximately half of all the measurements of discharge
frequency represented a slight increase, and half a slight decrease;
for results obtained with SP infusion some 60$ of results represented
decreases from control, and 40$ represented increases.
Chemodepression evoked by NA (0.1-10 yg; n=4) or DA (0.1-10 yg;
n=4) was not markedly affected in any experiment during SP infusion,
although there was a consistent tendency for the depressant effect of
the highest doses injected to be potentiated, when compared with
results obtained during Locke infusion (e.g. Fig 9.2 C,E). Chemodep¬
ression evoked by 5-HT (1-25 yg; n=4) was consistently enhanced during
SP-infusion (cf. Fig. 9.2 D). Delayed excitatory reponses to NA and
5-HT were affected differently during peptide infusion. NA-evoked
excitation (without distinction between Ex- and E2- effects) was
slightly reduced (see Fig 9-2 A), whilst secondary excitation evoked
by 5-HT was clearly potentiated (e.g. Fig. 9.2 B). Initial transient
excitation in response to 5-HT was not seen in these experiments.
Three-minute infusions of SP (10 yg min-1) or Locke solution (0.1
ml min-1) were made in four experiments during ventilation with 0, 2,
4, and 6$ C02 in 15, 21 ('room air'), and 50$ 02, plus nitrogen. The
average discharge at 1, 2, and 3 minutes after the onset of infusion
at all levels of Pa02 and PaC02 was not different when results
obtained during SP infusion were compared with those obtained during
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Figure 9.1. (A) and (B): recordings of 2-3 chemoreceptor units
showing discharge before, and from 40 s after onset of a 2 min.
infusion of (A) SP 10 yg min-1 i.e. or (B) Locke solution 0.1 ml min-1
i.e. A ramped counter output beneath each neurogram gives the number
of action potentials counted in succesive 1 s intervals.
(C) Infusion of Locke solution (0.1 ml min-1; n=63) caused a minimal
reduction in chemoreceptor discharge apparent 30-40 s after onset of
infusion. When SP (D) was infused (10 yg min-1; n=49) there was a
small but significant decrease (PC0.05; Student's t-test) in
discharge, commencing within the first 15 s of infusion. The hatched
blocks show the mean pre-infusion control discharge, and chemosensory
discharge is expressed as mean (± s.e.m.) over 15 s intervals during
a 90 s infusion period.
* = P<0.05 with respect to pre-i-njection control values.
control during infusion
SP 10|jg min-'
i i 1 > i : i *
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Figure 9.2. Results from single experiments showing the effects of
SP infusion upon chemodepressant and excitatory effects evoked by
injections of monoamines.
Integrated responses for the secondary chemoexcitation evoked by NA
(A) and 5-HT (B) during Locke infusion (0.1 ml min-1 - open symbols)
and during SP infusion (10 pg min-1 - closed symbols), showing a
slight reduction of the effect of NA and a potentiation of the
response to 5- HT during SP infusion.
Integrated responses for initial chemodepression evoked by NA (C) and
5-HT (D), and for the depressant response to DA (E) during Locke
infusion (0.1 ml min-1 - open symbols) and during SP infusion (10 pg
min-1 - closed symbols). Chemodepression evoked by 5-HT was





with vasoactive intestinal polypeptide.
9.2.1 Introduction and methods.
Experimental reports demonstrating the presence of VIP in the cat
carotid body and the limited descriptions of its effects upon chemosen-
sory afferent activity have been cited in Section 1. The limited
availability of the peptide meant that only a few experiments could be
performed. Experimental procedures were as described previously, and
the possible interactions of monoamines and the peptide were investig¬
ated using the same methodology as in experiments with other peptides.
9.2.2 Results.
The effects of VIP were studied in two cats. Injection (i.e.) of
1 or 5 ug of the peptide caused variable but dose-related chemoexcit-
ation in both experiments, with a latency of onset of less than 5 s
(Fig. 9.3). There was a fall in systemic arterial blood pressure, but
this commenced a few seconds after the increase in chemoreceptor
discharge.
VIP infusions were carried out in both experiments. There was
no obvious effect upon chemoreceptor discharge during infusion of VIP
1 pg min-1 i.e. for two minutes; when analysed in consecutive 15 s
intervals, discharge was variously slightly increased or slightly
reduced in comparison with the mean rate of discharge measured before
the onset of infusion, and no consistent pattern of response was
discernable, nor was there any correlation of these slight fluctuat¬
ions in discharge with the time elapsed from onset of infusion. When
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Figure 9.3. Effects of injection of VIP 1 or 5 pg i.e. (at t=0 s)
upon chemoreceptor activity at low (A) and high (B) levels of back¬
ground discharge, in the same experiment. Discharge frequency was
averaged in successive 5 s intervals and plotted against time from
injection. The mean discharge in the 15 seconds immediately prior to
injection is shown by the solid block.
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VIP was infused at 5 yg min-1 there was a clear hypotensive effect,
but again no consistent effect upon chemoreceptor activity.
In both experiments dose-response curves were obtained for ACh
(10-100 yg i.e.), DA (0.1-10 yg i.e.) and NA (1-25 yg i.e.), injected
at 90 s of a two minute infusion of Locke solution (0.1 ml min-1) or
VIP (5 yg min-1).
The integrated excitatory response (AIx) to ACh was not markedly
altered during VIP (Fig. 9.4A), but Amax was approximately 20?
higher at all doses during VIP infusion in one experiment. In the
second experiment AIx was not obviously altered, and with high doses
of ACh, Amax was actually reduced during VIP infusion (Fig 9.4B).
Chemodepression evoked by DA was affected differently by VIP
infusion in the two experiments. In one the integrated response and
(-)Amax were both increased, implying a slight enhancement of the
depressant effect, whilst in the other experiment AIx was not markedly
altered, and (-)Amax was reduced (Fig. 9.5).
In the experiment in which the excitatory effect of ACh appeared
to be potentiated, NA-evoked chemodepression and chemoexcitation were
reduced during VIP infusion (Fig. 9.6A). In the second experiment NA-
evoked chemodepression was not observed during VIP infusion (Fig 9.6B)
whilst secondary E2- (vascularly-mediated) chemoexcitation was reduced
and E!-excitation largely unaffected.
9.3 Summary of results presented in section 9.
1. Injection of SP or other tachykinins produced no consistent or
clearly dose-related effect upon chemoreceptor discharge, save that
depression preceded excitatory effects.
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Figure 9.4. Effects of VIP infusion upon responses to ACh in two
experiments, (A) and (B). The integrated response (AZx) and Amax
quantifying the excitatory effects of ACh during Locke infusion (0.1
ml min-1 - open symbols) and during VIP infusion (5 pg min-1 -
closed symbols) have been plotted against dose. In both experiments
AEx was not markedly different during the two infusions, but in the
experiment shown in (A) Amax was increased by approximately 20$ at all



































Figure 9.5. Effects of VIP infusion upon responses to DA in two
experiments, (A) and (B). The integrated response (AIx) and Amax
quantifying the chemodepressant effects of DA during Locke infusion
(0.1 ml min-1 - open symbols) and during VIP infusion (5 yg min-1 -
closed symbols) have been plotted against dose. The integrated
response was not clearly altered during VIP infusions, but in the
experiment shown in (A)j(-)Amax was reduced during infusion of the
peptide.
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Figure 9.6. Effects of VIP infusion upon responses to NA in two
experiments, (A) and (B).
In (A) The integrated responses (AEx) and Amax quantifying the effects
of NA during Locke infusion (0.1 ml min-1 - open symbols) and during
VIP infusion (5 qg min-1 - closed symbols) have been plotted against
dose. The integrated response was not clearly altered during VIP in¬
fusions, but Amax and (-)Amax were generally reduced during infusion
of the peptide, implying a reduced responsiveness to the
catecholamine.
In (B) The integrated responses (AEx), and Amax (for excitatory
effects only) to NA during an initial Locke infusion (0.1 ml min-1 -
Li), during VIP infusion (5 pg min-1 - VIP) and during a subsequent
infusion of Locke solution (Lii) have been plotted against dose. For
excitatory responses, Ex-excitation is represented by open symbols,
and E2-excitation by solid symbols. Chemodepression was not seen
during the infusion of VIP, and both AEx and Amax for the secondary
or delayed E2-excitatory effect were reduced during infusion of the
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decrease in chemoreceptor discharge frequency, but responses to SP
were unaltered during combined changes in PaO^ and PaCO^.
3. Chemodepressor responses to NA and DA were little affected by SP
infusion; NA-evoked chemoexcitation was slightly reduced. Both
initial chemodepression and delayed chemoexcitation evoked by 5-HT
were potentiated during infusion of SP, this being the most consistent
and most marked effect observed.
4. Bolus doses of VIP injected i.e. caused clear and relatively long-
lasting chemoexcitation, together with hypotension. Infusion of the
peptide at doses capable of reducing blood pressure had no clear
effects upon rate of chemoreceptor discharge, which alternately rose
and fell with no clear relationship to time from onset of infusion.
5. Chemoexcitation evoked by ACh was enhanced in one experiment and
unaltered or reduced during VIP infusion in the other. DA-evoked
chemodepression was enhanced in one experiment, and NA-evoked depres¬
sion of discharge was absent during VIP infusion. In the other
experiment DA- and NA- evoked chemodepression were both slightly
reduced, although the effect was not marked. NA-evoked chemoexcitat¬
ion during VIP infusion was reduced, although Ej-type excitation
was largely unaffected, where distinguishable.
9.4 Discussion.
9.4.1 Effects of Substance P.
Interpretation of the effects of SP upon chemoreceptor activity
is difficult because there was no consistent pattern of dose-related
changes in activity, making it impossible to determine how long a time
interval after injection of the peptide, or which part of this period,
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should be studied. McQueen's data (1980b)do show a dose-related, if
delayed, chemoexcitation in response to SP. In the present study the
most consistent effect of SP was a small but statistically significant
decrease in discharge frequency evoked during short infusions of SP,
1 0 tag min-1.
It was suggested (McQueen, 1980b) that the observed excitatory
response to SP may have been secondary to changes in PaC02 or cardiac
output. Eyzaguirre et al (see Eyzaguirre & Fidone, 1980) reported a
reduction in chemoreceptor discharge in response to SP in the cat,
rabbit, and mouse carotid bodies in vitro, and more recently Monti-
Bloch and Eyzaguirre (1985) reported that low doses of SP depressed,
and higher doses excited the cat carotid body superfused in vitro;
bolus doses of SP (43 ng - 0.5 yg) had similar effects in this
preparation. Variations in results obtained with SP have also been
seen, for example, in cultured mouse spinal neurones (Barker et al,
1980), so the ambivalent nature of results obtained in chemoreceptor
studies is not unique.
None of the tachykinins tested in the present study proved more
effective than SP, and this might indicate that it is a SP-P receptor
rather than the SP-E sub-type that should be sought after. Evidence
also suggests that there is no variation in the effect of SP at
differing levels of Pa02 and/or PaC02, although Monti-Bloch and
Eyzaguirre (1985) did report that SP reduced the response to hypoxia •
in the in vitro preparation.
9.4.2 Interactions with monoamines.
The location of SP in fibres of the carotid sinus nerve (Cuello &
McQueen, 1980) and the fact that exogenous SP depolarises type I
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cells in vitro (see Monti-Bloch & Eyzaguirre, 1985), together with
suggestions that the peptide may function as a transmitter in sensory
afferent pathways projecting to the nucleus tractus solitarius (e.g.
Gillis et al 1980; Helke et al, 1980a,b) suggests that SP could exert
'retrograde' effects upon the chemosensory mechanism. In this
respect, the potentiation of the depressant and excitatory effects of
5-HT during SP infusion (also reported by McQueen - 1980b) may be of
importance, particularly since the two have been shown to coexist in
certain neurones (for references see HOkfelt et al, 1980).
McQueen (1980b)showed that DA-evoked chemodepression was reduced
during SP infusion. In the present study the effect of DA was not
obviously altered during SP infusion, although the depressant effect
of 10 pg NA (perhaps higher doses could usefully have been studied)
was consistently slightly potentiated during infusion of the peptide.
This is more in accord with the potentiation of DA-evoked chemodep¬
ression in the in vitro study of Monti-Bloch and Eyzaguirre (1985).
The interactions of SP with monoamines gave qualitively better,
more consistent results than the other experiments using this
peptide. Chemodepression evoked by SP was much less intense than that
observed during [METjenk infusion (see section 8), and although NA-
evoked chemoexcitation was consistently reduced during SP infusion,
this is probably not accounted for by any marked reduction in back¬
ground discharge (cf. Section 8), and the potentiation of responses
to 5-HT also means that a reduction in rate of spontaneous discharge
does not account for the altered actions of monoamines during infusion
of SP.
Crucial to studies of the effects of SP in the carotid body would
be the establishment of whether or not the peptide can here affect the
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release or synthesis of transmitters such as DA or 5-HT, as it can in
the CNS (e.g. Carlsson et al, 1977ajReubi et al, 1978). Such studies
are hampered by the fact that SP-systems appear to be particularly
prone to desensitisation, and the lack of selective antagonists or
drugs capable of selectively modulating the synthesis, release, and
catabolism of SP does not allow the type of studies that have enabled
advances to be made in the understanding of the actions of some of the
other drugs used in this study.
9.4.3 Effects of vasoactive intestinal polypeptide.
The excitatory effect of injected VIP upon chemoreceptors repor¬
ted by Fitzgerald et al (1981) and McQueen and Ribeiro (1981a) was
confirmed in the present study. Chemoexcitation evoked by slow
injection of VIP (5 or 25 yg) in the experiments reported by the
former group did not display any marked dose-dependency, although the
blood pressure effect was related to dose. As in the present
experiments, the change in discharge frequency preceded changes in
systemic arterial blood pressure. The fact that VIP is a large and
complex molecule may mean that it does not easily reach or rapidly
gain access to the chemosensory complex after i.e. injection, and
perhaps a more active component of the molecule must be released by
enzymatic cleavage. However, specific binding of VIP to VIP-receptors
is held to be rapid, with achievement of 90% of maximum binding within
60 s in vitro (Makhlouf , 1985).
McQueen and Ribeiro reported sustained excitatory effects of
infusions of VIP at amounts of as little as 0.5 yg min-1, which were
still obtained when the hypotensive effects of the peptide were count¬
ered by administration of dextran, suggesting that the response was
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not a consequence of vascular effects of the peptide. In the present
experiments no clear chemoexcitatory response to infusion could be
discerned. In the earlier experiments (McQueen & Ribeiro,
1981a) a slight increase in discharge was apparent within the first
minute of infusion, and the effect was considerably greater from the
second minute onwards. In the present study infusions of VIP were
made for two minutes only, but in both this and in the earlier set of
experiments the infusion cannula was primed with polypeptide solution,
so that there was no dead-space to clear at the beginning of the
infusion. Furthermore, the vascular effects of infusing VIP 5 ug
min-1 in the present experiments were very clear, and commenced within
some 20-30 s of the onset of infusion. The dependence of the effects
observed (either here or in the other sets of experiments) upon
factors such as tissue penetration, association with or disocciation
from receptors, activation of second messengers or, indeed, peptide
activation or inactivation, is unknown.
9.4.4 Interactions with monoamines.
McQueen and Ribeiro (1981a) showed the effects of single doses of
ACh (50 pg i.e.) to be reduced during VIP infusion. Results obtained
in the present study do not confirm this, there being no clear change
in the dose-response curve for ACh-evoked chemoexcitation in one
experiment, and a clear potentiation of the effect in the other. It •
must be acknowledged that in the experiments of McQueen and Ribeiro
there was more certainty that VIP was exerting effects upon the chemo-
receptors at the time of injection. The present results are perhaps
more akin to the synergistic activity of VIP and ACh in the feline
salivary gland (Lundberg etal, 1980).
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DA-evoked chemodepression (5 pg i.e.) was reduced during VIP
infusion in the earlier experiments (McQueen & Ribeiro, 1981a), and
there was no recovery after VIP infusion. In the current study VIP
was only associated with a reduction of the depressant response to DA
in one experiment. However, NA-evoked chemodepression (which appears
to be mediated through the same receptors as the response to DA) was
reduced during VIP infusion in both experiments (abolished in one), as
was subsequent chemoexcitation (excluding Ej-excitation, which could
be analysed independently in one experiment, and was unaffected by VIP
infusion).
If VIP exerts actions in the carotid body through increases in
intracellular cAMP levels (as in isolated gastric cells - Bitar &
Makhlouf, 1982), then the interaction with D2-receptors (perhaps
negatively linked to adenylate cyclase) and with g-adrenoceptors
(positively linked to the enzyme) will depend largely upon the relat¬
ive amounts of peptide or monoamines injected (or reaching their
respective receptors, or, indeed, the chemosensory complex), and the
temporal relationship of the delivery of the different types of
neurotransmitter.
Clearly, further studies of the effects of these two peptides must
be performed before a definite role in chemoreception can be proposed
or precluded for either. It might appear that the capacity of SP to
alter chemoreceptor responses to other transmitters, particularly 5-HT
may be of greater importance than its own rather weak and inconsistent






This study represents an attempt to determine the pharmacology of
the effects upon carotid chemoreceptor discharge of exogenous adminis¬
tration of several different classes of neurotransmitters which have
been located within the carotid body. Such information will prove
useful in defining the possible role of these substances contained in
the organ.
The assumptions made were that monoamines such as NA, DA, 5-HT
and ACh could act as typical neurotransmitters at an early stage in
the mechanism of chemotransduction; polypeptides such as enkephalins,
SP and VIP may also act as 'discrete' transmitters in defined path¬
ways, but could also act more generally as 'neurohormones', possibly
modulating the responsiveness of target cells to other transmitters.
Quantification of the chemoreceptor response is desirable so as
to establish whether an effect is dose related, and to enable compar¬
isons to be made between individual animals, or before and after
selective antagonists. It was, however, one of the more difficult
aspects of this study. Changes in Amax evoked by NA were usually a
constant function of dose, but after DA-blockade with domperiaone this
parameter appeared to be dose-related. This might support the idea
that DA normally suppresses spontaneous activity (e.g. Osborne &
Butler, 1975). In the case of excitatory responses to NA an obvious
contrast exists between the integrated response (AEx) and the
difference in mean discharge (pre-injection control ana post-drug
excitation). The mean increase in discharge evoked by NA did not
- 3^2 -
generally vary with dose, and with NA or SAL, where the mean discharge
in the period of drug-evoked excitation did increase, background
(control) discharge appeared to be increased by the same amount.
Integration of either excitatory or depressant responses proved the
best or only means of producing a measure of the dose-dependency of
the observed changes in chemoreceptor activity in response
to injections of catecholamine-related agonists, but it is probably
wise to use this measurement in comparison with an assessment of
maximal or mean discharge frequency, since, in the case of NA, AZx
appears to further support the correlation of catecholamine-evoked
excitation with the duration of the systemic effects.
When comparing depressor responses to NA and DA both were seen to
cause a complete suppression of discharge, hence Ax? was often of the
order of 90-100$ for all doses. Since duration of the effect is
shorter with NA, integration allowed a more meaningful comparison of
the effects of these two drugs. This may be compared with depressor
responses to 5-HT (see Section 7) where the depressor response was
rarely -100? of control and Ax? was more obviously correlated with
dose. In certain circumstances Ax? is meaningful if restricted to a
particular time interval, but this appears to depend upon the property
of chemoreceptors to respond minimally at low doses, so that
depression of discharge in, for instance, the first five seconds (cf.
effects of 5-HT - Section 7) or the first thirty seconds (cf. effects'
of opioid peptides - Section 8) after injection ranges from threshold
(£0) towards 100? or maximum, as dose is increased. With NA such
analysis was not feasible since chemodepression was rather an 'all-or-
none' event, being complete, but of variable duration, thus tending
always to represent a 100? depression of chemoreceptor activity. It is
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not meaningful with complex responses to extend the duration of this
period to accomodate the time-dependency of higher doses since the
onset of excitation confounds the analysis. Similarly, with
excitatory responses that follow depressant effects, it is not
possible to standardise quantification in this way since the time of
onset canno.t be accurately related to the time of injection. The
interphase between chemodepression and chemoexcitation must represent
a particularly complex dynamic state of neural and biochemical
activity. Data obtained during infusions of drugs are clearly of value
because the effect of a drug may be studied when steady-state
conditions prevail.
Several important conclusions may be drawn from this work. With
respect to the actions of NA, evidence has been provided that this
catecholamine could function essentially as an 'inhibitory' substance,
causing a decrease in the frequency of spontaneous discharge. This
action is almost certainly mediated through the activation of DA D2-
receptors within the carotid body. That this is the primary action of
NA is suggested not only by the rapid onset of the effect, but also by
the fact that chemodepression is maintained during the infusion of the
drug, even when cardiovascular changes (which appear to underly the
delayed chemoexcitation following injections of NA) are as marked as
those evoked by injections of NA.
Vasoconstrictive-hypertension almost certainly does not directly '
cause the increase in chemoreceptor discharge following injection of
NA (as evidenced by the failure of the cij-selective agonist PHEN to
cause chemoexcitation) unless accompanied by other changes which alter
(reduce) cardiac output or otherwise result in changes in arterial
blood gas tensions.
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A transient chemoexcitatory response to NA was also observed in
some 67% of recordings; this effect was not susceptible to blockade
with adrenoceptor antagonists (nor to blockade with cholinoceptor
antagonists), and it remains to be established whether it is mediated
through atypical adrenoceptors. The biochemical mechanisms that
subserve this transient excitatory response are yet to be determined.
There is a strong possibility that the effect is the same as that
observed by O'Regan (cf. O'Regan, 1983) in response to sympathetic
nerve stimulation. The significance of this effect in terms of
'continuous' chemoreceptive activity is uncertain.
The pattern of results obtained suggests some similarities with
the DA-receptor mechanism characterised in the intermediate lobe of
the rat pituitary gland. In this tissue enhanced formation of cAMP,
in response to 8-adrenoceptor stimulation by ISO, results in release
of a-melanocyte stimulating hormone; both responses are inhibited by
DA, acting through D2-receptors (Kebabian & Calne, 1979). Apomorphine
too causes a non-competitive decrease in the maximum response of the
8-adrenoceptor to ISO, whereas PROP is a competitive antagonist at the
8-adrenoceptor (see Kebabian & Cote, 1981). NA is able to stimulate
both the 8-adrenoceptor in the intermediate lobe of the pituitary
(causing an increase in cAMP levels - Cote et al, 1980) and the DA
D2-receptor (see Kebabian & Cote, 1981). Responses to MA are smaller
than those to ISO, but are potentiated after the DA-antagonist flupheri-
azine, which does not alter the response to ISO. The suggested
mechanism for the observed effects of NA in the pituitary model is
that stimulation of the D2-receptor causes a non-competitive reduction
in the responsiveness of the 8-adrenoceptor, resulting in a sub-maximal
enhancement of adenylate cyclase activity (Kebabian & Cote, 1981).
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Such a mechanism could account for the effects of NA upon chemorec-
eptor discharge observed in the present study, and the sustained
depressant effect of NA during infusions of the drug implies that D2-
receptor activation might indeed be a mechanism for attenuating
chemoreceptor discharge. This accords with theories that tonic
release of DA exerts a 'braking' effect upon chemoreceptor discharge.
Evidence from the present study suggests that g-adrenoceptors are not
important in the intrinsic proccesses of chemotransduction, and
perhaps other candidates (amino acids or purines?) must be investigat¬
ed as the 'primary' transmitters involved in chemotransduction, if,
indeed, the response to physiological stimulation is mediated by the
release of transmitter substances.
The role of 5-HT contained in the carotid body still remains to
be determined. The use of novel antagonists has allowed a tentative
classification of receptors involved in the complex response to 5-HT.
Thus, initial transient chemoexcitation, observed in about half the
recordings, and the more consistent chemodepression evoked by 5-HT,
are blocked by the antagonist MDL 72222. This novel antagonist
'selectively' blocks the effects of 5-HT at 'neuronal' receptor sites,
which, together with the rapid onset of these effects of 5-HT is
suggestive of a direct action upon the sensory nerve endings, or at a
site close to a mechanism inducing depolarisation of these nerves.
The less intense, delayed chemoexcitatory responses to 5-HT (which
initially appear to coincide with vascular changes evoked by the drug)
are blocked by the 5-HT2 antagonist ketanserin, but it was also
observed that this type of response was more prominent after
administration of the antagonist MDL. It is possible that the effect
is mediated by a less-sensitive 5-HT-receptor in the carotid body,
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which, like the proposed excitatory DA-receptors (see Section 1) can
only be seen to cause changes in chemoreceptor discharge after the
effects of stimulating more-sensitive receptors have been abolished.
How such a desensitisation would occur in vivo is unclear, but it
could be a potentially useful homeostatic mechanism.
The failure of blockade of 5-HT receptors or of adrenoceptors to
prevent the response of chemoreceptors to hypoxia suggests that
neither indole- nor catechol- amines are involved in the intrinsic
mechanism of hypoxic chemotransduction.
Opioid peptides, namely the enkephalins, cause chemodepression,
and the results of this pharmacological study indicate that the effect
is mediated through the 6-sub-type of opioid receptor.
Chemodepression caused by NA and by [Met]enk is capable of
reducing the response of chemoreceptors to hypoxia (and in the case of
the opioid at least, to hypercapnia). The physiological stimuli app¬
lied in these experiments were relatively severe; possibly, transient
release of these substances in the carotid body could 'smooth out' the
effects of momentary fluctuations of gas tensions in the blood
supplying the carotid body. Such an action might also be synergistic
with efferently controlled regulation of blood flow, or direct
efferent control of nerve activity (cf. Section 1), and the whole
subject of efferent control of the carotid body has yet to be fully
investigated.
Least conclusive are the effects of the polypeptides SP and VIP.
The former had no readily definable action upon the chemoreceptors,
whilst the latter was a chemoexcitant, and might be seen potentially
to complement the actions of the opioids. This must remain
speculative until circumstances for its release in the carotid
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body are determined.
The interaction of polypeptides with monoamines deserves further
consideration. In this respect, the most consistent and striking
observation was the potentiation of chemodepression and subsequent
excitation in response to 5-HT during infusion of SP. This is
consistent with reports of only slight alterations of membrane
potential by SP (see Section 1), followed by facilitated responses to
other neurotransmitters.
Since it appeared that the depressant effects of DA and NA were
not amplified during infusion of [Met]enk, this (as previously sugges¬
ted - Section 8) may indicate that both classes of neurotransmitter
act through (inhibition of?) a common (cAMP?) mechanism.
All forms of response to NA, DA, and ACh were potentiated during
NAL infusion, and after the potent 6-selective antagonist ICI 174864,
the response to hypoxia was also potentiated. This suggests that
endogenous opioids tonically suppress spontaneous chemoreceptor
activity, as proposed by Pokorski and Lahiri (1981), and an action also
proposed for DA (Osborne & Butler, 1975; McDonald & Mitchell, 1975a;
Krammer, 1978). It is unclear why both DA and opioids should mediate
the same homeostatic effect, unless the dynamics of the actions they
exert are different, thus allowing the possibility of 'coarse' and
'fine' tuning of regulatory actions.
In this study no attempt was made to evaluate the effects of
monoamines upon the responsiveness of chemoreceptors to peptides, and
this allows scope for future studies. Of critical importance is the
careful balancing of the amounts of drugs applied in these in vivo
pharmacological studies, so as not to mask subtle effects of one drug
by gross effects of another. The marked depressant effects of [Metjenk
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seen in the present study may well account for the equivocal nature of
the results obtained in the study of interactions with monoamines.
Catechol- and indole- amines and opioid peptides depress
chemoreceptor activity; SP may also partially depress chemoreceptor
activity. None of the drugs studied would appear to bea likely
candidate as an 'essential' excitatory transmitter in the proccesses
of chemotransduction; most of these drugs appear more capable of act¬
ing as depressors, thus modulating spontaneous activity. Clearly, if
released substances are to be held accountable for modulating
spontaneous activity in a way meaningful to the accepted excitatory
effects of physiological stimulation, then much more information must
be obtained concerning both the evoked release of these substances,
and the possible role of the efferent nerves in causing their
release. In this respect, it would be necessary to establish what
form of 'dialogue' takes place between centres in the brain stem that
receive an afferent input from the chemoreceptors, and the centres
from which efferent activity is initiated.
Two problems must be solved in order to determine how the carotid
body chemoreceptors function. First, the identity of the structure
within the carotid body, responsible for detection of changes in Pa02
and PaC02 must be identified. The type I cells may be necessary to
obtain chemosensory activity on a moment-to-moment basis, and could do
this by release of a transmitter, triggering activity in the sensory
nerve endings. They may also, or instead, be essential for chemorecep-
tion through the production of some trophic factor(s) which, on a long
term basis may induce chemosensory properties in the nerve endings.
The second problem concerns the establishment of what biochemical
or biophysical changes in the transducer mechanism are caused by the
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stimulus. Here, the studies directed towards the 'metabolic' effects
of 02 may suggest how changes in Pa02 are sensed, and the use of
techniques to study changes in membrane potential (e.g. Zapata & Eyza-
guirre, 1985) will become increasingly more important. All the drugs
and stimuli that have been applied to the carotid body to evoke
changes in afferent neural activity will have to be reapplied to
determine their effects upon membrane potentials and resistances,
trans-membrane ionic currents, respiratory enzyme chains, intracel¬
lular Ca2+ homeostasis and so forth. The effects upon neural activity
of the drugs used in the present study may be useful in interpreting
effects upon these other parameters, but it should always be borne in
mind that exogenously administered transmitter substances may act at
sites not normally affected by the same substances, contained or
released within the carotid body.
The enigma of this tiny organ, about which volumes have been
written, will continue to engage scientists and theoreticians for many
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APPENDIX 1: DETAILS AND SOURCES OF DRUGS USED IN THIS INVESTIGATION
(Doses referred to in the text are those of the salt) •
Drug M.Wt. Source
Acetylcholine iodide 273.1 B.D.H.
[D-Ala2,D-Leus]enkephalin 569.7 C.R.B.
[D-Ala2 jMePhe1* ,Glyol5]enkephalin 51 4.6 C. R. B.
Betaxolol hydrochloride 343.9 Synthelabo, Paris
ct-Chloralose 309.5 B.D.H.
Corynanthine hydrochloride 390.9 Sigma
Dobutamine hydrochloride 337.8 Lilly
Domperidone 425.9 Janssen, Belgium
Dopamine hydrochloride 189.6 Koch Light
Dynorphin(j_a) octapeptide 981 .3 C.R.B.
Eledoisin 1188.6 Penninsula Labs
Ethylketocyclazocine methanesulphonate 403.1 Sterling Winthrop
Gallamine triethioaide ('Flaxedil') May & Baker
8-Hydroxy-DPAT hydrobromide 328.3 Merrell, France
5-Hydroxytryptamine, creatinine 387.4 Sigma
sulphate complex
ICI 118,551 hydrochloride 339.5 I.C.I.
ICI 154,129 arginate 922.0 I.C.I.
ICI 174,864 base 715.0 I.C.I.
Isoprenaline sulphate 556.6 Pharmacy Dept.,
Royal Inf. Edin.
Kassinin 1334.7 Peninsula Labs
Ketanserin tartrate 545.5 Janssen, Belgium
[Leucines]enkephalin acetate 555.7 C.R.B.
MDL 72222 methanesulphonate 419.3 Merrell, France
[Methionines]enkephalin acetate 573.7 C.R.B.
5-Methoxy-tryptamine hydrochloride 226.7 Sigma
2-Methyl 5-hydroxytryptamine, 401 .4 Glaxo
creatinine sulphate complex
Metoprolol tartrate 684.8 Ciba Geigy
Morphiceptin [g-casomorphin()amide] 558.1 Sigma
hydrochloride
(-)-Naloxone hydrochloride 363.8 Sigma
L-Noradrenaline bitartrate 337.3 Sigma
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Drug M.Wt. Source
Oxymetazoline hydrochloride 296.5 Merck Sharp & Dohme
L-Phenylephrine hydrochloride 203.7 Koch Light
Physalaemin 1265.6 Peninsula Labs
Prenalterol hydrochloride 261 .7 Astra
DL-Propranolol hydrochloride 295.8 I.C.I.
Rauwolscine base (a-yohirabine) 354.4 Inverni della Beffa,
Milan, Italy
RU 24969 succinate 346.1 Roussel, France
Salbutamol base 239.3 Allen & Hanburys
Sodium cyanide 49.0 B.D.H.
Sodium pentobarbitone ('Sagatal') May & Baker
Substance K (neurokinin a) 1133.5 C.R.B.
Substance P 1347.7 C. R. B.
Substance P, methyl ester 1364.8 C.R.B.
L-Sulpiride 341 .4 Ravizza, Italy
Vasoactive intestinal polypeptide (,.28) 3326.3 C.R.B.
Common reagents for the preparation of Locke solution etc. were
obtained commercially, and were of 'analar' grade.
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APPENDIX 2: MOLECULAR STRUCTURES OF AGONISTS & ANTAGONISTS USED IN
THIS INVESTIGATION.
(The receptor type at which a substance is expected to exhibit
activity is indicated in parentheses.)
1. MISCELLANEOUS CHEMORECEPTOR STIMULANTS.
















Phenylephrine (at) Oxymetazoline (a2)
2.3 Selective a - Adrenoceptor antagonists,
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3.2 Selective 5-HT agonists.
h3co ch2-ch2-nh2
5-Methoxytryptamine










8-OH DPAT (5-HT1a) RU 24969 (5-HT1b)















(All the tachykinins display approximately equal potency at
the 'SP-P' receptor, whilst the 'SP-E' receptor is consider -
ably more sensitive to eledoisin and kassinin than to the
other tachykinins.)
4.2 Synthetic Substance P analogues.
The methyl ester of Substance p is formed by the substitution of a















































Key to amino acids:
Ala: Alanine His: Histidine Ser: Serine
Arg: Arginine lie: Isoleucine Thr: Threonine
Asn: Asparagine Leu: Leucine Trp: Tryptophane
Asp: Aspartic acid Lys: Lysine Tyr: Tyrosine
Gin: Glutamine Met: Methionine Val: Valine
Glu: Glutamic acid Phe: Phenylalanine
Gly: Glycine Pro: Proline
Aib = cc-aminoisobutyric acid
PCA = Pyrrolidine carboxylic acid, the cyclic derivative


















[From the Proceedings of the Physiological Society, 23-24 September 1983
Journal of Physiology, 346, 96P]
Changes in responses of cat carotid body chemoreceptors to 5-HT after
administration of the antagonist MDL 72222
By G. C. Kxrby and D. S. McQueen. Department of Pharmacology, University of
Edinburgh Medical School, Edinburgh EH8 9JZ
The physiological role of the 5-hydroxytryptamine (5-HT) that is present in the
cat carotid body (Chiocchio, Biscardi & Tramezzani, 1967) has yet to be established.
Nishi (1975) found that intracarotid (i.e.) injection of 5-HT in cats caused a transient
increase in carotid chemoreceptor discharge that was followed by a period of
chemodepression. These responses were unaffected by the putative 5-HT antagonists
LSD, gramine and methysergide.
In the present study we have investigated the effects of MDL 72222 (a new
compound which appears to be a selective antagonist at neuronal 5-HT receptors -
Fozard, 1983) on the responses of carotid-body chemoreceptors to 5-HT, dopamine
and to changes in Pa< 0j. Experiments were performed on cats anaesthetized with
a-chloralose (70 mg kg-1 i.v.) artificially ventilated and paralysed with gallamine
(3 mg kg-1 i.v.). Chemoreceptor activity was recorded from the peripheral end of a
carotid sinus nerve, and drugs were injected into the common carotid artery, as
previously described (Docherty & McQueen, 1978).
Injection of 5-HT (OT-lOO /ig i.e.) caused a dose-dependent depression of 'spon¬
taneous' chemoreceptor discharge which was followed by a delayed excitation of
variable duration. Only occasionally was the chemodepression preceded by a
transient burst of activity, in agreement with the findings of Black, Comroe & Jacobs
(1972). After MDL 72222 the dose-response curve for 5-HT-evoked chemodepression
was shifted to the right, and following the higher dose of antagonist 5-HT caused a
prolonged dose-dependent chemo-excitation of rapid onset. The initial transient burst
of activity, when present, was also abolished by the antagonist. Chemodepression
evoked by dopamine and chemo-excitation caused by sodium cyanide were unaffected
by the doses ofMDL 72222 studied, and there were no marked changes in spontaneous
discharge or, as judged from preliminary experiments, in the response of the
chemoreceptors to alterations in Pa 0,-
Our results show that MDL 72222 is capable of antagonizing the depressant effect
of 5-HT on carotid chemosensory discharge and may prove useful in helping to
determine the physiological role for 5-HT in the carotid body.
This work is supported by a project grant from the M.R.C. G.C.K. is a Houldsworth Scholar
of Edinburgh University. MDL 72222 was kindly donated by Merrell (Strasbourg).
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Effects of the antagonists MDL 72222 and ketanserin
on responses of cat carotid body chemoreceptors to
5 -hydroxytryptamine
G.C. Kirby&D.S. McQueen
Department of Pharmacology, University of Edinburgh Medical School, Edinburgh EH8 9JZ
1 The effects of intracarotid (i.e.) injections of 5-hydroxytryptamine (5-HT; 1-50 pig) on carotid
chemoreceptor activity recorded from the carotid sinus nerve have been studied in anaesthetized
cats.
2 Three separate components in the complex response of the chemoreceptors to injected 5-HT
were identified. Firstly, a transient burst of activity was obtained during the injection period in 56%
of the recordings. Secondly, in all the recordings a period of chemodepression commenced a few
seconds after completing the injection and was usually dose-related. Thirdly, a delayed longer-
lasting chemoexcitation occurred in many experiments, concomitant with a fall in systemic blood
pressure.
3 The neuronal 5-HT receptor antagonist MDL 72222 (10-100 pg kg"1, i.e.) virtually abolished
the transient chemoexcitation evoked during 5-HT injections and also significantly increased the
mean ID50 for 5-HT-induced chemodepression; in 37% of recordings 5-HT caused a dose-related
chemoexcitation after the high dose of MDL 72222. Neither the delayed chemoexcitation nor the
hypotension caused by 5-HT were much affected by the antagonist. MDL 72222 itself had a biphasic
effect on chemosensory discharge, causing depression followed by a delayed excitation.
4 The 5-HTj-receptor antagonist ketanserin (lOOpgkg"1, i.e.) had no appreciable effect on the
transient chemoexcitation evoked during 5-HT injections and caused a slight but significant increase
in the mean ID50 for 5-HT-induced chemodepression. The delayed chemoexcitation and accom¬
panying hypotension associated with 5-HT were both substantially reduced or abolished by the
antagonist. Ketanserin itself caused a short-lasting period of chemoexcitation.
5 All the effects of injected 5-HT on chemosensory discharge could be abolished by the combina¬
tion of MDL 72222 and ketanserin (100 pg kg-1, i.e.).
6 Neither MDL 72222 nor ketanserin had any significant effect upon the response of the carotid
chemoreceptors to hypoxia. The rate at which discharge increased, and also the steady-state
discharge before and during hypoxia, were unaffected by the antagonists, alone or in combination.
7 At least two types of 5-HT receptor appeared to be involved in the response of carotid body
chemoreceptors to 5-HT. Transient excitation and chemodepression were mediated via
MDL 72222-sensitive (peripheral neuronal) receptors whereas the delayed chemoexcitation and
associated hypotension involved a ketanserin-sensitive, presumably 5-HT2-, receptor. It appears
unlikely that 5-HT plays a crucial role in chemoreception.
Introduction
Although it is well known that 5-hydroxytryptamine
(5-HT, serotonin) is present in the carotid body of
many species, including the cat (e.g. Chiocchio etal.,
1967), its physiological role there remains to be
determined. The effects of exogenous 5-HT on
chemosensory activity recorded from the carotid
sinus nerve have been studied in anaesthetized cats
(Black et al., 1972; Nishi, 1975; Docherty &. Mc¬
Queen, 1978). A complex response is obtained fol¬
lowing the intracarotid injection of 5-HT, with a
common pattern being a brief period of chemoexcita¬
tion followed by a longer-lasting depression of back¬
ground chemoreceptor discharge. Nishi (1975)
found that the response to 5-HT was unaffected by
© The Macmillan Press Ltd 1984
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atropine or hexamethonium, which eliminates in¬
volvement of acetylcholine (ACh) receptors, but the
putative 5-HT antagonists lysergic acid diethylamide
(LSD), gramine and methysergide were also without
effect on the response of the carotid chemoreceptors
to 5-HT. Categorization of 5-HT receptors in the
peripheral nervous system is a complex problem (see
Gyermek, 1961; Wallis, 1981) and the value of
studies with drugs such as methysergide or LSD in
helping to characterize the carotid body 5-HT recep¬
tors has been questionable because they lack specific¬
ity as 5-HT antagonists. However, the recent advent
of more specific 5-HT antagonists such as
MDL 72222, shown to be potent in antagonizing the
actions of 5-HT at peripheral neuronal sites (e.g.
fibres mediating the Bezold-Jarisch reflex in rat -
Fozard, 1984), and ketanserin, which is reputed to be
a highly selective antagonist at 5-HT2-receptor sites
but inactive at 5-HTi-receptor sites (Leysen era/.,
1981), prompted us to study their effects on the cat
carotid chemoreceptors. The aim was to attempt a
characterization of 5-HT receptors involved in the
response of cat carotid chemoreceptors to 5-HT and,
by investigating the influence of the antagonists on
responses of the chemoreceptors to a physiological
stimulus, hypoxia, obtain information regarding the
physiological role of 5-HT in the carotid body.
A preliminary account of some of the results has
previously been presented (Kirby & McQueen,
1984).
Methods
Experiments were performed on fifteen cats of either
sex, weighing between 2.3 and 3.9 kg, median weight
3.0 kg. Animals were anaesthetized with a-chloralose
(65-70 mg kg-1, intravenously) following induction
with haiothane (5% in oxygen) and supplements of
chloralose were administered intravenously as re¬
quired. In two experiments pentobarbitone
(42mgkg~l, intraperitoneally) was used instead of
a-chloralose.
Full details of the experimental procedures have
been given previously (McQueen, 1977; Docherty &
McQueen, 1978) so only a brief description is pro¬
vided here. The carotid sinus region on one side was
dissected and the ganglioglomerular nerves, which
carry the sympathetic nerve supply from the superior
cervical ganglion to the carotid body, were cut. The
cats were artificially ventilated with room air, apart
from periods when hypoxic gas mixtures were used.
Gallamine triethiodide (3 mg kg"1) was administered
intravenously to prevent spontaneous and drug-
induced muscle movements. Drugs were dissolved in
modified Locke solution or in 0.9% w/v NaCl solu¬
tion (saline) and injected, in volumes of 0.1 ml, into
the common carotid artery ipsilateral to the sinus
nerve from which electrical activity was recorded.
They were washed in with 0.2 ml Locke solution
which had been bubbled with 5% C02:95% air at
37°C; injections were generally completed within
1-2 s.
Electrical activity of single or multiple (2-4)
chemoreceptor units was recorded from the
peripheral cut end of the sinus nerve and stored on
tape for subsequent analysis using a pulse height
voltage discriminator linked to a microcomputer
(McQueen et al., 1984). The units were confirmed as
chemoreceptors by their random pattern of dis¬
charge, their increase in discharge frequency follow¬
ing injection of sodium cyanide (2.5 pg) into the
ipsilateral common carotid artery or in response to
hypoxia (breathing 10% oxygen in nitrogen), and by
the depression of discharge in response to hyperoxia
(breathing 100% oxygen).
Data analysis
A plot of chemosensory discharge (counts per
0.1s bin) against time was made for each test, and the
change in discharge frequency (xc.p.s.) from the
pre-injection control frequency calculated. In order
to standardize results from experiments with differ¬
ent absolute discharge frequencies, the response oc¬
curring in the first 5 s of the post-injection period was
expressed as a percentage change from control level
and plotted against logio dose. From lines fitted to the
dose-response data it was possible to calculate the
dose causing a particular response (e.g. ID50, dose
causing a 50% reduction in control discharge) and
obtain a mean value by pooling data from different
experiments.
Hypoxia
The animals were made hypoxic by switching the
inspired gas from air to 10% O2 plus 90% Nj for
4 min. For each test the control (air-breathing) dis¬
charge and steady-state discharge (hypoxia) were
measured and arterial blood samples taken before
and 3.5 min after onset of the hypoxic stimulus for
blood gas analysis. Discharge was measured over
consecutive 15 s periods and plotted against time,
and a straight line fitted to the values obtained when
discharge was increasing in response to the hypoxic
stimulus (i.e. until a steady-state maximum (100%)
or plateau discharge was obtained). The slope of this
line provided an index of the rate of increase in
chemoreceptor discharge in response to hypoxia, and
was expressed as % maxs"1.
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Statistics Results
Mean values are given ± s.e.mean. Statistical analysis
of differences between means was carried out using
the Wilcoxon two-sample test and the null hypothesis
rejected at the 0.05 level of probability (2-tailed).
Drugs
The following compounds were used, and doses are
expressed in terms of the salt: 5-hydroxytryptamine
creatinine sulphate complex, dopamine hydroch¬
loride (Sigma); MDL72222 (laH, 3a, 5aH-tropan-
3-vl 3,5-dichlorobenzoate) methanesulphonate salt,
kindly donated by Merrell International, Strasbourg;
domperidone and ketanserin, tartaric acid salt, kind¬
ly donated by Janssen Pharmaceuticals, Beerse,
Belgium.
5-HT injections
Sixteen recordings of chemosensory activity were
obtained, and intracarotid injection of 5-HT
(1-50 fig) consistently caused a depression of
chemosensory discharge which lasted for 3 -15 s. The
effect was dose-related in twelve of the recordings
(75%), as shown in Figure 1. In the other four
experiments chemodepression was not clearly re¬
lated to dose. 5-HT doses of less than 1 ng had only
slight effects on background discharge and these did
not differ significantly from those associated with
injection of the drug vehicle; the latter had variable
effects on chemosensory discharge causing, on aver¬
age, a 20.5% reduction during the 5 s post-injection















Figure 1 (a and b) Neurograms showing the effects of a single intracarotid (i.e.) injection of 5-hydroxytryptamine
(5-HT; lOfxg, at arrow) on chemosensory discharge (3 units) and illustrating in (a) the initial burst of activity which is
followed by a period of relative inhibition. A delayed phase of excitation can be seen in (b), which shows the same test
displayed at a slower sweep speed. A ramped output below the neurograms gives the number of action potentials
counted cumulatively in successive 1 s intervals, (c) Dose-response data showing the relationship between 5-HT
dose and the percentage change in chemosensory discharge (from pre-injection control levels) that occurred during
the first 5 s after injecting 5-HT. The straight line was fitted to the data by the least squares method, and the ID50 (i.e.
dose of 5-HT causing a 50% depression of discharge - see broken lines) determined. The mean of the five individual
control discharge values, from which the percentage changes were calculated, was 8.03 ±0.26 c.p.s.. (♦) Effect
associated with injection of the drug vehicle.
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Figure 2 Neurograms of chemosensory discharge illus¬
trating the response to injecting, at the arrow, (a)
MDL72222 (lOOpgkg-1, i.e.) and, from a separate
experiment, (b) ketanserin (lOOpgkg"1, i.e.). The
ramped trace below each neurogram gives the number
of action potentials counted cumulatively in 1 s intervals.
was preceded by a transient burst of chemoreceptor
action potentials, usually occurring within the injec¬
tion period (Figure 1). The threshold for this more
variable excitatory effect (^10 fig) was generally
higher than that for chemodepression, but although
discharge increased substantially, by 800-1000% in
some experiments, a clear dose-response relation¬
ship was obtained in only three of the experiments,
and the response appeared to be subject to
tachyphylaxis. In the remaining 25 % of recordings in
which 5-HT did not cause transient excitation,
chemodepression was still obtained. The averaged
ED50 for the dose-dependent chemodepression in the
recordings where the effect was dose-related was
5.8 ±1.9 fig (n = 12).
In many of the experiments a delayed increase in
chemosensory discharge was observed following the
chemodepression (Figure 1). This effect was rather
variable, lasted for 10-60 s, and had no consistent
dose-response relationship. It appeared to be as¬
sociated with the fail in systemic blood pressure that
occurred following 5-HT injection (Figure 5).
Effects of the antagonist MDL 72222
Intracarotid injection of MDL 72222 (10-
100figkg~l) caused a depression of background
chemosensory discharge which was followed by a
delayed increase in discharge frequency (Figure 2a).
No chemoexcitation was observed during the period
of injection, and systemic blood pressure was not
significantly affected by the antagonist. MDL 72222
(10figkg~l, i.e.) was studied on seven recordings and












10 100 500 1000
5-HT (fig) i.e.
5 10 25 50100 250 1000
5-HT (pig) i.e.
Figure 3 (a) Chemodepressant effect of 5-hydroxytryptamine (5-HT) injected before (O O) and after
(• •) a low dose of MDL 72222 (10 fig kg-1, i.e.). The rightward shift in the logio dose-response curve caused
by the antagonist is shown. An additional dose of MDL 72222 (100 fig kg"1, i.e.) caused a further shift upwards and
to the right (■). (b) In aseparate experiment the higher dose of MDL 72222 (100 pg kg-1, i.e.) completely abolished
the 5-HT-induced chemodepression (■ ■) and slight chemoexcitation was obtained in response to the lower
doses of 5-HT. Lines were fitted to the data by the method of least squares.
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Figure 4 Responses of chemoreceptors (multi-unit recordings) to intracarotid injections of 5-hydroxytryptamine
((a) 5and(b) 25 fig at arrows)before and after MDL 72222 (100 fig kg"1, i.e.). The initial transient chemoexcitation
and the subsequent depression of chemoreceptor discharge were both virtually abolished by the antagonist, and
chemoexcitation became evident within the 5 s post-injection period. The ramps show the number of action
potentials counted cumulatively in 1 s intervals.
5-HT to chemodepression was shifted upwards and
to the right (Figure 3), and the mean ID50 was
increased to 49.4 ±33.6 fig (n = 7; P<0.05 with re¬
spect to controls). When a dose of 100 fig kg"1 was
given (8 recordings, in 6 of which it followed the
lower dose) the ID50 increased to 63 8 ± 408 fig in five
(63%) of the recordings. In the other three cases
(37%) a dose-dependent chemoexcitation was ob¬
tained in the 5 s post-injection period (Figure 3), and
no chemodepression occurred unless very high doses
of 5-HT (250-1000 fig) were injected. It was possi¬
ble to calculate an EDjo (dose causing 30% increase
in discharge above pre-Lnjection level), and this was
103.1 ±9.0 fig (n = 3).
During the nine experiments in which 5-HT caused
an initial transient excitation, this part of the re¬
sponse was substantially reduced (totally abolished


























0 5 10 15 s 0 5 10 15 s
Figure 5 (a) Injection of 5-hydroxytryptamine (5-HT) injected (10 fig i.e., at arrow) affected chemosensory
discharge (lower trace, count of action potentials per 1 s interval) and aiso caused a fail in systemic blood pressure
(upper trace), (b) After administering ketanserin (100 fig kg"1, i.e.) the same dose of 5-HT had much less effect upon
blood pressure and there was less delayed chemoexcitation 10-15 s after the injection. However, both the initial
burst of activity and the subsequent chemodepression were relatively unaffected by the antagonist.
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MDL72222 (lOfigkg"1), and further reduced or
abolished by the higher dose (100 fig kg-1) - see
Figure 4. In one experiment the 5-HT-induced trans¬
ient chemoexcitation appeared only after
MDL72222 (lOfigkg"1) and was abolished by ad¬
ding the higher dose (100 fig kg-1) of antagonist. The
delayed or secondary chemoexcitation, which was
more obvious following higher doses of 5-HT, gener¬
ally increased in magnitude and became more rapid
in onset after MDL 72222 (10-100 ftg kg"1), as
shown in Figure 6a.
Effects of the antagonist ketanserin
Intracarotid injection of ketanserin (100 fig kg-1) in¬
creased chemosensory discharge in the five record¬
ings studied, an effect which lasted for 10-30 s (Fig¬
ure 2b), and caused a longer-lasting fall in systemic
blood pressure. There was no depression of discharge
following ketanserin and no transient chemoexcita¬
tion during the injection period. The initial excitation
caused by 5-HT was present in three of these record¬
ings and was unaffected by the antagonist (Figure 5).
The ID50 for 5-HT-induced chemodepression was
14.2±5.0fig (n = 4), which represents a small but
significant (P< 0.05) decrease in the average re¬
sponse after ketanserin - although much less marked
than the antagonism caused by MDL 72222
(10 fig kg"1), and ketanserin had little orno influence
in some of the tests (e.g. Figure 5). In all five record¬
ings the delayed increase in discharge was substan¬
tially reduced, as was the hypotensive effect of 5-HT
(Figure 5).
Effects of the two antagonists in combination
In five experiments where MDL 72222 (100 fig kg"1)
was administered sifter ketanserin (100 fig kg"1) the
normal responses to 5-HT injections were absent.
Dose-response data for the first 5 s of the responses
gave lines of such shallow slope that meaningful ID50
or ED30 values could only be obtained by extrapola¬
tion far beyond the range of doses that could feasibly
be used in the experiments, and these were not
considered to be meaningful. This was also the case in
the five experiments where ketanserin (100 fig kg"1)
was injected after MDL 72222 (100 fig kg"1).
Responses to dopamine, and the effects of
domperidone
The chemodepressant effect of dopamine (0.1-
10 fig, i.e.) was obtained in all 16 recordings and
was unaffected by either ketanserin or MDL 72222
(Figure 6). The dopamine Dj-receptor antagonist
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Figure 6 Neurograms showing the response of a single chemoreceptor unit to injections (arrows) of (a) 5-
hydroxytryptamine 25 ng, i.e.) and (b) dopamine (lfig, i.e.) before and after administering MDL 72222
(100 fig kg"1, i.e.). It can be seen that, whereas the chemodepression evoked by 5-HT was greatly reduced by the
antagonist, the dopamine-induced effect was unaltered. The ramps show the number of action potentials counted
cumulatively in 1 s intervals.
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Figure 7 Neurograms showing the responses of chemoreceptor units to injections (arrows) of (a) 5-
hydroxytryptamine 10 fig, i.e.) and (b) dopamine (1 fig, i.e.) before and after administering the dopamine antagonist
domperidone (10 fig kg "1, i.e.). The antagonist virtually abolished the chemodepressant effect of dopamine but had
no appreciable effect upon the response evoked by 5-HT. The ramps show the number of action potentials counted
cumulatively in 1 s intervals.
eight preparations and reduced the depressant effect
of dopamine on the chemoreceptors without altering
the responses to 5-HT (Figure 7), whether injected
before (4 experiments) or after (4 experiments) the
5-HT antagonist(s). ID<0 values for 5-HT-induced
chemodepression obtained after domperidone alone
were 10.8 ± 2.5 ug (n = 4) and 8.1 ± 3.1 fig(n = 2) for
the 10 and 100fig kg""1 doses, respectively (P>0.05
in comparison with controls).
Responses to physiological (hypoxic) stimulation
The effect of hypoxic stimulation was studied in 14
experiments, and chemoreceptor responses obtained
before and after administering MDL 72222 or
ketanserin.
MDL 72222 Control chemosensory discharge fre¬
quency averaged 6.8 ±1.5 c.p.s. on air, and increased
to 26.8±5.3 c.p.s. on 10% O2 (n — 6). After
MDL 72222 (10 fig kg""1) background discharge on
air increased to 10.8 ±3.2 c.p.s., and rose to
27.3 ±5.8 c.p.s. (n = 6) on 10% O?. The slope of the
line relating discharge to time during the period of
increasing discharge was 1.08 ±0.11% maxs"1 be¬
fore, and 1.04 ±0.12 after MDL 72222. The time
taken to reach the plateau or steady state discharge
(i.e. maximum or 100%) was 112±6s before, and
109 ± 11 s after the low dose of MDL. A higher dose
of MDL 72222 (100 fig kg~1)^was studied in 12 ex¬
periments (see Figure 8) in three of which ketanserin
had previously been injected. Background discharge
on air was 5.3 ± 1.0 c.p.s., and it increased to
21.9 ±3.2 c.p.s. on 10% O2, the slope being
1.02±0.07% maxs"1 and the time taken to reach
plateau (max) 114±4s. After MDL 72222 back¬
ground discharge was 7.7 ± 1.8 c.p.s., discharge on
10% O2 26.3±5.5, slope 1.08±0.11, and the time
taken to reach plateau 116±7s. None of these
parameters was significantly different from control
values, following either dose of MDL 72222.
Ketanserin In 6 hypoxia tests performed immediate¬
ly before the injection of ketanserin (in one of which
MDL 72222 had been administered previously)
background activity in the pre-ketanserin control
state was 6.9 ±2.0 c.p.s., and increased to
25.6±6.5c.p.s. on 10% O^, the slope of the line
being 0.99±0.06% maxs"1, reaching the plateau or
maximum value 112±6s after changing gases. Fol¬
lowing ketanserin (100 fig kg"1) five hypoxia tests
were carried out, and there was no significant change
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Figure 8 Increase in chetnoreceptor discharge caused
by ventilating the animals with a hypoxic gas mixture
(10% O;:90% Ns during the d min period starting at 0 s,
black bar) instead of room air. (a) Shows the discharge
averaged over 15 s intervals, obtained before (O O)
and after (•—•) administering ketanserin
(100 jig kg-1, i.e.). (b) Shows the responses obtained,
from a separate experiment, before (O O) and after
(•—•) administering MDL 72222 (lOOngkg-1, i.e.).
Lines were fitted to the data in the ranges shown by using
the least squares method. Neither of the antagonists had
any significant effect upon the response to hypoxia.
in any of the parameters (Figure 8). Background
discharge was 6.9 ± 2.0 c.p.s., increasing to 26.0 ±9.5
during 10% Oj, the slope was 1.02 ± 0.14% max s~l,
and time to plateau was 116 ± 17 s.
The mean values of arterial blood gas tensions and
pH during air breathing (PaCh 12.7 ± 0.7 kPa; PaCOz
4.3 ± 0.1 kPa; pH 7.30±0.01,n = 17) showed no sig¬
nificant differences between control values and those
obtained after the administration of antagonists.
Similarly, when the animals were made hypoxic,
there were no significant differences in blood gas
tensions and pH between the values obtained be¬
fore (PaCh 4.8±0.2kPa; PaCOi 4.1±0.2kPa;
pH7.32±0.01, n = 17) and after administration of
the antagonists.
Discussion
The present results show that 5-HT has complex and
somewhat variable effects upon chemosensory dis¬
charge in anaesthetized cats. We identified three
separate components in the response to 5-HT and
found that the 5-HT antagonists MDL 72222 and
ketanserin selectively affected different parts of the
response. Previous studies using respiration as an
index have provided evidence for both inhibitory and
excitatory effects of 5-HT on chemoreceptors in
various species including cat (Page, 1952; Douglas &
Toh, 1953; Ginzel & Kottegoda, 1954). 5-HT also
induces complex neurogenic and circulatory effects
which influence respiration independently of the
chemoreceptors (Mott & Paintal, 1953; Comroe et
al., 1953), which makes the respiratory effect a poor
index of chemoreceptor activity. We shall confine
ourselves to a consideration of neural data, looking at
the effects of antagonists on each of the components
of the chemoreceptor response to 5-HT.
Chemoexcitation
Transient chemoexcitation occurred during the in¬
jection period in about half the recordings, and this
effect has previously been described by Black er al.
(1972), Nishi (1975), and Docherty & McQueen
(1978). The increase was only occasionally dose-
related and seemed subject to tachyphylaxis. The
rapid onset suggests a direct or perhaps indirect (via
release of endogenous substance(s)) action on the
sensory nerve fibres (Eyzaguirre & Nishi, 1974), and
makes it unlikely to be due to vascular effects of
5-HT. The possible influences on the chemorecep¬
tors of increased sympathetic activity arising from the
ganglion-stimulating action of 5-HT (Trendelen¬
burg, 1958) were prevented by sectioning the gang-
liogiomerular nerves. This does not exclude the pos¬
sibility that 5-HT may release noradrenaline from
the terminals of sympathetic nerves within the
carotid body; such an action might be expected to
reduce blood flow through the carotid body and
could cause a delayed increase in discharge. The
finding that transient excitation was not obtained in
all recordings, in accord with Black et al. (1972),
could be because fibres differ in their sensitivity:
unmyelinated fibres may be more sensitive than
myelinated, or the concentration of 5-HT at the
receptor site following intracarotid injection may
vary between experiments. Tachyphylaxis to 5-HT
cannot explain the absence of excitation in response
to the initial doses of 5-HT, although in recordings
where excitation was occurring, repeated administra¬
tion of 5-HT in high doses did tend to attenuate the
response and may explain why there was no dose-
response relationship in many experiments. Nishi
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(1975), who evidently found transient chemoexcita-
tion by 5-HT to be more common and induced by
lower doses than was our experience, reported that
various antagonists were ineffective in blocking the
response. He was unable to characterize the receptor
responsible for excitation, although he did exclude
direct or indirect involvement of nicotinic and mus¬
carinic ACh receptors. Docherty & McQueen (1978)
found that the dopamine antagonist a-flupenthixol
could reduce excitatory responses to 5-HT, but in¬
consistently. We have not studied putative 5-HT
antagonists such as LSD or methysergide because of
concern over their specificity, but instead used the
newer 5-HT antagonists MDL 72222 and ketanserin.
The latter had no appreciable effect on the transient
chemoexcitation but MDL 72222 inhibited it. Thus
in some, but not all recordings of chemoreceptor
activity, 5-HT increases discharge transiently and
this occurs via actions, directly or indirectly
mediated, at a receptor, presumably within the
carotid body and perhaps associated with sensory
nerve endings, which is sensitive to the antagonist
MDL 72222. Recent studies have shown that
MDL 72222 blocks the excitatory action of 5-HT on
the cell bodies of rabbit vagal primary afferents
(Azami et al., 1984), and this evidence supports the
concept of 5-HT acting on neuronal or sensory recep¬
tors in the carotid body. The fact that MDL 72222
itself had some 5-HT-like actions could mean the
drug is a partial agonist.
Chemodepression
5-HT caused a short-lasting period of chemodepres-
sion which commenced almost immediately upon
completion of the injection and was dose-related in
the majority of experiments. Again, the rapid onset
of the effect makes it unlikely to be secondary to
vascular changes caused by 5-HT. It was the most
commonly encountered component of the response
and occurred regardless of whether or not the initial
excitation was present. Depression of chemoreceptor
discharge has been demonstrated previously (Black
et al., 1972; Nishi, 1975; Docherty & McQueen,
1978). Earlier studies showed that very high doses of
x-flupenthixol reduced the relative inhibition caused
by 5-HT (Docherty & McQueen, 1978), but none of
the putative 5-HT antagonists examined by Nishi
(1975) had any effect. His suggestion that depression
might be secondary to the initial excitation seems
unlikely, for if this were the case, chemodepres-
sion should not occur in the absence of an initial
depolarization, yet it did in our experiments. We
found that ketanserin had a rather variable effect
upon 5-HT-induced chemodepression, usually caus¬
ing a slight reduction (although sometimes a potenti¬
ation) of the effect. In contrast, MDL 72222
caused a substantial dose-related antagonism of
chemodepression, as shown by the increase in ID50
values, and higher doses (lOOpgkg-1) could com¬
pletely abolish the response, unmasking an excitatory
component. Dopamine also causes chemodepression
when injected in cats (Docherty & McQueen, 1978),
and in view of the fact that high doses of a-
flupenthixoi can reduce responses to 5-HT as well as
to dopamine, we examined the responses to
dopamine and 5-HT before and after administering
the selective dopamine D^-receptor (Kebabian
& Calne, 1979) antagonist, domperidone. Dom-
peridone had no significant effect on any phase of the
chemoreceptor response to 5-HT when given in
doses which substantially reduced dopamine-
induced chemodepression, and responses to
dopamine were unaffected by either MDL 72222 or
ketanserin. Thus, we can conclude that chemodep¬
ression evoked by 5-HT does not involve a dopamine
Di-receptor and is mainly mediated by mechanisms
which are sensitive to MDL 72222. The results with
ketanserin could mean that a small part of the depres¬
sion is attributable to actions on 5-HT2-receptors,
assuming the antagonist is selective and does not
affect MDL 72222-sensitive sites in the doses
studied. Whether the depression of discharge results
from direct actions of 5-HT, or is secondary to the
release of an inhibitory substance, cannot be deter¬
mined from our study.
Delayed excitation
The final component of the response to injected
5-HT was a delayed (10-30s) increase in discharge
that lasted longer than any of the other components.
However, it was very variable and tended to be
concurrent with the fail in blood pressure caused by
5-HT. The antagonist MDL 72222 had no effect on
blood pressure responses to 5-HT or on the delayed
excitation whereas ketanserin inhibited both the
hypotensive effect and the increase in discharge. The
chemoexcitation caused by ketanserin alone may
reflect some partial agonist activity of the drug. We
cannot tell from the data whether the delayed
chemoexcitation was due to the hypotension caused
by 5-HT, or resulted from actions of the amine on
S-HIVreceptors in the carotid body, perhaps as¬
sociated with the vasculature (Leysen et al., 1981) or
the nerves (e.g. sympathetic terminals - see earlier
discussion). Further experiments are needed to resol¬
ve the matter.
Classification of5-HT receptors
In the peripheral nervous system classification of
5-HT receptors is complicated (see Wallis, 1981)
and, in addition, new antagonists such as MDL 72222
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have yet to be fully characterized in vivo. According¬
ly, we can only conclude that at least two 5-HT
receptors appear to be responsible for changes in
carotid chemosensory discharge evoked by injected
5-HT. It is not possible to say whether or not the
transient excitation and depression are mediated
through a common MDL 72222-sensitive mechan¬
ism, but overall our findings are consistent with re¬
ports showing that MDL 72222 is a selective an¬
tagonist of responses mediated through 5-HT recep¬
tors on peripheral nerves (Fozard, 1984) and that
ketanserin appears to be an effective antagonist at
vascular 5-inVreceptors (Leysen era/., 1981).
Physiological stimulation
Although the combination of MDL 72222 and
ketanserin antagonized the effects of exogenous 5-
HT on chemosensory discharge, the response of the
chemoreceptors to physiological stimulation by
hypoxia was unaltered. Assuming the antagonists
studied reach effective concentrations at sites within
the carotid body where locally-released 5-HT acts,
the implication is that endogenous 5-HT has no vital
role in the mechanism of chemoreception. However,
the possibility that 5-HT might exert subde influ¬
ences, perhaps as a modulator or co-transmitter, that
were not detected in these experiments, cannot en¬
tirely be excluded. Neuronal co-storage of 5-HT with
polypeptides, some of which are present in the cat
carotid body (e.g. substance P; Cuello Sc. McQueen,
1980), and may be neurotransmitters (see Hokfelt et
al., 1980), could mean that if 5-HT is involved in
chemoreception it may function more as a modulator
than as a 'primary' transmitter. The conditions of our
experiments do not allow us to reach any conclusions
on this possibility, nor on the question of whether
5-HT may be released within the carotid body by
efferent nerves. However, the abundance of 5-HT in
the carotid body does imply that it has some function
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EFFECTS OF A NEW 5-HYDROXYTRYPTAMINE (5-HT) ANTAGONIST, MDL
72222, ON RESPONSES OF CAT CAROTID CHEMORECEPTORS TO 5-HT
AND HYPOXIA
Kirby, G.C. & McQueen, D.S. Department of Pharmacology,
University of Edinburgh Medical School, Edinburgh, Scotland.
The cat carotid body contains 5-HT, and exogenous 5-HT
has complex effects on carotid chemoreceptor activity. In
order to characterise the receptors involved in the response
to 5-HT we have used a new 5-HT antagonist, MDL 72222 (MDL);
previous antagonists were not selective enough for receptor
characterisation. 5-HT (1-50 pg i.e.) elicited three distinct
effects on chemosensory discharge recorded from filaments of
the carotid sinus nerve in anaesthetised cats. In all experi¬
ments chemodepression occurred, and this was preceded by a
transient burst of activity in 56% of recordings. The third
component involved a delayed slight increase in discharge,
associated with hypotension. MDL (10-100 pg kg--'- i.e.) it¬
self caused a brief period of chemodepression and delayed
secondary excitation. Following MDL there was a dose-related
antagonism of both the transient excitation and the chemo¬
depression evoked by 5-HT, without any change in the delayed
excitation or associated hypotension. The mean ID50 for 5-HT-
induced chemodepression increased from 5.8 ± 1.9 pg (± s.e.m.;
n=12) before, to 49.4 ± 33.6 (n=7; P < 0.05) after 10 pg k^~^
antagonist, and 638 ± 408 (n=5; P < 0.05) after 100 pg kg" .
The increase in chemosensory discharge caused by ventilating
the animal with 10% Oo instead of air was not significantly
affected by MDL (10-100 pg kg-1 i.e.).
Carotid chemoreceptors are affected by 5-HT, and the
greater part of the response involves MDL-sensitive (neuronal)
receptors. However, the fact that the antagonist has r.o
appreciable effect on the responsiveness of the chemoreceptors
to a physiological stimulus such as hypoxia suggests it is
unlikely that endogenous 5-HT, acting via MDL-sensitive recep¬
tors has an important role in chemoreception, although it
might be a modulator.
MDL was kindly donated by Merrell, Strasbourg.
385
- 380 -
[From the Proceedings of the British Pharmacological Society,
11-14 September 1984. Br. J. Pharmac., 83, 455P.]
455P
EFFECTS OF SUBSTANCE P ON RESPONSES OF CAT CAROTID BODY CHEMO-
RECEPTORS TO DOPAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE
G.C. Kirby 4 D.S. McQueen, Department of Pharmacology, University of Edinburgh
Medical School, 1 George Square, Edinburgh EH8 9JZ, Scotland, UK
The cat carotid body contains substance P (SP)-like material (Cuello 1 McQueen,
1980) as well as the putative transmitters dopamine (DA), noradrenaline (NA), and
5-hydroxytryptamine (5-HT). Preliminary investigations 3howed that SP can modify
spontaneous discharge and 3cme drug-induced responses of the carotid chemo-
receptor3 (McQueen, 1980), and we have now studied the Influence of SP on
responses of cat carotid chemoreceptor3 to DA, NA and 5-HT. Experiments were
performed on pentobarbitone-anaesthetized cats (12 mg kg"1 i.p., supplemented as
necessary), artificially ventilated and paralysed with gallamine (3 mg kg"1 i.v.).
Chemosensory discharge was recorded from the peripheral end of a cut sinus nerve,
and drugs were injected or infused into the common carotid artery as previously
described (McQueen, 1980). Infusions of SP (10 ug min"1) or drug vehicle (Looke
solution) were made at a rate of 0.1 ml min"1 for 2 min and injections of the
amines made 90 s after starting the infusion. This protocol was chosen to
minimise the tachyphylaxis caused by SP.
Within 15 s of onset of SP infusion there was a small but significant decrease
(P < 0.05) in spontaneous discharge fran the pre-infusion control frequency;
Locke solution had no marked effect on discharge.
NA (0.1 - 50 ug i.e.) caused chemodepres3ion followed by chemoexcitation;
chemodepression evoked by the higher, but not the lower doses of NA was poten¬
tiated during SP Infusion, whereas the delayed chemoexcitation was reduced.
5-HT (1 - 25 ug i.e.) caused dose-related chemodepression that was potentiated
during SP infusion. Secondary excitation following chemodepression was smaller
in magnitude than that associated with NA, but, in contrast, was potentiated
during SP infusion. DA (0.1 - 10 ug i.e.) induced dose-related chemodepression
which was greater than that evoked by NA or 5-HT, but the effect was largely
unaltered during SP infusion.
Our results indicate that SP-monoamine interactions are rather complex, and there
is evidence for a differential effect of the peptide on the responsiveness of
carotid chemoreceptor3 to the amines studied. Thus, SP potentiated NA and 5-HT-
induced chemodepression, but had no effect on the depressant action of DA.
Delayed chemoexcitation caused by NA was reduced during SP infusion, but that
evoked by 5-HT was potentiated. It remains to be established whether SP modifies
chemoreceptor activity by acting directly on some element of the chemosensory
complex within the carotid body rather than indirectly by a non-specific action
(e.g. vascular effects which in turn influence chemoreceptor discharge).
Further studies are needed to determine whether the peptide-amine interactions
described have any physiological significance, and also to characterize the
type(s) of SP receptor involved in modifying chemoreceptor activity.
This work is supported by an M.R.C. project grant. G.C.K. is an Houldsworth
Scholar of Edinburgh University.
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Effects of selective ^-adrenergic antagonists on the response of carotid
chemoreceptors to hypoxia in anaesthetized cats
By G. C. Klrby and D. S. McQueen. Department of Pharmacology, Edinburgh
University Medical School. 1 George Square, Edinburgh EH9 SJZ
Folgering, Ponte & Sadig (1982) reported that propranolol reduced or abolished
hvpoxia-induced chemo-excitation in cats, but Gonsalves. Smith, Nolan & Dutton
(1983) found no clear attenuation of this response by propranolol. We have studied
the effects of selective //-adrenoceptor antagonists on steady-state and dynamic
responses of carotid chemoreceptors to hypoxia. Chemosensory discharge was
recorded in pentobarbitone-anaesthetized cats (42 mg kg-1 i.p.. see McQueen, 1977).
Discharge during normoxia. plateau (maximum) discharge during 4 min ventilation
with 10% 02, and the rate of increase of discharge in response to hypoxia were
measured before and after injection of an antagonist (Table 1).
Table 1
ti — 3 n = 5
Control Propranolol Control Betaxolol
Discharge (air) 6-7 + 2-9 3-8 + 0-8 6-9+ 1-6 7-3 + 2-2
(c.p.s. +s.e. of mean)
Discharge (10% 0.) 26-8±12-2 121 ±2-9 29-8±9-2 29-5±9-5
(c.p.s. +S.e. of mean)
Rate of Increase 0-62 ±0-12 0-36±0-09 0-57±0-06 0-57±0-06
(% max. s"' + s.e. of mean)
Single injections of propranolol (1-6-5-8 mg kg-1 i.v.) tended to reduce normoxic
and hypoxic discharge, but responses after the drug were not statistically different
from the controls (P > 0-05. paired t test). Since propranolol has membrane-stabilizing
properties we studied the effects of betaxolol. a selective //x antagonist which has only
weak local anaesthetic properties (Boudot, Cavero, Fenard. Lefevre-Borg, Manoury
& Roach. 1979). A dose of 1 mg kg-1 blocked both the chemoreceptor excitation and
the increased arterial pulse pressure elicited by intracarotid injection of noradrenaline
(1-50/tg) but did not significantly alter any of the parameters measured. During
ventilation with 10% G, mean Pa 0, values were 4-99 + 0-7 kPa before and
5-25 + 0-4 kPa after betaxolol: corresponding Pa co, values were 3-90 + 0-1 kPa and
3-52 +0-2 kPa [n = 4; P > 0-05. paired t tests). ICI 118551. a selective /?, antagonist,
caused no significant reduction in the chemoreceptor response to hypoxia.
Assuming the antagonists in the doses used are capable of blocking the actions of
endogenous catecholamines, the present results do not support the direct involvement
of a //-receptor-mediated mechanism in the chemo-excitation evoked by hypoxia.
Supported by the M.R.C. G.C. K. is a Houldsworth Scholar of Edinburgh University.
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EFFECTS OF SELECTIVE 5-HYDROXYTRYPTAMINE AGONISTS ON CAROTID BODY
CHEMORECEPTOR DISCHARGE IN ANAESTHETIZED CATS
G.C. Kirby 4 D.S. McQueen, Department of Pharmacology, University of Edinburgh
Medical School, EDINBURGH, EH8 9JZ.
Intracarotid (i.e.) injection of 5-hydroxytryptamine (5-KT) in cats has the follow¬
ing effects on chemosensory discharge: dose-related chemodepression, selectively
blocked by the 'neuronal' 5-HT antagonist MDL 72222 (MDL); delayed chemoexcitation,
selectively blocked by the 5-HT2 antagonist ketanserin, and intense, but transient
chemoexcitation preceding 5-HT-evoked chemodepression, which is also selectively
blocked by MDL (Xirby 4 McQueen, 1984). We have further studied the 5-HT receptors
that might be responsible for these effects using the following selective agonists:
2-Methyl,5-hydroxytryptamine (2Me5-HT), active at MDL-sensitive sites (see Humphrey,
1984); 5-methoxytryptamine (5-MeT), which is inactive at MDL-sensitive sites
(Fozard, 1984); 8-OH-DPAT, a 5 —HT1^ agonist (Middlemiss 4 Fozard, 1983), and
RU 24969, a selective 5-HT 13 agonist (Cortes et al, 1984).
Chemoreceptor discharge was recorded in pentobarbitone-anaesthetized cats, artif¬
icially ventilated with air and paralysed with gallamine (for details see McQueen,
1977), and responses evoked by i.e. injections of the 5-HT agonists were compared.
During experiments in which the typical effects of injection of 5-HT (1-25 ug) were
obtained, 2Me5-HT (1-50 ug; n»4) caused chemodepression equal to, or greater than
that seen with 5-HT; marked transient chemoexcitation was elicited by 5-HT in all
four experiments, whereas 2Me5-HT had only weak effects. 2Me5-HT caused variable
secondary chemoexcitation, and hypotension similar to that induced by 5-HT. In
contrast, 5-MeT (1-100 ug: n-3) caused only slight changes in chemoreceptor dis¬
charge, although its vascular effects were similar to th.03e evoked by 5-HT.
RU 24969 (0.5-50 ug; n=>2) caused marked dose-deoendent prolonged chemoexcitation,
preceded in one experiment by slight chemodepression - less than that seen with
5-HT. There was no initial transient chemoexcitation, nor any obvious effect on
blood pressure. 8-OH-DPAT (0.5-50 ug; n»2) caused prolonged dose-related hypo¬
tension; there was neither initial transient nor delayed chemoexcitation, but
chemodepression, greater than that caused by 5-HT occurred, and persisted after
5-HT-evoked chemodepression had been blocked by MDL (100 ug kg-1) in one of the
experiments.
The rank order of potency of these agonists for the three phases of the '5-HT
response' appears to be: transient excitation 5-HT >> 2Me5-HT; chemodepression
8-OH-DPAT > 2Me5-HT and 5-HT >> RU24969 and 5MeT; secondary excitation RU 24969 >
5-HT > 2Me5-HT >> 8-OH-DPAT and 5-MeT. These results provide further evidence that
'neuronal' 5-HT receptors are associated with the carotid chemoreceptors, and also
emphasise the complexity of the 5-HT effects on chemosensory discharge, the signif¬
icance of which remains to be determined.
Supported by the M.R.C.; G.C.K. is a Houldsworth Scholar of Edinburgh University.'
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ICI 154,129 antagonizes [met]enkephalin-induced depression of cat chem-
osensory discharge
By G. C. Kirby and D. S. McQueen. Department of Pharmacology, University of
Edinburgh Medical School, Edinburgh EHS 9JZ
[Metjenkephalin appears to be present in the cat carotid body (Wharton etal. 1980).
Intracarotid injection of the peptide depresses chemosensory discharge in cats, and
this effect is antagonized by naloxone (McQueen & Ribeiro, 1980). In the present
study we have used the selective 8 opioid receptor antagonist ICI 154,129 (Shaw et
al. 1982) to help characterize the type of opioid receptor involved in the enkephalin-
induced depression of chemosensory discharge.
Experiments were performed on cats anaesthetized with pentobarbitone
(42 mg kg-1 i.p.), artificially ventilated with air, and paralysed with gallamine
(3 mg kg-1 x.v.). Chemosensory discharge was recorded from the peripheral end of a
sectioned carotid sinus nerve using techniques previously described (see McQueen &
Ribeiro, 1980). Drugs were injected into the common carotid artery close to the
carotid body from which chemoreceptor activity was recorded and the averaged
discharge frequency during the 30 s post-injection period was expressed as a
percentage change from the pre-injection discharge. The ID50 (dose causing a 50%
reduction in discharge over the 30 s period) was calculated for [Metjenkephalin from
dose-response lines using data obtained before and after administering ICI 154,129
(0T-10 mg kg-1 i.e.).
The mean ID30 for [Metjenkephalin-induced chemodepression was 089 + 016 (s.E.
of mean. N = 9) nmol before the antagonist. After ICI 154,129 in doses of OT, 1 and
10 mg kg-1 i.e. the mean IDS0 values were 1-01 ±0*38 {N = 3), 4-32 + 1'27 {N — 4) and
72-5 + 26 1 {N = 6) nmol respectively. ICI 154,129 itself had only slight effects on
discharge, tending to increase discharge at the low dose and decrease it after the high
dose. The intermediate dose of 1 mg kg"1 had no significant effect: none of the doses
had any appreciable effect on arterial blood pressure.
The finding that ICI 154,129 causes dose-related antagonism of [Metjenkephalin-
induced chemosensory depression is consistent with actions of the opioid at 8 type
receptors in the carotid body.
We thank I.C.I, for generously providing the ICI 154.129. Supported by an M.R.C. grant. G.C'. K.
is a Houldsworth Scholar of Edinburgh University.
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